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Abstract 
Background:  
 
Synbiotics, probiotics and prebiotics are being added to infant formula. This study was an in-depth 
evaluation of research on infants fed infant formula containing synbiotics, probiotics or prebiotics and was 
carried out in two phases. Phase one included two systematic reviews that assessed if synbiotics, probiotics 
or prebiotics led to improved growth and clinical outcomes in formula fed full term and preterm infants. 
Phase two included two studies: A systematic review compared the methodological quality and outcomes of 
industry and non-industry sponsored randomized controlled trials (RCTs) and a descriptive study evaluated 
how the food industry applies the knowledge and evidence gained from probiotics, prebiotics or synbiotics 
research in infants. 
 
The research questions were: Does the consumption of probiotics, prebiotics or synbiotics supplemented 
infant formula lead to improved clinical outcomes in infants? Is there an association between source of 
funding and methodological quality, clinical outcomes and author’s conclusions in trials using probiotics, 
prebiotics or synbiotics supplemented formula in infants? Does the food industry use the evidence gained 
through probiotics, prebiotics and synbiotics research trials on infants for the benefit of the general paediatric 
population? 
 
The hypotheses were: Consumption of probiotics, prebiotics or synbiotics by infants leads to improved 
clinical outcomes; The source of funding in research trials using probiotics, prebiotics or synbiotics 
supplemented formula in infants is associated with outcomes in favour of the sponsor’s products and authors’ 
conclusions; Methodological qualities of non-industry sponsored trials are equivalent to industry sponsored 
trials; Evidence gathered through probiotics, prebiotics and synbiotics research is implemented by the food 
industry. 
 
Methods:  
 
Phase one:  
Both systematic reviews on preterm and full term infants: Cochrane methodology was followed using RCTs 
which compared preterm or full term formula containing probiotics, prebiotics or synbiotics to conventional 
infant formula with / without placebo among healthy preterm or full term infants. The mean difference (MD) 
and corresponding 95% confidence intervals (CI) were reported for continuous outcomes, risk ratio (RR) and 
corresponding 95% CI for dichotomous outcomes.  
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Phase two:  
In the systematic review, Cochrane methodology was used to assess the risk of bias of included RCTs. 
Association between source of funding and risk of bias, clinical outcomes and conclusions were assessed. In 
the descriptive study, all listed companies that manufacture infant food products with added synbiotics, 
probiotics or prebiotics for infants were identified and invited to participate. A letter of invitation was sent 
and if they expressed willingness to take part in the study, a questionnaire with a written consent form was 
sent. Descriptive statistics and associations between categorical variables were to be tested using a Chi-
square test. 
 
Results: 
 
Phase one:  
Review on preterm infants: 8 studies were included. Probiotics increased stool frequency with no effect on 
other clinical outcomes. Prebiotics increased stool frequency and bifidobacteria counts only. 
 
Review on full term infants: 25 studies were included. Synbiotics improved stool frequency but had no effect 
on other clinical outcomes. Probiotics did not have an effect on any clinical outcome. Prebiotics increased 
weight gain and stool frequency with no effect on other outcomes.  
 
Phase two:  
Systematic review: 67 studies were included, majority were funded by food industry.  There was no 
significant association between the source of funding and four domains (sequence generation, allocation 
concealment, blinding, selective reporting), majority of reported clinical outcomes or authors’ conclusions. 
Source of funding was significantly associated with two domains (incomplete outcome data, free of other 
bias), antibiotic use and conclusions on weight gain. 
 
Descriptive study: 25 companies were identified and invited to participate. No company agreed to participate 
in the survey for different reasons. 
 
Conclusions 
Phase one:  
Review on preterm infants: There is not enough evidence to state that supplementation with probiotics or 
prebiotics results in improved growth and clinical outcomes in exclusively formula fed preterm infants. 
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Review on full term infants: There is not enough evidence to state that supplementation of term infant 
formula with synbiotics, probiotics or prebiotics does result in improved growth or clinical outcomes in term 
infants. There is no data available to establish if synbiotics are superior to probiotics or prebiotics.  
 
Phase two:  
Systematic review: In RCTs on infants fed infant formula containing probiotics, prebiotics or synbiotics, the 
source of funding does not influence majority of outcomes in favour of the sponsors’ products. More non-
industry funded research is needed to further assess the impact of funding on reported clinical outcomes and 
authors’ conclusions. 
 
Descriptive study: Due to companies refusing to participate in this study, no conclusion could be drawn on 
how the food industry applies evidence gained through probiotics, prebiotics or synbiotics research on 
infants. More transparency is needed from the infant formula manufactures on how they apply the evidence 
gained from probiotic, prebiotic or synbiotic research on infants.  
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Abstrakt 
 
Agtergrond 
 
Synbiotika, probiotika en prebiotika word gereeld by baba formule gevoeg. Hierdie studie was 'n in-diepte 
evaluering van navorsing oor babas gevoed met formule melk wat synbiotika, probiotika of prebiotika bevat 
en is uitgevoer in twee fases. Fase een het twee sistematiese oorsigte ingesluit wat die rol van synbiotika, 
probiotika en prebiotika op verbeterde groei en kliniese uitkomste van formule gevoede volterm babas en 
vroeg gebore babas evalueer het. Fase twee het bestaan uit  twee studies: 'n sistematiese oorsig wat die 
metodologiese kwaliteit en uitkomste van die bedryf en nie-bedryf geborgde ewekansige gekontroleerde 
proewe (RCTs) evalueer het, asook 'n beskrywende studie wat die kennis en toepassing van bewyse oor die 
effektiewiteit van probiotika, prebiotika of synbiotika in die voedsel industrie bestudeer het.   
 
Die hipotese stellings was: verbruik van probiotika, prebiotika of synbiotika by babas lei tot verbeterde 
kliniese uitkomste; die bron van befondsing vir synbiotics, probiotika of prebiotika navorsing beïnvloed 
uitkomste ten gunste van die borg se produkte; bewyse ingesamel deur middel van probiotika, prebiotika en 
synbiotika navorsing word geïmplementeer deur die voedselindustrie. 
 
Metodes 
 
Fase een: 
Beide sistematiese oorsigte op volterm en premature babas: Cochrane metodes is gevolg deur ewekansige, 
gekontroleerde studies wat vol termyn of premature formule met probiotika, prebiotika of synbiotika met 
konvensionele baba formule met / sonder plasebo onder gesonde volterm of premature babas bestudeer. Die 
gemiddelde verskil (MD) en die ooreenstemmende 95% vertrouensintervalle is gebruik vir deurlopende 
uitkomste, risiko verhouding (RR) en die ooreenstemmende 95% CI vir tweeledige uitkomste. 
 
Fase twee: 
In die sistematiese oorsig is Cochrane metodiek gebruik om die risiko van vooroordeel van ingesluite 
ewekansige, gekontroleerde studies te evalueer. Assosiasie tussen bron van befondsing en die risiko van 
vooroordeel, asook kliniese uitkomste en gevolgtrekkings was beoordeel. In die beskrywende studie, is alle 
genoteerde maatskappye wat babavoeding produkte vervaardig met bygevoegde synbiotika, probiotika of 
prebiotika vir babas geïdentifiseer en uitgenooi om deel te neem. 'n Uitnodigingsbrief is vir die relevante 
maatskappye gestuur om hul bereidwilligheid om deel te neem te  bevestig. Indien hulle wel bereid was om 
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deel te neem was 'n vraelys met 'n skriftelike toestemming vorm gestuur. Beskrywende statistiek en 
assosiasies tussen kategoriese veranderlikes was getoets met behulp van 'n Chi-kwadraat toets. 
 
Resultate 
 
Fase een: 
Oorsig oor premature babas: 8 studies was ingesluit. Probiotika verhoog stoelgang frekwensie met geen effek 
op ander kliniese uitkomste. Prebiotika verhoog ook stoelgang frekwensie en slegs bifidobakteriële tellings. 
Oorsig oor die vol termyn babas: 25 studies was ingesluit. Synbiotika verbeter stoelgang frekwensie, maar 
het geen effek op ander kliniese uitkomste gehad nie. Probiotika het nie 'n effek op enige kliniese uitkoms 
gehad nie. Prebiotika verhoog gewigstoename en stoelgang frekwensie met geen effek op ander uitkomste. 
 
Fase twee: 
Sistematiese oorsig: 67 studies was ingesluit, en die meerderheid was befonds deur die voedsel bedryf. Daar 
was geen beduidende assosiasie tussen die bron van befondsing en vier gebiede (toekenningsvolgorde, 
toekenningsverberging, studie verblinding, selektiewe verslaggewing), en die meerderheid van 
gerapporteerde kliniese uitkomste of skrywers se gevolgtrekkings. Die bron van befondsing was beduidend 
verbind  met twee gebiede (onvolledige uitslag data, vry van ander vooroordeel), antibiotika gebruik en 
gevolgtrekkings op gewigstoename. 
 
Beskrywende studie: 25 maatskappye is geïdentifiseer en genooi om deel te neem. Geen maatskappy het 
ingestem om deel te neem aan die studie om verskillende redes. 
 
Gevolgtrekkings 
 
Fase een: 
Oorsig oor premature babas: Daar is nie genoeg bewyse dat die aanvulling met probiotika of prebiotika 
resultate in verbeterde groei en kliniese uitkomste in uitsluitlik formule gevoede premature babas tot gevolg 
het nie. 
Oorsig oor die volle termyn babas: Daar is nie genoeg bewyse om te sê dat die aanvulling van term baba 
formule met synbiotika, probiotika of prebiotika lei tot verbeterde groei of kliniese uitkomste in termyn 
babas. Daar is geen inligting beskikbaar om te stel of synbiotika beter is as probiotika of prebiotika nie. 
 
Fase twee: 
Sistematiese oorsig: In studies op babas gevoed met formule melk wat probiotika, prebiotika of synbiotika 
bevat het,  het die bron van befondsing nie meerderheid van die uitkomste in die guns van die borge se 
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produkte beïnvloed nie. Meer nie-industrie befondsde navorsing is nodig om verder die impak van 
befondsing op kliniese uitkomste en skrywers se gevolgtrekkings te evalueer. 
 
Beskrywende studie: Aangesien al die maatskappy deelname geweier het, kon geen gevolgtrekking gemaak 
word of die voedsel bedryf bewyse oor die gebruik van probiotika, prebiotika of synbiotika toepas nie. Meer 
deursigtigheid is nodig van die formule vervaardigers oor hoe hulle die bewyse oor die gebruik van 
probiotika, prebiotika of synbiotika toepas.  
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Definition of terms 
 
In this study, specific terms were used which had several meanings. They include:  
 Infants  referred to preterm, low birth weight, very low birth weight or extremely low birth weight and 
full term infants 
 Infant formula referred to preterm formula, full term formula (standard formula, protein hydrolysates, 
soy based formula, amino acid based formula), follow-on formula. 
 Review referred to Systematic review 
 Probiotics was all live bacteria added to infant formula and included strains that are normally found in 
the gastrointestinal system. Examples include bifidobacteria, lactobacillus among others. 
 Prebiotics were fructooligosaccharide, inulin, galactooligosaccharides, oligosaccharides and other 
prebiotics such as Arabica gum. 
 Synbiotics were a combination of any live probiotic bacteria with any prebiotic added simultaneously to 
infant formula. 
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1.0 Introduction  
 
1.0.1 Overview of study 
 
Twenty five years of research confirms that breastfeeding is the optimal way to feed infants, since it contains 
all the essential nutrients babies need, and antibodies that fight off infection. [1 - 5] The World Health 
Organisation (WHO) estimates that 1.4 million infant deaths could be prevented annually if women breastfed 
their infants. [6] Despite the well documented benefits of breastfeeding, more women are choosing to 
formula feed instead of breastfeeding. As a result, global breastfeeding rates have decreased and formula 
feeding has increased. The high demand for formula has resulted in stiff competition among companies to 
manufacture new and innovative infant formula. [6] To identify how infant formula can be adapted to more 
closely resemble the composition and function of human milk, rigorous research has been done. This has 
resulted in different components being added to infant formula, such as docosahexaenoic acid (DHA), 
arachidonic acid, probiotics and prebiotics or synbiotics. [7]  
 
This two phase research project was an in-depth evaluation of research done on infants, given infant formula 
containing probiotics and prebiotics or synbiotics.  
 
Phase one was a critical appraisal of the evidence on probiotics, prebiotics and synbiotics in infants. It 
included two systematic reviews. The first review explored the effects of probiotics, prebiotics and synbiotics 
on growth and clinical outcomes in formula fed preterm infants and low birth weight infants. The second 
review explored the effects of synbiotics, probiotics or prebiotics on growth and clinical outcomes on 
formula fed full-term infants.  
 
Phase two was an evaluation of the application of evidence by the food industry on probiotics, prebiotics and 
synbiotics in infants.  This phase included both a systematic review and a descriptive study. The systematic 
review explored the association between the source of funding, methodological quality and research 
outcomes in randomized clinical trials of probiotics, prebiotics and synbiotics studies in infants. The 
descriptive study explored how the food industry implements research evidence on probiotics, prebiotics and 
synbiotics in infants for the benefit of the general paediatric population. 
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1.1 Background  
 
1.1.1 Growth  
 
The health status of newborn infants is assessed using various indicators of growth and development. 
Indicators usually include weight, length and head circumference for gestational age.  Tracking growth in an 
infant over a time period helps to identify health problems and prevent or minimize a slow growth rate. A 
steady weight and length gain over time is a sign that enough calories and nutrients are being provided. 
Therefore, a nutritional goal for infants is to provide enough calories and nutrients to maintain adequate 
growth. [6, 8, 9] Below is a brief description of growth in preterm and full term infants.  
 
1.1.1a Premature infants 
 
In premature and low birth weight infants, growth is a major challenge. By definition, premature infants are 
infants born before 37 weeks gestation. Low birth weight infants (LBW) weigh less than 2500 g at birth, 
very low birth weight infants (VLBW) weigh less than 1500 g and extremely low birth weight infants 
(ELBW) weigh less than 1000 g. [10 - 12] They have several risk factors that may result in nutritional 
deficiencies and poor growth including: poor nutrient stores of glycogen, fat, protein, fat soluble vitamins, 
calcium, phosphorus, magnesium and trace minerals [11 - 14]; immature gastrointestinal tracts (GI) and  
intestines; and villi and microvilli are short and fewer in number, decreasing overall absorptive capacity and 
utilization of nutrients. [11, 12, 14] In addition, they have a lengthy nil by mouth (NPO) status due to 
prolonged illnesses such as NEC (Necrotising Enterocolitis) or bowel obstruction which delays the 
introduction of enteral feeds. [3, 11 - 13] They also have increased nutritional demands due to a rapid growth 
phase, tissue development, stress from surgery and poor temperature control. [11, 15] 
 
Therefore, for premature infants, the goals are to provide adequate nutrition to foster: intra-uterine growth 
rate (in an extra-uterine environment); adequate weight gain without metabolic complications; foster catch-
up growth and nutrient accumulation, during the post discharge period. [3, 11, 12, 15, 16 – 18] For preterm 
infants, this is important because infants lose weight after birth (up to 6% to 8% for extreme low birth weight 
infants) and they often do not regain the weight for up to 1 to 2 weeks. [15, 16, 19] Daily growth monitoring 
(weight gain, linear and head circumference) then becomes vital. [3]  
 
To achieve optimum growth, a weight gain of 15 to 20 g / kg /day; length of 0.75 to 1.0 cm / week; and head 
circumference 0.75 cm / week is required. This is difficult to achieve and requires between 130 – 135 kcal / 
kg / day to maintain this growth rate. [3, 15, 18, 20] For optimum growth, full feeds of 150 mls / kg / day are 
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needed to meet the nutritional goals of: 120 to 130 kcals / kg / day; 3.0 to 4.0 g protein / kg / day (to promote 
weight gain similar to in foetuses in utero); 10.8 to 16.8 g carbohydrate / kg / day; 4.4 g to 6 g fat / 100 kcals 
(to promote fat deposition similar to foetuses in utero which is 3g/kg/day); 120 to 230 mg calcium / kg / day; 
and 60 to 140 mg phosphorus / kg / day (to decrease risk of fractures and osteopenia). [3, 11, 12, 14, 15, 20, 
21]  
 
Constant surveillance is required to detect early signs of feed intolerance including: increased gastric 
residuals, abdominal distension, vomiting, heme- positive stools, change in bowel sounds, apnea or 
bradycardia with feeds and unstable body temperature. Depending on the findings, enteral feeds are either 
withdrawn, decreased, diluted, discontinued or feed frequencies are changed. [11, 12, 15]  
 
1.1.2b Full term infants 
 
Healthy full term infants do not have the complex challenges of the preterm infants. However, for full term 
infants, the first year of life is also characterized by very rapid growth. Weight increases by 115%, body 
length 34% and head circumference 22%. [8, 22, 23] Initially, infants lose weight after birth and take 8-10 
days to regain it.  Weight gain increases by approximately 1.1 to 1.2 kg / month during the first 6 months, 
slowing down to 0.4 to 0.5 kg / month during the second 6 months. Length increases by 3.5 to 3.9 cm / 
month during the first 4 months, slowing down to 1.8 cm / month at 6 month of age. [8, 22] At birth, average 
head circumference is 35 cm and increases by an estimated 12 cm during the first year of life, to 
approximately 47 cm. A faltering head circumference has serious implications for neural growth, maturation 
and is an indicator for possible problems with brain growth. [23] Monitoring growth (weight, length and 
head circumference) evaluates the overall health of the infant and determines adequacy of nutritional intake. 
[8, 22, 24]  
 
For optimum growth, the formula fed infant at birth must consume 6 to 10 feeds of 30 to 90 mls / day of 
formula, gradually increasing to 3 feeds of 210 to 240 mls / day at 10 to 12 months of age. [25] To maintain 
optimum growth during the first 6 months of life, infants must consume formula providing more than 500 
kcals / day (males 570 kcals, females 520 kcals); 9.1 g / day (or 1.5g / kg / day) protein; and 31 g / day (0.98 
g / kg / day) of fat. From 6 months to 1 year, infants must consume more than 670 kcals / day (males 743 
kcals / day, females 676 kcals / day); 11g / day protein; and 30 g /day of fat. [26, 27]  
 
1.2 Infant feeding 
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Infant feeding choices for mothers of newborn infants are either to breastfeed, formula feed or to give both 
(mixed feeds). WHO and UNICEF’s guidelines for optimal infant feeding state that infants should receive 
exclusive breastfeeding for their first 6 months, then nutritionally adequate and safe complementary feeds 
should be initiated from the 6 months of age, with continued breastfeeding up to 2 years of age or beyond. [1, 
2, 6] Breastfeeding has several documented advantages over formula including: superior nutritional 
composition; immunologic and enzymatic components; health benefits for mothers; lower cost and 
convenience; enhanced maternal-infant bonding; decreased incidence of respiratory, gastrointestinal 
infections; leaner body composition of infants at 1 year of age and improved cognitive development. [25, 28, 
29] 
 
Despite these documented benefits of breastfeeding, more mothers are choosing not to breast feed but to 
formula feed their infants. There are health conditions in which formula feeding is indicated. These include: 
 
Infant conditions 
 Rare medical conditions such as galactosemia, maple syrup urine disease and phenylketonuria all 
require specialized infant formula. [6] 
 Premature infants with less than 32 weeks gestation and very low birth weights of of less than 1500 g 
require specialized infant formula as a supplement to breastmilk for a limited time period. [6, 28, 29] 
 Inadequate weight gain requires infant formula to be given as a supplement to breastmilk. [28, 29] 
 
Maternal conditions 
 
 HIV infection requires formula feeding if it is feasible, affordable, sustainable and safe. [6] 
 Severe illness that diminishes maternal capacity to care for her infant requires infant formula. [6]  
 Herpes simplex [6] 
 Maternal medication [6]  
 
In the absence of breast milk, commercial infant formulas are available for preterm and full term infants. The 
different types of preterm, full term formulas given to infants are also used as a vehicle to deliver probiotics, 
prebiotics and synbiotics to infants. These are briefly described below. 
 
 
 
1.2.1 Preterm infant formula 
 
Preterm infant formulas are designed to meet the nutritional needs of preterm infants without exceeding 
volume requirements or tolerance. [3, 11, 15, 21] Preterm formulas are fed to preterm infants of less than 36 
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weeks gestation when breastmilk is not available. [3] Preterm formulas have higher concentrations of 
vitamins, minerals and electrolytes than standard formulas. [11 - 13, 15] In general, in preterm formulas, 
glucose polymers make up 50 to 60 % of carbohydrate calories, decreasing the lactose load to the infant, 
because lactose contibues 40 to 50 % of carbohydrate calories to facilitate calcium absorption. Medium chain 
triglycerides (MCT) are 40 to 50 % of fat calories, aiding fat absorption and weight gain, because preterm 
infants have limited pancreatic lipase secretion and small bile acid pools. [11 - 13, 15] The protein has a 60 / 
40 whey / casein ratio compared to 80 / 20 ratio of colostrum; 55 / 45 ratio of mature breast milk; and 18 / 82 
whey / casein ratio of cow milk. Since the preterm formulas are predominately whey based, this promotes 
gastric emptying and digestion. Preterm formulas also contain amino acids cysteine and taurine, because 
preterm infants are usually deficient in them. [3] The age and weight at which a preterm formula is 
terminated varies among neonatal intensive care units, the vitamin concentration in the formula and the 
volume of intake. [12, 21] Premature formulas can be used until the infant reaches a weight of 2.5 to 3.5 kg. 
[12]  
 
Transition formulas (also known as post discharge formula) are designed for premature infants at discharge, 
or when the infant should have reached a weight of at least 2.0 to 2.5 kg. [3, 12, 21] The aim of giving 
transition formulas is to provide enough nutrients to address any nutritional deficits; and to promote normal 
growth and neurodevelopment without over feeding the preterm infant. Transition formulas are given at least 
2 days before discharge to document tolerance and weight gain. These formulas have a nutrient composition 
that is between premature formula and standard infant formulas. [3] Glucose polymers contain 50 to 60 % of 
carbohydrate calories and lactose comprises 40 to 50 %.  MCTs are 20 to 25 % of the fat calories; and 
protein is either 60 / 40, or 50 / 50 whey to casein ratio. [12] Compared to term formula, transition formulas 
have higher levels of protein (1.8 to 1.9 g / 100 ml) than standard preterm formulas, more energy (72 to 74 
kcal / 100 ml), additional calcium, phosphorus, zinc, trace minerals and vitamins. [3]  
 
1.2.2 Full term infant formula 
 
Standard infant formulas are suitable for infants from birth to 12 months. In general, for every 100 mls, 
standard formulas provide approximately 65 kcals (272 kJ), 1.5 g protein, 7.0 g carbohydrate and 3.8 g fat. 
[21, 25, 27 - 29] Follow-on formulas are used after 6 months. Standard formulas are made from cow’s milk 
that is changed by removing the butterfat; adding vegetable oils and carbohydrates; and decreasing the 
protein. [25, 27, 29] In addition to standard formula, there are other formulas which were used by study 
participants: 
 Soy protein formula: For infants with cow milk protein allergy, soy protein-based formulas are used. 
They are free of lactose, with the carbohydrate source being a glucose polymer. [21] These formulas are 
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fortified with methionine, carnitine, taurine and iron. They also contain a soy protein isolate and 
vegetable oils. [21, 25, 27- 29]  
 Protein hydrolysate formulas: These formulas are given in cases of severe cow milk allergy or soy 
intolerance. The protein (such as casein, whey) is denatured using heat and hydrolysed using proteolytic 
enzymes, resulting in small peptides and free amino acids. The enzymes are then denatured by heat. [21, 
25, 27 - 29]  
 Amino acid based formulas contain only pure amino acid mixtures. They are indicated for infants who 
are extremely sensitive to protein and do not tolerate protein hydrolysate formulas. [21, 25, 29]  
 
1.3 Intervention 
 
1.3.1 Definitions of probiotics, prebiotics, synbiotics 
 
Probiotics have been defined as “live microorganisms which when administered in adequate amounts may 
confer a health benefit to the host.” [30, 31, 32, 33] A new definition by the American Academy of Pediatric 
Committee on Nutrition states that probiotics are “microbes that generate small molecular metabolic by-
products that exert beneficial regulatory influence on host biological functions and may function as 
immunomodulators.” [34] A number of genera of bacteria and yeast are used as probiotics, including 
leuconostoc, pediococcus, enterococcus, lactobacillus and bifidobacteria. The main probiotic organisms 
currently used worldwide belong to the genera lactobacillus and bifidobacteria and are found in the 
gastrointestinal microflora. [32] 
 
Prebiotics are “non- digestible food ingredients that may benefit the host by selectively stimulating the 
growth and / or activity of one or a limited number of bacteria in the colon and improving the host’s health.” 
[30, 31, 35] This definition was refined to “prebiotics are selectively fermented ingredients that allows 
specific changes in the composition and / or activity in the gastrointestinal microbiota thus conferring 
benefits to the host’s health.” [36, 37, 38] The most widely studied prebiotics are inulin and 
fructooligosaccharide (FOS), which are plant storage carbohydrates in vegetables, cereals and fruit. [30, 31] 
 
When probiotics and prebiotics are administered simultaneously, the combination is termed Synbiotics. The 
prebiotic in the synbiotic mixture improves the survival of the probiotic bacteria, and stimulates the activity 
of the host’s endogenous bacteria. [30, 31, 39]  
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1.4 Probiotics 
 
Probiotics are consumed in the form of fermented food, dairy products and more recently, infant and toddler 
formula. [33, 40] Probiotics can also be added to other foods such as cereals, biscuits, soy milk and sausages.  
[41 - 44]  
 
Not all bacteria qualify as probiotics. There are minimum requirements for bacteria to be classified as a 
probiotic for human use. The bacteria must be:  of human origin and completely identified to determine the 
genus, species and strain. They must also undergo: in vitro tests to screen for activity and safety; and in vivo 
studies to substantiate health effects in the target host. [30] Guidelines from the Food and Agriculture 
Organisation (FAO) and World Health Organisation (WHO) state that to qualify as a probiotic, a strain of 
bacteria must: be resistant to gastric acidity; be resistant to bile; exhibit bile salt hydrolase activity; adhere to 
mucus and / or human epithelia cells; have antimicrobial activity against potential pathogenic bacteria; and 
have the ability to reduce pathogenic adhesion surfaces. For vaginal probiotics, the bacteria must be able to 
resist spermicides.  [45, 46] Up to 56 species of lactobacillus and 29 species of bifidobacteria have been 
identified (Shah 2007) Examples include: Lactobacillus acidophilus NCFM, Lactobacillus acidophilus 
Johsonii La1, Lactobacillus casei Shirota, Bifidobacteria lactis Bb-02, Bifidobacteria infantis Shirota, 
Bifidobacteria longum BB536 
 
Most probiotics are registered as food supplements, therefore these do not have to meet the quality 
requirements for medicines. It is now mandatory to do research on the mechanisms of action of specific 
strains. Clinical trials with commercial products, with added probiotics are also mandatory. [30] This is 
because the effects conferred by probiotic bacteria are strain specific. The in vivo effects of one type of strain 
may be opposite to those shown in vitro. Therefore, effects demonstrated by one strain cannot be 
extrapolated to other strains. [30, 32, 40]  
 
1.4.1 Mechanism of action of probiotics 
 
Probiotics use several ways to exert their effects. However, no single strain of probiotics will use all the 
mentioned mechanisms of action to exert its effects on the host. [30, 40, 47] A few of the mechanisms of 
action of probiotics relating to its effects on the gastrointestinal tract are briefly summarised below. 
 
Strengthening the epithelial tight junctions 
The epithelial tight junctions are a major component of the intestinal barrier function. They act as a physical 
and functional barrier against the penetration of bacteria and macromolecules from the lumen. This prevents 
bacteria from gaining access to the sub-mucosa or even the circulation and causing illnesses such as sepsis. 
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The tight junctions consist of four types of proteins: occludins, claudens, tri-cellulin and junction adhesion 
molecules. A disruption of tight junctions is usually the beginning of many diseases. [48] Probiotics (such as 
L. plantarum) act on tight junctions by inducing the production of occludins and actinins. As a result, 
intestinal permeability is reduced. [31, 34]  
 
Mucus production 
The gut epithelium is covered by a gel-like mucus layer composed of mucins. Mucins are heavy molecular 
weight proteins secreted by goblet cells  located throughout the entire length of the intestines. The mucus 
layer provides protection from pathogens, enzymes, toxins, dehydration and abrasion. [49] Certain strains of 
probiotics (such as L. plantarum, L. rhamnosus) stimulate the production of MUC2, MUC3 intestinal 
mucins. This decreases adherence of pathogens to intestinal epithelial cells, preventing bacteria translocation 
from the lumen. [34, 50]  
 
Enhancing gut immune system 
Immunoglobulin-A (IgA), resistant to protease plays a crucial role in binding pathogens in the mucus layer, 
because IgA binds to mucins. This decreases the pathogen access to epithelial cells. [31, 34, 47, 51, 52] 
Probiotics increase IgA production and secretion by altering the cytokine environment in the gut mucosa. 
Probiotics induce the production of interleukin-10 (IL-10) and interleukin-6 (IL-6), enhancing IgA 
production. [49] Inducing the production of IL-10 results in an anti-inflammatory or suppressive response 
and IL-6 elicits a pro-inflammatory response. 
 
Regulation of appropriate bacterial colonisation 
Probiotics produce antibacterial substances, such as bacteriocins and microcins with bacteriocidal (kills 
bacteria) and bacteriostatic (inhibits growth) activity against pathogens. Bacteriocins and microcins are 
produced in a strain-specific manner by probiotics and commensal bacteria. Bacteriocins also act as 
signalling molecules to other bacteria and to the immune system. The presence of bacteriocins ensures the 
sustained presence of beneficial bacteria in the gut. Examples of bacteriocins include lactocidin, acidolin, 
acidophilin, lactacium-B produced by L. acidopohillus, bifidolin and bifilong produced by bifidobacteria. 
[49, 51, 53] Both bacteriocins and microcins ensure there is rapid bacteria death, maintaining an intestinal 
barrier free of pathogens. [53] Probiotics also produce defensins, which are antibacterial peptides rich in 
cysteine. Defensins disrupt the cytoplasm in susceptible pathogens. Probiotics such as Escherichia coli Nissle 
1917 stimulate the production of human beta-defensins. [49]  
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Probiotics also produce short chain fatty acids (SCFAs) including lactic acid, acetic acid, propionic acid and 
butyrate, lowering the pH of the gut, thus disrupting pathogen growth.  SCFAs also disrupt the outer 
membranes of gram negative pathogens, inhibiting their growth. [34, 51, 53]  
Probiotics also have the ability to adhere to the intestinal epithelial cells. They compete with pathogens for 
attachment sites and nutrients. This decreases the availability of attachment sites, decreasing the adhesion of 
pathogens and their toxins to the gastrointestinal tract. Ultimately this disrupts colonisation of the gut by 
pathogens. [31, 34, 47, 51] 
 
Modulation of the immune system 
The effects of probiotics on the immune system are well documented. The effects are strain specific and vary 
widely with complex chemical pathways; these are beyond the scope of this document. In general, probiotics 
stimulate a decrease in the production of pro–inflammatory cytokines, such as tumour necrosis factor – alpha 
(TNF-α), interferon – gamma (IFN-γ) and interleukin – 12 (IL-12). Probiotics also increase the production of 
anti-inflammatory cytokines, such as interleukin -10 (IL-10), which is produced by many cell types, such as 
monocytes, Th2 cells, B cells or Treg cells. Probiotics have antimicrobial properties; they induce an increase 
in the phagocytosis capacity of macrophages and natural killer cells (NK cells). [34]  
 
1.4.2 Minimum dose of probiotics required for an effect 
 
It is not possible to accurately state a minimum dose of probiotic needed for an effect. The required dose 
varies for different strains and for the specific health condition under investigation. A daily dose of probiotic 
is needed for any measurable effect. There is consensus that doses between 10
6
 and 10
9
 colony forming units 
per day (cfu/ day) are required. Some probiotics show positive effects at 10
8
 cfu / day, while others are more 
effective at 10
12
 cfu /day. [33, 34, 54]  
 
1.4.3 Safety of probiotics 
 
Probiotics have been granted GRAS (generally regarded as safe) status by the Food and Drug Administration 
(FDA) due to the long history of safe use, and the bacteria used in the probiotic preparations are identical to 
those found in the gastrointestinal and vaginal flora. [30, 55, 56]  
 
In healthy people, probiotics rarely cause disease. Systemic infections such as endocarditis, fungaemia have 
been reported but are extremely rare. Bacteraemia from ingested lactobacilli occurs in fewer than one in one 
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million users; and fungaemia (from Saccharomyces Boulardii) occurs in fewer than one in 5.6 million users. 
[57, 58] There are reported cases of bacteraemia, sepsis or endocarditis, occurring in immune-compromised 
or severely debilitated people.. Bacteraemia (from lactobacillus) and fungaemia (from saccharomyces 
Boulardii) have occurred in children with underlying risk factors such as immunodeficiency, short gut 
syndrome and antibiotic related diarrhoea. [59, 60] In these cases, the probiotic causing the disease is often 
from other sources, such as contaminated catheters and not from the consumed probiotic. [59, 60] In infants, 
risk factors associated with sepsis from probiotics include: prematurity, presence of central venous catheters, 
impairment of the intestinal epithelial barrier and concurrent administration of broad spectrum antibiotics to 
which the probiotic is resistant. [30, 61] There is consensus that caution should be exercised when using 
probiotics in individuals with these risk factors. [62, 63]  
 
In a recent review, the ESPGHAN Committee on Nutrition reviewed the evidence on probiotic use in infants. 
The committee concluded that “the available data on probiotic supplemented infant formula for infants, does 
not raise any safety concerns on growth and adverse events in healthy infants.” [64, 65] The safety and 
efficacy of each probiotic strain, however must be tested separately. [60] This is because the health effects 
and safety profile of one probiotic strain cannot be extrapolated to another strain. [60, 64]  
 
1.5 Prebiotics 
 
Fructooligosaccharide (FOS) and inulin are added to different foods as fat and sugar replacements to 
improve texture, or for their functional benefits. [30, 31] Inulin occurs naturally in food such as onions, 
garlic, leeks, artichokes, asparagus, wheat, oats and soybeans. [37] Formula companies also add prebiotics to 
infant formula. [35, 66] For an ingredient to be classified as a prebiotic, it must be resistant to gastric acidity, 
hydrolysis by mammalian enzymes and absorption in the upper gastrointestinal tract. It must also be 
fermented by beneficial bacteria in the intestine, selectively stimulating the growth and or activity of colonic 
microflora, resulting in a healthier composition. [36, 37, 38]  
 
1.5.1 Mechanism of action of prebiotics 
 
Most RCTs on prebiotics have used fructans, such as fructooligosaccharide, inulin and oligosaccharides. [67] 
The mechanism of action of these fructans on the GI are briefly described below. 
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Short chain fatty acids (SCFAs) 
Prebiotics are not digested or absorbed in the upper gastro intestinal tract. Once they reach the colon, 
prebiotics are selectively fermented by the residential bacteria into SCFAs, such as acetic acid, propionic 
acid and butyrate. The SCFAs are not toxic to the host but are an essential fuel for the epithelial cells. 
Prebiotics are selectively fermented, because each bacteria genus or strain has a preferred substrate. Most 
strains of bifidobacteria and lactobacillus ferment fructans (such as fructooligosaccharides) more efficiently 
than glucose. [31, 36] An increase in short chain fatty acids results in a decrease in pH of the lumen, 
inhibiting pathogen growth. . [36] Prebiotics selectively stimulate the growth and / or activity of colon 
microflora towards a healthier composition by increasing bifidobacteria and lactobacillus levels. [36, 68]  
 
Immune modulation 
There are many complex mechanisms by which prebiotics modulate the adoptive and innate immune system. 
However, the human gastrointestinal (GI) immune system is inaccessible, resulting in human studies relying 
on ex-vivo systemic immune markers. [38] In general, consumption of prebiotics, such as 
galactooligosaccharides(GOS), fructooligosaccharide (FOS) and inulin, significantly increases phagocytosis, 
natural killer cells activity, increasing production of anti-inflammatory cytokines, such as IL-10 and reducing 
pro-inflammatory cytokines, such as IL-1β, IL-6, TNF-α. [38, 68]  
 
Disruption of attachment by pathogens and improved intestinal architecture 
Prebiotics inhibit the adherence of pathogens to the epithelial cells preventing colonisation. [36] For infants, 
prebiotics stimulate the growth of only beneficial bacteria, in the gastrointestinal tract, to the levels found in 
breastfed infants. [69 - 71] As these beneficial bacteria increase, they exclude pathogens; the gut mucosal 
barrier improves preventing infections with enteric pathogens or trans-located gut bacteria. [31, 66, 72] 
Prebiotics also improve the intestinal architecture by increasing villi height, thicker mucus layer, deeper 
crypts and increased globlet cells, which improves intestinal permeability. [73, 74]  
 
Enhanced mineral absorption 
Prebiotics enhance the absorption of minerals, including calcium, magnesium and iron. [67, 68] An increase 
in SCFAs and the corresponding decrease in lumen pH, calcium solubility is improved, resulting in its 
increased bioavailability. Ultimately, this leads to improved bone health (bone calcium content and bone 
mineral density). [37, 38, 67, 68] In addition, with the improved intestinal architecture (increased villi height, 
deeper crypts), the surface for mineral absorption is greatly improved and increased. [38]  
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Stool effects 
Consumption of prebiotics increases stool bulk, by 1.5 to 2 grams for each gram of non-digestible 
oligosaccharides. Prebiotics also normalize or increase stooling frequency (non –diarrhoea). [68]  
 
1.5.2 Minimum dose of prebiotics required for an effect 
 
A dose of 4 – 20 g / day of FOS or inulin, significantly increases bifidobacteria counts. [75] The stool 
bulking index for FOS or inulin is 1.5 to 2 grams of stool per gram consumed. Stool bulking index is an 
expression of increase in daily faecal mass. [66]  
 
1.5.3 Safety of prebiotics 
 
Prebiotics have a good safety record at levels found in existing food components. Cases of flatulence or 
abdominal bloating are reported at doses greater than 20 g / day. Abdominal cramps or diarrhoea are reported 
at doses greater than 50 g / day. [73, 74] In a recent review, the ESPGHAN Committee on Nutrition 
reviewed the evidence on prebiotic use in infants. The committee concluded that “the available data on 
prebiotic supplemented formula given to healthy infants indicated that prebiotics do not raise any safety 
concerns on growth and adverse events.” However, the clinical effects of one prebiotic cannot be 
extrapolated to another prebiotic. [64]  
 
1.6 Evidence of probiotics, prebiotics and synbiotics effects on gastrointestinal tract in infants  
 
1.6.1 Description of evidence 
 
Most randomized controlled trials (RCTs) on probiotics, prebiotics and synbiotics use in infants published 
from 1980 to 2010 varied in: intervention (RCTs used different strains and doses of probiotics, used GOS, 
FOS, inulin or different combinations of these prebiotics); duration (most studies had short treatment 
durations), methodological quality and  small sample sizes. There were very few studies using synbiotics on 
infants, most RCTs used probiotics or prebiotics. [64, 76]  
 
Numerous RCTs on probiotics and prebiotics were conducted on infants from 1980 to the 2010. Similarly, 
there are numerous systematic reviews using these published (and unpublished) RCTs. The Oxford Centre 
for Evidence- based Medicine guidelines state that systematic reviews of randomized clinical trials offer the 
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highest level of evidence for information on the effectiveness of an intervention, followed by RCT(s). [77 - 
79] The results from the RCTs and the systematic reviews on probiotics, prebiotics and synbiotics use in 
infants can be conflicting and confusing.  
 
Several systematic reviews report that probiotics and prebiotics have had a significant effect on clinical 
outcomes. Systematic reviews on full term infants given probiotics show different strains of probiotics 
improve stool consistency, frequency and support normal growth [64]. While other recent systematic reviews 
(published from 2007 to 2011) focused only on the prevention of allergic disease, food hypersensitivity, 
upper respiratory tract infections, antibiotic associated diarrhoea and acute infectious diarrhoea. Some 
conclude there is insufficient evidence that probiotics or prebiotics prevent these conditions [80 - 82], 
whereas others report positive effects [83 - 84]. [Table 1] 
 
Reviews on preterm infants are equally conflicting and confusing. One review reports that administration of 
probiotics did result in reduced risk of Necrotising Enterocolitis and mortality [85], whereas a recent 
systematic review reported that supplementation did not result in decreased incidence of NEC, late onset 
sepsis or time to full enteral feeds. [86] A third review reported supplementation with probiotics or prebiotics 
had no significant advantage over standard formula or placebo. [87]  
 
1.6.2 Routine use of probiotics and prebiotics in infants 
 
Some systematic reviews and research groups support routine supplementation with probiotics and prebiotics 
in infants, whereas others do not support routine supplementation. This also causes confusion. For example, 
the Cochrane Neonatal Review Group states that “the current evidence on probiotics to prevent Necrotising 
Enterocolitis (NEC) supports the routine administration of probiotics in preterm infants.” [34] Other 
systematic reviews do not support routine supplementation with probiotics or prebiotics in infants. (Table 1) 
For full term infants there is a lack of: consistent clinical effects in early infancy (less than 4 months of age); 
heterogeneity of studies (methodological quality, types of probiotics used, duration and doses of intervention 
used); improved growth and clinical outcomes. [64] For preterm infants, there is no conclusive evidence to 
support routine use since the effects of probiotics on NEC and mortality needs to be reconfirmed, using large 
adequately powered RCTs. For example, Mihatsch proposes an RCT consisting of at least 714 infants per 
study group is required to show that an intervention reduces the incidence of NEC by at least 50%. [87]. An 
RCT of this size on preterm infants given probiotics has not been conducted to date. In addition, there is still 
no convincing evidence that probiotics prevent sepsis in preterm infants. [87]   
 
Despite three decades of research using probiotics, prebiotics and recently synbiotics in infants, there are no 
probiotic products approved for routine use in preterm infants by regulatory agencies such as the Federal 
Drug Administration (FDA) in United States, or the Therapeutic Goods Administration of Australia. [34] 
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However, the FDA has approved a probiotic supplemented formula for full term infants. [88] In Southern 
Africa, infant formula with probiotics, prebiotics and synbiotics are sold directly to the public in retail 
outlets. 
 
1.6.3 Rationale for addition of probiotics, prebiotics or synbiotics to infant formula 
 
There is evidence that to achieve optimal health and growth, a healthy intestinal micro-flora in infants 
(preterm, low birth weight and full term infants) is necessary. [89] For infants who are not breastfed, there is 
a rationale to adapt infant formulas to promote an intestinal microbiota resembling that of breastfed infants. 
It has a greater concentration of bifidobacteria and fewer potentially pathogenic bacteria than formula fed 
infants. Strategies to achieve this goal include the addition of probiotics, prebiotics or synbiotics to infant 
formula for full term and preterm infants to improve growth, development and decreasing infection. [33, 76] 
Adding these ingredients to infant formula changes the intestinal microbiota.[39, 90] Adding prebiotics to 
formula stimulates the growth of only beneficial bacteria in the gastrointestinal tract, to levels found in 
breastfed infants. [69, 70, 71] 
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Table 1. Summary of systematic reviews of probiotics, prebiotics in infants and children 
 
Author, Year 
of publication 
Aim /objective of review 
Methodology,   
Inclusion criteria, N = Conclusion(s) 
AlFaleh 2011 
[85] 
To compare the efficacy and safety 
of prophylactic enteral probiotics 
administration versus placebo or no 
treatment in the prevention of severe 
NEC and/or sepsis in preterm 
infants. 
Methodology 
Review followed guidelines from the Cochrane 
Collaboration and its neonatal group.  
 
Inclusion criteria 
Only randomized or quasi-randomized controlled trials that 
enrolled preterm infants < 37 weeks gestational age and / 
or < 2500 g birth weight were considered. 
 
Intervention 
Enteral administration of any live microbial supplement 
(probiotics) at any dose for more than seven days 
compared to placebo or no treatment. 
 
Participants: 
Preterm infants < 37 weeks and / or birth weight < 2500 g. 
 
Results 
 N=16 trials.  
 Enteral probiotics supplementation: 
 Significant reduction in the incidence of severe 
NEC typical RR 0.35, 95% CI 0.24 to 0.52 and 
mortality RR 0.40, 95% CI 0.27 to 0.60.  
 No significant reduction of nosocomial sepsis RR 
0.90, 95% CI 0.76 to 1.07 
 No reported systemic infection with the probiotics 
supplemental organism.  
Statistical test of heterogeneity for NEC, mortality and 
sepsis was insignificant. 
 Enteral supplementation of 
probiotics prevents severe NEC and 
all-cause mortality in preterm 
infants.  
 This updated review of available 
evidence supports a change in 
practice.  
 More studies are needed to assess 
efficacy in ELBW infants and assess 
the most effective formulation and 
dose to be utilized. 
Allen 2010 [84] To assess the effects of probiotics in 
proven or presumed acute infectious 
Methodology 
Review followed guidelines from the Cochrane 
 
 Used alongside rehydration therapy, 
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diarrhoea. Collaboration.  
 
Inclusion criteria and intervention 
 Randomized and quasi-randomized controlled trials 
comparing a specified probiotic agent with a placebo or no 
probiotic in infants, children and adults with acute 
diarrhoea that is proven or presumed to be caused by an 
infectious agent. 
 
Participants: Infants, children, adults 
 
Results N= 56 
 No adverse events were attributed to the probiotic 
intervention.  
 Probiotics reduced the duration of diarrhoea, 
although the size of the effect varied considerably 
between studies. 
 Mean duration of diarrhoea (MD 24.76 hours; 95% 
CI 15.9 to 33.6 hours; n=4555, trials=35) diarrhoea 
lasting 4 days (RR 0.41; 0.32 to 0.53; n=2853, 
trials=29) and stool frequency on day 2 (MD 0.80; 
0.45 to 1.14; n=2751, trials=20). 
 Differences in effect size between studies was not 
explained by study quality, probiotic strain, the 
number of different strains, the viability of the 
organisms, dosage of organisms, the causes of 
diarrhoea, or the severity of the diarrhoea, or 
whether the studies were done in developed or 
developing countries. 
 
probiotics appear to be safe and have 
clear beneficial effects in shortening 
the duration and reducing stool 
frequency in acute infectious 
diarrhoea. However, more research is 
needed to guide the use of particular 
probiotic regimens in specific patient 
groups. 
Bragger 2011 
[64] 
Systematically reviews published 
evidence related to safety and health 
effects of administration of formula 
supplemented with probiotics and / 
or prebiotics compared to un-
supplemented formula 
Review followed guidelines from the Cochrane 
Collaboration.  
 
Inclusion criteria and intervention 
 
Studies that compared use of infant formula or follow-on 
formula supplemented with probiotics and or prebiotics 
Probiotics 
 Probiotics do not raise safety 
concerns with regard to growth and 
adverse effects.  
 Safety of 1 probiotic cannot be 
extrapolated to others.  
 There is lack of data on long term 
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during manufacture process. 
 
Participants: Healthy Term infants 
 
Results 
Probiotics: N = 20 studies 
Prebiotics: N = 23 studies 
Synbiotics: N = 3 studies 
 
Probiotics 
Summary and interpretation of data effects of probiotic 
supplementation of infant formula on: 
 
Growth:  
Interpreting studies on the effects of probiotic on growth is 
difficult due to the limited number of studies, which were 
with insufficient power to identify relevant effects on 
growth, follow-up periods were short.  
In general, for a few probiotic strains that were used 
support normal growth in healthy term infants 
 
GI infections:  
Limited evidence shows (B lactis;BL999 and LPR) does 
not reduce the risk of GI infections.  
 
Respiratory infections: 
Limited available evidence shows B lactis does not reduce 
the risk of respiratory infections.  
 
Antibiotic use 
Limited available evidence suggests that BL999 and LPR 
is not associated with a reduced use of antibiotics.  
 
Colic / irritability 
The administration of B lactis, BL999 and LPR, L reuteri, 
or LGG was not associated with a lower frequency of colic, 
effects of probiotic supplementation. 
Therefore ESPHGAN committee 
does not recommend probiotics for 
routine use in infants 
Prebiotics 
 Prebiotics do not raise safety 
concerns.  
 Effect of 1 prebiotic cannot be 
extrapolated to others. 
 There are some benefits (increased 
stool frequency, stool softening). 
 There is a lack of data on long term 
effects of prebiotic supplementation. 
 Therefore ESPHGAN committee 
does not recommend prebiotics for 
routine use in infants. 
Synbiotics 
 Only a few synbiotics preparations 
have been studied, there are no 
associated adverse effects. 
 Efficacy and safety of synbiotics 
need to be established. 
 Therefore ESPHGAN committee 
does not recommend prebiotics for 
routine use in infants. 
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crying, or irritability.  
 
Allergy 
Limited data available suggest no effect of the probiotics 
studied (BL999 and LPR) on allergy.  
 
Stool consistency 
LGG, but not B lactis or L reuteri ATCC 55730 or BL999 
and LPR, 
administration had a modest, statistically significant effect 
on stool consistency.  
Clinical significance of this effect is unclear. 
 
There is too much uncertainty to draw reliable conclusions 
from the available data on the effects of probiotics on GI 
infections, respiratory infections, antibiotic use, colic / 
irritability and allergy 
 
Prebiotics 
Summary and interpretation of data effects of prebiotic 
supplementation of infant formula on: 
 
Growth: 
Interpreting studies on the effects of prebiotics on growth 
can be difficult because few studies have analysed the 
effects on growth, studies were small with insufficient 
power, the follow-up periods were short. Prebiotic 
supplementation with a mixture of GOS/FOS, has no 
adverse effects on growth in healthy term infants, but the 
effect on improved growth is modest. 
 
Stool pH 
Prebiotic supplementation has the potential to reduce 
faecal pH, whether this reduction in 
faecal pH per se is of benefit to the infants is currently not 
established. 
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Stool frequency 
Prebiotic supplementation has the potential to increase 
stool frequency but the clinical significance 
of this is unclear. 
 
Stool consistency 
Prebiotic supplementation has the potential to soften 
stools but clinical significance of this finding 
is unclear. 
 
Synbiotics 
A limited number of synbiotic preparations in infant 
formulae in context of a formal RCT  
The available data suggest that the products are safe, but 
caution in over interpretation of the results.  
The efficacy and safety of each synbiotic product should 
be established. 
 
Hao 2011 [83] To assess the effectiveness and 
safety of probiotics for preventing 
acute URTIs. 
Methodology 
Review followed guidelines from the Cochrane 
Collaboration.  
 
Inclusion criteria 
Randomised controlled trials (RCTs) to prevent acute 
URTIs. 
 
Intervention 
Any probiotic (single or mixture of strains, any dosage 
regimen and any route of administration) for more than 
seven days compared to placebo, or no treatment. 
 
Participants 
Children and adults of all ages. 
 
Results  
 Available evidence shows that 
probiotics are better than placebo in 
reducing the number of participants 
experiencing acute episodes of  upper 
respiratory tract Infection. (URTI), 
the rate ratio of episodes of acute 
URTI and reducing antibiotic use, 
although there were no data 
concerning older people in the 
review. 
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 N=14 
 Probiotics were better than placebo in the number of 
participants experiencing episodes of acute URTI:  
 One episode URTI: odds ratio (OR) 0.58; 95% CI 0.36 
to 0.92;  
 Three episodes URTI: OR 0.53; 95% CI 0.36 to 0.80;  
 Rate ratio of episodes of acute URTI: rate ratio 0.88; 
95% CI 0.81 to 0.96;  
 Reduced antibiotic prescription rates for acute URTIs: 
OR 0.67; 95% CI 0.45 to 0.98.  
 Probiotics and placebo were similar when measuring 
the mean duration (MD) of an episode of acute URTI: 
MD -0.29; 95% CI -3.71 to 3.13 and adverse events: 
OR 0.92; 95% CI 0.37 to 2.28.  
 Side effects of probiotics were minor and GI 
symptoms were the most common.  
 Some subgroups had a high level of heterogeneity in 
the pooled analyses. 
 
Mihatsch 2012 
[87] 
Systematically analyse the level of 
evidence of published RCTs on 
probiotics in preterm infants 
Review used the levels of evidence-based single or meta 
analyses scored following the Oxford Centre for Evidence 
based Medicine guidelines. 
Methodological quality of RCTs assessed using the 
Cochrane Collaboration’s risk of bias tool. 
 
Inclusion criteria 
RCTs that had studied clinical outcomes: NEC, mortality, 
sepsis, feeding advancement or neurodevelopmental long 
term follow-up.  
 
Intervention: RCTs using terms: Infants, neonates, 
probiotic(s), prebiotic(s), lactobacillus(i), 
bifidobacterium(a), saccharomyces, Ecoli Nissle 
 
Participants: Preterm infants,  
 
Results:  
 No conclusive level of evidence  on 
which to base a general 
recommendation for routine use of 
probiotics in preterm or very low 
birth weight infants. 
 Available strains do not permit a 
decision to be made on optimum 
strains, dosing or protocol. 
 It is beyond the available evidence to 
decide if a single strain, or multiple 
strain products are more effective. 
 Data on one strain cannot be applied 
to another strain. 
 Safety and efficacy of each probiotic 
strain has to be proven separately. 
 Large adequately powered, multi- 
centre RCTs are required to 
reconfirm available results, 
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 N = 15 studie: Two 1b Levels of Evidence (LoE) 
trials and thirteen 2b LoE trials.  
 Methodological assessment revealed considerable 
heterogeneity.  
 Some probiotics may be beneficial in relation to 
reduction of severe NEC (2b LoE) and reduction 
of mortality (2b LoE).  
 Probiotics do not accelerate feeding advancement 
(1b and 2b LoE).  
 There was no convincing benefit with regard to 
prevention of sepsis (1b and 2b LoE).  
 
especially RCTs with severe NEC 
(Bell stage> 2) or mortality as 
primary outcomes. 
Osborn 2007 
[81] 
To determine the effect of probiotics 
given to infants for the prevention of 
allergic disease or food 
hypersensitivity. 
Methodology 
Review followed guidelines from the Cochrane 
Collaboration.  
 
Inclusion criteria 
Randomised and quasi-randomised controlled trials  
comparing the use of a probiotic to no probiotic; or the use 
a specific probiotic compared to a different probiotic; or a 
probiotic with added prebiotic to control. 
 
Intervention 
Probiotics added to human milk or infant formula, added in 
the manufacturing process or given separately compared to 
control (placebo or no treatment) 
 
Participants 
Enterally fed infants in the first six months of life, without 
clinical evidence of allergic disease or food 
hypersensitivity, both with and without risk factors for 
allergy and food hypersensitivity 
 
Results  
 
 N= 12 
 Studies had adequate randomisation, allocation 
 Insufficient evidence to recommend 
the addition of probiotics to infant 
feeds for prevention of allergic 
disease or food hypersensitivity. 
 There was a reduction in clinical 
eczema in infants but this effect was 
not consistent among studies. 
Stellenbosch University  http://scholar.sun.ac.za
Stellenbosch University  http://scholar.sun.ac.za
pg. 23 
concealment and blinding of treatment.  
 Treat finding with caution due to excess losses in 
patient follow-up (17% to 61%).  
 Significant reduction in infant eczema (typical RR 
0.82, 95%CI 0.70, 0.95) but there was significant 
heterogeneity between studies.  
 One study reported the difference in eczema between 
groups persisted to 4 years age. When analysis was 
restricted to trials reporting atopic eczema 
(confirmed by skin prick test or specific IgE), the 
findings were no longer significant (typical RR 0.80, 
95% CI 0.62, 1.02).  
 Studies reporting significant benefits used L. 
rhamnosus and enrolled infants at high risk of allergy.  
 No other benefits were reported for any other allergic 
disease or food hypersensitivity outcome. 
 
Osborn 2013  
[80] 
To determine the effect of prebiotics 
given to infants for the prevention of 
allergic disease or food 
hypersensitivity. 
Methodology 
Review followed guidelines from the Cochrane 
Collaboration.  
 
Inclusion criteria 
Randomised and quasi-randomised controlled trials that 
compared the use of a prebiotic to a control (placebo or no 
treatment); or used a specific prebiotic compared to a 
different prebiotic. 
 
Intervention 
Prebiotics added to human milk or infant formula, whether 
added in the manufacturing process or given separately 
compared to control (placebo or no treatment), or a 
different prebiotic. 
 
Participants: Infants in the first six months of life without 
clinical evidence of allergic disease or food 
hypersensitivity, both with and without 
risk factors for allergic disease. 
 
 Further research is needed before routine 
use of prebiotics can be recommended for 
prevention of allergy in formula fed 
infants.  
 There is some evidence that a prebiotic 
supplement added to infant feeds may 
prevent eczema.  
 It is unclear whether the use of prebiotic 
should be restricted to infants at high risk 
of allergy or may have an effect in low 
risk populations; or whether it may have 
an effect on other allergic diseases 
including asthma. 
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Results  
 N=4 studies 
 No significant difference in infant asthma but 
significant heterogeneity was found between studies.  
 Significant reduction in eczema: typical risk ratio 0.68, 
95% CI 0.48 to 0.97; typical risk difference -0.04, 95% 
CI -0.07 to -0.00; number needed to treat to benefit 
(NNTB) 25, 95% CI 14 to > 100; P = 0.03). No 
significant heterogeneity was found between studies.  
 One study reported no significant difference in 
urticaria. 
 No significant subgroup differences in to infants at risk 
of allergy or type of infant feed.  
 Individual studies reported a significant reduction in 
asthma and eczema from supplementation with a 
mixture of GOS/FOS 9:1 ratio, 8 g/L in infants at high 
risk of allergy 
 Significant reduction in eczema from supplementation 
with GOS/FOS (9:1) (6.8 g/L) and acidic 
oligosacccharide (1.2 g/L) in infants not selected for 
allergy risk. 
 
Srinivasjois 
2013 [86] 
To systematically review 
randomized controlled trials, 
evaluating the safety and efficacy of 
prebiotic oligosaccharide 
supplementation in preterm infants, 
with less than 37 weeks of gestation. 
Methodology 
Guidelines from the Cochrane Neonatal Review group, 
PRISMA Statement, Centre for Reviews and 
Dissemination group were followed for conducting and 
reporting this systematic review. 
 
Inclusion criteria 
Randomised controlled trials and quasi-randomised trials 
published in any language were eligible for inclusion. 
 
Intervention 
Trials comparing formula milk supplemented with 
prebiotic OS vs placebo or un-supplemented formula milk.  
The prebiotic OS could be GOS, FOS, acidic 
 
 Supplementation with prebiotic 
oligosaccharides was safe and did 
not result in decreased incidence of 
NEC, late onset sepsis and time to 
full enteral feeds but resulted in a 
significantly higher growth of 
beneficial microbes. 
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oligosaccharide (AOS), inulin or lactulose. The 
supplementation should be for a minimum of 2 weeks. 
 
Participants 
Preterm infants with gestation < 37 weeks at birth. 
 
Results  
 N=7 
 NEC: pooled RR (95% CI) of 1.24 (0.56 to 2.72), p 
0.23  
 Late onset sepsis: RR (95% CI) 0.81 (0.57 to 1.15) 
 3 trials did not observe any improvement in time to 
enteral feeds post intervention.  
 Statistically significant difference in the growth of 
bifidobacteria in the oligosaccharide group with a 
weighted mean difference of 0.53 (95% CI: 0.33, 
0.73) *106 colonies/g, p < 0.00001.  
 A reduction in stool viscosity and pH was also 
observed.  
 None reported life threatening adverse effects.  
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1.7 Rationale for study 
 
1.7.1 Phase 1: Both systematic reviews on preterm and full term infants 
 
A search of electronic databases, such as Medline, Embase, Scopus, using key term such as “probiotics, 
prebiotics, synbiotics, infants, preterm, premature, full term” reveals numerous studies on infants, using these 
ingredients. As a result, consumers, health care policy makers and providers are overwhelmed with large 
amounts of information on the topic of probiotics and prebiotics. Often, they do not have the time and 
resources to find, assess, interpret this evidence and incorporate it into health care decisions. A systematic 
review helps identify relevant research, assess the evidence, synthesize and present it in an accessible format. 
[91]  
 
The effects of probiotics on premature intestinal microbiota have been varied, and the effects on weight gain 
are mixed. Prebiotic effects on the growth of premature infants also vary; the effects on feed tolerance and 
the risk of NEC in very low birth weight infants are yet to be assessed more closely. With premature infants, 
issues around safety, the risk of invasive infections with probiotic bacteria, optimal strains and dose regimens 
are yet to be examined closely. [40, 90, 92]  
 
Past systematic reviews (published from 2005 to 2009) on the use of probiotics or prebiotics in preterm 
infants focused on the prevention of Necrotizing Enterocolitis and / or sepsis and the impact on diarrhoea. 
[82, 85, 93, 94] These published reviews were on studies that used breastmilk and mixed feeds (formula 
combined with breastmilk). The current reviews on preterm and full term infants focused on infants given 
only infant formula, with a focus on growth and clinical outcomes. The review on preterm infants further 
examined outcomes inadequately addressed by previous reviews, such as the impact of probiotics or 
prebiotics on intestinal permeability and gastrointestinal microbiota. 
 
The combination of probiotics and prebiotics (known as synbiotics) in infant formula is said to ensure the 
survival of probiotics in the synbiotic mixture and stimulate the growth of selected indigenous bacteria. [92, 
95, 96] The superiority of synbiotics compared to either probiotic or prebiotic has not been established. 
However, there is emerging data that the use of synbiotic mixtures leads to favourable health outcomes. The 
current review on full term infants examined the impact of synbiotics on growth, immune and 
gastrointestinal function compared to probiotics and prebiotics. A search of several databases, such as the 
Cochrane library revealed there were no systematic reviews listed on the use of synbiotics in full term 
infants. None of the reviews listed in other electronic databases such as PubMed compared the impact of 
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synbiotics infant formula to either probiotic or prebiotic containing infant formula in full term infants. In 
addition there were no reviews comparing the impact of probiotics to prebiotics in full term infants who were 
not breastfed. 
 
1.7.2 Phase 2: Systematic review: Association between funding source, methodological quality and 
research outcomes 
 
The relationship between financial sponsorship of biomedical research and published outcomes has been 
explored in numerous publications. [97] There is evidence that trials sponsored by industry are more likely to 
report results in favour of the sponsor’s products. This is especially true for the phamaceutical industry. [98 - 
102] A few reviews have explored the impact of funding by the food industry on outcomes of research 
studies. [103, 104] Two nutrition-related, systematic reviews found that industry-sponsored trials were more 
likely to report outcomes favourable to the sponsor. [103, 105] 
 
A sponsors’ financial risk is reduced significantly when only positive outcomes in a research trial are 
reported. This may create biases in design (methodology) and reporting of outcomes in research. In nutrition 
research, this type of bias could adversely affect public health; influence policy formulation; professional 
dietary guidelines; public health interventions design; and regulation of food product health claims. [103] 
 
There was little information available on the impact of funding by the food industry on outcomes and 
methodological quality of probiotic research in infants. This review explored whether financial sponsorship 
by the food industry affected outcomes and methodological quality of published studies on synbiotics, 
probiotics or prebiotics in infants. Methodological quality of studies may be compromised when insufficient 
information is provided regarding sequence generation, allocation concealment, blinding, bias introduced 
from other sources and incomplete outcome reporting. 
 
1.7.3 Phase 2: Descriptive study: Application of evidence by food industry 
 
There was little information about how the food industry applied the knowledge and evidence gained from 
research on probiotics, prebiotics or synbiotics on the general paediatric population. This study explored 
what happens after the research trials using infant formula were completed, and the data published or 
unpublished. Based on the new scientific evidence: did the companies develop and market new probiotic, 
prebiotic or synbiotic containing infant formula, or improve on ones that are already sold on the market? 
There is little or no information on the differences between the study formula and the retailed product. This 
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study tried to ascertain the differences between the two, such as genera of probiotic used with product 
viability at the end of shelf life. 
 
The consumer does not know or understand the meaning of scientific terms such as probiotic, lactobacillus, 
fructooligosaccharide, or inulin. Thus, there is a great need for clear information in a format the consumer 
can understand. It is not clear how the manufacturers of probiotics, prebiotics or synbiotics containing infant 
formula educate the consumers. This study explored the effectiveness and type of medium the infant formula 
manufacturers use to educate the consumers. 
 
World Health Organization(WHO) guidelines on infant formula preparations recommends that water with a 
minimum temperature of 70
0
 C should be used to minimize the risk of infections caused by Enterobacter 
Sakazakii, bacteria found in infant formula. [106, 107] However, two probiotic infant formula brands 
available in the Western Cape, South Africa retail outlets state that using water with temperatures above 40
0
 
C will compromise the natural cultures. This contradiction makes safety an area of concern. In addition, there 
is a lack of published evidence on clinical benefits from long term use of probiotic containing infant formula. 
[63] This study explored how  infant formula companies address the contradiction to the WHO guidelines on 
formula preparation  and safety issues of long term usage of probiotic infant formula. 
 
1.8 Ethics 
 
Ethics approval for the research project was sought from the Human Research Ethics Committee at the 
University of Stellenbosch, Faculty of Medicine and Health Sciences.  
 
Information for the systematic reviews in Phase 1 and 2 consisted of completed RCTs reports that were 
published (unpublished RCTs were provided by the companies). This information was already in the public 
domain, therefore the systematic reviews were exempt from ethical review.  
 
For the descriptive study (survey) in phase 2, the ethical issues considered were: 
 
 Adequate written communication 
Each study participant was to receive a letter of invitation to take part in the study. The letter of 
invitation (in addition to the informed consent form) explained to all aspects of the study to study 
participants: objective, rationale for study, method of data collection, the requirements of a study 
participant and anonymity issues.  
 
 Informed consent 
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Each study participant was expected to sign an informed consent form. The standard informed consent 
form for the University of Stellenbosch was adopted for this study. The informed consent form also had 
information on all aspects of the study.  
 
 Participant confidentiality 
Participant confidentiality was ensured during all stages of the study. During data processing, only 
product and company name were to be used. In the final published report, only a list of participating 
companies was given; and all study participants were to be anonymously acknowledged for contributing 
to the success of the study. The following clause was to be inserted in the published study report to 
thank the participants:  
“We wish to thank all the people who participated in the study. Your insights contributed to the 
successful completion of this study.” 
 
Ethics approval was granted by the Human Research Ethics Committee at the University of Stellenbosch, 
Faculty of Medicine and Health Sciences. Reference numbers: N11/02/135 (for the entire research project) 
and N11/07/203 (for the descriptive study). [See Appendix 1] 
 
1.9 Research questions, objectives, hypotheses. 
The research questions, objectives, null hypotheses and study hypotheses for phase 1 and 2 are listed in 
tables 2 to 4 below: 
 
Table 2. Phase 1: Research questions, objectives and hypotheses for systematic reviews 
 
Phase 1: Systematic Reviews  
General research question 
Does the consumption of probiotics, prebiotics or synbiotics supplemented infant formula lead to 
improved clinical outcomes in infants? 
Objectives 
1. To assess if addition of probiotics, prebiotics and synbiotics to pre- term infant formula led to  
improved growth and clinical outcomes in preterm or low birth weight infants 
2. To determine the effects of infant formula containing probiotics, prebiotics or synbiotics on clinical 
outcomes in full term infants 
3. To explore if synbiotics are superior over probiotics or prebiotics 
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Null Hypothesis 
Consumption of probiotics, prebiotics or synbiotics supplemented formula by infants has no distinct 
advantage over conventional infant formula. 
Study Hypothesis 
Consumption of probiotics, prebiotics or synbiotics supplemented formula leads to improved clinical 
outcomes in infants. 
 
Table 3. Phase 2: Research questions, objectives and hypotheses for systematic review 
 
Phase 2: Systematic review  
General research question 
Is there an association between source of funding and methodological quality, clinical outcomes and 
author’s conclusions in trials using probiotics, prebiotics or synbiotics supplemented formula in 
infants? 
Objectives 
To compare the methodological quality and outcomes of industry sponsored trials versus non industry 
sponsored trials with regards to supplementation of synbiotics, probiotics and prebiotics in infant 
formula.  
Null Hypothesis 
The source of funding has no influence over methodological quality, study outcomes or authors’ 
conclusions in research trials using probiotics, prebiotics or synbiotics supplemented formula in 
infants. 
Study Hypotheses 
1. The source of funding in research trials using probiotics, prebiotics or synbiotics supplemented 
formula in infants is associated with outcomes and authors’ conclusions in favour of the sponsor’s 
products.  
 
2. Methodological qualities of non-industry sponsored trials are equivalent to industry sponsored 
trials. 
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Table 4: Phase 2 Continued: Research questions, objectives and hypotheses for descriptive study 
 
Phase 2 continued: Descriptive study  
General research question 
How does the food industry apply  the evidence gained through probiotics, prebiotics and synbiotics 
research trials on infants for the benefit of the general paediatric population? 
Objective 
To investigate how the infant food industry applies evidence gained through probiotic, prebiotic and 
synbiotic research trials on infants. 
Null Hypothesis 
The food industry does not implement evidence gathered through research trials that use probiotics, 
prebiotics or synbiotics in infants for the benefit of the general paediatric population. 
Study Hypothesis 
 Evidence gathered through research trials that use probiotics, prebiotics and synbiotics in infants is 
implemented by the food industry for the benefit of the general paediatric population. 
 
1.10 Scope of work: 
 
1.10.1 Phase 1: Two systematic reviews and meta-analysis were conducted.  
 
The first systematic review was on pre-term infants given probiotics, prebiotics containing formula. The 
review explored effects of probiotics and prebiotics, on growth and clinical outcomes. All randomized 
controlled trials (RCTs), irrespective of language, comparing pre-term infant formula containing probiotic(s) 
OR prebiotic(s) to conventional pre-term infant formula, with or without placebo amongst preterm infants 
born <37 weeks gestation or low birth weight infants weighing <2.5 kg at birth. All infants were hospitalized 
and receiving formula feeds and / or parenteral feed were considered. 
The second systematic review was on full term infants given probiotics, prebiotics and synbiotics containing 
formula. The review explored the effects of probiotics, prebiotics and synbiotics on growth, and clinical 
outcomes in full term infants The review considered all randomized controlled trials (RCTs), irrespective of 
language, which compared the use of term infant formula containing synbiotics, probiotics or prebiotics to 
conventional infant formula, with or without placebo amongst healthy full term infants (>37 weeks gestation 
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or > 2.5 kg birth weight, age: 0-12 months, with no disease, congenital abnormality, allergy or eczema) 
receiving formula feeds only. 
 
Systematic reviews were conducted using Cochrane methodology. The two review processes were identical 
and began with literature searches in all languages using different electronic databases. RCTs published in 
non-English language journals were translated by independent translators familiar with the subject matter. A 
hand search was conducted on abstracts of major conference proceedings, cross checked references cited in 
RCTs and in recent reviews (published from 2005 to 2009) for additional studies not identified by electronic 
searches and specialty journals not included in any database. Two reviewers independently reviewed all 
abstracts and citations to identify potentially eligible studies. The full reports of eligible studies were 
retrieved and the pre-specified selection criteria applied independently, by two reviewers, using a study 
eligibility form. (See Appendix 2, 4) If more than one publication of a study existed, all reports of the study 
were grouped together under one study name. Any disagreements between the reviewers were resolved 
through discussion, or a third party was consulted. A third party was consulted regarding the eligibility of 8 
studies (4 studies on the systematic review for preterm infants and 4 on the systematic review on full term 
infants). 
 
The inclusion criteria for the systematic reviews included the following: 
1. Study participants: Infants (preterm, low birth weight, full term infants) who were fed formula containing 
synbiotics, probiotics or prebiotics. The infants were: Preterm infants: less than 37 weeks gestation or less 
than 2500 g birth weight. Healthy full term infants: > 37 weeks gestation, age: birth to12 months, birth 
weight > 2.5 kg. 
2. Type of studies: Randomized controlled trials (in all languages) comparing infant formula with probiotics, 
prebiotics or synbiotics to conventional formula, with or without placebo were included 
 
Data was independently extracted by two reviewers using a pre tested data extraction form. (See Appendix 3, 
5) The risk of bias of included studies was assessed according to the Cochrane Handbook for Systematic 
Reviews for Interventions in the following 6 components. 1) sequence generation; 2) allocation concealment; 
3) blinding; 4) incomplete outcome data; 5) selective outcome reporting; and 6) other sources of bias. The 
extracted data were cross-checked and any differences resolved through discussion, or third party 
consultations.  If necessary, trial authors were contacted for missing data, or for clarification on the 
methodology of their studies. Results for probiotic and prebiotic and synbiotic studies were analysed 
separately.  
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For continuous outcomes, the mean difference (MD) and corresponding 95% confidence intervals (CI) were 
calculated. For dichotomous outcomes, the risk ratio (RR) and corresponding 95% CI were calculated. 
Heterogeneity of the trials used in the review was assessed by visually inspecting the forest plots to detect 
overlapping confidence intervals and by performing a chi
2
 test. A p<0.1 was considered statistically 
significant. An I-square test (I
2
) was used to test for inconsistencies across studies. A statistician was 
consulted at every step of the review process. One reviewer drafted the manuscript and other reviewers 
critically reviewed the manuscript before publication. 
 
1.10.2 Phase 2: Two studies were conducted: a systematic review and a descriptive (survey) study 
 
Systematic review 
All randomized controlled trials (RCTs) conducted from 1980 to 2012 (irrespective of language) on 
synbiotics, probiotics, or prebiotics added to infant formula were included. Study participants were healthy 
full term infants (>37 weeks gestation or > 2.5 kg birth weight, 0-12 months old); preterm infants (born < 37 
weeks gestation); low birth weight (<2.5 kg at birth); and extreme low birth weight infants (<1000 g at birth). 
Infants were fed either infant formula (preterm or full term formula); and mixed feeds (breast milk with 
infant formula) with added synbiotics, probiotics or prebiotics, or conventional infant formula, with or 
without placebo. 
 
A literature search regardless of language was conducted on different electronic databases. The search 
strategy was modified for each electronic database. A hand search was conducted on: major conference 
proceeding abstracts; and cross-checked references cited in RCTs and in recent reviews (published from 
2003 to 2012) for additional RCTs. These additional RCTs had not been identified by electronic searches and 
speciality journals which were not included in any database. To identify ongoing and unpublished trials, 
experts in the field and manufacturers of infant formula containing probiotics and prebiotics were contacted; 
web sites of companies that have conducted or were conducting RCTs on probiotics and prebiotics were 
searched. Prospective trial registries were searched. Two reviewers independently reviewed all abstracts and 
citations to identify potentially eligible studies. The full reports of eligible studies were retrieved and the pre-
specified selection criteria applied independently by two reviewers using a study eligibility form. (See 
Appendix 6)  If more than one publication of a study existed, all reports of the study were grouped together 
under one study name. Any disagreements between the reviewers were resolved through discussion or a third 
party was consulted. A third party was consulted regarding the eligibility and data presentation of 4 studies. 
The inclusion criteria for the systematic review included the following: 
1. Types of studies: Randomized controlled trials (irrespective of language) on synbiotics, probiotics, or 
prebiotics added to infant formula published from 1980 – 2012. Study participants: Healthy full term infants, 
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pre-term infants (born < 37 weeks gestation); low birth weight (<2.5 kg at birth); and extreme low birth 
weight infants (<1000 g at birth)  
3. Intervention: The study group was fed infant formula; and mixed feeds (breast milk with infant formula) 
with added synbiotics, probiotics or prebiotics. The control group was fed conventional infant formula with 
or without placebo and without synbiotics, probiotics or prebiotics. 
 
Data was independently extracted by two reviewers using a pre-tested data extraction form designed for this 
review. (See Appendix 7) The risk of bias of included studies was assessed, as described in the Cochrane 
Handbook for Systematic Reviews for Interventions, according to the following 6 components. 1) sequence 
generation; 2) allocation concealment; 3) blinding; 4) incomplete outcome data; 5) selective outcome 
reporting; and 6) other sources of bias. The extracted data, cross checked data and any differences were 
resolved through discussion, or a third party was consulted. Trial authors were contacted for missing data or 
for clarification. A total of 16 authors were contacted, only 3 replied with the requested data: Indrio 2008 
[84], Indrio 2009 [85] and Mihatsch 2006 [90]. 
 
The source of funding or support of the RCTs was defined and categorized as industry, non-industry and 
none. The primary and secondary outcomes from each study report were independently evaluated and 
categorized by two reviewers as positive, negative and neutral. The authors’ overall study conclusion and 
conclusions on reported clinical outcomes were evaluated and categorized as positive, negative, neutral and 
no clear conclusion. All the review outcomes were dichotomous and are described in frequencies and 
percentages. The association between funding source and methodological quality, clinical outcomes and 
author’s conclusions were assessed using both the Pearson’s Chi-square test and the Fisher’s exact test. A 
statistician was consulted at every step of the review process. One reviewer drafted the manuscript and other 
reviewers critically reviewed the manuscript before publication. 
 
Descriptive study 
 
In the descriptive study (a survey), a structured questionnaire developed for the study was used. Companies 
that manufacture and / or market food products with added probiotics, prebiotics or synbiotics for infants and 
children were identified through several electronic databases, such as EBSCOhost, Business Source Premier 
and DATAMONITOR360. Company websites were searched to obtain their contact information. People 
responsible for research and development in the infant food companies were invited to participate in the 
survey, including clinical research managers and individual researchers. The inclusion criteria included only 
companies that manufacture infant formula and baby food that contained probiotics, prebiotics or synbiotics. 
There are few formula manufacturers and infant food companies, so all listed companies were invited to 
participate in the study.  
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A letter of invitation was sent to selected study participants, explaining all aspects of the study. (See 
Appendix 8)  If they expressed willingness to take part in the study, a questionnaire with a written consent 
form was sent to them via post, email or fax. (See Appendix 9, 10) A maximum of four reminders were 
given to the participants to complete the questionnaire. Due to the expected small sample size, maintaining 
anonymity of study participants with the corresponding company name was difficult. Therefore, data 
processing was done according to product and company name. During report writing, all identifying details 
(name of study participant, product and company name) were excluded. Only the researcher and statistician 
had access to the data. 
 
The questionnaire sent to companies focused on product specific questions, research-based questions, 
consumer education and safety issues. The questionnaire was validated for content by sending it to experts in 
the field of probiotics, prebiotics, infant nutrition and experience in research. The experts reviewed the study 
protocol, consent form and questionnaire. They then gave feedback on how to adopt the questionnaire in 
order to meet the study objectives. These experts did not participate in the study nor were they associated 
with the infant food industry. Data was entered into SPSS (Statistical Program for Social Sciences) for 
analysis. Descriptive statistics were used and associations between categorical variables tested using a Chi-
square test. A p<0.05 was considered statistically significant. A statistician was consulted at every step of the 
study process. One author drafted the manuscript and other authors critically reviewed the manuscript before 
publication.  
 
1.10.3 Exclusion criteria of research project 
 
This research project excluded (both in Phase 1 and 2) the following: 
1. Publications that were not RCTs such as commentaries, editorials, letters to the editor and studies that 
were not RCTs 
2. Randomized controlled trials which included: 
a. Infants with cardiac defects, pulmonary diseases, gastrointestinal diseases, major congenital abnormalities, 
chromosomal abnormalities or received other types of milk such as cow, buffalo, goat milk  
b. Children above 1 year of age 
c. Comparisons of synbiotic containing preterm infant formula to conventional preterm formula. At the 
drafting of protocol for this study and conducting of systematic reviews, there were no trials that had tested 
the use of synbiotics in preterm infants. Therefore the trials could not be included in the reviews, nor the 
effects of synbiotics on preterm infants be evaluated. 
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1.11 Chapter overviews 
 
1.11.1 Chapter 2  
 
Probiotics, prebiotics infant formula use in preterm or low birth weight infants: a systematic review 
 
Chapter 2 is a systematic review and meta-analysis of preterm infants given probiotics and prebiotics 
containing formula; and was conducted using Cochrane methodology. The review explored the effects of 
probiotics and prebiotics on growth; and clinical outcomes not adequately addressed by previous reviews.  
The RCTs which were used compared preterm formula containing probiotic(s) OR prebiotic(s) to 
conventional preterm formula, in preterm infants. A total of eight studies were included and 27 studies were 
excluded.  
 
Primary outcomes included short term growth parameters: weight gain (grams/day or grams/week); linear 
growth (centimeters/week) and head growth (cm/week). Secondary outcomes included complications: 
Incidence of NEC, sepsis, other infections and mortality / death. Adverse events during entire study duration: 
number of days on parenteral; number of days to full enteral nutrition; and maximal enteral feed 
(millilitres/day, millilitres/kilogram/day, millilitres /kilogram). Feed intolerance: of vomiting, gastric 
aspirates and abdominal distension incidences. Stool characteristics: stooling frequency and stool consistency 
as firm, loose or watery. Changes in intestinal permeability as measured by ratio of lactulose / mannitol in 
urine or other sugar absorption tests (such as lactulose / L – rhamnose ratio, D- xylose, 3-Ο- methyl-D- 
glucose tests). Gastrointestinal (GI) micro flora: number of colony forming units (cfu) of bifidobacteria, 
lactobacillus and pathogens post intervention. 
 
This systematic review has been published in Nutrition Journal and is cited as:  
Mugambi MN, Musekiwa A, Lombard M, Young T, Blaauw R. Probiotics, prebiotics infant formula use 
in preterm or low birth weight infants: A systematic review. Nutr J 2012, 11:58 doi:10.1186/1475-2891-
11-58 
 
Involvement of the PhD candidate:  
 
For this systematic review, the PhD candidate: 
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 developed and edited the protocol 
 sought ethics approval before commencement of study 
 developed study materials (study eligibility and data extraction form) 
 identified studies by: conducting literature searches using electronic databases;  hand search of 
conference proceedings; crossed-checked references cited in RCTs and systematic reviews 
  contacted experts in the field for unpublished studies 
 screened and selected RCTs using a study eligibility form  
 extracted data  using a data extraction form 
 assessed risk of bias in included studies, as described in the Cochrane Handbook for Systematic 
Reviews for Interventions 
 analysed data  using Review Manager (RevMan 5) and interpreted results (later verified by 
statistician) 
 developed, edited and critically reviewed the study manuscript for publication. 
 
For this systematic review, the second reviewer: 
 identified studies by: conducting literature searches using electronic databases;  hand search of 
conference proceedings; crossed-checked references cited in RCTs and systematic reviews 
  screened and selected RCTs using a study eligibility form  
 extracted data  using a data extraction form 
 assessed risk of bias in included studies, as described in the Cochrane Handbook for Systematic 
Reviews for Interventions 
 critically reviewed the study manuscript for publication. 
 
1.11.2 Chapter 3 
 
Synbiotics, probiotics or prebiotics in infant formula for full term infants: a systematic review. 
 
Chapter 3 is a systematic review and meta-analysis of full term infants given probiotics, prebiotics or 
synbiotics containing infant formula; and focused on growth and clinical outcomes. The Cochrane 
methodology was also followed, using randomized controlled trials (RCTs), which compared term infant 
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formula containing probiotics, prebiotics or synbiotics to conventional infant formula with / without placebo, 
among healthy full term infants. A total of 25 studies were included. 
 
Primary outcomes were: growth changes (assessed for entire study duration): weight gain (g/day); linear 
growth (cm/week, mm/month); and head growth (cm/week, mm/month).                                           
Secondary outcomes were: tolerance to formula.                                                                                          
Stool characteristics were: frequency, consistency, diarrhoea.                                                                  
Gastrointestinal symptoms were: colic incidences; spitting up/regurgitation, vomiting, crying and average 
formula intake (mls/day).                                                                                                                       
Infections: frequency and type of infections; use of medication (antibiotic intake);                          
Hospitalization: Number of days in hospital.                                                                                             
Changes in GI microflora: Changes in colony forming units (cfu/g of stool) of bifidobacteria, lactobacillus 
post intervention, colony forming units (cfu/g of stool) of pathogens post intervention.                                                                                                                                                           
Immune response: C- reactive protein levels (mg / dl), Interleukin 6 (IL-6) levels (mg/dl). 
 
This systematic review has been published in Nutrition Journal and is cited as:  
Mugambi MN, Musekiwa A, Lombard M, Young T, Blaauw R. Synbiotics, probiotics or prebiotics in 
infant formula for full term infants: A systematic review. Nutr J 2012, 11:81 doi:10.1186/1475-2891-11-
81 
 
Involvement of the PhD candidate:  
 
For this systematic review, the PhD candidate: 
 developed and edited the protocol 
 sought ethics approval before commencement of study 
 developed study materials (study eligibility and data extraction form) 
 identified studies by: conducting literature search using electronic databases, hand search of 
conference proceedings, crossed-checked references cited in RCTs and systematic reviews 
  contacted experts in the field for unpublished studies 
 screened and selected RCTs using a study eligibility form  
 extracted data using a data extraction form 
 assessed risk of bias in included studies, as described in the Cochrane Handbook for Systematic 
Reviews for Interventions 
Stellenbosch University  http://scholar.sun.ac.za
pg. 39 
 analysed data  using Review Manager (RevMan 5) and interpretated results (later verified by 
statistician) 
 developed, edited and critically reviewed the study manuscript for publication. 
 
For this systematic review, the second reviewer: 
 identified studies by: conducting literature searches using electronic databases;  hand search of 
conference proceedings; crossed-checked references cited in RCTs and systematic reviews 
  screened and selected RCTs using a study eligibility form  
 extracted data  using a data extraction form 
 assessed risk of bias in included studies, as described in the Cochrane Handbook for Systematic 
Reviews for Interventions 
 critically reviewed the study manuscript for publication. 
 
1.11.3 Chapter 4 
 
Associations between funding source, methodological quality and research outcomes in randomized 
controlled trials of synbiotics, probiotics and prebiotics added to infant formula:  A Systematic Review  
 
Chapter 4 is a systematic review exploring whether financial sponsorship by the food industry affected 
outcomes and methodological quality of published studies on synbiotics, probiotics or prebiotics used in 
infants. Cochrane methodology was used to assess the risk of bias of included studies in sequence 
generation, allocation concealment, blinding, incomplete outcome data, selective outcome-reporting and 
other sources of bias. From each trial, the primary and secondary outcomes, overall study conclusion and 
conclusions on outcomes were evaluated and categorized as positive, negative or neutral. Associations 
among funding source, bias risk, clinical outcomes and outcomes conclusions were evaluated. 
 
Outcomes included funding source, methodological quality (risk of bias), clinical RCTs outcomes, author’s 
conclusions (overall study conclusion) and conclusions on clinical outcomes. In addition, outcomes included 
the associations among funding source and methodological quality, clinical outcomes, author’s conclusions 
and conclusions on clinical outcomes. A total of 67 studies were included. 
 
This systematic review has been published in journal called BMC Medical Research Methodology and is 
cited as:  
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Mugambi MN, Musekiwa A, Lombard M, Young T, Blaauw R. Association between funding source, 
methodological quality and research outcomes in randomized controlled trials of synbiotics, probiotics 
and prebiotics added to infant formula: A systematic review. BMC Med Res Methodol. 2013, 13 (1) 
Article number 137 
 
Involvement of the PhD candidate:  
 
For this systematic review, the PhD candidate: 
 developed and edited the protocol  
 sought ethics approval before commencement of study 
 developed study materials (study eligibility and data extraction form) 
 identified studies by: conducting literature search using electronic databases, hand search of 
conference proceedings, crossed-checked references cited in RCTs and systematic reviews 
  contacted experts in the field for unpublished studies, 
 screened and selected RCTs  
 extracted data  using a pretested data extraction form 
 assessed  bias risk in included studies, as described in the Cochrane Handbook for Systematic 
Reviews for Interventions 
 Analysed data  using the SPSS version 19 and interpretation of results (later verified by statistician) 
 developed, edited and critically reviewed the study manuscript for publication. 
 
For this systematic review, the second reviewer: 
 identified studies by: conducting literature search using electronic databases, hand search of 
conference proceedings, crossed-checked references cited in RCTs and systematic reviews 
 screened and selected RCTs  
 extracted data  using a pretested data extraction form 
 assessed  bias risk in included studies, as described in the Cochrane Handbook for Systematic 
Reviews for Interventions 
 critically reviewed the study manuscript for publication. 
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1.11.4 Chapter 5 
 
Application of evidence on probiotics, prebiotics and synbiotics by food industry: A descriptive study. 
 
Chapter 5 is a descriptive study (survey).The aim was to determine how the food industry applied the 
evidence gained through probiotic(s), prebiotic(s) and synbiotic(s) research on infants. A survey was 
conducted on companies manufacturing and / or marketing food products with added probiotics, prebiotics or 
synbiotics for infants. 
 
The survey aimed to determine the following: 
Application of evidence: Did new research evidence result in new infant formula products? What are the 
differences in study and retailed infant formula, what is the frequency of research using probiotics, prebiotics 
or synbiotics containing infant formula? 
Publication of results: Did companies intentionally NOT publish study results viewed as: negative, or having 
no clinical benefit for infants? Was new research conducted to confirm the perceived negative results? 
Medium for consumer education: What type and how effective was the medium used to educate the 
consumer? Was there a presence of bias in promoting formula feeding more than breastfeeding? 
Compliance to WHO guidelines: How do companies comply with WHO guidelines on formula preparation 
with a focus on high water temperature and its effect on prebiotic, synbiotic containing infant formula? 
Safety of long term use of probiotic or synbiotic containing infant formula: How do companies address safety 
in the context of there being little published evidence on the clinical benefits of long term consumption of 
probiotic containing formula (longer than 1 year)? 
Product viability:  Does formula remain viable throughout storage, or are there substantial changes in the 
number of colony forming units at the end of shelf life? 
How companies keep abreast of the latest research on probiotics, prebiotics and synbiotics in infant formula 
and weaning foods: Do the formula companies have staff designated to track research, or is this on “ad hoc” 
basis? 
 
A total of 25 major infant formula and baby food manufacturers were identified and invited to participate in 
this survey. No company agreed to participate in the survey for various reasons.  
 
This descriptive study was submitted for publication to the journal titled BMC Research Notes on October 
11
th
 2013 and is currently under peer review and is titled: 
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Mugambi MN, Young T, Blaauw R. Application of evidence on probiotics, prebiotics and synbiotics by 
food industry: A descriptive study 
 
 
Involvement of the PhD candidate:  
 
For this descriptive study, the PhD candidate did the following: 
 developed and edited the protocol 
 sought ethics approval before commencement of study 
 developed study materials (letters of invitation to participate in study, questionnaire, informed 
consent form) 
 identified formula companies through electronic databases 
 acquired contact information through company websites 
 extended invitations to study participants in all listed companies to participate in study 
 dialogued with study participants and sent them study materials after they expressed willingness to 
participate  
 developed, edited and critically reviewed the study manuscript for publication. 
 
1.11.5 Chapter 6 
 
Conclusion and recommendations chapter 
Chapter 6 is a conclusion chapter which includes: a summary of findings of all the individual studies, 
limitations, conclusions from the different studies, an overall thesis conclusion, the summary of 
contributions, implications for practice and recommendations for further research in the field of probiotics, 
prebiotics and synbiotics in formula fed infants. 
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Probiotics, prebiotics infant formula use in 
preterm or low birth weight infants: a systematic 
review 
Mary N Mugambi1*, Alfred Musekiwa2,3, Martani Lombard1, Taryn Young3  and Reneé Blaauw1 
 
Abstract 
Background: Previous reviews (2005 to 2009) on preterm infants given probiotics or prebiotics with breast milk or 
mixed feeds focused on prevention of Necrotizing Enterocolitis, sepsis and diarrhea. This review assessed if 
probiotics, prebiotics led to improved growth and clinical outcomes in formula fed preterm infants. 
Methods: Cochrane methodology was followed using randomized controlled trials (RCTs) which compared preterm 
formula containing probiotic(s) or prebiotic(s) to conventional preterm formula in preterm infants. The mean 
difference (MD) and corresponding 95% confidence intervals (CI) were reported for continuous outcomes, risk ratio 
(RR) and corresponding 95% CI for dichotomous outcomes. Heterogeneity was assessed by visual inspection of 
forest plots and a chi2  test. An I2  test assessed inconsistencies across studies. I2> 50% represented substantial 
heterogeneity. 
Results: Four probiotics studies (N=212), 4 prebiotics studies (N=126) were included. Probiotics: There were no 
significant differences in weight gain (MD 1.96, 95% CI: -2.64 to 6.56, 2 studies, n=34) or in maximal enteral feed 
(MD 35.20, 95% CI: -7.61 to 78.02, 2 studies, n=34), number of stools per day increased significantly in probiotic 
group (MD 1.60, 95% CI: 1.20 to 2.00, 1 study, n=20). Prebiotics: Galacto-oligosaccharide / Fructo-oligosaccharide 
(GOS/FOS) yielded no significant difference in weight gain (MD 0.04, 95% CI: -2.65 to 2.73, 2 studies, n=50), 
GOS/FOS yielded no significant differences in length gain (MD 0.01, 95% CI: -0.03 to 0.04, 2 studies, n=50). There 
were no significant differences in head growth (MD −0.01, 95% CI: -0.02 to 0.00, 2 studies, n=76) or age at full 
enteral feed (MD −0.79, 95% CI: -2.20 to 0.61, 2 studies, n=86). Stool frequency increased significantly in prebiotic 
group (MD 0.80, 95% CI: 0.48 to 1.1, 2 studies, n=86). GOS/FOS and FOS yielded higher bifidobacteria counts in 
prebiotics group (MD 2.10, 95% CI: 0.96 to 3.24, n=27) and (MD 0.48, 95% CI: 0.28 to 0.68, n=56). 
Conclusions: There is not enough evidence to state that supplementation with probiotics or prebiotics results in 
improved growth and clinical outcomes in exclusively formula fed preterm infants. 
Keywords: Probiotic, Prebiotic, Preterm infant, Low birth weight infant 
 
Background 
Growth is a major challenge for premature and low birth 
weight infants (born < 37 weeks gestation or with a birth 
weight of < 2500 g). They have several factors that put 
them at risk for nutritional deficiencies resulting in poor 
growth. Decreased nutrient stores result in low body 
stores of glycogen, fat, protein, fat soluble vitamins, cal- 
cium,   phosphorus,   magnesium   and   trace   minerals. 
Preterm infants require increased  energy  and  nutrients 
for rapid growth and may need a 10 fold increase in 
weight gain in order to achieve optimum catch up 
growth [1,2]. To achieve optimum growth for the pre- 
term infant, the goals are to continue the process of 
intra-uterine growth in an extra-uterine environment 
until 40 weeks post conception, foster catch-up growth 
and nutrient accumulation in the post discharge period 
   [3-6]. A weight gain of 15 to 20 g/ kg/day, length of 0.75 
* Correspondence: nkmugambi@hotmail.com 
1Division of Human Nutrition, Faculty of Medicine and Health Sciences, 
Stellenbosch University, P.O Box 19063, Tygerberg 7505, South Africa 
Full list of author information is available at the end of the article 
to 1.0 cm/week and head circumference 0.75 cm/week is 
required. This is difficult to achieve and requires be- 
tween 130 – 135 kcal / kg /day to maintain this growth 
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rate [3]. Furthermore, infants lose weight after birth (up 
to 6% to 8% for extreme low birth weight infants) and 
they often do not regain the weight for up to  1  to  2 weeks 
[5]. Daily growth monitoring (weight gain, linear and 
head circumference) then becomes vital. 
Preterm infants have immature physiological systems 
due to an underdeveloped gastrointestinal barrier func- 
tion as reflected by increased intestinal permeability. As 
a result, potentially pathogenic bacteria translocate from 
the intestinal lumen and cause systemic infections [7]. 
Reducing intestinal permeability is associated with gut 
maturation which promotes growth and avoids severe 
infections [4]. In addition, digestive and absorptive cap- 
abilities are decreased due to low concentration of lac- 
tase, pancreatic lipase and bile salts. Gastrointestinal 
motility and stomach capacity are decreased which limits 
feeding volume and gastric emptying. A coordinated 
suck and swallow is not developed until 32 to 34 weeks 
gestation. Introduction of enteral feeding maybe delayed 
due to increased risk of aspiration [1,2,8,9]. Preterm 
infants in neonatal intensive care units (NICUs) develop 
a different intestinal microbiota compared to healthy 
breast fed infants. This is due to decreased exposure to 
the maternal microbiota, increased exposure to organ- isms 
that colonize NICUs, multiple courses of antibiotics and 
delays in feeding [8,9]. 
Humans have consumed probiotics in the form of fer- 
mented food, dairy products and more  recently  infant and 
toddler formula. Probiotics are defined as “live 
microorganisms” which when administered in adequate 
amounts confer a health benefit to the host  [10].  The main 
probiotic organisms used worldwide belong to the genera 
Lactobacillus and Bifidobacteria and are found in the 
gastrointestinal micro flora [10,11]. Prebiotics are found 
in fruit and vegetable components, they are non- 
digestible food ingredients that benefit the host by se- 
lectively stimulating the growth and/or activity of one or 
a limited number of bacteria in the colon and improving 
the host’s health [12,13]. The most widely studied pre- 
biotics are inulin, fructo-oligosaccharide (FOS) and 
galacto-oligosaccharide (GOS) which are plant storage 
carbohydrates in vegetables, cereals and fruit. FOS and 
inulin are added to different foods as fat and sugar repla- 
cements to improve texture or for their functional bene- 
fits [12,14-16]. Probiotics and prebiotics are added to 
infant formula to promote an intestinal microbiota re- 
sembling that of breastfed infants which have a greater 
concentration of bifidobacteria and less pathogenic bac- 
teria than formula fed infants [10,17]. 
There are a number of ways in which probiotics im- 
prove health. Health benefits conferred by probiotic bac- 
teria are strain specific and not species or genus specific 
[10]. Probiotic bacteria improve health by affecting the 
immune   system   in   different   ways.   They   increase 
cytokine production such as Interleukin-6 (IL-6), 
Interferon- gamma (IFN-γ), Tissue Necrosis Factor – 
alpha (TNF-α), Interleukin-1beta (IL-1β) and Interleukin-
10 (IL-10) [18]. Some strains increase phago- cytic 
activity of peripheral blood leukocytes (monocytes, 
polymorphonuclear cells). Other strains strengthen the 
mucosal barrier function  by  promoting  the  production of 
mucosal antibodies and reducing the trans mucosal transfer 
of antigens. This reduces the intestinal perme- ability 
which in turn promotes growth [19-22]. Probio- tics 
bacteria also enhance production of low molecular 
weight antibacterial substances produced by epithelial 
cells and production of short chain fatty acids, the main 
energy source for colonocytes. This maintains the integ- 
rity of colon mucosa [19,23-26]. 
Prebiotics are resistant to digestive enzymes and pH 
extremes found in the  human gastrointestinal tract. 
They transit through the upper gastrointestinal tract and 
reach the colon intact where they are selectively fermen- 
ted by indigenous bacteria, especially bifidobacteria and 
lactobacilli [12,15,26,27]. Beneficial bacteria (including 
bifidobacteria and lactobacilli) possess enzymes needed 
to metabolize prebiotics, while other bacteria (such as E 
coli, clostridia and salmonella) do not [15,27]. Consump- 
tion of prebiotics by preterm formula fed infants results 
in an increase of beneficial microorganisms in the colon, 
decreasing harmful bacteria to the levels found in breast- 
fed infants. This improves the gastrointestinal mucosal 
barrier (decreasing intestinal permeability) which pre- 
vents infections and eventually results in improved 
growth [27,28]. In general the aim of adding probiotics 
and prebiotics to preterm infant formula is to improve 
growth, development and decrease infections by promot- 
ing an intestinal microbiota resembling that of breastfed 
infants [9,29,30]. 
The effects of probiotics on the intestinal microbiota of 
premature infants have been varied due to differences on 
gestational age and products administered. Effects of 
probiotics on weight gain have also been varied. Admin- 
istration of Bifidobacteria breve led to improved weight 
gain while Saccharomyces bourladii did  not [9].  With 
premature infants optimal strains and dose regimens are 
yet to be examined closely [8]. The effects of prebiotics 
on the growth of premature infants are not clear. If pre- 
biotic supplementation reduces the risk of Necrotizing 
Enterocolitis (NEC) or improves feed tolerance in very 
low birth weight infants is yet to be established [8,9]. Re- 
cent systematic reviews (published from 2005 to 2009) 
on the use of probiotics or prebiotics in preterm infants 
have focused on prevention of NEC and / or sepsis, im- 
pact on diarrhea [31-34]. These reviews focused on stud- 
ies that used breast milk and mixed feeds (formula 
combined with breast milk). This review included infants 
given only infant formula and focused on growth with 
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clinical outcomes that were not adequately addressed by 
previous reviews. 
The Human Research Ethics Committee at the Univer- 
sity of Stellenbosch, South Africa reviewed the review 
protocol (unpublished), ruled that all data to be col- 
lected for this review was from the public domain and 
was therefore exempt from ethical approval. 
 
Objective 
To assess if addition of probiotics or prebiotics to pre- 
term infant formula led to improved growth and clinical 
outcomes in preterm or low birth weight infants. 
 
Methods 
Eligibility criteria 
All randomized controlled trials (RCTs), irrespective of 
language, which compared the use of preterm infant for- 
mula containing probiotic(s) or prebiotic(s) to  conven- 
tional preterm infant formula without or with placebo 
amongst preterm infants born <37 weeks gestation, low 
birth weight infants with <2.5 kg at birth and hospita- 
lized, receiving formula feeds and / or parenteral feed 
were considered. Studies published as abstracts were 
included if sufficient information could be obtained to 
assess study quality and obtain relevant study findings. 
 
Outcome measurements 
Primary outcomes included: Short term growth para- 
meters (assessed for entire study duration approximately 
4 weeks): weight gain (grams/day or grams/week), linear 
growth (centimeters/week), head growth (cm/week). Sec- 
ondary outcomes included: Complications: Incidence of 
NEC (defined as suspected  or confirmed positive Bell 
stage II or more), Sepsis (defined as signs or symptoms 
of infection and positive blood culture), Other infections 
(example bacteraemia defined as blood cultured positive 
for bacteria), Mortality / death. Adverse events during 
entire study duration: Number of days on parenteral, 
number of days to full enteral nutrition, maximal enteral 
feed  (millilitres/day,  millilitres/kilogram/day,  millilitres 
/kilogram). Feed intolerance: Incidence of vomiting, gas- 
tric aspirates, abdominal distension. Stool characteristics: 
Stooling frequency and stool consistency as firm, loose 
or watery. Changes in intestinal permeability as mea- 
sured by ratio of Lactulose / mannitol in urine or other 
sugar absorption tests (such as lactulose / L – rhamnose 
ratio, D- xylose, 3-O2- methyl-D- glucose tests). Gastro- 
intestinal (GI) micro flora: number of colony forming units 
(cfu) of bifidobacteria, lactobacillus and pathogens post 
intervention). 
 
Search method for identification of studies 
A literature search  in all  languages was conducted on 
electronic   databases   which   included   The   Cochrane 
Table 1 Search strategy used in PUBMED 
1) Search (probiotic* OR prebiotic*) AND (infant formula* OR infant 
feeding OR formula OR formula milk) AND (preterm or 
premature or low birth weight babies) AND (randomized 
controlled trial* 
OR controlled clinical trial* OR random allocation*) Limits: Human 
2) Search (probiotic* infant formula* OR prebiotic* infant formula* 
OR prebiotic* OR probiotic*) AND (infant formula* OR infant 
feeding) AND (premature OR preterm) AND (randomized 
controlled trial* OR controlled clinical trial OR random 
allocation* OR double blind method OR single-blind method 
OR clinical trial OR placebo* OR random* OR research design 
OR comparative study OR follow-up studies OR prospectiv* OR 
volunteer* OR control* (singl* OR doubl* OR trebl* OR tripl*) 
NEAR (blind* OR mask*) Limits: Human 
 
 
Central Register for Controlled Trials 2009, Scopus 
(1990 to 19/01/2010), EBSCO host (1960 to 15/11/ 
2009), OVID (1950 to 01/12/2009), SPORT Discus (1960 
to 19/01/2010), Web of Science (1970 to 19/01/2010), 
Science Direct (1950 to 30/11/2009), EMBASE (1980 to 
01/12/2009), CINAHL (1981 to 19/01/2010), PUBMED / 
MEDLINE (1966 to 10/04/2010), Latin American Carib- 
bean Health Sciences literature (LILACS), (1965 to 19/ 
01/2010), NLM Gateway (1950–1966). RCTs published 
in non-English language journals were translated by in- 
dependent translators who were familiar with the subject 
matter. The search strategy used to search PUBMED is 
shown on Table 1. This search strategy was modified to 
search other electronic databases. 
We conducted a hand search on abstracts of major 
conference proceedings such as the Pediatric Academic 
Society meetings (www.pas-meetings.org, www.abstracts2- 
view.com), cross checked references cited in RCTs and in 
recent reviews (published from 2005 to 2009) for additional 
studies not identified by electronic searches and specialty 
journals which were not included in any database such as 
Pediatrika, Chinese Journal of Microecology and Inter- 
national Journal of Probiotics and Prebiotics. 
To identify on-going and unpublished trials, we con- 
tacted experts in the field, manufacturers of infant for- 
mula containing probiotics and prebiotics, we searched 
web sites of companies that have conducted or were 
conducting RCTs on  probiotics  and  prebiotics  e.g. 
Pfizer (www.pfizerpro.com/clinicaltrials), Chris Hansen 
Laboratory (www.chr-hansen.com/research_development/ 
documentation.html). We also searched prospective trial 
registries such as World Health Organisation (WHO) 
International Clinical Trials Registry Platform Search Por- 
tal (www.who.int/trialsearch), Clinical Trials.gov register 
(www.clinicaltrials.gov), Current Controlled Trials meta 
Register of Controlled Trials [mRCT] (www.controlled- 
trials.com/mrct) and www.clinicaltrialresults.org. 
 
 
Selection of studies 
Two reviewers (MM, ML) independently reviewed all 
abstracts,  citations  and  identified  potentially  eligible 
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studies. The full reports of eligible studies were retrieved 
by one reviewer (MM) and the pre-specified  selection 
criteria applied independently by two reviewers (MM, ML) 
using a study eligibility form. (Figure 1) If more than 
one publication of a study existed, all reports of the 
study were grouped together under one study  name. Any 
disagreements between the reviewers were resolved 
through discussion. If disagreements could not be resolved 
a third party was consulted. Trial authors were contacted 
if eligibility was unclear. 
 
 
Figure 1 Study eligibility form. 
Review title:
Study ID (Author last name, initials)
Refworks ID number
Date of review for eligibility (DD-MM-YYYY)
Journal title
Title of study/article
Year/volume/issue/page
Extractor (Last name, initials)
Type of study
Is this study a Randomized controlled study? YES UNCLEAR NO
Exclude
Trial intervention
Preterm infant formula containing probiotic(s) YES UNCLEAR NO
Preterm infant formula containing prebiotic(s) YES UNCLEAR NO
Conventional preterm formula / placebo
Exclude
Study Participants
Premature infants <37 weeks gestation YES UNCLEAR NO
Low birth weight infants < 2.5 kg at birth YES UNCLEAR NO
Exclude
Study Outcomes ( >1 outcomes below)
Short term growth parameters (Wt, Ht, Hd Circum) YES UNCLEAR NO
Adverse events (# days on parenteral, full enteral 
nutrition, maximal enteral feed, vomiting, GI aspirates, 
abdomen distension, stool characteristics- consistency, 
frequency) YES UNCLEAR NO
Complications (NEC, Sepsis, other infection, death) YES UNCLEAR NO
Intestinal permeability YES UNCLEAR NO
YES UNCLEAR NO
Other reasons for excluding study NO Yes
Final decision Include Unclear Exclude
For 
discussion
GI Microflora (Bifidobacteria, Lactobacillus, pathogen cfu)
Go to next question
Put a check (√ ) mark in appropriate box.
Comments
STUDY ELIGIBILITY FORM
Probiotic, prebiotics infant formula use in preterm or low birth 
weight infants: A systematic review
Clarify missing information
Go to next question
Go to next question
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Assessment of quality of evidence 
Two reviewers (MM, ML) independently assessed  the risk 
of bias of included studies as described in the Cochrane 
Handbook for Systematic Reviews for Inter- ventions 
according to the following 6 components. 1) se- quence 
generation;  2) allocation concealment;  3) blinding; 4) 
incomplete outcome data; 5) selective out- come 
reporting; and 6) other sources of bias [35]. Where 
necessary, trial authors were contacted for clarification 
on the methodology of their studies. Any disagreements 
regarding risk of bias were resolved through discussion 
between MM, ML and RB. 
 
Data extraction and management 
Two reviewers (MM, ML) independently extracted data 
using a pre tested data extraction form. The reviewers 
(MM, ML) cross checked data and resolved any differ- 
ences through discussion. One reviewer (MM)  entered the 
data in Review Manager (RevMan 5) and the other 
reviewer (ML) validated the data. Trial authors were 
contacted for missing data or for clarification. 
 
Data synthesis and management 
Results for probiotic and prebiotic studies were analysed 
separately. For continuous outcomes the mean differ- ence 
(MD) and corresponding 95% confidence intervals (CI) 
were calculated. For dichotomous outcomes,  the risk 
ratio (RR) and corresponding 95% CI were calcu- lated. 
Trial authors were contacted if there was missing data in 
their reports. Available case analysis was used where 
there was missing data. The potential impact of the 
missing data on the results of the review is addressed in 
the discussion section. Heterogeneity of the trials used in 
the review was assessed by visually inspecting the for- est 
plots to detect overlapping confidence intervals and 
by performing a chi
2 
test. A p<0.1 was considered statis- 
tically significant. An I-square test (I
2
) was used to test 
for inconsistencies across studies. If the I
2 
exceeded 50% 
and visual inspection of the forest plot supported these 
results, this represented substantial heterogeneity. 
If the included studies were not clinically diverse and 
had similar outcome  measures, a Meta -  analysis was 
carried out in Review Manager software (RevMan 5) by 
one review author (AM). For continuous data, if hetero- 
geneity was low, an inverse variance fixed-effect method 
was used. If heterogeneity was high, an inverse variance 
random-effects method was used. For dichotomous data, 
if heterogeneity was low, a Mantel-Haenszel fixed-effects 
method was used. If heterogeneity was high, a Mantel- 
Haenszel random-effects method was used. The source 
of heterogeneity was explored through subgroup analysis 
with respect to the type of intervention. If studies were 
too diverse, no Meta-analysis was conducted and a nar- 
perform sensitivity analysis with respect to study quality 
in order to investigate the robustness of our findings but 
this could not be done mainly because most of the 
meta-analysis had too few studies (mostly two) to war- 
rant sensitivity analysis. In some cases, all the studies in 
the meta-analysis had similar study quality thus render- 
ing sensitivity analysis inappropriate. 
 
Results 
Results of the search and description of studies 
Electronic search of available databases yielded 151 cita- 
tions. After reading titles, abstracts, the duplicate reports 
were removed and 35 potentially relevant articles were 
identified. A hand search yielded 4 more articles. The 
full text reports were retrieved and reviewed for eligibil- 
ity. One study was published in two other reports. The 
three studies were considered as  one  study since they 
reported the same identical study and are referred to as 
Boehm  2002  in  this  review  [36-38].  Eight  published 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Process followed in the selection of studies. 
rative  synthesis  was  provided.  We  had  intended  to    
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Table 2 Excluded studies with reasons for exclusion 
Reasons for exclusion of studies  
Use of breast milk or mixed feeds No use of Follow up - Duplicate Different Type of feed 
(breast milk and formula) probiotic, 
prebiotic 
study, 
Not RCT 
publishing inclusion criteria 
and outcomes 
unspecified 
Agarwal 2003 [52]    Lin H-C 2008 [53]    Riskin 2009 [54] Andrews 1969 [55]   Chou I-C 2009 [56]   Stansbridge 
1993 [57] 
Cukrowska 
2002 [58] 
Karvonen 
2002 [51] 
Bin-Nun 2005 [59]       Manzoni 2006 [60]   Rouge 2009 [61] Taylor 2009 [62] Hoyos 1999 [63] Wang 2007 [64] 
Dani 2002 [65] Millar 1993 [66] Samanta 2005 [67] Lidesteri 2003 [68] 
Kitajima 1997 [69]      Mohan 2006 [70] Westerbeek 2008 [71] 
Lee 2007 [72] Mohan 2008 [73] Westerbeek 2010 [74] 
Lin H-C 2005 [75]         Patole 2005 [76] Yong Gu 2009 [77] 
 
studies (four probiotic and four prebiotic studies) [36,39-
45] and  five  on-going studies  were included  in this 
review [46-51]. The process followed is shown in 
Figure 2. Table 2 gives a list of 27 studies which were 
excluded for: use of breast milk or mixed feeds (18 stud- 
ies), no use of probiotic or prebiotic (2 studies), being a 
follow –up study, not RCT (3 studies), duplicate publish- 
ing  (1  study);  using  different  inclusion  criteria  with 
 
Table 3 A summary of four included probiotic studies 
 Costalos 2003 [39] Indrio 2008 [42] Reuman 1986 [41] Stratiki 2007 [40] 
Location of study Athens, Greece University of Bari, Policinico, 
Italy 
Gainesville, Florida, USA Alexandra Regional 
Hospital, Greece 
Participants - 
inclusion criteria 
28 - 32 weeks gestation 3- 5 days old, appropriate 
for gestational age, preterm 
infants with normal agpar 
scores 
Premature infants, 
<2000g at birth, 
less than 72 hours old 
(>24 old to <72 hours old) 
27 to 37 weeks gestation, 
in stable state 
Number of study 
participants 
Study  group=51  , Placebo 
=  36 
Study group = 10 , Placebo 
= 10 
Study group = 15, 
Placebo = 15 
Study group = 41, Placebo 
= 34 
Probiotic bacteria used Saccharomyces Bourlardii Lactobacillus  Reuteri 
ATCC  55730 
Lactobacillus acidophilus Bifidobacteriumlactis 
Dose of probiotic 109cfu at 50mg/kg 
every 12 hours 
1 X 108cfu/day 9 X 106cfu/ml formula 2 X 107cfu/g milk powder 
Placebo Maltodextrin Indistinguishable 
placebo 
Conventional preterm 
formula 
Conventional preterm 
formula 
Dose of placebo 50 mg /kg / 12 hours Not reported   
Treatment initiation 1st week of life as soon as 
enteral feed was tolerated 
At 3–5 days of life 1st 72 hours of life 1st 2 days of life 
Treatment duration 30 days 30 days Not specified 30 days 
Reported Outcomes     
Growth parameters Weight gain Weight gain Weight gain Weight gain, Linear growth, Head 
circumference 
Timing and duration of 
measurement of growth 
parameters 
Measured daily for 
30 days 
Measured daily for 
30 days 
Measured daily, duration 
not specified 
Weight gain: measured daily, 
Lineargrowth (measured weekly), 
Head  circumference 
(measured weekly) 
Feed tolerance Number of days to 
full enteral feed, 
Maximal enteral feed, 
vomiting 
Number of days to 
full enteral feed, 
Maximal enteral feed, 
vomiting 
Maximal enteral feed Number of days to full 
enteral feed, Maximal 
enteral feed 
Stool characteristics  Stooling frequency   
Complications NEC, Sepsis  Mortality / death NEC, Sepsis 
Intestinal permeability Changes in Intestinal 
permeability 
  Changes in Intestinal 
permeability 
Changes in gastrointestinal 
microflora 
cfu of bifidobacteria, 
lactobacillus, pathogens 
  cfu of bifidobacteria 
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different outcomes (2 studies) and type of feed was un- 
specified (1 study). No eligible studies were excluded for 
failure to report the review’s pre-specified outcomes. 
A summary of the included probiotic, prebiotic and on-
going studies are shown in Tables 3, 4 and 5. The 
included probiotic studies (N=212) were conducted in 
Greece, Italy and United States of America (USA). 
Treatment duration was 30 days using different probio- 
tics. All four probiotic studies reported short term 
growth parameters (weight gain) which were recorded daily 
during the entire study duration [Table 3]. None of the 
probiotic studies reported data on: other types of 
infections, use of parenteral nutrition, feed intolerance 
(gastric aspirate [ml], abdominal distension) and stool 
consistency. The included prebiotic studies (N=126) 
were conducted in conducted in Greece, Italy, and Ger- 
many. Treatment duration ranged from 14 days to  28 days. 
All four prebiotic studies reported short term growth 
parameters (weight gain, length, head growth) which were 
recorded at different intervals during the en- tire study 
duration [Table 4]. None of the prebiotic stud- ies 
reported data on: complications (NEC, sepsis, other types 
of infections, death / mortality), use of parenteral 
nutrition,  feed  intolerance  (vomiting,  gastric  aspirate 
[ml], abdominal distension) and changes in intestinal 
permeability. 
 
Risk of bias 
The quality of the included studies was assessed across 
six domains using guidelines from the Cochrane Hand- 
book for Systematic Reviews of Interventions [35] 
(Figure 3). 
Random sequence generation: Three trials described 
clearly the methods used for random sequence gener- 
ation [40,41,44]. Mihatsch used computer generated ran- 
dom lists with variable block sizes [44]. Stratiki used 
balance block randomization using random numbers 
[40] and Reuman used random numbers list combined 
with the last digit of the patients’ medical record [41]. 
The method used for random sequence generation was 
not clearly described 5 studies [36,39,42,43,45]. 
Allocation Concealment: In two trials treatment allo- 
cation was adequately concealed [33,40]. In the Stratiki 
trial, treatment allocation was conducted by a third party 
who was not involved in the study (Nutritional service) 
[40]. Mihatsch used precoded sachets in sealed envel- 
opes [44]. In one study treatment allocation was not ad- 
equately   concealed   because   the   method   used   was 
 
 
Table 4 A summary of four included prebiotic studies 
 Boehm 2002 [36] Indrio 2009 [43] Kapiki 2007 [45] Mihatsch 2006 [44] 
Location of study Milan, Italy University of Bari, Athens, Greece Ulm University, Germany 
  Policinico, Italy   
Participants - entry criteria <32 weeks gestation Healthy preterm newborns ≤ 36 weeks gestation < 1500 g birth weight 
Number of study participants Study group = 15, Study group = 10 , Study group = 36, Study group = 10, 
 Placebo = 15 Placebo = 10 Placebo = 20 Placebo = 10 
Prebiotic used GOS 90%, FOS 10% scGOS, lcFOS at ratio 9:1 FOS GOS, FOS 
Dose of prebiotic 1g/dl 0.8 g/dl 0.4g/100ml 1g/dl 
Placebo Maltodextrin Maltodextrin Maltodextrin Maltodextrin 
Dose of placebo 1 g/dl 0.8 g/dl 0.4 g 1.8 / 90 ml 
Treatment initiation When enteral feed ≥ Not clear Exclusively formula At full enteral feed at 
 80 mls /kg/day was tolerated  fed at start of study start of study 
Treatment duration 28 days 15 days 14 days 15 days 
Reported Outcomes     
Growth parameters Weight gain, linear growth Weight gain, linear growth, Weight gain, linear growth, Weight gain 
  head growth head growth  
Timing and duration of Measured on days 1, 7, 14, 28 Measured before start of Measured on days 1, 7, 14 Weight gain: reported as 
measurement of 
growth parameters 
 study, days 3, 5, 15  “Average weight 
gain during study.” 
Feed tolerance Number of days to full enteral Number of days to Number of days to Number of days to 
 feed, maximal enteral feed full enteral feed, full enteral feed full enteral feed, 
  maximal enteral feed  maximal enteral feed 
Stool characteristics Stooling frequency,  Stooling frequency, Stool viscosity, 
 consistency  consistency Stooling frequency, 
    consistency 
Changes in gastrointestinal cfu bifidobacteria  cfu bifidobacteria,  
microflora   pathogens  
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Table 5 A summary of five on-going studies 
 
 Jacobs 2007 [46] Lozano 2008 [47] Al-Hosni 2010 [48] Patole 2009 [49] Underwood 2009 [50] 
Location of study Australia Colombia USA Australia USA 
Participants - <32 weeks gestation, Birth weight Extremely Low Birth 32 weeks Gestation < 500grams birth weight, 
inclusion <1500 g birth weight, <2000 grams, weight infants: and 6 days, age less than 33 weeks 
criteria 1–3 days old < 48 hours of age, 
admission in NICU, 
Hemodynamic-ally 
stable 
< 1000 grams, 
1 to 14 old, intention 
to start enteral feeds 
<1500g birth weight, ready 
to commence 
on enteral feeds for 
up to 12 hours 
gestation, exclusively 
formula fed 
Probiotic Bifidobacteriuminfantis, Lactobacillus  reuteri Lactobacillus rhamnosus Lactobacillus acidophilus 1. ProlactPlus 
   bacteria used BifidobacteriumBifidus, 
Streptococcus 
thermophilus 
DSM 17938 GG,  Bifidobacteriuminfantis 375 million, 
bifidobacteriumbifidum, 
bifidobacteria  longus 
2..GOS 
3. Bifidobacteriuminfantis 
4. Bifidobacteriumanimalis 
Dose 1X109 1X108 CFU in 5 
drops of oil 
suspension 1/ 
day until 
discharge. 
L rhamnosus: 500  
million  cfu, 
B.infantis: 
500 million cfu 
L. acidophilus:375 m 
organisms, B bifidum, 
B. longus: 
125 million organisms 
1. week 1 95:5 
to week 5 75:25 
2. week: 0.25g/dL, to 
week 5: 2.0 g/dL 
3. week 1: 5X107, 
to week 5: 4.2 X109 
4. week 1: 5X107, 
to week 5: 4.2 X109 
Start date of 
study 
Reported 
Outcomes 
July- 2007 August 2008 February 2008 June 2009 June 2009 
Sepsis, Sepsis Average weight gain Sepsis Fecal microflora 
NEC NEC Growth velocity NEC 
Death Death Feed tolerance All-cause mortality 
Frequency of events  Volume of feed/day Time to reach full feeds 
(150 mls/kg/day) 
Length of 
hospital admission 
Number of antibiotic courses 
Days to full enteral feeds 
Gut colonisation by 
probiotic 
 
 
alternation, matching of infants by birth weight and ges- 
tational age [41]. In the  rest of the studies, allocation 
concealment was not clearly demonstrated or described 
[36,39,42,43]. 
Blinding: Blinding of study participants, care providers and 
assessors was clearly done in 4 trials [39-41,44]. In the 
other 4 trials, there was not enough information given on 
the blinding method to make a judgement  [36,42,43,45]. 
Incomplete outcome data: Reported outcome data was 
satisfactory for all the eight included studies. Five studies 
had no missing outcome data [36,41-44]. In other three 
studies, the missing outcome data was balanced across 
the intervention groups with similar reasons reported 
[39,40,45]. 
Selective reporting (reporting bias): In all eight studies, the 
pre-specified outcomes in the methods section were 
reported in the results section [36,39-45]. 
Other potential sources of bias: Only one trial had a 
baseline imbalance which was a potential source of bias. 
Costalos had 51 infants enrolled in the treatment group 
and 36 infants in the placebo group. No explanation was 
presented whether the imbalance was due to a problem 
at randomization stage [39]. All other studies appeared 
to be free from other potential sources of bias. 
 
Effects of interventions 
Probiotics versus control 
Four studies investigated the effect of probiotic adminis- 
tration versus no probiotic (control group) [39-42]. 
 
Primary outcomes: short term growth parameters 
 
Weight gain All four studies reported on weight 
gain [39-42]. Results from two studies (n=34) were 
pooled in a   meta-analysis   [41,42].   There   was   no   
statistically 
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Two studies [39,40] reported their results using med- 
ians and could not be pooled in a meta - analysis. Costa- 
los 2003 reported no statistically significant difference in 
weight gain (g/week) between the probiotic and control 
groups (p>0.05) [median (Interquartile range) of 163.5 
(17.7) for the probiotic group (n=51) compared to 155.8 
(16.5) for the control group (n=36)] [39]. Stratiki 2007 
also reported no statistically significant difference in 
weight gain (g/day) between the probiotic and  control 
groups (p=0.144) [median (range) of 28.3 (12 to 38) for 
the probiotic group (n=41) compared to 30 (10 to 40) 
for the control group (n=34)] [40]. 
 
Linear growth Only one study reported this 
outcome but found no statistically significant difference 
in length gain (cm/week) between the probiotic  and  
control groups (p=0.124) [median (range) of 1.4 (0 to 3) 
for the probiotic group (n=41) compared to 1.5 (0 to 
3.5) for the control group (n=34)] [40]. 
 
Head growth Only one study reported this outcome 
but found no statistically significant difference in head 
growth (cm/week) between the probiotic and control 
groups (p=0.124) [median (range) of 1.1 (0.45 to 1.9) for 
the probiotic group (n=41) compared to 0.9 (0 to 2) for 
the control group (n=34)] [40]. 
 
Secondary outcomes 
  Complications 
 
 
 
 
 
 Low risk of bias 
 Unclear risk of bias 
 High risk of bias 
Figure 3 Methodological quality of included studies. 
 
 
 
significant difference in weight gain (g/day) between the 
probiotic and control groups (MD 1.96, 95% CI: -2.64 to 
6.56).   No   statistically   significant   heterogeneity   was 
observed (Chi
2
=0.18, p=0.67, I
2
=0%) (Figure 4) 
Necrotizing enterocolitis [NEC] Two studies 
(n=162) reported on NEC and their results were pooled 
in a meta-analysis [39,40]. Administration of probiotics 
failed to significantly reduce the risk of NEC compared 
to controls (RR 0.42, 95% CI: 0.15 to 1.16). No 
significant het- erogeneity was observed (Chi
2
=1.06, 
p=0.30, I
2
=6%) (Figure 5). 
 
Sepsis Two studies (n=162) reported on sepsis and 
their results were pooled in a meta-analysis [39,40]. 
Adminis- tration of probiotics failed to significantly 
reduce the risk of sepsis compared to controls (RR 0.40, 
95% CI: 0.11 to 1.45. No significant heterogeneity was 
observed (Chi
2
=1.18, p=0.28, I
2
=15%). (Figure 6) 
 
 
 
 
 
 
 
 
 
     Figure 4 Effect of probiotic administration on weight gain (g/day). 
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     Figure 5 Effect of probiotic administration on NEC. 
 
 
Other infections No study reported on this outcome. 
 
 
Mortality Only one study [42] reported on  mortality. 
The risk ratio for this one study (n=30) was calculated 
and it showed that the probiotics failed to significantly 
reduce the risk of death compared to the  control (RR 
0.33, 95% CI: 0.04 to 2.85). 
 
 
Number of days on parenteral nutrition No 
study reported on this outcome. 
 
 
Number of days to full enteral feed Two studies 
reported this outcome but their results could not be 
pooled in a meta-analysis because they reported the out- 
come in terms of medians and ranges [39,40]. Costalos 
2003 reported no statistically significant difference in the 
number of days to full enteral feeding between the two 
groups (p>0.1) [median (IQR) of 9.3 (2.7) for the pro- 
biotic group (n=51) and 9.9 (4.5) for the control group 
(n=36)] [32]. Stratiki 2007 also reported no statistically 
significant difference in the number of days to full en- 
teral feeding [median (range) of 10 (0 to 52) for the pro- 
biotic group (n=41) and 10 (0 to 30) for  the  control group 
(n=34)] [40]. 
 
 
Maximal enteral feed  All four studies reported on 
this outcome [39-42]. Results from two studies (n=34) 
were pooled in a meta-analysis as they both reported the 
aver- age amount of feeding (ml/day) in terms of mean 
(SD) [41,42]. There was no statistically significant 
difference in the mean amount of feeding (ml/day) 
between the pro- biotic and control groups (MD 35.20, 
95% CI: -7.61 to 
78.02)   No   statistically   significant   heterogeneity   was 
observed between the studies (Chi
2
=1.65, p=0.20, I
2
=39%). 
Costalos 2003 reported no statistically significant dif- 
ference in the milk intake (ml/kg/day) at maximal en- 
teral feeding (p>0.1) [median (IQR) of 155 (15) for the 
probiotic group (n=51) versus 148 (13) for the control 
group (n=36)] [39]. Stratiki 2007 also reported no statis- 
tically significant difference in the maximal milk intake 
(ml/kg/day) (p=0.624)  [median  (range)  of  210  (165  to 
250) for the probiotic (n=41) group versus 192 (120 to 
250) for the control group (n=34)] [40]. 
 
Feed tolerance: vomiting, gastric aspirate, 
abdominal distension Two studies (n=107) 
reported on vomiting and were pooled in a meta-
analysis [39,42]. There was no statistically significant 
difference in the frequency of vomiting between the 
probiotic and control groups (RR 0.78, 95% CI: 0.18 to 
3.37). No statistically significant heterogeneity was observed 
(Chi
2
=0.41, p=0.52, I
2
=0%).In all four probiotic studies, 
there were no reported incidences of gastric aspirates, 
abdominal distension or diarrhea. Authors were further 
contacted for clarification and one responded [42] and 
stated categorically that none of these symptoms were 
observed. 
 
Stool characteristics 
 
Stool frequency Only one study (n=20) reported 
stool frequency as the number of episodes of evacuations 
per day in terms of mean (SD) [42]. The mean difference 
for this one study was calculated and it showed that 
pro- biotic consumption resulted in a statistically 
significant larger number of stools per day compared to 
the control group (MD 1.60, 95% CI: 1.20 to 2.00). 
 
 
 
 
 
 
 
 
 
 
    Figure 6 Effect of probiotic administration on sepsis. 
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Stool consistency No study reported on the effects 
of probiotics on stool consistency. 
 
Changes in intestinal permeability Two studies 
reported this outcome but their results could not be 
pooled in a meta-analysis [39,40]. The studies used two 
different tests to test for intestinal permeability. Costalos 
2003 used a 1-hour D-Xylose blood test and reported no 
statistically significant difference between the two groups 
(p>0.1) [median (IQR) of 1.5 (0.4) millimols/L for the 
probiotics (n=51) and 1.35 (0.3) mmol/L for the control 
(n=36)] [39]. Stratiki 2007 used a lactulose/mannitol 
(L/M) urine test and reported no statistically significant 
difference in the L/M ratios between the probiotic and 
control groups (p=0.073) but the values for median 
(range) were presented in a figure from which they could 
not be accurately extracted [40]. 
 
Changes in gastrointestinal micro flora 
 
Bifidobacteria Two studies reported  on  bifidobacteria 
but their results could not be pooled in a meta-analysis 
[39,40]. Costalos 2003 reported a significantly higher log 
viable Bifidobacteria counts per gram of positive infants in 
the probiotics group compared to the controls (p<0.001) 
[median (IQR) of 2.65 (0.083) for the probiotics group 
(n=51) and 2.27 (0.075) for the control group (n=36)] [39]. 
Stratiki 2007 reported bifidobacteria in terms of log 10 
cfu/g wet feces but found no statistically significant differ- 
ence between the two groups (p=0.075) [median (range) 
of 9.7 (7.5-10.3) for the probiotics group (n=41) and 8.9 
(7.2-10.2) for the control group (n=34)] [40]. 
 
Lactobacillus Only one study reported on 
lactobacillus [39]. This study reported no statistically 
significant dif- ference in the log viable bacterial 
lactobacillus counts per gram of positive infants between 
the two groups (p>0.05) [median (IQR) of 1.57 (0.285) for 
the probiotics group (n=51) and 1.42 (0.287) for the 
control group (n=36)]. 
 
Pathogens Only one study reported this outcome (en- 
terococci, bacteroides, and staphylococci) in terms of the 
median (IQR) of log viable bacterial counts per gram of 
positive infants [39] (Table 6). The study reported sig- 
nificantly higher counts of Enterococci (p<0.05) and 
Staphylococci (p<0.001) in the probiotic group com- 
pared to the controls. However, the study found no sta- 
tistically significant difference in the counts  of bacteroides 
between the two groups (p>0.05). 
 
Prebiotic versus control 
Four studies investigated the effect of prebiotics admin- 
istration versus no prebiotics (control group) [36,43-45]. 
Table 6 Log viable bacteria counts per gram of stool in 
 positive infants fed probiotics   
Costalos 2003 [39]                         Median (IQR) 
Pathogens Probiotic Control 
n= 51 n=36 
Enterococci                                      2.14 (0.359)                         2.19 (0.138) 
Bacteriodes                                          2.17 (0.164)                           2.25 (0.363) 
Staphylococci                                      1.23 (0.869)                             0.6 (0.281) 
 
 
Primary outcomes: short-term growth parameters 
 
Weight gain All four studies reported on weight gain 
[36,43-45]. Results from three studies (n=106) were 
pooled in a meta-analysis [36,43,45]. Moderate hetero- 
geneity  was  observed  between  the  studies  (Chi
2
=4.04, 
p=0.13, I
2
=51%). An investigation of heterogeneity by 
subgroup analysis with respect to the prebiotic type used 
(GOS/ FOS versus FOS only) yielded statistically signifi- 
cant subgroup differences (Chi
2
=4.04, df=1, p=0.04, 
I
2
=75.2%) implying that prebiotic type may be the source 
of heterogeneity. There was no statistically significant 
heterogeneity between the two studies in the GOS/ FOS 
subgroup (Chi
2
=0.01, df=1, p=0.94, I
2
=0%) [36,43]. The 
results for the GOS/FOS subgroup yielded no significant 
difference in weight gain (g/ day) between the two 
groups (MD 0.04, 95% CI: -2.65 to 2.73, n=50, 2 studies) 
while the other FOS subgroup yielded a significantly 
higher weight gain in controls compared to the prebio- 
tics (MD −4.60, 95% CI: -8.24 to −0.96, n=56, 1 study). 
(Figure 7) Sensitivity analysis with respect to study qual- 
ity could not be done because all three studies were of 
poor quality since the methods used for sequence gener- 
ation, allocation concealment and blinding were all not 
clear. 
Mihatsch 2006 reported no statistically significant dif- 
ference in weight gain (g/kg/day) between the two 
groups (p=0.4) [median (range) of 17.6 (8.1 to 23.4) for 
the prebiotic group (n=10) compared to 13 (9.3 to 21.9) 
for the control group (n=10)] [44]. 
 
Linear growth Three studies reported on length gain 
[36,43,45]. Meta-analysis of the results from these three 
studies (n=106) revealed significant heterogeneity be- 
tween the three studies (Chi
2 
= 139.41, df = 2, p < 
0.00001, I
2 
= 99%). An investigation of heterogeneity by 
subgroup analysis with respect to the prebiotic  type used 
(GOS/ FOS versus FOS only) yielded statistically 
significant subgroup differences (Chi
2
=139.41, df=1, 
p<0.00001, I
2
=0%) implying that prebiotic type may be 
the source of heterogeneity. There was no statistically 
significant heterogeneity between the two studies in the 
GOS/ FOS subgroup (Chi
2
=0.17, df=1, p=0.68, I
2
=0%). 
[36,43]. The results for the GOS/FOS subgroup yielded 
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     Figure 7 Effect of prebiotic administration of weight gain (g/day). 
 
no statistically significant difference in length gain (cm/ 
week) between the two groups (MD 0.01, 95% CI: -0.03 
to 0.04, n=50, 2 studies) while the other FOS subgroup 
yielded a significantly higher length gain (cm/ week) in 
prebiotics compared to the controls (MD 0.30, 95% CI: 
0.27 to 0.33, n=56, 1 study). (Figure 8) Sensitivity ana- 
lysis with respect to study quality could not be done 
because all three studies were of poor quality since the 
methods used for sequence generation, allocation con- 
cealment and blinding were all not clear. 
 
 
Head growth Two studies reported on head growth 
(cm/week) [43,45]. Meta-analysis of the results from 
these two studies (n=76) failed to yield statistically sig- 
nificant difference in head growth (MD −0.01, 95% CI: 
-0.02 to 0.00). No significant heterogeneity was detected 
between the two studies (Chi
2 
= 0.10, p =0.75, I
2 
= 0%). 
 
 
Secondary outcomes 
 
Complications No prebiotic study reported on 
Necrotizing Enterocolitis (NEC), Sepsis, other infections 
and mortality. 
Feeding tolerance 
 
Number of days on parenteral nutrition No 
study reported on parenteral nutrition. 
 
Age at full enteral feed Two studies reported on 
age at full enteral feeds [36,45]. Meta-analysis of the 
results from these two studies (n=86) did not find 
statistically significant difference in the age at full 
enteral feed (MD 
−0.79, 95% CI: -2.20 to 0.61). No significant heterogen- 
eity was detected between the two studies (Chi
2 
=1.16, 
p =0.28, I
2  
= 14%). 
Maximal enteral feed Two studies reported on this 
outcome but their results could not be pooled in a 
meta-analysis [36,44]. Boehm 2002 reported the feeding 
volume (ml/kg/day) in terms of the mean (SD) and 
therefore a mean difference was calculated. There was 
no statistically significant difference in feeding volume 
between the prebiotics group (n=15) and control groups 
(n=15) (MD −4.10, 95% CI: -18.16 to 9.96) [36]. 
Mihatsch 2006 reported no statistically significant dif- 
ference in the average formula intake within the study 
period (ml/kg/d) between the two groups (p=0.35) [me- 
dian (range) of 156 (127 to 165) for the prebiotic group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Figure 8 Effect of prebiotic administration of linear growth (cm/week). 
Stellenbosch University  http://scholar.sun.ac.za
 pg. 63 
 
 
 
(n=10) compared to 151 (117 to 169) for the  control group 
(n=10)] [44]. 
 
Feed tolerance: vomiting, gastric aspirate, abdominal 
distension, diarrhea All four studies reported this out- 
come [36,43-45]. In all 4 studies (n=126), there were no 
observed incidences of feed intolerance. There was no 
vomiting, gastric aspirate removed, no abdominal disten- 
sion or diarrhea reported. All infants tolerated the pre- 
term formula with prebiotic or control. From further 
communication with study authors, 2 study authors 
[43,44] responded that none of these outcomes were 
observed. 
 
Stool characteristics 
 
Stool frequency Three studies reported on stool fre- 
quency [36,44,45]. Two studies reported the results in 
form  of  mean  (SD)  of  the  number  of  stools  per  day 
(n=36) were significantly harder as compared to the control 
group (n=20). (MD −0.34, 95% CI: -0.66 to −0.02) [45]. 
Mihatsch 2006 reported a statistically significantly lower 
stool viscosity at day 14 (Newtons) for the prebio- tics 
compared to controls (p=0.006) [median (range) of 
31.8 (1.9 to 67.3) in the  prebiotic group  (n=10) com- 
pared to 157.5 (24.1 to 314.0) in the control group 
(n=10)] [44]. 
 
 
Changes in intestinal permeability 
No prebiotic study reported on changes in intestinal 
permeability. 
 
 
Changes in gastrointestinal micro flora 
 
Bifidobacteria Two studies reported on this outcome 
[36,45]. Meta-analysis of these two studies (n=84) revealed  
statistically  significant  heterogeneity  between 
(number/  day)  [36,45].  Meta-analysis  of  results  from the two studies (Chi
2
 =7.63, p =0.006, I
2
 = 87%). An in- 
these two studies (n=86) showed a significantly higher 
stool frequency in the prebiotic group compared to the 
control group (MD 0.80, 95% CI: 0.48 to 1.1). No signifi- 
vestigation of  heterogeneity by subgroup analysis with 
respect  to  the  prebiotic  type  used  (GOS/  FOS  versus 
FOS only) yielded statistically significant subgroup dif- 
cant heterogeneity was detected between the two studies ferences (Chi
2
 =7.63, p =0.006, I
2
 = 86.7%) implying that 
(Chi
2 
=0.13, p =0.72, I
2 
= 0%) (Figure 9). 
Mihatsch 2006 reported no statistically significant dif- 
ference in stool frequency between the two groups 
(p=0.059) [median (range) of 3.6(1.7 to 6.9) stools/day in 
prebiotic group (n=10) compared to 2.6 (2 to 4.9) stools/ 
day in control group (n=10)] [44]. 
 
Stool consistency Three studies reported on stool 
consistency but using three different scales of measurement 
[36,44,45]. Although two studies [36,45] both measured 
consistency in form of a scale ranging from 1 to 5 and 
reported their results as mean (SD), they could not  be 
pooled in a meta-analysis because their scales were going in 
opposite directions; Boehm 2002 (1=watery, 2=soft, 
3=seedy, 4=formed, 5=hard) [36]. Kapiki 2007 (5=watery, 
4=loose, 3=soft, 2=firm, hard=1) [45]. The mean differences 
for these two studies were therefore calculated separately. 
In Boehm 2002, the stools from the prebiotic group (n=15) 
were significantly more watery as compared to the control 
group (n=15). (MD −0.91, 95% CI: -1.41 to −0.37) [36]. In 
Kapiki 2007, the stools from the prebiotic group 
prebiotic type may be the source of heterogeneity. The 
results for the GOS/FOS subgroup yielded significantly 
higher bifidobacteria counts in prebiotics compared to 
controls (MD 2.10, 95% CI: 0.96 to 3.24) [36]. The other 
FOS subgroup also yielded significantly higher bifidobac- 
teria counts in prebiotics compared to controls (MD 0.48, 
95% CI: 0.28 to 0.68) [45] (Figure 10). 
 
 
Lactobacilli Only one study [36] reported this 
outcome but the actual values were not given. 
 
 
Pathogens [Post-intervention] Two studies  
reported on this but their results could not be pooled in 
a meta- analysis [36,45]. Boehm 2002 reported the sum of 
clinic- ally relevant pathogens at the end of the 
intervention period in the form of mean (SD) log cfu/g 
stool. The values were used to calculate the mean 
difference which showed that the sum of the studied 
pathogens was sig- nificantly lower in the prebiotic 
group (n=12) compared to the control group (n=13). 
(MD −0.43, 95% CI: -0.79 to −0.07) [36]. 
 
 
 
 
 
 
 
 
 
     Figure 9 Effect of prebiotic administration on stool frequency. 
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     Figure 10 Effect of prebiotic administration on total counts of Bifidobacteria. 
 
Kapiki 2007 reported this outcome (staphylococci, E. 
coli, bacteroides, and enterococci) in terms of mean (SD) 
log 10 CFU/g wet feces [45]. Mean differences for each 
of these pathogens were calculated. There was no 
statistically significant difference in the number of 
staphylococci (MD 0.00, 95% CI: -0.17 to 0.17) between 
the two groups but there were significantly fewer E. coli 
(MD  −1.69,  95%  CI:  -1.85  to  −1.53)  and  enterococci 
(MD  −0.80,  95%  CI:  -0.99  to  −0.61)  in  the  prebiotic 
group (n=36) compared to the control group (n=20). With 
regards to bacteroides, there were significantly more 
bacteroides in the prebiotic group (n=36) com- pared to 
the control group (n=20) (MD 0.50, 95% CI: 0.36 to 
0.64) [45]. 
 
Discussion 
The objective of this review was to assess if addition of 
probiotics or prebiotics to preterm infant formula led to 
improved growth and clinical outcomes in  preterm  or low 
birth weight infants. Studies that used breast milk or 
mixed feeds (breast milk and infant formula) were 
excluded. All RCTs evaluated probiotics or prebiotic use 
in preterm infants, were of small sample size, varied in 
enrolment criteria, intervention, treatment initiation and 
duration. 
 
Summary of main findings 
Probiotics 
This review was under powered to detect clinically 
important differences in  primary  outcomes  (weight gain, 
linear growth, head growth) because of the few number of 
studies, small sample size (n=34) and poor 
methodological quality of studies.  This  review  found no 
significant effect on weight gain from use of pro- biotics 
added to infant formula. There was also no significant 
probiotic effect on linear and head growth from the one 
study measuring these two outcomes. Probiotic 
supplementation failed to significantly reduce the risk of 
complications such as NEC, sepsis and death  compared  
to  control  group.  Outcomes  such  as 
number of days on parenteral nutrition and other 
infections were not reported. There was no significant 
difference in the amount of feed volume (ml/day) and 
frequency of vomiting between study groups. Preterm 
infant formula with probiotics  was  well  tolerated  as no 
gastric aspirates, abdominal distension or  diarrhea was 
reported. Effects of probiotics on stool character- istics 
were under reported. Results from one study showed 
probiotics supplementation did result in a lar- ger 
number of stools per day. 
Effects on intestinal permeability could not be evalu- 
ated since two different laboratory tests (lactulose / 
mannitol ratio and  D- xylose tests) were reported  and 
the results could not be pooled. Sugar absorption tests 
(such as lactulose / mannitol ratio) are a direct measure 
of intestine integrity which reflects gut maturation and 
in research; they demonstrate the effects of experimental 
therapy [78,79]. Monitoring changes in intestinal perme- 
ability in preterm infants is essential since there is evi- 
dence that initiation of enteral feeds decreases intestinal 
permeability [78,80]. However, this could not be estab- 
lished in this review. Other outcomes such as age at full 
enteral feeds and intestinal  micro flora (pathogens) 
could not be evaluated as medians (inter quartile ranges) 
were reported. No probiotic study reported any data on 
low birth weight infants therefore no conclusions could 
be made on this population. 
The included probiotic studies had short treatment 
duration of 30 days. This confirms the European Society 
for Pediatric, Gastroenterology,  Hepatology and  Nutri- 
tion (ESPGHAN) statement that there is a “lack of pub- 
lished evidence on clinical benefits from long term use 
of probiotic containing infant formula” [81]. This review 
confirms that there is a need for long term  follow-up RCTs 
on preterm infants. Live probiotic bacteria were used in 
the trials. There have been few reports of bacter- aemia 
from probiotic use in the biomedical literature [82-84]. 
There were no cases of sepsis reported as a re- sult of 
probiotic consumption in the included studies. In recent 
reviews, the time to reach full enteral feeds was 
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earlier in the preterm infants given probiotics with 
breast milk or mixed feeds. This review could not evalu- 
ate this outcome. Well-designed RCTs with similar feed- 
ing regimes are needed to evaluate this outcome. 
 
Prebiotics 
This review was under powered to detect clinically im- 
portant differences in primary outcomes (weight gain, 
linear growth, head growth) because of few number of 
studies, small sample size (n=106) and poor methodo- 
logical quality of studies. Addition of prebiotic combina- 
tions of GOS /FOS or FOS alone to preterm infant 
formula did not have any significant effect on weight gain. 
Addition of GOS / FOS to preterm infant formula did 
not have any effect on linear growth. However, addition 
of FOS alone did have a significant effect on linear 
growth. Neither GOS / FOS combination nor FOS alone 
had any effect on head growth. 
None of the prebiotic studies reported on NEC, sepsis, 
other infections, mortality  (death),  parenteral  nutrition or 
changes in intestinal permeability; therefore these 
outcomes could not be evaluated. Prebiotics did  not 
have any significant effect on the age at which infants 
reached full enteral feeds or volume of feed tolerated. 
Prebiotic preterm formula was well tolerated because 
there were no reports of vomiting, gastric aspirates, ab- 
dominal distension or diarrhea. Prebiotic supplementa- tion 
did result in a higher stooling frequency compared to 
control. Effects on stool consistency were inconclusive as 
results from one study resulted in more watery stools in 
the prebiotic study group compared to control group, in 
a second study, the prebiotic group experienced harder 
stools compared to control group. The third study 
results were presented in medians (range) there- fore 
no conclusions could be made. In preterm infants, 
frequent watery stools may signify intolerance, a transi- 
ent lactase deficiency or another pathological state which 
always require further investigation [6]. 
Prebiotics did have a significant effect on intestinal micro 
flora. Addition of GOS / FOS  combination  or FOS alone 
significantly increased counts of bifidobac- teria. Effects 
on lactobacillus counts could not be evalu- ated as actual 
figures were not available. The sum of studied pathogens 
and some selected pathogens (E- coli, enterococci) were 
significantly fewer in the prebiotic group compared to 
control group. There was no effect on staphylococci 
levels while bacteroides were signifi- cantly higher in 
the probiotic group compared to control group. No 
prebiotic study reported any data on low birth weight 
infants; therefore no evaluations could be made. 
The prebiotic studies were of short duration ranging 
from 14 to 28 days. The dose of the prebiotic  used (GOS, 
FOS) varied from 0.4 g/dl o 1g/dl. The European 
Committee on Food recommends that prebiotics added 
to formula milk do not exceed 0.8 g/100 ml. The ration- 
ale for prebiotic doses not exceeding 1g/ml in clinical 
trials is an attempt to maximize the bifidogenic effect 
with minimal intolerance as exhibited by, abdominal dis- 
tension [85]. The preterm infants tolerated the prebiotic 
formula as there were no symptoms of feed intolerance 
reported. 
Prebiotic supplementation did have some short term 
benefits: increased stooling frequency and bifidobacteria 
counts, fewer pathogens in the prebiotic group com- 
pared to control group. However, large RCTS with long 
term follow -up are needed to find out if these short 
term benefits translate into improved general  health and 
reduced morbidities in preterm infants. Due to the short 
duration of prebiotic studies, routine supplemen- tation 
with prebiotics in preterm infants cannot be 
recommended. 
 
Quality of the evidence and potential biases 
In this review, the quality of the evidence was compro- 
mised by several factors: Sample size: included studies 
were of small individual sample size, number of study 
participants ranged from 20 to 87 in the probiotic stud- 
ies, 20 to 56 in prebiotic studies. Intervention: Different 
types of probiotic and prebiotics, doses and treatment 
duration were used. Methodological quality: Inadequate 
information was published to assess methodological 
quality of the studies. Information was missing on se- 
quence generation, allocation concealment, blinding, in- 
complete outcome data, selective reporting and free of 
other bias domains. The significance of any relationship 
between methodological quality and study outcomes 
could not be verified since no subgroup analysis with re- 
spect to study quality could be done as a result of either 
too few studies in a meta-analysis or having all studies 
with similar quality in a meta-analysis. Not all the 
reviews pre- specified outcomes were addressed by the 
included studies. 
At the conclusion of the review process and prepar- 
ation of the manuscript (for this review), one on- going 
study was terminated due to being under powered [47]. 
One study was completed and data analysis commenced. 
The results from this study could not be included in this 
review [48]. The other three studies were still on-going 
[46,49,50]. The reviewers used thorough comprehensive 
search strategies adopted for the available databases. All 
attempts were made to minimize publication bias. All steps 
of this review were  conducted  independently  by the 
reviewers. 
 
Agreements and disagreements with other reviews 
No significant difference was found in contrast with past 
reviews and that the potential reasons are lack of power, 
poor quality of studies or a lack of effect in formula fed 
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infants. This review did agree with some aspects of past 
reviews. Prebiotics did have an impact on GI micro flora 
(increased bifidobacteria counts, reduction in certain 
pathogens); feed tolerance (no reported gastric aspirates, 
abdominal distension). 
 
Conclusion 
There is not enough evidence to state that supplementa- 
tion of preterm infant formula with probiotics or prebio- 
tics does result in improved growth and clinical outcomes 
in preterm infants. Therefore this review does not 
support the routine supplementation of preterm for- mula 
with probiotics or prebiotics. 
 
Implications for research 
For clear recommendations to be made, long term large 
RCTs on exclusively formula fed preterm and low birth 
weight infants are required to investigate the effects of 
probiotics and prebiotics supplementation in preventing 
NEC, sepsis, death/mortality; changes in intestinal micro 
flora and intestinal permeability; explore the efficacy of 
different doses of the same probiotic on clinical out- 
comes because available studies used different probiotic 
doses; similarly, explore the efficacy of different doses of 
the same prebiotic on clinical outcomes because avail- 
able studies used similar prebiotics with different doses 
and treatment duration. 
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R E V I E W Open Access 
Synbiotics, probiotics or prebiotics in infant 
formula for full term infants: a systematic review 
Mary N Mugambi1*, Alfred Musekiwa2,3, Martani Lombard1, Taryn Young3  and Reneé Blaauw1 
 
Abstract 
Background: Synbiotics, probiotics or prebiotics are being added to infant formula to promote growth and 
development in infants. Previous reviews (2007 to 2011) on term infants given probiotics or prebiotics focused on 
prevention of allergic disease and food hypersensitivity. This review focused on growth and clinical outcomes in 
term infants fed only infant formula containing synbiotics, probiotics or prebiotics. 
Methods: Cochrane methodology was followed using randomized controlled trials (RCTs) which compared term 
infant formula containing probiotics, prebiotics or synbiotics to conventional infant formula with / without placebo 
among healthy full term infants. The mean difference (MD) and corresponding 95% confidence intervals (CI) were 
reported for continuous outcomes, risk ratio (RR) and corresponding 95% CI for dichotomous outcomes. Where 
appropriate, meta-analysis was performed; heterogeneity was explored using subgroup and sensitivity analyses. 
If studies were too diverse a narrative synthesis was provided. 
Results: Three synbiotic studies (N = 475), 10 probiotics studies (N = 933) and 12 prebiotics studies (N = 1563) 
were included. Synbiotics failed to significantly increase growth in boys and girls. Use of synbiotics increased stool 
frequency, had no impact on stool consistency, colic, spitting up / regurgitation, crying, restlessness or vomiting. 
Probiotics in formula also failed to have any significant effect on growth, stool frequency or consistency. Probiotics 
did not lower the incidence of diarrhoea, colic, spitting up / regurgitation, crying, restlessness or vomiting. 
Prebiotics in formula did increase weight gain but had no impact on length or head circumference gain. 
Prebiotics increased stool frequency but had no impact on stool consistency, the incidence of colic, spitting up / 
regurgitation, crying, restlessness or vomiting. There was no impact of prebiotics on the volume of formula 
tolerated, infections and gastrointestinal microflora. The quality of evidence was compromised by imprecision, 
inconsistency of results, use of different study preparations and publication bias. 
Authors’ conclusions: There is not enough evidence to state that supplementation of term infant formula with 
synbiotics, probiotics or prebiotics does result in improved growth or clinical outcomes in term infants. There is no 
data available to establish if synbiotics are superior to probiotics or prebiotics. 
Keywords: Synbiotic, Probiotic, Prebiotic, Full term infant 
 
Background 
The first year of life is characterized by very rapid 
growth. Weight increases by 115%, body length 34% and 
head circumference 22% [1,2]. Many full term infants 
lose weight  after  birth  and  take  8–10  days  to  regain 
it back. The average infant achieves a weight gain of 
approximately 1.1  to  1.2  kg/month  during  the  first 
6 months, slowing down to 0.4 to 0.5 kg/month during 
the second 6 months. Length increases by 3.5 to 3.9 cm/ 
month  during  the  first  4  months,  slowing  down  to 
1.8 cm/month at 6 month of age [1]. At birth average 
head circumference is 35 cm and increases by an esti- 
mated 12 cm during the first year of life to approxi- 
mately 47 cm. A faltering head circumference has 
serious implications  for  neural  growth,  maturation  and 
is diagnostic for possible problems of brain growth [2]. 
   Monitoring growth (weight, length and head circumfer- 
* Correspondence: nkmugambi@hotmail.com 
1Division of Human Nutrition, Faculty of Medicine and Health Sciences, 
Stellenbosch University, Stellenbosch, Western Cape, South Africa 
Full list of author information is available at the end of the article 
ence) evaluates the overall health of the infant and deter- 
mines adequacy of nutritional intake [1]. 
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To promote optimum growth, development and de- crease 
infections, probiotics, prebiotics are added to infant 
formula to promote an intestinal micro flora resembling 
that of breastfed infants [3]. The intestinal micro flora of 
breastfed infants have a greater concentra- tion of 
bifidobacteria and fewer potentially pathogenic bacteria 
compared to formula fed infants. Probiotics are “live 
microorganisms” which when administered in adequate 
amounts confer a health benefit to the host [3]. The main 
probiotic organisms used worldwide belong to the genera 
Lactobacillus and Bifidobacteria and are found in the 
gastrointestinal micro flora [3,4]. Probiotics are consumed 
in the form of fermented food, dairy pro- ducts, infant 
and toddler formula. Prebiotics are non- digestible food 
ingredients that benefit the host by selectively 
stimulating the growth and/or activity of one or a limited 
number of bacteria in the colon and thereby improving 
the host’s health [4,5]. The most widely stud- ied 
prebiotics are inulin, fructooligosaccharide (FOS) and 
galactooligosaccharide (GOS) which are plant stor- age 
carbohydrates in vegetables, cereals and fruit. Fruc- 
tooligosaccharide and inulin are added to different foods 
as fat and sugar replacements to improve texture or for 
their functional benefits [5-8]. 
Probiotics improve health in different ways [3,9]. The 
health benefits conferred by probiotic bacteria are strain 
specific [3,9]. Some strains increase phagocytic activity 
of peripheral blood leukocytes, others strains promote 
production of mucosal antibodies reducing the trans- 
mucosal transfer of antigens. This strengthens the mucosal 
barrier function [10-12]. Other probiotic strains increase 
cytokine production such as interleukin 6 (IL-6) [13]. In 
healthy people probiotics rarely cause disease. The risk 
of developing bacteraemia from ingested lacto- bacilli is 
less than 1 per 1 million users; risk of develop- ing 
fungaemia (from Saccharomyces Boulardii) is less than1 
per 5.6 million users [14-16]. In many studies on infants, 
C- reactive protein (CRP) and IL-6 have been used to 
diagnose the early onset of  infection  [17,18]. CRP is an 
acute phase protein, blood levels begin to rise to 10 – 
1000 fold from 1 ug/ml within 4–6 hours at the onset of 
an infective or inflammatory process. C- reactive protein 
has a relatively short half-life making it useful in  
monitoring   infection,   inflammation   and   response to 
treatment [19]. IL-6 is a pro-inflammatory cytokine 
which stimulates the production of acute phase  pro- 
teins (such as CRP) [20]. It is readily detected in serum 
during inflammation and indicates the presence of 
infection [18,19]. 
Adding prebiotics to formula stimulates the growth of 
beneficial bacteria (such as bifidobacteria, lactobacilli) in 
the gastrointestinal tract to levels found in breastfed 
infants [9,21]. As these beneficial bacteria increase, they 
occupy  more  of  the  “microbiological  niches”  in  the 
intestine excluding pathogens. This improves the gut 
mucosal barrier, prevents infections with enteric patho- 
gens or trans-located gut bacteria [22,23]. Prebiotics 
have a good safety record at levels  found  in  existing 
food components. Flatulence or abdominal bloating is 
reported at doses greater than 20g / day. Abdominal 
cramps or diarrhoea are reported at doses greater than 
50 g / day [23]. 
When probiotics and prebiotics are administered sim- 
ultaneously, the combination is termed Synbiotics. The 
prebiotic in the synbiotic mixture improves the survival 
of the probiotic  bacteria  and  stimulates  the  activity 
of the host’s endogenous bacteria [9,21,24,25]. The 
superiority of synbiotics  compared  to  either  probiotics 
or prebiotics have not been  demonstrated.  No  review 
has examined the impact of synbiotics on clinical out- 
comes in formula fed term infants. Recent systematic 
reviews (published from 2007 to 2011) on the use of 
probiotics or prebiotics in term infants have focused on 
prevention of allergic disease and food hypersensitivity 
[26,27]. Reviews on children and adults focused on 
upper respiratory tract infections, antibiotic associated 
diarrhoea and acute infectious diarrhoea [28-30]. This 
review focused on full term infants given only infant for- 
mula with synbiotics, probiotics or prebiotics. 
The Human Research Ethics Committee at the Univer- 
sity of Stellenbosch, South Africa reviewed the protocol, 
ruled that all data to be collected for this review was 
from the public domain and was therefore exempt from 
ethical approval. 
 
 
Objectives 
The objectives of this systematic review were: 
 
1) To determine the effects of infant formula 
containing synbiotics, probiotics or prebiotics on 
clinical outcomes in full term infants. 
2) To explore if synbiotics are superior over 
probiotics or prebiotics. 
 
 
Methods 
Criteria for considering studies for this review 
All randomized controlled  trials  (RCTs),  irrespective 
of language, which compared the use of term infant 
formula containing synbiotics,  probiotics  or  prebiotics 
to conventional infant formula with or without placebo 
amongst healthy full term infants (>37  weeks  gesta- 
tion or ≥ 2.5 kg birth weight, age: 0–12 months, with 
no disease, congenital abnormality, allergy or eczema) 
receiving formula feeds only. Studies published as 
abstracts were included if  sufficient  information  could 
be obtained to assess study quality and obtain relevant 
study findings. 
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Types of outcome measures 
Primary outcomes 
Growth changes (assessed for entire study duration): 
weight gain (g/day), linear growth (cm/week, mm/ month), 
head growth (cm/week, mm/month). Secondary 
outcomes: Tolerance to formula: Stool characteristics: 
frequency, consistency, diarrhoea; Gastrointestinal symp- 
toms (incidence of colic, spitting up/ regurgitation, 
vomiting, crying), average formula intake (mls/day). 
Infections: frequency and type of infections, use of medi- 
cation (antibiotic intake); Hospitalization: Number of 
days in hospital. Changes in GI microflora: Changes in 
colony forming units (cfu/g of stool) of bifidobacteria, 
lactobacillus post intervention, colony forming units 
(cfu/g of stool) of pathogens post intervention. Immune 
response: C- reactive protein levels (mg/dl), Interleukin 
6 (IL-6) levels (mg/dl). 
 
 
Search methods for identification of studies 
A literature search regardless of language was conducted 
on electronic databases including The Cochrane CEN- 
TRAL Register for Controlled Trials (2010), EMBASE 
(1980+), Scopus (1990 present), EBSCO host (1960 to 
2010),  PUBMED  /  MEDLINE  (1966  to  2010),  OVID 
(1950 to 2010), SPORTDiscus (1960 to 2010), Web of 
Science (1970 to 2010), Science Direct (1950 to 2010), 
CINAHL (1981 to 2010), Science citation index (1970 to 
2010), Latin American Caribbean Health Sciences litera- 
ture  (LILACS)  (1965  to  2010),  NLMGateway  (1950– 
1966). RCTs published in non-English language journals 
were translated by independent translators who were fa- 
miliar with the subject matter. The search strategy used 
to search PUBMED is shown below. This search strategy 
was modified to search other electronic databases. 
 
(synbiotic* and probiotic* OR prebiotic*) AND 
(FOS or fructooligosaccharide or inulin or GOS 
or galactooligosaccharide) AND (infant formula* 
OR infant feeding OR formula OR formula milk) 
AND (infant* or baby or babies) NOT (preterm 
or premature or low birth weight babies or allergy 
or eczema) AND (randomized controlled trial* 
OR controlled clinical trial* Or random 
allocation*) Limits: Humans. 
 
 
We also conducted a hand search on abstracts of major 
conference proceedings such as the Pediatric Aca- demic 
Society meetings from 1990 (www.pas-meetings. org, 
www.abstracts2view.com), cross checked references cited 
in RCTs and in recent reviews (published  from 2005 to 
2009) for additional studies not identified by electronic 
searches and specialty journals  which  were not included 
in any database such as Pediatrika and Chinese Journal of 
Microecology. 
To identify on-going and unpublished trials, we contacted 
experts in the field, manufacturers of infant formula con- 
taining probiotics and prebiotics, we searched web sites of 
companies that have conducted or were conducting RCTs 
on probiotics and prebiotics e.g. Pfizer (www.pfizerpro. 
com/clinicaltrials), Chris Hansen Laboratory (www.chr- 
hansen.com/research_development/documentation.html). 
We also searched prospective trial registries such as 
World Health Organization (WHO) International  Clin- 
ical Trials Registry Platform Search Portal (www.who.int/ 
trialsearch), Clinical Trials.gov register (www.clinical- 
trials.gov), Current Controlled Trials metaRegister of 
Controlled Trials [mRCT] (www.controlled-trials.com/ 
mrct) and www.clinicaltrialresults.org. 
 
Selection of studies 
One reviewer (MM) independently reviewed  all 
abstracts, citations and identified potentially eligible 
studies. The full reports of eligible studies were retrieved 
by one reviewer (MM) and the pre-specified  selection 
criteria applied independently by two reviewers (MM, 
ML) using a study eligibility form (Figure 1). If more 
than one publication of a study existed, all reports of the 
study were grouped together under one study  name. 
Any disagreements between the reviewers were resolved 
through discussion. Unresolved disagreements were 
resolved by a third party. Trial authors were contacted if 
eligibility was unclear. 
 
Assessment of quality of evidence 
Two reviewers (MM, ML) independently assessed  the 
risk of bias of included studies as described in the 
Cochrane Handbook for Systematic Reviews for Inter- 
ventions according to the following 6 components: 1) 
allocation sequence generation; 2) allocation conceal- 
ment; 3) blinding; 4) incomplete outcome data; 5) select- 
ive outcome reporting; and 6) other sources of bias [31]. 
Where necessary, trial authors were contacted for clarifi- 
cation on the methodology of their studies. Any dis- 
agreements regarding risk of bias were resolved through 
discussion between MM, ML and RB. The quality of 
evidence was assessed using guidelines from the Grading 
of Recommendations Assessment, Development and Evalu- 
ation Working Group (GRADE), www.gradeworkinggroup. 
org (accessed 2012-06-07). 
 
Data extraction and management 
Two reviewers (MM, ML) independently extracted data 
using a pretested data extraction form. The reviewers 
(MM, ML) cross checked data and resolved any differ- 
ences through discussion. One reviewer (MM)  entered 
the data in Review Manager (RevMan 5) and the other 
reviewers (AM, ML) validated the data. Trial authors 
were contacted for missing data or for clarification. 
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Figure 1 Study Eligibility form 
Review title:
Study ID (Author last name, initials)
Refworks ID number
Date of review for eligibility (DDMMYYYY):
Title of study/article
Journal title
Year/volume/issue/page
Extractor (Last name, initials)
Type of study
Is this study a Randomized controlled study? YES UNCLEAR NO
Exclude
Intervention used 
in study:
Trial intervention Circle below
Experimental group: Term infant formula containing either probiotic(s) 
or prebiotic(s) or synbiotic(s) YES UNCLEAR NO Probiotic
Control group: Conventional term formula with or without placebo YES UNCLEAR NO Prebiotic
Note: All formulas are Cow based milk formula, no soy based formula. 
Breastmilk when used as reference only YES UNCLEAR NO Synbiotic
Study Participants Exclude
Healthy Full term infants (>37 weeks gestation or > 2.5 kg birth weight), 
Age: 0-12 months. Strictly formula fed infants only. YES UNCLEAR NO
Exclude: If infants have Congenital malformations, chromosomal 
abnormalities. Breastfed infants (unless they are used as a reference 
group) NO UNCLEAR YES
Study Outcomes. Does the study have one or more of the 
following outcomes: Exclude
Growth parameters: (weight, Height/length, Head Circum) YES UNCLEAR NO
Tolerance to feed: stool pattern (frequency, consistency), vomiting, 
diarrhoea, volume of feed tolerated YES UNCLEAR NO
Infections: frequency, type, use of meds YES UNCLEAR NO
Immune respone: CRP, IL-6, other immune system parameters YES UNCLEAR NO
Stool Microbiology: levels of bifidobacteria, lactobacilli, pathogens YES UNCLEAR NO
Hospitalization: # days in hospital, ICU (if any) YES UNCLEAR NO
Other reasons for excluding study NO Yes
Final decision Include Unclear Exclude
For 
discussion
Comments
STUDY ELIGIBILITY FORM
Clarify missing 
information
Go to next question
Go to next question
Go to next question
Put a check (√ ) mark in 
appropriate box.
Effects of probiotic, prebiotic and, synbiotic 
containing infant formula on clinical outcomes in 
term infants
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Data synthesis and management 
Results for probiotic, prebiotic and synbiotics studies 
were analysed separately. No imputation measures for 
missing data were applied. Trial authors were contacted 
if there was missing data. Available case analysis was 
used where there was missing data. The potential impact 
of missing data on results is addressed in the discus- 
sion section. 
Heterogeneity of the trials used in the review was 
assessed by visually inspecting the forest plots to detect 
overlapping  confidence  intervals  and  by  performing 
a Chi
2  
test (p<0.1 was considered statistically signific- 
ant because of the low statistical power of this test). An 
I-square test (I
2
) was also used to test for inconsistencies 
across studies. If the I
2 
exceeded 50% and visual inspec- 
tion of the forest plot supported these results, this 
represented substantial heterogeneity. Since all of our 
meta-analyses had less than ten studies, the assessment 
of publication bias using funnel plots could not be done 
[31]. If the included studies were not clinically diverse and 
had similar outcome measures, a meta-analysis was carried 
out in Review Manager (RevMan 5) by two reviewers (AM, 
MM). The random effects meta-analysis model was ap- 
plied to all meta-analyses since the studies were clinically 
heterogeneous in terms of different settings (countries), 
doses and strains of synbiotics, probiotics or type of pre- 
biotics, different treatment durations, and other  unfore- 
seen factors. The inverse-variance method was used for 
continuous data and the Mantel-Haenszel method was 
used for dichotomous data. For continuous outcomes the 
mean difference (MD) and corresponding 95% confidence 
intervals (CI) were calculated. For dichotomous outcomes, 
the risk ratio (RR) and corresponding 95% CI were calcu- 
lated. The source of statistical heterogeneity was explored 
using subgroup and sensitivity analyses. If studies were 
too diverse, no meta-analysis was conducted and a narra- 
tive synthesis was provided. 
 
Results 
Results of the search and description of studies 
Electronic search of available databases yielded 142 cita- 
tions. After reading titles and abstracts, duplicate reports 
were removed, 118 articles were screened and 55 articles 
were excluded. A hand search yielded 2 more articles. 
Potentially relevant full text reports were retrieved, 
reviewed for eligibility and a further 38 studies were 
excluded. One study was published in two other reports [32-
34]. The three studies were considered  as  one  study and 
are referred to as Moro  2006  [32].  Another  study was 
also published in two reports; and is referred  as Moro 
2002 [35,36]. Twenty five studies (3 synbiotic, 10 
probiotic and 12 prebiotic studies) and three on-going 
studies were included in this review  [21,24,25,37-56]. 
The selection process is shown in Figure 2. Table 1 gives 
a list of 38 studies which were excluded for:  use  of 
breast milk or mixed feeds (12 studies), no use of pro- 
biotic or prebiotic (2 studies), being a cross over study, 
not RCT (5 studies), type of feed was unspecified (3 stud- 
ies), different inclusion criteria or outcomes (12 studies), 
no data available for end of treatment period (1 study) 
and data presentation  inappropriate  for  meta-  analysis 
(3 studies) [57-94]. No eligible studies were excluded for 
failure to report the review’s pre-specified outcomes. 
 
Included studies 
Summary of the included synbiotics, probiotics, pre- 
biotics, and on-going studies are shown in Tables 2 3, 
4, 5. All studies were conducted  on  healthy  infants 
and  used  standard  infant  formula. 
Synbiotic studies: Three studies (N = 475) used various 
synbiotic (probiotic and prebiotic) combinations [21,24,25]. 
Two studies [21,24] used a probiotic combination of 
Bifidobacterium longum BL999 with Lactobacillus rham- 
nosus; Bifidobacterium animalis ssp lactis with Lacto- 
bacillus paracasei.One study [25] used Bifidobacterium 
longum alone. Dosage varied from 1 × 10
7 
to 2 × 10
7 
cfu/g 
powder to 1.28 × 10
8 
to 2.5 × 10
8 
cfu/100 ml. The prebio- 
tics  used  were  a  combination  of  90%  GOS  10%  FOS 
[24,25] or GOS alone [21]. The prebiotic doses ranged 
from 0.24 g to 0.4 g/100ml. Treatment duration varied 
from 4 months to 6 months. The synbiotic studies were 
conducted in France, Italy and Netherlands. None of the 
synbiotic studies reported data on volume of feed tole- 
rated, hospitalization, changes in GI microflora and im- 
mune response. 
Probiotic studies: Ten probiotic studies (N = 933) were 
included. One study [55] used a reduced protein infant 
formula and one study [50] used an acidified formula 
given to healthy infants born to HIV positive mothers. 
The most widely studied probiotics were Bifidobacter- 
ium lactis (BB-12) which was administered alone 
[40,44,46,50-52]. Other probiotic strains used were 
Lactobacillus reuteri and Bifidobacterium bifidum. Doses 
ranged widely. For Bifidobacteria: 1.5 x 10
6  
to 3.85 x 10
8
 
cfu/g powder and Lactobacillus: 1 x 10
6 
to 1 x 10
8 
cfu/g 
powder.  Treatment  duration  varied  from  14  days  to 
7 months. The probiotic studies were conducted in 
Australia (Adelaide), Belgium, Chile (Santiago), France, 
Israel (Beersheva), South Africa (Johannesburg) and 
USA (Iowa). None of the probiotic studies reported data 
on immune response. 
Prebiotic studies: Twelve prebiotic studies (N = 1563) 
were included. The studied prebiotics were FOS [37], 
GOS [43,47,53,54], acidic oligosaccharide [42] or a mix- 
ture of GOS and FOS [32,35,39,41,49]. Two studies used 
long chain FOS [32,41]. One study used poly dextrose 
with GOS [56]. The doses ranged from 0.15 g to 0.8 g/ 
100 ml. Treatment duration ranged from 28 days to 12 
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     Figure 2 Process of study selection. 
 
 
 
months. The prebiotic studies were conducted in China 
(Nanjing), Greece, Germany (Griefswald), Italy (Ferrara, 
Milan, Turin, Verona), Spain (Los Palmas, Seville) and 
USA (Iowa). None of the prebiotic studies reported data 
on hospitalisation and immune response. 
Risk of bias 
The risk of bias of the included studies was assessed 
across six domains using guidelines from the Cochrane 
Handbook for Systematic Reviews of Interventions (Hig- 
gins 2008). See Figure 3. 
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Table 1 Excluded studies, with reasons for exclusion 
 
 
Reasons for exclusion of studies 
Use of breast milk or mixed feeds (breast 
milk, formula, other milk – cow, buffalo, 
goat milk) 
No use of probiotic, 
prebiotic 
Cross over trial / 
study, Not RCT 
Type of feed not 
clear / specified 
Different inclusion criteria or outcomes Data for end of 
treatment period not available 
Data presentation 
inappropriate for 
Meta -analysis 
Allen 201061 Magne 200879 Brunser 198967 Bongers 200766 Panigrahi 200882 Augustina 200760 Isolauri 200073 Rautava 200983 Decsi 200570 
Baldeon 200865 Mah 200780 Thibault 200491 Euler 200571 Karvonen 199996 Alliet 200762 Knol 200575  Rinne 200585 
Chandra 200268 Rinne 200686  Kim 200774 Karvonen 200197 Bakker-Zierikzee 200563 Nopchinda 200281  Velaphi 200894 
Kuitunen 200976 Saavedra 200488  Rigo 200184  Bakker-Zierikzee 200664 Rivero 200487   
Kukkonen 200777 Sepp 199390  Savino 200389  Correa 200569 Urao 199992   
Kukkonen 200878 Vendt 200695    Hol 200872 Van der Aa 201093   
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Table 2 Summary of 10 included probiotic studies 
Probiotic studies Location  Inclusion criteria Treatment used in study 
groups, n =  
Treatment duration Reported outcomes 
Brunser 200638 Santiago - Chile 37 – 42 weeks gestation 3000 – 4200 
g birth weight 
1) Probiotic: L Johnsonii La1 
108 cfu/ g powder n=25 
2) Prebiotic: FOS 2g n= 32/L  
3) Breastfeeding n= 26 
4) In Placebo group: 
Conventional infant formula no 
probiotic or  
 prebiotic n= 33  
13 weeks Average formula intake (ml/kg)  
Fecal excretion of bifidobacteria, 
Lctobacillus, Enterobacteria 
(Log10(CFU)/g stool) 
Chouraqui 200440 France Infants < 8 months  1) Probiotic: B. lactis Strain 
Bb12 1.5 X106 cfu/g powder,  
n=46 
2) In Placebo group: 
Conventional infant formula no 
probiotic  
 or prebiotic, n=44 
148 days Diarrhea, stools/day, Spitting , 
regurgitation 
Gibson 200944 Adelaide -Australia > 37 weeks gestation, birth weight 
2500 - 4500 g,<10 days old 
1) Probiotic group: Bifibacterium 
lactis. 3.85 X 108 cfu/g  
100kcal, n=  72 
2) Placebo group: Conventional 
infant formula no probiotic,  
 n=70 
7 months Growth: Weight, length, head 
circumference 
Stool characteristics (data not 
shown) 
Stools, colic, spitting up, vomiting 
and restlessness 
Mean daily volume of formula 
intake 
GI infections, Respiratory 
infections 
Haschke-Becher 200845 Santiago - Chile 36 - 44 weeks gestation, birth weight 
> 2500 g at 16 weeks of age 
1) Probiotic group: Lactobacillus 
Johnsonii 1X108 cfu/g powder  
 yielding 0.8 to 1.1 X108 cfu/ 
200 mls formula, n= 17 
2) Placebo group: conventional 
infant formula no probiotic,  
 n= 18 
3) Reference group: Human 
milk, n==23 
4 weeks Growth: Weight, length, 
Formula intake 
Langhendries 199546 Belgium, St Joseph-
Montegnee-Rocourt 
Healthy Full term infants 1) Probiotic group: Bifibacterium 
Bifidum 106 cfu/g powder,  
 n= 20 
2) Placebo group: conventional 
infant formula no probiotic,  
 n= 20 
3) Reference group: Human 
milk, n= 14 
2 months Bifidobacteria, Bacteriodes, 
Enterobacteria Log10 (CFU) / g of 
faeces 
Petschow 200548 Iowa, USA Healthy full term infants, weight 
>2500g, appropriate for gestational 
age (0-3 months of age) 
1) Probiotic group: Lactobacillus 
GG 1X106 cfu/g powder  
 ielding 108 cfu/day, n=15 
2) Probiotic group: Lactobacillus 
GG 1X107 cfu/g powder   
yielding 109 cfu/day, n= 14 
7 day baseline, 14 days 
treatment period, 14 days follow 
up 
Stool frequency, stool consistency 
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Table 2 Summary of 10 included probiotic studies (Continued) 
   3) Probiotic group:: Lactobacillus GG 1X108 
cfu/g powder  yielding 1010 cfu/day, n= 15 
4) Placebo group: Conventional infant 
formula no probiotic,  n= 15 
  
Urban 200850 Johanesburg South 
Africa 
37 - 42 weeks gestation, 2500 - 
4200 g birth weight, born to HIV+ 
mothers but infants tested HIV-  
1) Probiotic group Acidified formula and 
Bifidobacterium lactis n= 29 (cfu/g powder is 
not specified) 
2) No probiotic group: Acidified formula no 
probiotic, n= 28 
3) Placebo group: Conventional infant 
formula, (whey adapted  formula), n= 28 
4 months (119 days) Growth: Males: Weight gain, 
length and head circumference 
Females: Weight gain, length 
and head circumference 
Weizman 200551 Beer - Sheva Israel > 38 weeks gestation, 4-10 months 
old 
1) Probiotic group: Bifidobacterium Lactis 
(BB-12) 1X107 cfu/g  powder , n= 73 
2) Probiotic group: Lactobacillus reuteri 
1X107 cfu/g powder, n= 68 
3) Placebo group: Conventional infant 
formula no probiotic,  n= 60 
12 weeks Episodes of diarrhea,  
Volume of feed / day 
Episodes of respiratory illness, 
antibiotic use, clinic visits 
Weizman 200652 Beer - Sheva Israel > 38 weeks gestation, < 4 months 
(3 - 65 days of age) 
1) Probiotic group:: Bifidobacterium Lactis 
(BB-12) 1X107 cfu/g  powder yielding 2.2 
X108 cfu/180 mls reconstituted formula,  
 n= 20 
2) Probiotic group: Lactobacillus reuteri 
1X107 cfu/g powder yielding 2.2 X108 
cfu/180 mls reconstituted formula , n= 20 
3) Placebo group: Conventional infant 
formula no probiotic,  n=19 
4 weeks Growth: Weight, length, head 
circumference (final percentiles) 
Stooling effort score, stooling 
consistency score 
Daily crying score and daily 
crying episodes 
Formula volume (mls/kg) 
Ziegler 200355 Iowa USA > 37 weeks gestation, Birth weight 
2500g - 4500g (6 - 10 days of age) 
1) No probiotic group: Reduced Protein 
formula no probiotic or  prebiotic n=40 
2) Probiotic group: Reduced protein formula, 
Bifidobacterium   lactis 3.6 X107 cfu/g 
powder yielding 4.8 X109 cfu/L  reconstituted 
formula , n= 40 
3) Placebo group: Conventional infant 
formula, no probiotic,     n=42 
112 days Growth: Males: Weight, length, 
Females, weight, length 
Stool consistency 
Crying, colic (data not shown) 
Hospitalization, diarrhea, 
diarrhea (No. of episodes) 
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Table 3 Summary of 12 included prebiotic studies 
 
 
Prebiotic studies Location  Inclusion criteria Treatment used in study groups, n =  Treatment 
duration 
Reported outcomes 
Bettler 200637 USA <14 days postnatal age, birth weight 
and current weight between 10 - 90 
percentiles for age, 
1) Prebiotic group: FOS 1.5 g/L n=72 12 weeks Growth: Weight, length, Head circumference 
2) Prebiotic group: FOS 3.0 g/L n= 74 
3) Placebo group: Conventional infant formula no 
prebiotic,  n=66 
Bruzzese 200939 Milan, Napoli, Verona 
Italy 
37 to 42 weeks gestation, > 2500g 
birth weight, 4 to 6 months old 
1) Prebiotic group: GOS, FOS (ratio 9:1) 0.4 g/100 ml 
n= 96 
12 months Growth, Weight, length. Stool consistency 
Infections: diarrhea episodes / child 12 
months, episodes of acute diarrhea, 
episodes of  URTI, antibiotic use 
2) Placebo group: conventional formula with no 
prebiotic, N= 105 
Costalos 200841 Greece Birth weight between 10th and 90th 
percentiles, no breastfeeding after 
age of 14 days 
1) Prebiotic group: 90% G0S 10% LcFOS 0.4 g/100 ml 
n=70 
6 weeks Growth: Weight gain, length  and head 
circumference gain 
Stool frequency, consistency. GI Microflora: 
Bifidobacteria, E coli 
2) Placebo group: Conventional formula no prebiotic 
n=-70 
Fanaro 200542 Ferrara, Italy Healthy full term infants, without 
antibiotic treatment 
1) Prebiotic group: Acidic Oligosaccharides 0.2 g/dl,  
Maltodextrin 0.2 g/dl n= 16 
6 weeks Growth: Weight  and length gain. Stool 
consistency, Crying, regurgitation and 
vomiting episodes, GI Microflora 2) Prebiotic group: Acidic Oligosaccharides 0.2 g/dl, 
Neutral GOS FOS 0.6 g/dl n= 15 
3) Placebo group: Maltodextrin at 8g/dl n=15 
Fanaro 200843 Ferrara, Turin Italy, Las 
Palmas, Seville Spain 
Appropriate for gestational age, birth 
weight > 1500g, 4 to 6 months old 
1) Prebiotic group: GOS 5 g/L n= 56 18 weeks Growth: Weight, length, Stool frequency, 
consistency 
GI microflora: Bifidobacteria, Lactobacilli, 
Bacteriodes, Clostridia, Enterobacteriacae 
2) Placebo group: Maltodextrin at 5g/L n=59 
Moro 200235 (Moro 2003, 
considered as one study) 
Milan Italy 39 to 40 weeks gestational age 1) Prebiotic group: GOS, FOS 0.4 g/dl n=30 28 days Growth: Weight  and length gain 
Stool frequency, consistency 
Crying, regurgitation and vomiting, Feeding 
volume 
GI microflora: Bifidobaceria, Lactobacilli 
2) Prebiotic group: GOS FOS 0.8 g/dl n= 27 
3) Placebo group: Maltodextrin at 0.8g/dl n=33 
4) Reference group: Breast milk n=15 
Moro 200547 Italy Healthy full term infants, appropriate 
for gestational age 
1) Prebiotic group: GOS 0.8g/dl, n= 16 28 days Growth: Weight,  length gain 
Feeding volume, GI microflora 2) Placebo group: Maltodextrin at 0. 8g/dl n=16 
Moro 200637 (Arslanoglu 2007, 
Arslanoglu 2008 considered 
as one study) 
Milan Italy 37 - 42 weeks gestational age 1) Prebiotic group: ScGOS Lc FOS at 8g/L, n= 104 6 months Growth: Weight gain, length gain, head 
circumference 
Stool frequency, consistency 
Crying, regurgitation and vomiting 
GI microflora: Bifidobacteria, Lactobacilli, 
Infectious episodes: Overall infections, URTI, 
Otis Media, GI infections, UTI, antibiotic use 
2) Placebo group: Maltodextrin at 8g/L, n=102 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 pg. 80 
 
Table 3 Summary of 12 included prebiotic studies (Continued) 
 
 
Prebiotic studies Location  Inclusion criteria Treatment used in study groups, n =  Treatment 
duration 
Reported outcomes 
Schmelzle 200349 Griefswald Germany 37 to 42 weeks gestational age, birth 
weight between 10 to 90 percentiles, 
exclusive formula feeding by age 14 
days old. 
1) Prebiotic group: 90% GOS, 10% FOS 0.8/100ml 
n=76 
12 weeks Growth: Males - Weight gain, length gain, 
head circumference, 
Females - Growth: Weight gain, length gain, 
head circumference 
Volume of feed (formula) 
GI microflora: Bifidobacteria 
2) Placebo group: Conventional infant formula,  
no prebiotic,   n=78 
Xiao-Ming 200453 Nanjing China Healthy full term infants 1) Prebiotic group: Galactooligosaccharide 0.24 g/ dl 
n=69 
6 months GI Microflora: Bifidobacteria, Lactobacilli, E 
coli 
2) Prebiotic formula with Human milk n= 124 
3) Placebo group: Conventional infant formula, no 
prebiotic, n=52 
4) Reference group : Human milk n= 26 
Xiao-Ming 200854 Nanjing China > 38 weeks gestation, Birth weight > 
3kg. 
1) Prebiotic group 1: Galactooligosaccharide 0.24 g/ 
100 ml  
n=37 
3 months Growth: Weight gain, length gain 
Stool consistency 
Crying, regurgitation and vomiting scores, 
Volume of feed  
GI Microflora: Bifidobacteria, Lactobacilli, E 
coli 
2) Prebiotic group 2:  Prebiotic formula with Human 
milk  n= 58 
3) Placebo group: Conventional infant formula, no 
prebiotic,   n=45 
4) Reference group : Human milk n= 24 
Ziegler 200756 USA > 37 weeks gestation, Birth weight 
2500g, solely formula fed 
1) Prebiotic group 1: Polydextrose, 
Galactooligosaccharide  n=58 
120 days Growth: Weight gain, length gain, head 
circumference 
Stool frequency, consistency 
Intolerance to formula: Vomiting, diarrhea, 
excessive spitting, colic 
2) Prebiotic group 2: Polydextrose, 
Galactooligosaccharide, Lactulose n= 48 
3) Placebo group: Conventional infant formula, no 
prebiotic, n=58 
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Table 4 Summary of 3 included synbiotic studies 
 
Probiotic studies Location  Inclusion criteria Treatment used in study groups, n =  Treatment duration Reported Outcomes 
Chouraqui 200824 France (Marseille) 
37 – 42 weeks, gestation,  < 14 
days singletons, 2500 – 4500g 
birth weight 
1) Probiotic group: Bifibacterium Longum BL999 
1.29 X108  cfu/100 ml formula, L.Rhamnosus 6.45 
X108 cfu/100 ml formula, n=60 
4 months, observation: 
16 – 52 weeks 
Growth: Length, Head circumference 
Stool frequency, consistency,  
Incidence of diarrhea during treatment period  
Frequency of infections 2) Synbiotic group 1: Bifibacterium.Longum BL999 
1.29 X108 cfu/100 ml, L Rhamnosus 6.45 X108 
cfu/100 ml, 90% GOS, 10% ScFOS 0.4 g/100 ml 
n=54 
3) Synbiotic group 2: Bifibacterium Longum BL999 
2.58 X108  cfu/100 ml, LParacasei 2.58 X108 
cfu/100 ml, 90% GOS, 10% ScFOS 0.4 g/100 ml,  
n=60 
4) Placebo group: Conventional infant formula no 
probiotic or prebiotic, n=53 
Puccio 200725 Palermo Italy 
Healthy Full term infants with 
gestational age 39 weeks 
1) Synbiotic group: Bifibacterium Longum BL 999 2 
X 107 Cfu/g powder, GOS 90% FOS 10% at 4g/L, 
n=42, n=67 
112 days 
Growth: Weight, length, head circumference  
2) Conventional infant formula no synbiotic, n=55 Stool frequency (evacuations/day)  
Crying, restlessness, colic, spitting  
and vomiting 
Volume of feed tolerated  
Frequency of respiratory tract infections 
Vlieger 200921 
Niewegein, 
Netherlands 
Healthy Full term infants with 
gestational age > 37 weeks, < 7 
days, formula fed 
1) Synbiotic group: : Bifibacterium animalis ssp 
Lactis 1 X 107 Cfu/g powder, Lactobacillus. 
paracasei 1 X 107 Cfu/g powder, GOS 0.24 g/100 
ml, n=67 
6 months 
Growth: Weight, length, head circumference  
2) Placebo group: Prebiotic infant formula GOS 
0.24 g/100 ml, n=59 
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Table 5 Summary of 3 on-going studies 
On-going studies Location  Inclusion criteria Treatment used in study 
groups, n =  
Outcomes, Estimated date of 
completion.  
Cabana 201057 USA >37 weeks gestation, birth 
weight >2500 g and < 4500 
g, 14+3 days of age on 
enrollment, singleton birth, 
non- breastfed, not received 
solid foods. 
1) Study group 1: Test starter infant 
formula 
Primary: Weight gain (g/day) at 14 to 
112 days of life (4 months) 
2) Study group 2: Test starter infant 
formula  with synbiotics 
Secondary: Tolerance, morbidity, 
protein status, metabolic markers, 
 December 2011 3) Control /placebo group: Standard 
formula 
Zegerman  200958 Israel 37th and 42 week gestation, 
birth weight > 2500 g, 
recruitment age: 0 -28 days, 
non-breastfed 
1) Study group 1: Dietary Supplement:  
probiotic microorganism and/or 
prebiotic 
Primary: weight, length, head 
circumference 
2) Dietary Supplement: probiotic 
microorganism and/or prebiotic 
Secondary: Microbiology, August 2012 
2) Dietary Supplement: probiotic 
microorganism and/or prebiotic 
Ye 201059 Singapore > 37 weeks to < 42 weeks 
gestation, singleton birth. 
Age at enrolment < 14 days 
old 
1) Study group 1: Standard infant 
formula with prebiotics 
Primary: Mean Weight gain 
2) Study group: Infant formula with 
synbiotics 
Secondary: Digestive tolerance,  
December 2011 
 
Random sequence generation 
Fifteen trials described clearly the methods used for 
random sequence generation [21,24,32,37-41,43,44,46, 
49-52]. Random sequence generation was done through 
computer randomization [21,37,38,43,44,50-52], random 
number tables [39,46] or block randomization [32,40,41]. 
The  method  used  for  random   sequence   generation 
was not clearly described in 10 studies [25,35,42,45, 
47,48,53-56]. 
 
Allocation concealment 
In seven trials, treatment allocation was adequately con- 
cealed  [32,38,42,44,46,49,50].  Allocation   concealment 
was adequate due to central allocation using a computer 
[38], use of sealed envelopes [43,44,49], pre – coded or 
colour coded containers [32,50] and use of  independent 
staff outside of study [46]. In the rest of the 18 studies, 
allocation concealment was not clearly demonstrated or 
described  [21,24,25,35,37,39-42,45,47,48,51-56]. 
 
Blinding 
Adequate blinding of study participants, care providers 
and assessors was done in 9 trials. Blinding was ensured 
by using pre-coded or colour coded formula tins 
[21,24,25,32,38,43,44,46,50]. In the other 16 trials, there 
was not enough information given on the blinding method 
to make a judgement [35,37,39-42,45,47-49,51-56]. 
 
Incomplete outcome data 
Reported outcome data was satisfactory for 19 studies. 
In 3 studies, there was no missing outcome data 
[38,40,54]. In 16 studies, missing outcome data was 
balanced  across  the  intervention  groups  with  similar 
reasons reported  [21,24,25,32,37,39,41-45,49-52,55].  In 
4 studies there was insufficient information given to per- 
mit a judgement [35,46,47,53]. In 2 studies there were 
no reasons given for missing data [48,56]. 
 
Selective reporting 
In 7 studies, the pre-specified  outcomes  in  the  meth- 
ods section were reported in the results section 
[21,25,32,45,49,54,56]. In 18 studies the pre-specified 
outcomes were not reported [24,35-44,46,48,50-55]. 
 
Other potential sources of bias 
Nineteen studies appeared to be free from other poten- 
tial sources of bias [21,24,25,32,38-46,49-52,54,56]. 
There was insufficient information given to permit a 
judgment in 6 studies [35,37,47,48,53,55]. 
 
Effects of interventions 
Synbiotics versus controls 
Three studies (N = 475) investigated the effect of synbio- 
tic administration versus no synbiotic or placebo (con- 
trol group) [21,24,25]. 
 
Primary outcomes 
Growth parameters 
 
(i) Weight gain 
Only one study [24] reported weight gain in terms of 
grams per day (g/day). In this study, two types of 
synbiotics (Type 1 and Type 2) were evaluated and 
results for boys and girls were reported separately. The 
results of the two synbiotics were combined using the 
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  Figure 3 Methodological qualities of included studies. 
combined mean and pooled standard deviation. 
The calculated treatment effects showed that 
synbiotics failed to significantly increase weight 
gain for boys (MD 0.90, 95% CI: -1.95 to 3.75, n 
= 81) and girls (MD 0.90, 95% CI: -1.81 to 3.61, 
n = 86) compared to the controls. One study 
[21] reported weight gain in terms of some 
score scale. A calculated treatment effect 
showed that synbiotics failed to significantly 
increase weight gain compared to controls (MD 
−0.07, 95% CI: -0.43 to 0.29, n = 79). Since the 
score scale can take negative values, the values 
of mean and standard deviation in this analysis 
do not necessarily imply that the data is skewed. 
One study [25] reported weight gain (g/day) in 
terms of mean difference (MD) and 90% CI. 
These values were used in calculating the 
corresponding standard error (SE). The MD and 
SE were used in calculating the treatment effect 
(via the generic-inverse variance method in 
RevMan). Synbiotics again failed to significantly 
increase weight gain compared to controls (MD 
−1.09, 95% CI: -3.54 to 1.36, n= 97). 
(ii) Length gain 
Two studies [24,25] reported length gain in 
terms of millimetres per month (mm/month) 
for boys and girls separately. Results from these 
two studies were pooled in a meta-analysis but 
for Chouraqui 2008 [24] results for the two 
types of synbiotics were combined before meta-
analysis. Results from the meta-analysis showed 
that synbiotics failed to significantly increase 
length gain compared to controls for both boys 
(MD 0.75, 95% CI: -0.66 to 2.17, n = 126) and 
girls (MD 0.75, 95% CI: -0.63 to 2.13, n = 138) 
[Figure 4]. There was no significant 
heterogeneity detected between the two studies 
for boys (Chi
2
=0.50, df=1, p=0.48, I
2
=0%) and 
girls (Chi
2
=0.53, df=1, p=0.47, I
2
=0%). 
One study [21] reported length gain in terms of 
some score scale. A calculated treatment effect 
showed that synbiotics failed to significantly 
increase length gain compared to controls (MD 
0.01, 95% CI: -0.43 to 0.45, n = 79). Since the 
score scale can take negative values, the values 
of mean and standard deviation in this analysis 
do not necessarily imply that the data is skewed. 
(iii) Head circumference gain 
Two studies [24,25] reported head 
circumference gain in terms of mm/month for 
boys and girls separately. Results from these 
two studies were pooled in a meta-analysis but 
for Chouraqui 2008 [24] results for the two types 
of synbiotics 
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   Figure 4 Synbiotics versus controls, Outcome: Length gain (mm/month) for girls. 
 
were combined before meta-analysis. Results from 
the meta-analysis showed that synbiotics failed 
to significantly increase head circumference 
gain compared to controls for both boys. 
(MD −0.06, 95% CI: -0.96 to 0.85, n = 126) and 
girls (MD −0.05, 95% CI: -0.94 to 0.85, n = 138). 
There was no significant heterogeneity detected 
between the two studies for both boys (Chi
2
=0.64, 
df=1, p=0.43, I
2
=0%) and girls (Chi
2
=0.67, df=1, 
p=0.41, I
2
=0%). 
One study [21] reported head circumference gain in 
terms of some score scale. A calculated treatment 
effect showed that synbiotics failed to significantly 
increase head circumference gain compared to 
controls (MD 0.01, 95% CI: -0.38 to 0.36, n = 79). 
Since the score scale can take negative values, the 
values of mean and standard deviation in this 
analysis do not necessarily imply that the data is 
skewed. 
 
Secondary outcomes 
Tolerance to formula 
 
(i) Stool frequency 
Two studies [21,25] reported stool frequency 
(evacuations per day) and their results were pooled 
in a meta-analysis. Synbiotics significantly 
increased stool frequency compared to the 
controls (MD 0.28, 95% CI: 0.08 to 0.48, n = 176) 
and therewas no significant heterogeneity detected 
between the two trials (Chi
2
=0.93, df=1, p=0.33, 
I
2
=0%) [Figure 5]. 
One study [25] reported stool frequency 
(evacuations per day) but values for standard 
deviations were not given and as a result, no 
treatment effect could be calculated. 
(ii) Stool consistency 
One study [21] evaluated stool consistency using a 
consistency score (1=hard to 4=watery and loose) and 
a calculated treatment effect showed no significant 
difference between the synbiotic and control treated 
groups (MD 0.13, 95% CI: -0.15 to 0.41, n = 79). 
One study [24] study reported that liquid stools 
occurred significantly more frequently in the 
synbiotic group compared to the control group (OR 
3.17, 95% CI: 1.59 to 3.60, n = 66). 
Puccio 2007 [25] reported that data on stool 
consistency showed no statistically significant 
differences between the two study groups (data not 
shown in study report). 
(iii) Incidence of colic, spitting up / regurgitation, 
vomiting, crying 
Data on frequency of crying, restlessness, colic, 
spitting and vomiting reported by Puccio 2007 [25] 
showed no statistically significant differences 
between the two study groups (data not shown in 
study report). 
Results from Vlieger 2009 [21] showed no significant 
differences in the frequency of vomiting (RR 0.46, 95% 
CI: 0.12 to 1.72, n = 79) and colic (RR 2.50, 95% 
CI: 0.46 to 13.73, n = 79) between the two study 
groups. The same study showed no difference in crying 
(hours per day) between the two study groups (MD 
−0.10, 95% CI: -0.46 to 0.26, n = 79). 
(iv) Average formula intake 
One study [25] reported the mean daily intake of 
formula in a graph where no values could be retrieved. 
 
 
 
 
 
 
 
 
 
 
    Figure 5 Synbiotics versus controls, outcome: Stool frequency (evacuations per day). 
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One study [25] reported the mean daily intake of 
formula in a graph where no values could be retrieved. 
 
Infections 
 
(i) Infections 
Puccio 2007 [25] reported data on frequency of 
respiratory tract infections but there were no 
significant differences between the synbiotic and 
control treated groups (RR 0.71, 95% CI: 0.31 to 
1.59, n = 97). 
Vlieger 2009 [21] reported the mean (SD) of upper 
respiratory tract infections and gastrointestinal 
infections (times per month) but no treatment 
effect could be calculated because the data was 
skewed (mean < SD). 
(ii) Antibiotic intake 
Vlieger 2009 [21] reported the mean (SD) of the 
use of antibiotics (times per month) but no 
treatment effect could be calculated because the 
data was skewed (mean < SD). 
 
Probiotics versus controls 
Ten studies (N = 933) investigated the effect of probiotic 
administration versus no probiotic (Control group) 
[38,40,44-46,48,50-52,55]. 
 
Primary outcomes: growth parameters 
 
(i) Weight gain 
Four studies [24,44,50,55] reported weight gain 
(g/day) for boys and girls separately. The results 
from these four studies were pooled in meta- 
analyses separately for boys and girls. Probiotics 
failed to significantly increase weight gain compared 
to the controls for boys (MD 1.64, 95% CI: -0.36 to 
3.64 n = 158), no statistically 
significant heterogeneity was detected between the 
studies for boys (Chi
2
=3.43, df=3, p=0.33, I
2
=13%). 
However, statistically significant heterogeneity was 
observed for girls (Chi
2
=9.90, df=3, p=0.02, 
I
2
=70%). An investigation of heterogeneity using 
subgroup analysis with respect to the type of 
formula (normal/ acidified/ reduced protein) 
yielded the following results. Two studies [24,44] 
showed that normal formula with probiotics failed 
to significantly increase weight gain compared to 
the controls for girls (MD 1.33, 95% CI: -0.76 to 
3.41, n = 113) with no significant heterogeneity 
between the two studies (Chi
2
=0.08, df=1, p=0.78, 
I
2
=0%). Urban 2008 [50] showed that acidified 
formula with probiotics significantly increased 
weight gain in probiotic group compared to 
controls for girls (MD 5.30, 95% CI: 0.46 to 10.14, 
n = 28). Ziegler 2003 [55] showed that reduced 
protein formula with probiotics significantly 
reduced weight gain compared to controls for girls 
(MD −4.80, 95% CI: -9.18 to −0.42, n = 29)  
(Figure 6). 
(ii) Length gain 
Four studies [24,44,50,55] reported length gain 
for boys and girls separately. Two studies reported 
in terms of mm/month and two studies reported in 
terms of mm/day. The latter two studies results 
were converted to mm/month by multiplying both 
the mean and SD by 28, assuming a 4 week/ 28-
day month. Results from these four 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Figure 6 Probiotics versus controls, outcome: Weight gain (g/ day) for girls. 
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studies were pooled in meta-analyses separately for 
boys and girls. Probiotics failed to significantly 
increase length gain compared to the controls for 
both boys (MD −0.37, 95% CI: -1.64 to 0.90, n = 
158) and girls (MD 0.32, 95% CI: -0.81 to 1.45, n 
=165). No statistically significant heterogeneity was 
detected between the studies for both boys 
(Chi
2
=3.49, df=3, p=0.32, I
2
=14%) and girls 
(Chi
2
=2.94, df=3, p=0.40, I
2
=0%).  
(iii) Head circumference gain 
Three studies [24,44,50] reported length gain for 
boys and girls separately. Two studies reported in 
terms of mm/month and one study reported in 
terms of mm/day. The latter study's results were 
converted to mm/month by multiplying both the 
mean and SD by 28 (assuming a 4 week/ 28-day 
month). Probiotics failed to significantly increase 
head circumference gain compared to the controls 
for both boys (MD 0.76, 95% CI: -1.02 to 2.54, n = 
125) and girls (MD 0.27, 95% CI: -0.70 to 1.23, n = 
139). No statistically significant heterogeneity was 
detected between the studies for both boys 
(Chi
2
=3.87, df=2, p=0.14, I
2
=48%) and girls 
(Chi
2
=1.12, df=2, p=0.57, I
2
=0%). 
 
Secondary outcomes 
Tolerance to formula 
 
(i) Stool frequency 
Two studies [40,48] reported stool frequency 
(evacuations per day) and meta-analysis of results from 
these studies showed that probiotics failed to 
significantly increase stool frequency compared to 
controls (MD 0.01, 95% CI: -0.44 to 0.46, n = 120). 
There was no significant heterogeneity between the 
studies (Chi
2
=0.19, df=1, p=0.66, I
2
=0%). Since 
Petschow 2005 [48] evaluated different probiotic 
dosages, the highest dosage was chosen for the analysis. 
(ii) Stool consistency 
One study [48] reported stool consistency score 
(1–5: 1=hard, 2=formed, 3=soft, 4=loose, 
5=watery). A calculated treatment effect showed 
that there was no difference in consistency score 
between the probiotic and control groups (MD 
0.00, 95% CI: -0.33 to 0.33, n = 30). 
Chouraqui 2008 [24] reported that liquid stools 
occurred significantly more frequently in the 
probiotic group compared to the control group (OR 
2.79, 95% CI: 1.48 to 5.29, n = 64). 
Ziegler 2003 [55] reported stool consistency in 
terms of mean (SD) separately for hard, formed, 
soft and liquid stools but no treatment effect was 
calculated because the data was skewed (mean < 
SD). Weizman 2006 [52] reported results for stool 
consistency score but again the data was skewed  
(mean < SD). 
(iii) Episodes of diarrhoea 
Ziegler 2003 and Weizman 2005 [52,55] reported 
episodes of diarrhoea in terms of mean (SD) but no 
meta-analysis was done because their results show 
that the data was skewed (mean < SD). 
Chouraqui 2004 and Chouraqui 2008 [24,40] 
reported the frequency of diarrhoea but meta- 
analysis of their results showed no benefit from 
probiotic treatment compared to controls (RR 0.80, 
95% CI: 0.46 to 1.38, n = 209). No statistically 
significant heterogeneity was detected between the 
studies (Chi
2
=0.61, df=1, p=0.44, I
2
=0%). 
(iv) Incidence of colic, spitting up / regurgitation, 
vomiting, crying 
Chouraqui 2004 [40] reported the number of infants 
having spitting or regurgitation and there was no 
difference observed between the probiotic and 
control groups (RR 0.80, 95% CI: 0.26 to 2.42, n = 
90). Weizman 2006 [52] reported the daily crying 
episodes and there were significantly less crying 
episodes in favour of the control group (MD 0.60, 
95% CI: 0.20 to 1.00, n = 59). The results from the 
two probiotic groups were combined before meta-
analysis. Gibson 2009 [44] reported that stools, 
colic, spitting up, vomiting, restlessness occurred at 
similar frequencies in the two groups (data not 
shown in report). Ziegler 2003 [55] reported that 
that there was no significant formula effects on 
crying and colic (data not shown in report). 
(v) Average formula intake 
One study [38] reported the average formula intake 
(ml/kg body-weight /day) and the calculated 
treatment effect showed no differences between the 
probiotic and control groups (MD 5.00, 95% CI: -
12.60 to 22.60, n = 58). Two studies [44,51] reported 
the average formula intake (ml/day) and meta-
analysis showed that infants in the probiotic group 
had a significantly higher formula intake compared to 
the controls (MD 46.74, 95% CI: 23.93 to 69.54, n = 
292). No statistically significant heterogeneity was 
detected between the studies (Chi
2
=0.45, df=1, 
p=0.50, I
2
=0%). 
 
Infections 
 
Infections 
One study [44] reported the number of infants 
having respiratory infections and the calculated 
treatment effect showed no differences between the 
probiotic and control groups (RR 0.93, 95% CI:0.74 
to 1.17, n = 142). One study [51] reported 
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episodes of respiratory illness in terms of mean 
(95% CI). The mean (95% CI) were used in 
calculating the SDs. However, no treatment effect 
was calculated because the data was skewed (mean < 
SD). One study [44] reported the number of infants 
having gastrointestinal infections and the calculated 
treatment effect showed no differences between the 
probiotic and control groups (RR 0.70, 95% CI: 
0.45 to 1.11, n = 142). 
(i) Antibiotic intake 
One study [51] reported prescription of antibiotics 
in terms of mean (95% CI). The mean (95% CI) 
were used in calculating the SDs. However, no 
treatment effect was calculated because the data 
was skewed (mean < SD). 
 
Hospitalization 
Only one study [55] reported hospitalization but no 
treatment effect was calculated because the data was 
skewed (mean < SD) 
 
Changes in gastrointestinal microflora 
 
(i) Bifidobacteria 
Two studies [38,46] reported results for bifidobacteria 
measured as log10 (CFU) per gram stool. A meta- 
analysis showed that the control group had 
significantly increased counts of bifidobacteria 
compared to probiotic group. (MD −1.27, 95% CI: -
2.03 to −0.51, n = 57). No statistically significant 
heterogeneity was detected between the studies 
(Chi
2
=0.71, df=1, p=0.40, I
2
=0%) [Figure 7]. 
(ii) Lactobacillus 
Only one study [38] reported results for 
lactobacillus, measured as log10 (cfu) per gram 
stool and the calculated treatment effect showed 
that probiotics failed to increase the counts of 
Lactobacillus compared to the controls (MD 0.22, 
95% CI: -0.72 to 1.16, n = 41). 
 
Pathogens 
 
(iii) Enterobacteria 
Two studies [38,46] reported results for 
enterobacteria measured as log10 (cfu) per gram 
stool and meta-analysis showed that probiotics 
significantly reduced counts of Enterobacteria 
compared to the controls (MD −0.61, 95% CI: 
-1.20 to −0.03, n = 51). No statistically significant 
heterogeneity was detected between the studies 
(Chi
2
=0.62, df=1, p=0.43, I
2
=0%). 
(iv) Bacteriodes 
Two studies [38,46] reported results for bacteriodes 
measured as log10 (cfu) per gram stool and meta- 
analysis showed that probiotics failed to significantly 
reduce counts of Bacteriodes compared to the 
controls (MD −0.11, 95% CI: -1.01 to 0.78, n = 51).  
No statistically significant heterogeneity was 
detected between the studies (Chi
2
=0.95, df=1, 
p=0.33, I
2
=0%). 
 
Prebiotics versus controls 
Twelve studies (N = 1563) investigated the effect of 
pre- biotic administration versus placebo or no 
prebiotic in for- mula (Control group) [32,35,37,39,41-
43,47,49,53,54,56]. 
 
Primary outcomes: growth parameters 
 
(i) Weight gain 
Eight studies [32,35,41,42,47,49,54,56] reported 
weight gain (g/day) and meta-analysis of their results 
showed that prebiotics significantly increased weight 
gain compared to the controls (MD 0.97, 95% CI: 
0.24 to 1.70, n = 861). No statistically significant 
heterogeneity was detected between the studies 
(Chi
2
=4.67, df=7, p=0.70, I
2
=0%). Three studies 
[35,42,56] evaluated different types of prebiotics 
(acidic oligosaccharides with maltodextrin or neutral 
GOS FOS, GOS FOS, GOS with polydextrose alone 
or with lactulose). The results for the prebiotics 
in each of these studies were combined before meta-
analysis using combined mean and pooled standard 
deviation (Figure 8). 
(ii) Length gain 
Seven studies [32,35,41,42,47,49,54] reported 
length gain either as cm/week or in units that were 
converted to cm/week. Meta-analysis of their 
results showed that prebiotics failed to significantly 
increase length gain compared to the controls (MD 
0.01, 95% CI: -0.01 to 0.04, n = 697). No 
statistically significant heterogeneity was detected 
 
 
 
 
 
 
 
 
 
    Figure 7 Probiotics versus controls, outcome: Bifidobacteria -log10(CFU) per gram of stool. 
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      Figure 8 Prebiotics versus controls, outcome: weight gain (g/day). 
 
between the studies (Chi2=5.05, df=6, p=0.54, 
I
2
=0%). Two studies [35,42] each evaluated different 
types of prebiotics (Acidic oligosaccharides 0.2 g/dl 
with maltodextrin, acidic oligosaccharides 0.2 g/dl 
with neutral GOS FOS 0.6 g/dl; GOS, FOS 0.4 g/dl 
and GOS FOS 0.8 g/ dl). The results for the 
prebiotics in each of these studies were combined 
before meta-analysis using combined mean and 
pooled standard deviation. 
(iii) Head circumference gain 
Three studies [32,41,49] reported head 
circumference gain either as cm/week or in units 
that were converted to cm/week. Meta-analysis of 
their results showed that prebiotics failed to 
significantly increase head circumference gain 
compared to the controls  
(MD −0.01, 95% CI: -0.02 to 0.00, n = 438). No 
statistically significant heterogeneity was detected 
between the studies (Chi
2
=2.18, df=2, p=0.34, 
I
2
=8%). 
Results from Ziegler 2007 [56] were not used 
because they reported head circumference gain only 
at 30 days and not at the end of treatment period 
which was 120 days. (All other studies reported 
results for end of treatment period). 
 
Secondary outcomes 
Tolerance to formula 
 
(i) Stool frequency 
Four studies [32,35,43,56] reported stool frequency 
(evacuations per day) and meta-analysis of their 
results showed that prebiotics significantly 
increased stool frequency compared to the controls 
(MD 0.18, 95% CI: 0.06 to 0.30, n = 539). No 
statistically significant heterogeneity was detected 
between the studies (Chi
2
=2.97, df=3, p=0.40, 
I
2
=0%). Two studies [35,56] each evaluated 
different types of prebiotics (GOS FOS; GOS with 
polydextrose alone or with lactulose). The results 
for the prebiotics in each of these studies were 
combined before meta- analysis using combined 
mean and pooled standard deviation. 
Costalos 2008 [41] reported the median (range) of 
stool frequency (Table 6). 
(ii) Stool consistency 
Results from the two studies [32,42] using a 5-point 
scale (1=watery, 2=soft, 3=seedy, 4=formed, 
5=hard) were pooled in a meta-analysis but due to 
significant heterogeneity detected between the two 
studies, their results are reported separately. Stools 
from the prebiotic group were significantly softer 
compared to controls for both Fanaro 2005 [42] 
(MD −1.20, 95% CI: -1.61 to −0.79, n = 46) and 
Moro 2006 [32] (MD −0.78, 95% CI: -1.00 to −0.56, 
n = 206). Fanaro 2005 [42] evaluated two types of 
prebiotics (acidic oligosaccharides with 
maltodextrin or neutral GOS FOS), the results for 
the prebiotics were combined before meta-analysis 
using combined mean and pooled standard 
deviation.  
Fanaro 2008 [43] used an opposite 5 point scale 
(1=hard, 2=formed, 3=seedy, 4=soft, 5=watery) and 
reported the mean (SD) of area under the curve. 
 
Table 6 Stool characteristics 
 
 
Costalos 200841: Median (range) stool characteristics 
Prebiotics (n=70) Controls (n=70) 
Stool frequency 1.9 (1.2-2.1) 1.6 (1.1-1.9) 
Stool consistency 3 (2–3.5) 3.1 (2.5-3.5) 
Moro 200235: Median (IQR) Stool consistency score 
 Prebiotic1 (n=30) Prebiotic2 (n=27) Control (n=33) 
Stool consistency score 3 (1.5) 2.5 (0.75) 4 (1.5) 
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A calculated treatment effect showed that stools 
from the prebiotic group were significantly softer 
compared to controls (MD 0.53, 95% CI: 0.31 to 
0.75, n = 88). 
Results from two studies [54,56] used a 4-point 
scale (1=watery, 2=soft, 3=seedy, 4=formed) were 
pooled in a meta-analysis but due to significant 
heterogeneity detected between the two studies, 
their results are reported separately. Stools from 
the prebiotic group were significantly softer 
compared to controls for both Xiao-Ming 2008 
[54] (MD −0.65, 95% CI: -0.87 to −0.43, n = 82) 
and Ziegler 2007 [56] (MD −0.25, 95% CI: -0.44 to 
−0.06,  
n = 157). Ziegler 2007 [56] evaluated two types of 
prebiotics (GOS with polydextrose alone or with 
lactulose). The results for the prebiotics were 
combined before meta-analysis using combined 
mean and pooled standard deviation. Costalos 
2008 [41] reported the median (range) of stool 
consistency score (Table 6). 
Moro 2002 [35] reported the median (IQR) of stool 
consistency score (Table 6). 
(iii) Diarrhoea 
Two studies [39,56] reported the number of infants 
having diarrhoea and a meta-analysis showed that 
prebiotics failed to significantly decrease the 
incidence of diarrhoea compared to the controls 
(RR 0.62, 95% CI: 0.19 to 1.99, n = 237). No 
statistically significant heterogeneity was detected 
between the studies (Chi
2
=1.65, df=1, 
p=0.20,I
2
=39%). Since Ziegler 2007 [56] evaluated 
two types of prebiotics (GOS with polydextrose 
alone or with lactulose), the number of events and 
totals for the prebiotics were summed before meta-
analysis. 
(iv) Incidence of colic, spitting up / regurgitation, 
vomiting, crying 
Moro 2006 [32] reported no vomiting and very few 
infants crying but the number of infants 
experiencing regurgitation were significantly reduced 
in the prebiotic group compared to the control group 
(RR 0.11, 95% CI: 0.02 to 0.49, n = 206). 
According to Xiao-Ming 2008 [54], there was no 
difference in crying score (MD 0.01, 95% CI: -0.00 
to 0.02, n = 82), regurgitation score (MD −0.01, 95% 
CI: -0.27 to 0.25, n = 82), and vomiting score (MD 
−0.03, 95% CI: -0.21 to 0.15, n = 82) between the 
prebiotic and control groups. All scores were 3 
point scores. Crying score: 1= practically not crying, 
2 = crying in connection to feeding, 3 = crying 
independently from meals. Regurgitation score: 
1 = no regurgitation, 2 = 1–2 regurgitations, 3 = > 2 
regurgitations per day. Vomiting score: 1= no 
vomiting, 2 = 1 episode of vomiting, 3 = >1 episode 
of vomiting. 
Ziegler 2007 [56] reported that none of the infants 
had colic; the numbers having excessive spitting 
were too few; vomiting was similar between the 
two groups (RR 1.12, 95% CI: 0.43 to 2.89, n = 32). 
The prebiotic results were summed for the two 
types before calculation of treatment effect. 
Both Moro 2002 and Fanaro 2005 [35,42] reported 
no difference in the incidence of crying, 
regurgitation and vomiting episodes (data values 
not shown in study reports). 
(v) Average formula intake 
Five studies [35,38,47,49,54] reported formula 
intake (ml/kg body-weight/ day) and meta-analysis 
of their results showed statistically significant 
heterogeneity between the studies (Chi
2
=10.80, 
df=4, p=0.03, I
2
=63%,). Sensitivity analysis by 
removing the one study [49] showing significantly 
less formula intake for the prebiotics (MD −21.00, 
95% CI: -31.86 to −10.14, n = 101) yielded no 
significant heterogeneity between the four 
remaining studies (Chi
2
=1.79, df=3, p=0.62, I
2
=0%) 
but no significant difference between the two 
groups (MD 0.31, 95% CI: -8.40 to 9.02, n = 269). 
The prebiotic results for the two types of 
prebiotics (GOS, FOS 0.4 g/dl, GOS FOS 0.8 g/dl) 
in Moro 2002 [35] were combined before meta-
analysis using combined mean and pooled 
standard deviation. 
 
Infections 
 
(i) Infections 
According to Moro 2006 [32], prebiotics 
significantly reduced overall infections compared 
to the controls (RR 0.45, 95% CI: 0.29 to 0.69, n = 
204). The number of infants having 
gastrointestinal infections, urinary tract infections 
(UTI) and otitis media were very few [32]. 
Two studies [32,39] reported the number of 
infants with upper respiratory tract infections 
(URTI) and their results were pooled in a meta-
analysis. However, due to significant heterogeneity 
detected between the two studies (Chi
2
=7.69, 
df=1, p=0.006, I
2
=87%), their results are reported 
separately. Although Moro 2006 [32] showed that 
the prebiotic group significantly reduced the 
number of infants with URTI compared to the 
controls (RR 0.48, 95% CI: 0.27 to 0.84, n = 206), 
there was no difference between the two groups 
according to Bruzzese 2009 [39] (RR 1.07, 95% CI: 
0.86 to 1.33, n = 203). 
(ii) Antibiotic intake 
According to Moro 2006 [32], prebiotics failed 
to significantly reduce antibiotic intake compared 
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to the controls (RR 0.51, 95% CI: 0.26 to 1.00, 
n = 206). 
 
Changes in gastrointestinal microflora 
 
(i) Bifidobacteria 
Five studies [38,42,47,53,54] (n = 280) reported 
Bifidobacteria (log10 CFU per gram stool) and their 
results were pooled in a meta-analysis. However, 
statistically significant heterogeneity was detected 
between the studies (Chi
2
=60.23, df=4, p < 0.00001, 
I
2
=93%). Heterogeneity persisted after conducting 
subgroup analysis with respect to duration of 
supplementation or dosage of treatment. The results 
for each study are therefore reported separately. 
Four studies showed that prebiotics significantly 
increased bifidobacteria: Fanaro 2005 [42] (MD 
0.30, 95% CI: 0.13 to 0.47, n = 46); Moro 2005 [47] 
(MD 2.70, 95% CI: 0.37 to 5.03, n = 32); Xiao-Ming 
2004 [53] (MD 1.90, 95% CI: 1.51 to 2.29, n = 121); 
Xiao-Ming 2008 [54] (MD 0.85, 95% CI: 0.16 to 
1.54, n = 38). The prebiotic results for the two types 
of prebiotics (acidic oligosaccharides with 
maltodextrin or neutral GOS FOS) in Fanaro 2005 
[42] were combined before meta-analysis using 
combined mean and pooled SD. However, Brunser 
2006 [38] showed no significant difference in the 
number of bifidobacteria between the two groups 
(MD −0.39, 95% CI: -1.49 to 0.71, n = 43) 
[Figure 9]. 
Four studies reported their results in median; 
therefore no conclusions could be made. Costalos 
2008 [41] reported the median (range) of 
Bifidobacteria (log10 CFU per gram stool) as a 
percentage of total bacteria (Table 7). Three studies 
[32,35,43] reported the median (IQR) of 
Bifidobacteria (log10 CFU per gram stool) (Table 8). 
(ii) Lactobacillus 
Three studies [38,53,54] reported Lactobacillus 
(log10 CFU per gram stool) and meta-analysis of 
their results showed statistically significant 
heterogeneity between the studies (Chi
2
=26.44, 
df=2, p < 0.00001, I
2
=92%). Sensitivity analysis 
was done by removing the one study [38] that 
showed no difference between the two groups 
(MD −0.30, 95% CI: -1.08 to 0.48, n = 43). This 
yielded no significant heterogeneity (Chi
2
=0.33, 
df=1, p =0.57, I
2
=0%) between the remaining two 
studies. Meta-analysis showed that prebiotics 
significantly increased lactobacillus counts 
compared to the controls (MD 1.96, 95% CI: 1.58 
to 2.34, n = 159). 
Three studies reported their results in median; 
therefore no conclusions could be made. Fanaro 
2008, Moro 2002 and Moro 2006 [32,35,43] 
reported the median (IQR) of Lactobacillus (log10 
CFU per gram stool) (Table 8). 
 
Pathogens 
 
(iii) Enterobacteria 
According to Brunser 2006 [38], there was no 
difference in the number of Enterobacteria counts 
between the prebiotic and control groups (MD 
−0.48, 95% CI: -1.88 to 0.22, n = 43). Fanaro 2008 
[43] reported the median (IQR) of Enterobacteria 
(log10 CFU per gram stool) (Table 8). 
(iv) Bacteriodes 
According to Brunser 2006 [38], there was no 
difference in the number of Bacteriodes between 
the prebiotic and control groups (MD −0.35, 95% 
CI:  
-1.40 to 0.70, n = 43). Fanaro 2008 [43] reported 
the median (IQR) of Bacteriodes (log10 CFU per 
gram stool) (Table 8). 
(v) E. coli 
Two studies [53,54] reported E. coli (log10 CFU per 
gram stool) and their results were pooled in a meta- 
analysis. However, statistically significant 
heterogeneity was detected between the studies 
(Chi
2
=5.96, df=1, p=0.01, I
2
=83%). The results are 
therefore reported separately. Xiao-Ming 2004 [53] 
showed that prebiotics significantly reduced E. coli 
counts compared to the controls (MD −0.90, 95% CI: 
-1.29 to −0.51, n = 121) while Xiao-Ming 2008 [54] 
showed no significant difference between the two 
groups (MD 0.67, 95% CI: -0.53 to 1.87, n = 38). 
 
 
 
 
 
 
 
 
 
 
 
    Figure 9 Prebiotics versus controls, outcome: Bifidobacteria -log10(CFU) per gram stool. 
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Table 7 Summary of findings table: Synbiotic studies 
Effects of infant formula containing Synbiotics on clinical outcomes in full term infants 
Patient or population: Full term infants, Settings: Multi-centre trials, Intervention: Infant formula with synbiotics, Comparison: Conventional infant formula 
Outcomes Illustrative comparative risks* (95% CI) Measure of 
effect         
(95% CI) 
No of Participants 
(studies) 
Quality of the 
evidence (GRADE) 
Assumed risk Corresponding risk 
 
Conventional formula Infant formula with synbiotics 
   
Weight gain (g/day) for boys 
Follow-up: mean 4 months 
The mean (SD) weight gain (g/day) in control group 
was 30.9 (6.1)  
Mean (SD) weight gain in synbiotic group 
was 31.8 (5.9)  
MD (95% CI): 
0.90 (-1.95 to 
3.75) 
81 (1 study) ⊕⊕⊝⊝ 
low1,2 
Weight gain (g/day) for girls 
Follow-up: mean 4 months 
The mean (SD) weight gain (g/day) in control group 
was 26.9 (6)  
Mean (SD) weight gain in synbiotic group 
was 27.8 (6) 
MD (95% CI): 
0.90 (-1.81 to 
3.61) 
86 (1 study) ⊕⊕⊝⊝ 
low3,4 
Length gain (mm/mo) for boys 
Follow-up: mean 4 months 
The mean (SD) length gain (mm/month for boys in 
control group ranged from 32.6 (3.6) to 35.1 (4.4) 
The mean length gain (mm/mo) for boys in 
the intervention groups was 
0.75 higher (0.66 lower to 2.17 higher) 
MD (95% CI): 
0.75 (-0.66 to 
2.17) 
120 (2 studies) ⊕⊕⊝⊝ 
low5,6,7 
Length gain (mm/mo) for girls 
Follow-up: mean 4 months 
The mean length gain (mm/month) for girls in the 
control groups ranged from 31.2 (3.7) to 32.2 (4.6) 
The mean length gain (mm/mo) for girls in 
the intervention groups was 
0.75 higher (0.63 lower to 2.13 higher) 
MD (95% CI): 
0.75 (-0.63 to 
2.13) 
138 (2 studies) ⊕⊕⊝⊝ 
low8,9,10 
Head circumference gain (mm/mo) for boys 
Follow-up: 4 to 6 months 
The mean head circumference gain (mm/month) for 
boys in the control groups ranged from 17.4 (2.9) to 
18.4 (2.3) 
The mean head circumference gain 
(mm/mo) for boys in the intervention groups 
was 0.06 lower (0.96 lower to 0.85 higher) 
MD (95% CI): -
0.06 (-0.96 to -
0.85) 
126 (2 studies) ⊕⊕⊝⊝ 
low11,12 
Head circumference gain (mm/mo) for girls 
Follow-up: 4 to 6 months 
The mean head circumference gain (mm/month) for 
girls in the control groups ranged from 15.5 (3) to 
16.7 (2.4) 
The mean head circumference gain 
(mm/mo) for girls in the intervention groups 
was 0.05 lower (0.94 lower to 0.85 higher) 
MD (95% CI): -
0.05 (-0.94 to 
0.85) 
138 (2 studies) ⊕⊕⊝⊝ 
low13,14 
Stool frequency (evacuations per day) 
Follow-up: 4 to 6 months 
The mean (SD) stool frequency (evacuations per 
day) in the control group ranged from 1.4 (0.49) to 
1.8 (0.9) 
The mean stool frequency (evacuations per 
day) in the intervention groups was 0.28 
higher (0.08 to 0.48 higher) 
MD (95% CI): 
0.28 (0.08 to 
0.48) 
176 (2 studies) ⊕⊕⊝⊝ 
low15,16 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the 
measure of effect of the intervention (and its 95% CI).CI: Confidence interval, MD: Mean Difference. 
GRADE Working Group grades of evidence. High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate. 
1 Small sample size n=81, 95% CI includes no effect. 
2 Possible publication bias. 
3 Small sample size n=86, 95% CI includes no effect. 
4 Possible publication bias. 
5 Allocation concealment not described in 2 studies. 
6 Small sample size n=126,  
7 Possible Publication bias 
8 Allocation concealment not described in 2 studies,  
9 Small sample size n=138,  
10 Possible Publication Bias 
11
 Small sample size n=126,  
12 Possible publication bias,  
13 Small sample size n=138, 14 Possible publication bias,  
15
 Small sample size n=176, 
16
 Possible publication bias. 
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Table 8 Gastrointestinal microflora 
 
 
Costalos 200841: Median (range) as % of total bacteria 
Prebiotics (n=70) Controls (n=70) 
% Bifidobacteria 39.69 (0–143.3) 14.87 (0–101) 
% E.coli 1.95 (0–69.32) 4.06 (0–59.31) 
Fanaro 200843: Median (IQR) microflora -log10(CFU) per gram stool 
 Prebiotics (n=56) Controls (n=59)  
Bifidobacteria 9.86 (8.99-10.18) 9.38 (8.35-9.90) 
Lactobacilli 4.62 (2–6.5) 4 (2–5.05) 
Bacteriodes 7.95 (6.64-9.6) 8.16 (6.3-9.04) 
Clostridia 4.3 (3–5.28) 4.29 (2.48-5.43) 
Enterobacteria 8.65 (8.12-9.13) 8.53 (7.96-9.01) 
E. coli 8.50 (7.9-8.99) 8.33 (7.59-8.83) 
Moro 200235: Median (IQR) 
 Prebiotic1 (n=30) Prebiotic2 (n=27) Control (n=33) 
Bifidobacteria 9.3 (1.6) 9.7 (0.8) 7.2 (4.9) 
Lactobacilli 5.9 (1.5) 5.6 (2.1) 3.4 (1.8) 
Moro 200632: Median (IQR) log10(CFU) per gram stool 
 Prebiotics (n=50) Controls (n=44)  
Bifidobacteria 10.28 (0.7) 8.65 (1.2)  
Lactobacilli 5.99 (3.6) 5.9 (2)  
 
 
Two studies reported their results in median; 
therefore no conclusions could be made. Costalos 
2008 [41] reported the median (range) of E. coli 
(log10 CFU per gram stool) as a percentage of total 
bacteria (Table 8). Fanaro 2008 [43] reported the 
median (IQR) of E. coli and clostridia (log10 CFU 
per gram stool) (Table 8). 
 
Discussion 
The objectives of this systematic review were to 
deter- mine the effects of infant formula containing 
probiotics, prebiotics or both (synbiotics) on clinical 
outcomes in full term infants and to explore if 
synbiotics are superior over probiotics or prebiotics. 
Studies that used  breast milk or mixed feeds (breast 
and infant formula or other types of milk) were 
excluded. All included RCTs evalu- ated either 
synbiotics, probiotics or prebiotics use in full term 
infants. The studies varied in enrolment criteria, 
sample size, intervention and treatment duration. 
 
Summary of main findings 
Synbiotics 
Addition of synbiotics to infant formula did not have any 
significant effect on growth (weight gain, length and head 
circumference). Synbiotics significantly increased stool 
frequency. However, two studies [21,25] reported no 
differences in stool consistency, while one study [24] 
reported an increase in liquid stools in synbiotic  group.  
There were no significant
 
differences between study groups on the incidence and 
frequency of colic, spitting up / regurgitation, crying, 
restlessness or vomiting.  The effect of synbiotics on 
the volume of formula tolerated was not reported. Ef- 
fect of synbiotics on frequency of infections was under 
reported. In one study [25], there were no differences 
in the frequency of infections between study groups, 
while in another study [21], the treatment effect could 
not be calculated or any conclusions made on the fre- 
quency of infections or antibiotic intake. Effects of 
synbiotics on hospitalization, GI microflora and im- 
mune response were not reported in any study there- 
fore these parameters could not be evaluated. 
Interpreting the effects of synbiotic supplementation 
of infant formula on clinical outcomes was difficult due 
to the limited number of studies. The synbiotic studies 
had short treatment duration (4 to 6 months) and treat- 
ment varied in all 3 studies. There was not enough 
evidence to state that synbiotics in infant formula have a 
significant effect on growth or lower the incidence of 
colic, spitting up / regurgitation, crying, restlessness. 
There is limited evidence that synbiotics do increase 
stool frequency and effects on stool consistency were in- 
conclusive. There is not enough evidence to state that 
synbiotics reduce the risk of infections or decrease use 
of antibiotics. There is no data on the effects of synbio- 
tics on GI microflora. The available data is very limited 
to draw reliable conclusions on the effects of synbiotics 
on clinical outcomes in formula fed infants. 
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Table 9 Summary of findings table: probiotic studies 
 
Effects of infant formula containing Probiotics on clinical outcomes in full term infants 
Patient or population: Full term infants, Settings: Multi-centre trials (hospitals), Intervention: Infant formula with probiotics, Comparison: Conventional infant formula 
Outcomes Illustrative comparative risks* (95% CI) Measure of effect 
(95% CI) 
No of Participants 
(studies) 
 Quality of the evidence 
 (GRADE) Assumed risk Corresponding risk 
 
Conventional formula Infant formula with probiotics 
   
Weight gain (g/day) for boys The mean (SD) weight gain (g/day) for 
boys in the control group ranged from 
30.9 (6.1) to 32.8 (4.1) 
The mean weight gain (g/day) for boys in the 
intervention groups was 
1.64 higher 
(0.36 lower to 3.64 higher) 
MD (95% CI): 1.64 (-0.36 
to 3.64)  
158 
(4 studies) 
⊕⊕⊝⊝ 
low1,2 Follow-up: 4 to 7 months 
Weight gain (g/day) for girls The mean (SD) weight gain (g/day) for 
girls in the control group ranged from 26.5 
(4.9) to 29 (6.3) 
The mean weight gain (g/day) for girls in the 
intervention groups was 
0.76 higher 
(2.57 lower to 4.09 higher) 
MD (95% CI): 0.76 (-2.57 
to 4.09) 
170 
(4 studies) 
⊕⊕⊝⊝ 
low3,4,5 
Follow-up: 4 to 7 months 
Length gain (mm/month) for boys The mean (SD) length gain (mm/month) 
for boys in the control group ranged from 
31.36 (4.48) to 37.3 (4.9) 
The mean length gain (mm/month) for boys 
in the intervention groups was 
0.37 lower 
(1.64 lower to 0.9 higher) 
MD (95% CI): -0.37 (-1.64 
to 0.90) 
158 
(4 studies) 
⊕⊕⊝⊝ 
low6,7 
Follow-up: 4 to 7 months 
Length gain (mm/month) for girls 
Follow-up: 4 to 7 months 
The mean (SD) length gain (mm/month) 
for girls in the control group ranged from 
28 (3.64) to 32 (4.6) 
The mean length gain (mm/month) for girls in 
the intervention groups was 
0.32 higher 
(0.81 lower to 1.45 higher) 
MD (95% CI): 0.32 (-0.81 
to 1.45) 
165 
(4 studies) 
⊕⊕⊝⊝ 
low8,9 
 
Head circumference gain (mm/month) for boys The mean (SD) head circumference gain 
(mm/month) for boys in the control group 
ranged from 17.5 (3.4) to 35.28 (7) 
The mean head circumference gain 
(mm/month) for boys in the intervention 
groups was 
0.76 higher 
(1.02 lower to 2.54 higher) 
MD (95% CI): 0.76 (-1.02 
to 2.54) 
125 
(3 studies) 
⊕⊕⊝⊝ 
low10,11 
Follow-up: 4 to 7 months 
Head circumference gain (mm/month) for girls The mean (SD) head circumference gain 
(mm/month) for girls in the control group 
ranged from16 (3) to  36.68 (15.4) 
The mean head circumference gain 
(mm/month) for girls in the intervention 
groups was 
0.27 higher 
(0.7 lower to 1.23 higher) 
MD (95% CI):0.27 (-0.70 
to 1.23) 
139 
(3 studies) 
⊕⊕⊝⊝ 
low12,13 
Follow-up: 4 to 7 months 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 pg. 94 
M
u
gam
b
i et al. N
utrition Jo
u
rn
a
l 201
2, 
1
1
:81 
http://w
w
w
.n
u
tritio
n
j.co
m
/co
n
ten
t/11/1/81 
Table 9 Summary of findings table: probiotic studies (Continued)
 
Bifidobacteria -log10(CFU) per gram of stool The mean (SD) bifidobacteria -log10(cfu) 
per gram of stool in the control group 
ranged 9.75 (0.5) to 10.11 (1.67) 
The mean bifidobacteria -log10(cfu) per 
gram of stool in the intervention groups was 
1.27 lower 
(2.03 to 0.51 lower) 
MD (95% CI): -1.27 (-2.03 
to -0.51) 
57 
(2 studies) 
⊕⊕⊝⊝ 
low14, 15 
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison 
group and the measure of effect of the intervention (and its 95% CI). CI: Confidence interval, CFU: colony forming units, MD: Mean Difference, RR: Risk ratio. 
GRADE Working Group grades of evidence. High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on 
our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the 
estimate. Very low quality: We are very uncertain about the estimate. 
1 Small sample size n=158, 95% CI includes no effect. 
2 Possible publication bias. 
3  Unexplained heterogeneity). 
4 Small sample size n=170. 
5 Possible publication bias. 
6 Small sample size n=158, 95% CI includes no effect. 
7 Possible publication bias. 
8 Small sample size n=165, 95% CI includes no effect. 
9 Possible publication bias. 
10 Small sample size n=125, 95% CI includes no effect. 
11 Possible publication bias. 12 
Small sample size n=139. 13 
Possible publication bias. 14 
Small sample size n=57. 15 
Possible publication bias. 
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Table 10 Summary of findings table: prebiotic studies 
Effects of infant formula containing Prebiotics on clinical outcomes in full term infants 
Patient or population: Full term infants, Settings: Multi-centre trials, Intervention: Infant formula with prebiotics, Comparison: Conventional formula 
Outcomes Illustrative comparative risks* (95% CI) Measure of effect 
(95% CI) 
No of Participants 
(studies) 
Quality of the 
evidence (GRADE) Assumed risk Corresponding risk 
 
Conventional formula Infant formula with 
prebiotics    
Weight gain (g/day)s The mean (SD) weight gain 
(g/day) in the control  group 
ranged from 26.4 (3.7) to 40.59 
(3.95) 
The mean weight gain 
(g/day) in the intervention 
groups was 0.97 higher 
(0.24 to 1.7 higher) 
MD (95% CI): 0.97 
(0.24 to 1.70) 
861 (8 studies) ⊕⊕⊝⊝ 
low1,2,3 
Follow-up: 1 to 6 month 
Length gain (cm/week) The mean (SD) length gain 
(cm/week) in the control  group 
ranged from 0.74 (0.1) to 0.96 
(0.11) 
The mean length gain 
(cm/week) in the 
intervention groups was 
0.01 higher (0.01 lower to 
0.04 higher) 
MD (95% CI): 0.01(-
0.01 to 0.04) 
697 (7 studies) ⊕⊕⊝⊝ 
low4,5,6 
Follow-up: 1 to 6 months 
Head circumference gain (cm/ week) The mean (SD) head 
circumference gain (cm/ week) in 
the control  group ranged from 
0.34 (0.05) to 0.63 (0.1) 
The mean head 
circumference gain (cm/ 
week) in the intervention 
groups was 0.01 lower 
(0.02 lower to 0 higher) 
MD (95% CI): -0.01 
(-0.02 to 0.00) 
438 (3 studies) ⊕⊕⊝⊝ 
low7,8 
Follow-up: 1.5 to 6 months 
Stool frequency (evacuations per day) The mean (SD) stool frequency 
(evacuations per day) in the 
control group ranged from1.5 
(0.6) to 2.4 (1.64) 
The mean stool frequency 
(evacuations per day) in 
the intervention groups 
was 0.18 higher (0.06 to 
0.3 higher) 
MD (95% CI): 0.18 
(0.06 to 0.30) 
579 (4 studies) ⊕⊕⊝⊝ 
low9,10 
Follow-up: 1 to 6 months 
Diarrhea 
Follow-up: 4 to 12 months 
Study population RR 0.62  
(0.19 to 1.99) 
237 (2 studies) ⊕⊕⊝⊝ 
low11,12 
23 per 100 14 per 100 (4 to 46) 
 
Moderate 
19 per 100 12 per 100 (4 to 38) 
URTI 
Follow-up: 6 to 12 months 
Study population RR 0.74  
(0.32 to 1.73) 
409 (2 studies) ⊕⊕⊝⊝ 
low13, 14, 15 
45 per 100 33 per 100 (14 to 77) 
 
Moderate 
44 per 100 33 per 100 (14 to 76) 
Bifidobacteria -log10(CFU) per gram stool 
Follow-up: 1 to 6 months 
The mean(SD) bifidobacteria -
log10(cfu) per gram stool in the 
control  group ranged from 6(0.9) 
to 10.11 (1.67) 
The mean bifidobacteria -
log10(cfu) per gram stool 
in the intervention groups 
was 0.92 higher (0.02 
lower to 1.86 higher) 
MD (95% CI): 0.92  
(-0.03 to 1.86) 
280 (5 studies) ⊕⊕⊝⊝ 
low16, 17, 18  
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Lactobacilli -log10(CFU) per gram stool 
Follow-up: 3 to 6 months 
The mean (SD) lactobacilli -
log10 (cfu) per gram stool in the 
control group ranged from 3.95 
(1.57) to 4.27 (2.02) 
The mean lactobacilli -
log10(cfu) per gram stool 
in the intervention groups 
was 1.12 higher (0.44 
lower to 2.67 higher) 
MD (95% CI): 1.12 
(-0.44 to 2.67) 
202 (3 studies) ⊕⊕⊝⊝ 
low19,20,21 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the 
comparison group and the measure of effect of the intervention (and its 95% CI). CI: Confidence interval, CFU: Colony Forming Units, MD: Mean Difference, RR: Risk ratio. 
GRADE Working Group grades of evidence: High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important 
impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to 
change the estimate. Very low quality: We are very uncertain about the estimate. 
1  Allocation concealment not clearly described in 6 studies. 
2  Blinding not clearly demonstrated or described in 7 studies. 
3 Possible publication bias. 
4  Allocation concealment not clearly demonstrated in 5 studies. 
5  Blinding not clearly demonstrated in 6 studies. 
6 Possible publication bias. 
7  Blinding not clearly described in 2 studies. 
8 Possible publication bias. 
9  Incomplete outcome data (with no reasons given for missing data) was present in 1 study. 
10 Possible publication bias. 
11 Small sample size n=237, 95% CI includes no effect. 
12 Possible publication bias. 
13 Unexplained heterogeneity. 
14 95% CI includes no effect. 
15 Possible publication bias. 
16 Unexplained heterogeneity. 
17 Small sample size n=280. 
18 Possible publication bias. 
19 Unexplained heterogeneity. 
20 Small sample size n=202. 
21 Possible publication bias. 
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Probiotics 
A limited number of studies analyzed the effects of pro- 
biotic supplementation on growth by gender. These 
studies had small sample sizes and the follow-up periods 
were short. Addition of probiotics to infant formula did 
not have any significant effect on growth (weight gain, 
length gain or head circumference) in boys or girls. No 
study reported any weight loss. Probiotic infant formula 
was well tolerated. The limited available data shows that 
probiotics did not have any significant effect on stool 
frequency or consistency. Probiotic supplementation was 
not associated with fewer episodes of diarrhoea, a lower 
incidence of colic, spitting up / regurgitation, restless- 
ness, vomiting. In one study [52] there were fewer crying 
episodes in the control group than probiotic group. Pro- 
biotic effects on infections, antibiotic use and length of 
hospitalization were inconclusive. Probiotic supplemen- 
tation did result in a significantly higher formula intake 
compared to controls. 
Effects of probiotic supplementation on intestinal 
microflora were conflicting. Probiotics failed to increase 
counts of bifidobacteria and lactobacillus. Probiotics sig- 
nificantly reduced counts of enterobacteria but failed to 
reduce counts of bacteriodes. None of  the  studies reported 
on immune response (CRP, IL-6), therefore the impact of 
probiotics on  these  parameters  could  not be evaluated. 
All 10 probiotic studies used various strains of 
bifidobacteria and lactobacillus with different doses. 
Treatment duration also varied from 14 days to 7 
months. This confirms the ESPGHAN Committee on 
nutrition statement that there is a lack of published evi- 
dence on clinical benefits from long term use of pro- 
biotic containing infant formula [95]. Well designed long 
term follow – up RCTs using similar treatment regimens 
(same probiotics strains, dose  and  treatment  duration) 
are needed to establish the effects of probiotics on 
healthy formula fed infants. 
 
Prebiotics 
Prebiotic addition to infant formula did have a signifi- 
cant effect on weight gain but had no significant effect 
on length and head circumference. None of the studies 
reported any weight  loss. Prebiotic  supplementation 
increased stool frequency but failed to improve stool 
consistency or decrease incidence of diarrhoea. Prebiotic 
supplementation did not reduce the incidence of spitting 
up / regurgitation, vomiting or crying (no study reported 
colic) or increased volume of formula tolerated. Pre- 
biotic supplementation failed to significantly reduce 
upper respiratory infections. However, one  study  [32] did 
report a significant reduction  in  overall  infections and 
antibiotic intake. Prebiotics supplementation failed to 
increase counts of bifidobacteria, lactobacillus or de- 
crease the levels of pathogens (enterobacteria, bacteriodes, 
E – coli). None of the studies reported on hospitalization 
(days in hospital) and immune response (CRP, IL-6), there- 
fore the impact of prebiotics on these parameters could 
not be evaluated. 
Majority of the studies had a short treatment duration 
ranging from 28 days to 12 months. The prebiotic doses 
ranged from 0.15 g to 0.8 g/100 ml which did not exceed 
the level recommended by the European Committee on 
food in order to minimize intolerance and maximize the 
bifidogenic effect of the prebiotic. 
 
Quality of the evidence and potential biases in the review 
process 
We used guidelines from GRADE working group and 
GRADEpro 3.6 software to assess the quality of evidence 
in this review (Table 7, 9, 10). Overall the quality of evi- 
dence for primary outcomes is low, meaning that further 
research is very likely to have an important impact on 
our confidence in the estimate of effect and is likely to 
change the estimate. The quality of the evidence was 
compromised by: Imprecision (majority of studies had a 
small sample size ranging from 97 to 227 in the synbio- 
tic studies, 54 to 201 in probiotic studies, 32 to 271 in 
the prebiotic studies); limitations in study design and 
execution (inadequate information was published to as- 
sess methodological quality of the study.  Information 
was missing on sequence generation, allocation conceal- 
ment, blinding, incomplete outcome data, selective 
reporting, free of other bias domains; Inconsistency of 
results); unexplained heterogeneity;  use  of  different 
study preparations (types of synbiotic, probiotic, prebio- 
tics) and different doses regimens were used and publi- 
cation bias. 
At the conclusion of the review process and prepar- 
ation of the manuscript (for this review), one on-going 
study [96] was recruiting, one study [97] was not yet 
recruiting, one study [98] was still on-going, no longer 
recruiting. Therefore data from these studies could not 
be included in this review. The reviewers used thorough 
comprehensive search strategies adopted for the  avail- 
able databases. All attempts were made to minimize 
publication bias. All steps of this review were conducted 
independently by the reviewers. Only randomised con- 
trolled studies were included in this review. 
 
Breast feeding statement 
By conducting this review on exclusively formula fed 
infants, the authors do not seek to diminish the import- 
ance of breastfeeding and promote formula feeding. The 
reviewers acknowledge the importance of breastfeeding 
for infants. They support exclusive breastfeeding for 6 
months, thereafter safe  complementary feeding from 6 
months of age with continued breastfeeding up to  2 
years and beyond as per the global recommendations for 
Stellenbosch University  http://scholar.sun.ac.za
Mugambi et al. Nutrition Journal 2012, 11:81 
http://www.nutritionj.com/content/11/1/81 
 
pg. 98 
 
 
 
optimal infant feeding of WHO and United Nations 
Children's Fund (UNICEF). This is because breastfeeding 
is the ideal feeding method for infants [99]. 
 
Conclusion 
There is not enough evidence to state that supplementa- 
tion of term infant formula with synbiotics, probiotics or 
prebiotics does result in improved growth and clinical 
outcomes in full term infants. There is no data available 
to establish if synbiotics are superior to probiotics or 
prebiotics. Therefore this review does not support the 
routine supplementation of term infant formula with 
synbiotics, probiotics or prebiotics. 
 
Implications for practice 
Probiotics: The limited evidence shows synbiotic or pro- 
biotic supplementation of infant formula did  not  have any 
adverse effects, significant impact on growth or clin- ical 
outcomes. All studies used different  probiotic strains, the  
effects of one type of probiotic cannot be extrapolated 
to other types of probiotic bacteria. Pre- biotic 
supplementation of infant formula also did not result in 
any adverse effects on infants. There  are some clinical 
benefits such as improved weight gain and stool 
frequency. 
 
Implications for research 
For clear recommendations to be made, well designed 
large RCTs with long term follow - up are required on 
exclusively formula fed term infants to investigate the ef- 
fect of the same synbiotic combinations on clinical out- 
comes; the effect of the  same probiotics (with  similar 
doses and treatment duration) on clinical outcomes 
because available studies used different probiotic doses 
and treatment durations; the effect of the same prebio- 
tics (with similar doses and treatment duration) on clin- 
ical outcomes because available studies used similar 
prebiotics with different doses  and  treatment  duration; 
the effects of synbiotics, probiotics or prebiotics on clin- 
ical outcomes that have not been adequately addressed in 
previous studies; if synbiotics are superior to probiotics or 
prebiotics. Future RCTs should have treatment arms that 
include both synbiotics, probiotic and prebiotics. 
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Abstract 
Background: There is little or no information available on the impact of funding by the food industry on trial 
outcomes and methodological quality of synbiotics, probiotics and prebiotics research in infants. The objective of this 
study was to compare the methodological quality, outcomes of food industry sponsored trials versus non industry 
sponsored trials, with regards to supplementation of synbiotics, probiotics and prebiotics in infant formula. 
Methods: A comprehensive search was conducted to identify published and unpublished randomized clinical trials 
(RCTs). Cochrane methodology was used to assess the risk of bias of included RCTs in the following domains: 1) 
sequence generation; 2) allocation concealment; 3) blinding; 4) incomplete outcome data; 5) selective outcome 
reporting; and 6) other bias. Clinical outcomes and authors’ conclusions were reported in frequencies and percentages. 
The association between source of funding, risk of bias, clinical outcomes and conclusions were assessed using 
Pearson’s Chi-square test and the Fisher’s exact test. A p-value < 0.05 was statistically significant. 
Results: Sixty seven completed and 3 on-going RCTs were included. Forty (59.7%) were funded by food industry, 11 
(16.4%) by non-industry entities and 16 (23.9%) did not specify source of funding. Several risk of bias domains, 
especially sequence generation, allocation concealment and blinding, were not adequately reported. There was no 
significant association between the source of funding and sequence generation, allocation concealment, blinding and 
selective reporting, majority of reported clinical outcomes or authors’ conclusions. On the other hand, source of 
funding was significantly associated with the domains of incomplete outcome data, free of other bias domains as 
well as reported antibiotic use and conclusions on weight gain. 
Conclusion: In RCTs on infants fed infant formula containing probiotics, prebiotics or synbiotics, the source of 
funding did not influence the majority of outcomes in favour of the sponsors’ products. More non-industry funded 
research is needed to further assess the impact of funding on methodological quality, reported clinical outcomes and 
authors’ conclusions. 
Keywords: Synbiotics, Probiotics, Prebiotics, Funding source, Methodological quality 
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Background 
There are numerous studies that explore the relationship 
between industrial sponsorship of biomedical research and 
published outcomes [1]. Several reviews have docu- 
mented how trials funded by industry are more likely to 
report results in favour of the sponsor’s products [2-5]. 
These reviews focused on trials sponsored by the 
pharmaceutical industry. Few reviews have explored the 
impact of funding by the food industry on outcomes of 
research trials [6,7]. A review by Nkansah et al.  also found 
that majority of trials investigating the effects of 
calcium supplementation in healthy children were indus- 
try funded and all supported calcium supplementation, in 
favour of the sponsor [8]. Similarly, a review by Lesser et 
al. found that scientific nutrition related articles 
(intervention trials, observational studies and scientific 
reviews) on common consumed beverages (soft drinks, 
juice, milk) funded by the food industry, were more likely 
to be favourable to the sponsor than articles that did not 
have industry funding [6]. 
Reporting only positive outcomes in a research trial 
significantly reduces a sponsors’ financial risk. Pressure 
to show a food product causes favourable outcomes in a 
specific population, may result in biases in trial design 
(methodology) and reporting of outcomes in industry 
sponsored research. This type of bias in nutrition re- 
search could adversely affect public health. Results from 
nutrition research also influence policy formulation, pro- 
fessional dietary guidelines, design of public health inter- 
ventions and regulation of food product health claims. 
In addition, findings from nutrition research often re- 
ceive publicity from the media, which influences con- 
sumer behaviour [6]. 
More studies are needed to explore the relationship be- 
tween the food industry and nutrition research [7]. There 
is little or no information available on the impact of fund- 
ing by the food industry on trial outcomes and methodo- 
logical quality of synbiotics, probiotics and prebiotics 
research in infants. There are no systematic reviews that 
have explored if sources of funding affects outcomes and 
methodological quality of randomized controlled trials 
(RCTs) conducted on infants given probiotics, prebiotics 
or synbiotics supplemented infant formula. 
Probiotics are defined as “live microorganisms” which 
when administered in adequate amounts may confer a 
health benefit to the host [9]. The main probiotic organ- 
isms that are currently used worldwide belong to the gen- 
era Lactobacillus and Bifidobacteria and are found in the 
gastrointestinal microflora [9]. The probiotics preparations 
of interest for this review are those added to infant formu- 
las. Prebiotics are non- digestible food  ingredients  that may 
benefit the host by selectively stimulating the growth 
and/or activity of one or a limited number of bacteria in 
the colon and improving the host’s health [10-12]. The 
most widely studied prebiotics are galactooligosaccharides 
(GOS), inulin and fructooligosaccharide (FOS) [13,14]. 
GOS, FOS and inulin are added to different foods as fat 
and sugar replacements to  improve texture or for their 
functional benefits [10,15,16]. When probiotics and prebi- 
otics are administered simultaneously, the combination is 
termed Synbiotics. 
The aim of this review was to explore whether finan- 
cial sponsorship by the food industry affects outcomes 
and methodological quality of trials on synbiotics, pro- 
biotics or prebiotics used in infants. Methodological 
quality may be compromised when insufficient informa- 
tion is provided regarding sequence generation, alloca- 
tion concealment, blinding, bias introduced from other 
sources and incomplete outcome reporting. 
 
Objective 
The objective of this systematic review was to compare 
the methodological quality and outcomes of food indus- 
try sponsored trials versus non industry sponsored trials 
with regards to supplementation of synbiotics, probiotics 
and prebiotics in infant formula. 
 
Hypothesis 
The source of funding in research trials using probiotics, 
prebiotics or synbiotics supplemented formula in infants 
is associated with outcomes in favour of the sponsor’s 
products and authors’ conclusions. 
 
Methods 
Criteria for considering studies for this review 
Types of studies 
All randomized controlled trials (RCTs) conducted from 
1980 to 2012 (irrespective of language) on synbiotics, pro- 
biotics, or prebiotics added to infant formula were in- 
cluded. Study participants were healthy full term infants 
(>37 weeks gestation or > 2.5 kg birth weight, 0–12 months 
old), preterm infants (born < 37 weeks gestation), low birth 
weight (<2.5 kg at birth) and extreme low birth weight in- 
fants (<1000 g at birth). Infants were fed either infant for- 
mula (preterm or full term formula), mixed feeds (breast 
milk with infant formula) with added synbiotics, probiotics 
or prebiotics or conventional infant formula with or with- 
out placebo. RCTs were excluded if they included infants 
with cardiac defects, pulmonary diseases, gastrointestinal 
diseases, major congenital abnormalities or chromosomal 
abnormalities. Commentaries, editorials, letters to the 
editor and studies that were not RCTs were excluded. 
 
Types of outcome 
The outcomes included: 1) Source of funding, 2) Methodo- 
logical quality (Risk of bias), 3) Clinical outcomes in RCTs, 
Conclusions (Overall study conclusions and conclusions on 
reported clinical outcomes) and 5) Association between 
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source of funding and methodological quality, clinical out- 
comes and author’s conclusions. 
 
Search methods for identification of studies 
A literature search regardless of language was conducted on 
electronic databases including The Cochrane CENTRAL 
Register for Controlled Trials (2012), EMBASE (1980+), 
Scopus  (1980  to  2012),  EBSCO  host  (1960  to  2012), 
PUBMED / MEDLINE (1966 to 2012), OVID (1950 to 
2012), SPORTDiscus (1960 to 2012), Web of Science (1970 
to 2012), Science Direct (1950 to 2012), CINAHL (1980 to 
2012), Science citation index (1970 to 2012), Latin American 
Caribbean Health Sciences literature (LILACS) (1965 to 
2012), NLMGateway (1950–1966). RCTs published in non- 
English language journals were translated by independent 
translators who were familiar with the subject matter. 
The search strategy used to search PUBMED for 
studies on full term infants is: (synbiotic* and probiotic* 
OR prebiotic*) AND (FOS or fructooligosaccharide or 
inulin or GOS or galactooligosaccharide) AND (infant 
formula* OR infant feeding OR formula OR formula 
milk) AND (infant* or baby or babies) NOT (preterm or 
premature or low birth weight babies or allergy or ec- 
zema) AND (randomized controlled trial* OR controlled 
clinical trial* OR random allocation*) Limits: Humans. 
This search strategy was modified to search other elec- 
tronic databases and for studies on preterm infants. 
A hand search was conducted on abstracts of major 
conference proceedings such  as the Pediatric Academic 
Society meetings from 1990  (www.pas-meetings.org), 
cross checked references cited in RCTs and in recent re- 
views (published from 2003 to 2012) for additional RCTs 
not identified by electronic searches and speciality journals 
which were not included in any database such as Pedia- 
trika and Chinese Journal of Microecology. To identify 
on-going and unpublished trials, experts in the field, man- 
ufacturers of infant formula containing probiotics and pre- 
biotics were contacted. Web sites of companies that have 
conducted or were conducting RCTs on probiotics and 
prebiotics were searched. 
Examples: Pfizer (www.pfizerpro.com/clinicaltrials), Chris 
Hansen Laboratory (www.chr-hansen.com/research_ 
development/documentation.html). A search was con- 
ducted on prospective trial registries such as World 
Health Organization (WHO) International Clinical Trials 
Registry Platform Search Portal (www.who.int/trialsearch), 
Clinical Trials.gov register (www.clinicaltrials.gov), 
Current Controlled Trials metaRegister  of  Control- 
led Trials [mRCT] (www.controlled-trials.com/mrct) 
and www.clinicaltrialresults.org. 
 
Selection of studies 
One reviewer (MM) independently reviewed all abstracts, 
citations and identified potentially eligible RCTs. The full 
reports of eligible RCTs were retrieved by one reviewer 
(MM) and the pre-specified selection criteria applied in- 
dependently by two reviewers (MM, ML) using a study 
eligibility form designed for this review. If more than one 
publication of a study existed, all reports of the study 
were grouped together under one name. Any disagree- 
ments between the reviewers were resolved through dis- 
cussion. Unresolved disagreements were resolved by a 
third party (RB). 
 
Data extraction and management 
Two reviewers (MM, ML) independently extracted data 
using a pretested data extraction form that was designed 
for this review. The reviewers (MM, ML) cross checked 
data and resolved any differences through discussion. 
Unresolved disagreements were resolved by a third party 
(RB). One reviewer (MM) entered the data in SPSS ver- 
sion 19 and the other reviewer (AM) conducted quality 
control checks. The data obtained from each RCT 
included: 
 
A) Source of funding or support of RCTs 
The source of funding or support of the RCTs was 
defined and categorized as: 
 
1) Industry included: 
• For – profit company, donation of study product 
by a for – profit company which manufactured 
the study product, 
• Not – for profit company that promoted the 
consumption of synbiotics, probiotics or 
prebiotics, 
• Mixed sources (for-profit company and other 
source). 
2) Non – industry included: 
• Government: National, regional (provincial, 
county) government body with NO industry 
association. 
• Foundation / Philanthropies: examples include 
Rockefeller foundation, Bill and Melinda Gates 
foundation. 
• Institution: University, Research centres, teaching 
and academic hospitals. 
• Other source of funding. 
3) None: No source of funding was disclosed in study 
report. 
 
B) Assessment of methodological quality of evidence 
(Risk of bias) 
Two reviewers (MM, ML) independently assessed the 
risk of bias of included RCTs as described in the 
Cochrane Handbook for Systematic Reviews for Inter- 
ventions  according  to  the  following  6  components: 
1) sequence  generation;  2)  allocation  concealment;  3) 
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Table 1 Included studies and on-going studies 
 
 
Included studies On-going  studies 
Author publication year Full term/Preterm 
infant 
Sponsor Author publication year Full term/Preterm 
infant 
Sponsor  Author, Year 
study commenced 
Full term/Preterm 
infant 
Allen 2010 [18] Full Term Knowledge exploitation 
fund, collaborative industrial 
research, others 
Soh 2009 [19] Full Term National  Medical Research 
Council, Singapore 
 Jacobs 2007 [20] Pre-Term 
Alliet 2007 [21] 
Scholtens 2008 [22] 
Full Term Numico Urban 2008 [23] Full Term Nestle  Patole 2009 [24] Pre-Term 
Ashley 2012 [25] Full Term Mead Johnson Velaphi 2008 [26] Full Term Nestle  Underwood 2009 [27] Pre-Term 
Bakker-Zierikzee 2005 [28] 
Bakker-Zierikzee 2006 [29] 
Full Term None/Not clear Vendt 2006 [30] Full Term Valio Ltd    
Bettler 2006 [31] Full Term Wyeth Nutrition Vlieger 2009 [32] Full Term Friesland    
Brunser 2006 [33] Full Term None/Not clear Weizman 2005 [34] Full Term Materna Laboratories    
Bruzzese 2009 [35] Full Term Numico Weizman 2006 [36] Full Term Marterna  Laboratories    
Chouraqui 2004 [37] Full Term Nestle Xiao-Ming 2004 [38] Full Term Friesland    
Chouraqui 2008 [39] Full Term Nestle Xiao-Ming 2008 [40] Full Term None / Not clear    
Copper 2010 [41] Full Term Nestle Ziegler 2007 [42] Full Term Mead Johnson    
Costalos 2008 [43] Full Term Numico Bin-Nun 2005 [44] Pre-Term Mr and Mrs Stephen 
Hammerman, Mirsky 
Research fund 
   
Decsi 2005 [45] Full Term Numil Ltd Boehm 2002 [46] 
Boehm 2003 [47] 
Knol 2005 [48] 
Pre-Term Numico    
Fanaro 2005 [49] Full Term None / Not clear Chrzanowska-Liszewska 2012 [50] Pre-Term None/Not clear    
Fanaro 2008 [51] Full Term Humana GmbH Costalos 2003 [52] Pre-Term None/Not clear    
Gibson 2009 [53] Full Term Nestle Dani 2002 [54] Pre-Term None/Not clear    
Gil-Campos 2012 [55] Full Term Puleva Indrio 2008 [56] Pre-Term Bio Gaia    
Hascoet 2011 [57] Full Term Nestle Indrio 2009 [58] Pre-Term Numico    
Holscher 2012a [59] Full Term Nestle Kapiki 2007 [60] Pre-Term None/Not clear    
Holscher 2012b [61] Full Term Nestle Kitajima 1992 [62] Pre-Term None/Not clear    
Kim 2010 [63] Full Term Ministry of Health, Welfare 
and family affairs. Republic 
of Korea 
Lin H-C 2008 [64] Pre-Term National Science 
Council of Taiwan 
   
Knol 2005 [65] Full Term Numico Mihatsch 2006 [66] Pre-Term Milupa GmbH    
Magne 2008 [67] Full Term Numico Mihatsch 2010 [68] Pre-Term Nestle    
Mah 2007 [69] Full Term National Medical Research 
Council  Singapore 
Millar 1993 [70] 
Stansbridge 1993 [71] 
Pre-Term Wessex Regional Health 
Authority and childrens 
Research fund 
   
Maldonado 2010 [72] Full Term Puleva Modi 2010 [73] Pre-Term Danone    
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Table 1 Included studies and on-going studies (Continued) 
 
Moro 2002 [74] 
Moro 2003 [75] 
Full Term None/Not clear Mohan 2006 [76] Pre-Term None/Not clear 
Moro 2005 [77] Full Term None/Not clear Reuman1986 [78] Pre-Term None/Not clear 
Moro 2006 [79] 
Arslanoglu 2007 [80] 
Arslanoglu 2008 [81] 
Van Hoffen 2009 [82] 
Schouten 2011 [83] 
Full Term Numico Riskin 2009 [84] Pre-Term None/Not clear 
Piemontese 2011 [85] Full Term Danone Rouge 2009 [86] Pre-Term French Ministry of Health 
Puccio 2007 [87] Full Term Nestle Sari 2011 [88] Pre-Term None/Not clear 
Rautava 2006 [89] 
Rautava 2009 [90] 
Full Term Microbes and Man Research 
program, Academy of Finland, 
others 
Stratiki 2007 [91] Pre-Term Nestle 
Rinne 2005 [92] Full Term Academy of Finland, Turku 
University Central Hospital 
Research Funds 
Westerbeek 2010 [93] 
Westerbeek 2011a [94] 
Westerbeek 2011b [95] 
Pre-Term Danone 
Saavedra 2004 [96] Full Term Nestle Yong 2009 [97] Pre-Term None/Not clear 
Scalabrin 2009 [98] Full Term Mead Johnson    
Scalabrin 2012 [99] Full Term Mead Johnson    
Schmelzle 2003 [100] Full Term Numico    
Stellenbosch University  http://scholar.sun.ac.za
Mugambi et al. BMC Medical Research Methodology 2013, 13:137 
http://www.biomedcentral.com/1471-2288/13/137 
 
pg. 108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Figure 1 Process of study selection. 
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Table 2 Table of 56 Excluded studies with reasons for exclusion 
Use of Exclusive 
breast milk or Other 
milk feeds (buffalo, 
goat milk) 
Type of feed 
not clear/specified 
Probiotic administered 
in water, saline or other 
fluid that is 
not infant formula 
No use of probiotic, 
prebiotic 
Not RCT, (Cross 
over, Follow up, 
Observational study) 
Different inclusion 
criteria 
Lack of suitable/ 
knowledgeable 
translator 
Data presentation 
inappropriate 
Out dated 
(published 
before 1980) 
Agarwal 2003 [101] Al Hosni 2012 [102] FengJuan 2008 [103] Morisset 2011 [104] Huet 2006 [105] Agustina 2007 [106] Akiyama1994a [107] 
(Japanese) 
Baldeon 2008 [110] Campeotto 2011 [111]      Kuitunen 2009 [112] Patole 2005 [113] Bongers 2007 [114] Correa 2005 [115] Akiyama1994b [116] 
(Japanese) 
Grzéskowak 2012 [108]    Andrews 1969 [109] 
 
 
Robinson 1952 [117] 
Braga 2011 [118] Cukrowska 2002 [119] Kukkonen 2007 [120] Rochat 2007 [121] Chou I-C 2009 [122] Hol 2008 [123] 
Chandra 2002 [124] *Karvonen 1999 [125] Kukkonen 2008 [126] Taipale 2011 [127] Euler 2005 [128] Isolauri 2000 [129] 
Lin H-C 2005 [130] *Karvonen 2001 [131] Taylor 2009 [132] Hoyos 1999 [133] Nopchinda 2002 [134] 
Manzoni 2006 [135] *Karvonen 2002 [136] Thibault 2004 [137] Kim 2007 [138] Rivero 2004 [139] 
Rinne 2006 [140] Li 2004 [141] Lee 2007 [142] Urao 1999 [143] 
Samanta 2009 [144] Panigrahi 2008 [145] Lidesteri 2003 [146] Van der Aa 2010 [147] 
Rojas 2012 [148] Marini 2003 [149] Waliogora-Dupriet 2007 [150] 
Taylor 2007 [151] Rigo 2001 [152] Wang 2007 [153] 
Underwood 2009 [154] Savino 2003 [155] 
Sepp 1993 [156] 
Key: *  Unpublished  trials. 
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Quality of studies N = 67 Low risk High risk Unclear 
Sequence generation 42 (62.7)  25 (37.3) 
Allocation concealment 32 (47.8)  35 (52.2) 
Blinding 31 (46.3)  36 (53.7) 
Incomplete Outcome data 52 (77.6) 1 (1.5) 14 (20.9) 
Selective reporting 57 (85.1) 7 (10.4) 3 (4.5) 
Other bias 53 (79.1)  14 (20.9) 
 
 
 
 
blinding; 4) incomplete outcome data; 5) selective out- 
come reporting; and 6) other sources of bias [17]. Each 
domain was assessed as having either a low risk of bias, 
high risk of bias or unclear to permit judgment. Any 
disagreements regarding risk of bias were resolved 
through discussion between MM, ML and RB. The asso- 
ciation between risk of bias (domains) and type of funding 
(industry, non – industry, none declared) was explored. 
 
C) Assessment of clinical outcomes 
The primary and secondary outcomes from each study 
report were evaluated and categorized as: 
 
1. Positive: synbiotic, probiotic or prebiotic 
supplementation had a statistically significant effect, p < 
0.05. 
Examples of positive outcomes included: adequate growth 
(weight gain, length gain, head circumference), tolerance 
(no feeding problems), microflora (increase in colony 
forming units of bifidobacteria, lactobacillus, decrease in 
pathogens), decreased infections (decrease in frequency, 
incidence of infections). 
2) Negative: synbiotic, probiotic or prebiotic 
supplementation had a statistically significant effect 
in an adverse event / negative outcome such as 
weight loss, diarrhoea, p < 0.05 
3) Neutral: synbiotic, probiotic or prebiotic 
supplementation did not have a statistically 
significant effect, p > 0.05, no significant differences 
between study groups. Clinical outcomes included: 
growth parameters, gastrointestinal parameters 
(tolerance to feed, stool characteristics, microflora); 
immune response, infections and mortality. 
 
D) Overall study conclusions and conclusions on 
reported outcomes 
The  authors’ overall  study  conclusion  and  conclusions 
on reported clinical outcomes were evaluated and cate- 
gorized as: 
 
1. Positive: The author’s conclusion preferred the 
sponsor’s products over control/placebo. 
Interpretation of data supported the sponsor’s 
products over control. 
2. Negative: The sponsors’ products were not preferred 
over control / placebo. Interpretation of data did 
NOT support the sponsors’ products. 
3. Neutral: The author’s conclusion was neutral to the 
sponsor’s products. 
4. No clear conclusion was offered by author. 
 
In this review, the “conclusions on reported outcomes” 
referred to the authors’ conclusions on individual reported 
Table 3 Source of funding and study participants 
Study participants 
Sponsor Full term 
infant 
 Preterm Infant  Total 
 n  n  n (%) 
Industry 33  7  40 (59.7) 
None / Not Clear 6  10  16 (23.9) 
Non Industry 6  5  11 (16.4) 
Total 45  22  67 (100.0) 
 
 
RCTs outcomes. Examples include conclusions on weight 
gain, length gain, vomiting, necrotizing enterocolitis, sepsis. 
 
Statistical Analysis 
All the outcomes in this review were dichotomous and 
are described in frequencies and percentages. The asso- 
ciation between source of funding (industry/non- 
industry/ none) and methodological quality (low/un- 
clear/high risk of  bias), clinical outcomes and author’s 
conclusions were assessed using both the Pearson’s Chi- 
square test and the Fisher’s exact test. A p-value of less 
than 0.05 was considered statistically significant. SPSS 
version 19 statistical software was used. A statistician 
(AM) was consulted throughout the review process. 
 
Ethics 
The Human Research Ethics Committee at Stellenbosch 
University, South Africa reviewed the protocol for this 
review, ruled that all data to be collected for this review 
was from the public domain and was therefore exempt 
from ethical approval. 
 
Results 
Results of the search and description of studies 
Electronic search of available databases yielded 290 cita- 
tions. After reading titles and abstracts, duplicate reports 
were removed, 226 articles were screened and 100 articles 
were excluded. A hand search yielded 6 more articles. Po- 
tentially relevant full text reports were retrieved, reviewed 
for eligibility and a further 56 RCTs were excluded. Studies 
that had multiple publications were considered as  one trial. 
Sixty seven RCTs and three on-going RCTs were 
 
 
Table 4 Methodological quality (Risk of bias) 
N (%) 
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Table 5 Reported outcomes and conclusions  
 
N (%) 
Variable N= No conclusion Positive Neutral Negative 
Variable N (%) Overall study conclusion 67 4 (6) 49 (73.1) 7 (10.4) 7 (10.4) 
Reported Outcomes  N=  Positive* Neutral* Negative*  Conclusion on reported outcomes  
Weight gain  56  4 (7.1) 52 (92.9)   Weight gain  56  40 (71.4)  15 (26.8)    1 (1.8) 
Length gain  40  3 (7.5) 37 (92.5)   Length gain  40  26 (65)  14 (35)     
Head circumference  31  4 (12.9) 27 (87.1)   Head circumference  31  17 (54.8)  14 (45.2)     
Colic  13  1 (7.7) 12 (92.3)   Colic  13  11 (84.6)  2 (15.4)     
Spitting  up/Regurgitation  26  2 (7.7) 23 (88.5) 1 (3.8)  Spitting  up/Regurgitation  26  23 (88.5)  3 (11.5)     
Vomiting  31  1.5 (3.2 30 (96.8)   Vomiting  32  24 (75)  8 (25)     
Crying/Fussiness  22  3 (13.6) 18 (81.8) 1 (4.5)  Crying/Fussiness  20  12 (60)  8 (40)     
Gastric Residuals, Abdominal distension  5  1 (20) 4 (80)   Gastric Residuals, Abdominal distension  6  3 (50)  3 (50)     
Volume of formula consumed  31  3 (9.7) 27 (87.1) 1 (3.2)  Volume of formula consumed  30  26 (86.7)  3 (10)    1(3.3) 
Time to full enteral feeds  9  2 (22.2) 7 (77.8)   Time to full enteral feeds  8  5 (62.5)  2 (25)    1 (12.5) 
Stool frequency  37  10 (27) 27 (73)   Stool frequency  38  27 (71.1)  11 (28.9)     
Stool consistency  37  18 (48.6) 19 (51.4)   Stool consistency  39  23 (59)  16 (41.0)     
Stool pH  13  11 (84.6) 2 (15.4)   Stool pH  12  7 (58.3)  5 (41.7)     
Short chain fatty acids  9  3 (33.3) 6 (66.7)   Short chain fatty acids  9  5 (55.6)  4 (44.4)     
Flatulence/Gas  16   16 (100)   Flatulence/Gas  15  11 (73.3)  4 (26.7)     
Diarrhoea, Diarrhoea episodes  19  3(15.8) 15 (78.9) 1(5.3)  Diarrhoea, Diarrhoea episodes  18  12 (66.7)  5 (27.8)    1 (5.6) 
Constipation  3  1 (33.3) 2 (66.7)   Constipation  4  3 (75)  1 (25)     
Microflora - Bifidobacteria  31  23 (74.2) 8 (25.8)   Microflora - Bifidobacteria  30  10 (33.3)  17 (56.7)  2 (6.7)  1 (3.3) 
Microflora - Lactobacillus  19  8 (42.1) 11 (57.9)   Microflora - Lactobacillus  19  9 (47.4)  8 (42.1)  1 (5.3)  1 (5.3) 
Microflora - Pathogens  25  5 (20) 19 (76) 1 (4)  Microflora - Pathogens  25  12 (48)  11 (44)    2 (8) 
Immune response CRP, IL6, Cytokines  0      Immune response CRP, IL6, Cytokines  1  1 (100)       
Immunoglobulins (IgA,IgG, Ig-Flc, IgE)  10  6 (60) 4 (40)   Immunoglobulins (IgA,IgG, Ig-Flc, IgE)  10  4 (40)  6 (60)     
Allergy  3  1 (33.3) 2 (66.7)   Allergy  3  2 (66.7)  1 (33.3)     
Eczema, Dermatitis, Rash, Skin Alterations  7  2 (28.6) 4 (57.1) 1 (14.3)  Eczema, Dermatitis, Rash, Skin Alterations  7  5 (71.4)  1 (14.3)    1 (14.3) 
Infections - Acute Otitis Media  3   3 (100)   Infections - Acute Otitis Media  3  1 (33.3  2 (66.7)     
Respiratory Infections  9  3 (33.3) 6 (66.7)   Respiratory Infections  8  5 (62.5)  3 (37.5)     
Gastrointestinal infections  6  1 (16.7) 5 (83.3)   Gastrointestinal infections  4  1 (25)  3 (75)     
Total infections, other unspecified infections  8  1 (12.5) 7 (87.5)   Total infections, other unspecified infections  10  6 (60)  2 (20)    2 (20) 
Urinary tract infections  2   2 (100)   Urinary tract infections  2  1 (50)  1 (50)     
Stellenbosch University  http://scholar.sun.ac.za
 pg. 112 
M
u
gam
b
i et al. B
M
C M
edical R
esearch M
ethodology 2013, 
1
3
:137 
http://w
w
w
.b
io
m
ed
cen
tral.co
m
/1471-2288/13/137 
Table 5 Reported outcomes and conclusions (Continued) 
 
Necrotizing Enterocolitis 11 2 (18.2) 9 (81.8) Necrotizing Enterocolitis 12 7 (58.3) 3 (25) 2 (16.7) 
Sepsis 10  10 (100) Sepsis 10 9 (90) 1 (10)  
Fever, Febrile Episodes 4 2 (50) 2 (50) Fever, Febrile Episodes 2 2 (100)   
Antibiotic use 19 4 (21.1) 15 (78.9) Antibiotic use 16 13 (81.3) 3 (18.8)  
Hospitalization 12  12 (100) Hospitalization 10 10 (100)   
Biochemical measures 9  9 (100) Biochemical measures 6 5 (83.3) 1 (16.7)  
Adverse events 18 2 (11.1) 16 (88.9) Adverse events 17 13 (76.5) 4 (23.5)  
Death / Mortality 7 1 (14.3 6 (85.7) Death/Mortality 8 7 (87.5) 1 (12.5)  
Intestinal permeability 3 1 (33.3) 2 (66.7) Intestinal permeability 3 1 (33.3) 2 (66.7)  
Duration of TPN 5  5 (100) Duration of TPN 5 4 (80) 1 (20)  
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, p < 0.05. 
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant effect, p > 0.05. 
*Negative: synbiotic, probiotic or prebiotic supplementation had a statistically significant increase in an adverse event / negative outcome, p < 0.05. 
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N = 67 studies   n (%)
$$
  n (%)
$$
  n (%)
$$
 
Sequence generation Industry  26 (38.8)    14 (20.9) 
 None/Not clear  8 (11.9)    8 (11.9) 
 Non industry  8 (11.9)    3 (4.5) 
Allocation concealment Industry  21 (31.3)    19 (28.4) 
 None/Not clear  5 (7.5)    11 (16.4) 
 Non Iindustry  6 (9.0)    5 (7.5) 
Blinding Industry  18 (26.9)    22 (32.8) 
 None/Not clear  6 (9.0)    10 (14.9) 
 Non industry  7 (10.4)    4 (6.0) 
Incomplete outcome data Industry  36 (53.7)  1 (1.5)  3 (4.5) 
 None/Not clear  9 (13.4)    7 (10.4) 
 Non industry  7 (10.4)    4 (6.0) 
Selective reporting Industry  36 (53.7)  2 (3.0)  2 (3.0) 
 None/Not clear  11 (16.4)  4 (6.0)  1 (1.5) 
 Non industry  10 (14.9)  1 (1.5)  0 
Free of other bias Industry  35 (52.2)    5 (7.5) 
 None/Not clear  9 (13.4)    7 (10.4) 
 Non industry  8 (13.4)  1 (1.5)  2 (3.0) 
*Significant p < 0.05. 
$$Overall  percentage. 
       
 
 
 
 
Table 6 Association between Sponsor and methodological quality (risk of bias) 
Methodological quality Source of funding Yes (Low risk) No (High risk) Unclear Chi-square 
p value 
 
 
Fisher’s exact p 
value 
  
0.435 0.465 
 
 
 
0.315 0.338 
 
 
 
0.395 0.457 
 
 
 
0.023* 0.005* 
 
 
 
0.224 0.188 
 
 
 
0.033* 0.038* 
 
 
 
 
 
 
included in this review. (Table 1) The selection process is 
shown in Figure 1. Table 2 gives a list of 56 RCTs which 
were excluded for: use of exclusive breast or non-formula 
milk (8 RCTs), type of feed not clear (11 RCTs), probiotic 
administered in saline, water or other fluid (4 RCTs), no 
use of probiotic or prebiotic (6 RCTs), not RCT (12 studies), 
different inclusion criteria (10 studies), lack  of  suit- 
able  translator (2 RCTs), data presentation inappropriate 
(1 RCT) and out of date [published before1980] (2 
RCTs). Three excluded RCTs were unpublished trials. 
 
Characteristics of included studies 
Table 1 lists included and on-going trials. Sixty 
seven RCTs were included, 45 (67.2%) on full term 
infants, 22 (32.8%) on preterm infants. All included 
RCTs were published trials. All trials were conducted 
on healthy full 
 
Table 7 Association between Sponsor and clinical outcomes: Growth 
Assessment of outcome 
Growth Source of funding Positive*  Neutral* Chi-square p value Fisher’s exact p value 
  n (%)$$  n (%)$$   
Weight gain N = 56 Industry 2 (3.6)  35 (62.5) 0.309 0.266 
 None/Not clear 2 (3.6)  10 (17.9)   
 Non industry 0  7 (12.5)   
Length gain N = 40 Industry 3 (7.5)  29 (72.5) 0.667 1.00 
 None/Not clear   6 (15)   
 Non industry   2 (5)   
Head Circumference N = 31 Industry 4 (12.9)  23 (74.2) 0.712 1.00 
 None /Not clear   3 (9.7)   
 Non industry   1 (3.2)   
$$Overall  percentage. 
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, p < 0.05. There were significant differences between study groups (in 
favour of experimental group). 
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant effect, p > 0.05, No significant differences between study groups. 
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 None/Not clear      
 Non industry     1 (7.7) 
Spitting up/Regurgitation N = 26 Industry 2 (7.7)  1 (3.8)  17 (65.4) 
 None/Not clear     4 (15.4) 
 Non industry     2 (7.7) 
Vomiting N = 31 Industry 1 (3.2)    23 (74.2) 
 None/Not clear     5 (16.1) 
 Non industry     2 (6.5) 
Crying fussiness N =22 Industry 3 (13.6)  1 (4.5)  14 (63.6) 
 None/Not clear     4 (18.2) 
 Non industry     0 
Gastric residuals, Abdominal distension N = 5 Industry     1 (20) 
 None/Not clear     1 (20) 
 Non industry 1 (6.7)    2 (40) 
Volume of formula consumed/daily intake N = 31 Industry 3 (9.7)  1 (3.2)  18 (58.1) 
 None/Not clear     4 (12.9) 
 Non industry     5 (16.1) 
Days to full enteral feeding N = 9 Industry     4 (44.4) 
 None/Not clear 1 (11.1)    1 (11.1) 
 Non industry 1 (11.1)    2 (22.2) 
 
 
 
 
term or preterm infants and used standard (full term or 
preterm) infant formula (Table 3). 
 
 
Funding 
Out of 67 trials, 40 (59.7%) were funded by food indus- 
try, 11 (16.4%) were funded by  non-industry  entities, and 
16 (23.9%) did not specify their source of funding, 
10 RCTs on preterm infants, 6 RCTs on full infants (Table 
3). 
 
 
Methodological quality (Risk of bias) 
In this review, several domains were not adequately re- 
ported, particularly, the domains of sequence generation, 
allocation concealment and blinding. Out of 67 RCTs, 
25 (37.3%) failed to report sequence generation, 35 
(52.2%) failed to report allocation concealment and 36 
(53.7%) did not report blinding. Majority of the RCTs 
were assessed as having a low risk of bias in the domains 
of incomplete outcome data 52 (77.6%), selective reporting 
57(85.1%) and other bias 53 (79.1%) (Table 4). 
Outcomes and study conclusions 
In most RCTs, majority of outcomes were assessed as 
neutral, (intervention did not have a statistically signifi- 
cant effect, p > 0.05). A total of 49 (73.1%) of RCTs had a 
positive overall study conclusion in favour of the spon- 
sors’ products, while 7 (10.4%) had negative¸ 7 (10.4%) 
had neutral conclusions and 4 (6%) had no clear conclu- 
sion. The included RCTs either did not provide any con- 
clusion on their reported clinical outcomes or, they 
provided a positive conclusion for their reported out- 
come in-favour of the sponsors’ products. Few  RCTS 
had either negative or neutral conclusions on their re- 
ported clinical outcomes (Table 5). 
 
Association between source of funding (sponsor) and 
methodological quality of studies 
There was no significant association between the source 
of funding and the domains of sequence generation (Chi – 
square p = 0.435, Fisher exact p = 0.465), allocation con- 
cealment (Chi – square p = 0.315, Fisher exact p = 0.338), 
blinding (Chi – square p = 0.395, Fisher exact p = 0.457) 
 
Table 8 Association between Sponsor and clinical outcomes: Tolerance symptoms 
Tolerance Source of funding Positive* Negative* Neutral* Chi-square Fisher’s exact 
n (%)$$              n (%)$$                       n (%)$$ 
Colic N = 13 Industry 1 (7.7) 11 (84.6) 
p value p value 
0.764 1.00 
 
 
 
0.907 1.00 
 
 
 
0.860 1.00 
 
 
 
0.581 1.00 
 
 
 
0.659 1.00 
 
 
 
0.758 1.00 
 
 
 
0.325 0.444 
 
 
 
$$Overall percentage. 
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, p < 0.05. There were significant differences between study groups (in favour 
of experimental group). 
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant effect, p > 0.05, No significant differences between study groups. 
*Negative: synbiotic, probiotic or prebiotic supplementation had a statistically significant increase in an adverse event / negative outcome, p < 0.05. 
Stellenbosch University  http://scholar.sun.ac.za
Mugambi et al. BMC Medical Research Methodology 2013, 13:137 
http://www.biomedcentral.com/1471-2288/13/137 
 
pg. 115 
 
 
 
Table 9 Association between sponsor and clinical outcomes: stool characteristics  
Stool characteristics Source of funding Positive*  
n (%)$$ 
Negative* n 
(%)$$ 
Neutral* n 
(%)$$ 
Chi-square p 
value 
Fisher’s exact p 
value 
Stool Frequency N = 37 Industry 7 (18.9)  22 (59.5) 0.501 0.540 
 None/Not clear 3 (8.1)  4 (10.8)   
 Non industry   1 (2.7)   
Stool Consistency n =37 Industry 14 (37.8)  15 (40.5) 0.562 1.00 
 None/Not clear 4 (10.8)  3 (8.1)   
 Non industry   1 (2.7)   
Stool pH N =13 Industry 7 (53.8)  2 (15.4) 0.305 1.00 
 None/Not clear 4 (30.8)     
 Non industry      
Stool Short Chain Fatty Acids N = 9 Industry 2 (22.2)  4 (44.4) 0.687 1.00 
 None / Not clear 1 (11.1)  1 (11.1)   
 Non industry   1 (11.1)   
Flatulence / Gas N = 16 Industry   15 (93.8) Not valid  
 None/Not clear   1 (6.3)   
 Non industry   0   
Diarrhoea, Diarrhoea episodes N = 19 Industry 3 (15.8) 1 (5.3) 10 (52.6) 0.771 1.00 
 None/Not clear   2 (10.5)   
 Non industry   3 (15.8)   
Constipation N = 3 Industry 1 (33.3)  1 (33.3) 0.386 1.00 
 None/Not clear   1 (33.3)   
 Non industry   0   
$$Overall percentage. 
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, p < 0.05. There were significant differences between study groups (in 
favour of experimental group). 
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant effect, p > 0.05, No significant differences between study groups. 
*Negative: synbiotic, probiotic or prebiotic supplementation had a statistically significant increase in an adverse event / negative outcome, p < 0.05. 
 
 
 
 
 
 
Table 10 Association between sponsor and clinical outcomes: Microflora 
Microflora Source of funding Positive 4*  
n (%)$$ 
Negative 5*  
n (%)$$ 
Neutral 6*  
n (%)$$ 
Chi-square    
p  value 
Fisher’s exact     
p  value 
Bifidobacteria N = 31 Industry 12 (38.7)  6 (19.4) 0.416 0.583 
 None/Not clear 8 (25.8)  2 (6.5)   
 Non industry 3 (9.7)     
Lactobacillus N = 19 Industry 2 (10.5)  6 (31.6) 0.155 0.176 
 None/Not clear 4 (21.1)  5 (26.3)   
 Non industry 2 (10.5)  0   
Pathogens N = 25 Industry 2 (8.0)  11 (44.0) 0.532 0.612 
 None/Not clear 3 (12.0) 1 (4.0) 6 (24.0)   
 Non industry   2 (8.0)   
$$ Overall percentage. 
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, p < 0.05. There were significant differences between study groups (in favour 
of experimental group). 
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant effect, p > 0.05, No significant differences between study groups. 
*Negative: synbiotic, probiotic or prebiotic supplementation had a statistically significant increase in an adverse event / negative outcome, p < 0.05. 
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32 (47.8) 2 (3.0) 3 (4.5) 3 (4.5) 40 (59.7%) 0.505 0.373 
10 (14.9) 3 (4.5) 2 (3.0) 1 (1.5) 16 (23.9%)   
7 (10.4) 2 (3.0) 2 (3.0) 0 11 (16.4%)   
49 (73.1%) 7 (10.4%) 7 (10.4%) 4 (6.0%) 67 (100)   
 
 Source of funding Positive*  
n (%)$$ 
Neutral*  
n (%)$$ 
Chi-square  
p value 
Fisher’s exact  
p value 
Necrotising enterocolitis N = 11 Industry  4 (36.4) 0.118 0.273 
 None/Not clear  3 (27.3)   
 Non industry 2 (18.2) 2 (18.2)   
Sepsis N = 10 Industry  2 (20) Not Valid  
 None/Not clear  3 (30)   
 Non industry  5 (50)   
Antibiotic use N = 19 Industry 4 (21.1) 4 (21.1) 0.031# 0.039# 
 None/Not clear  5 (26.3)   
 Non industry  6 (31.6)   
$$ Overall percentage. 
*Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, p < 0.05. There were significant differences between study groups (in favour 
of experimental group). 
*Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant effect, p > 0.05, No significant differences between study groups. 
# Significant p < 0.05. 
 
 
and selective reporting (Chi – square p = 0.224, Fisher 
exact p = 0.188) (Table 6). 
There was a significant association between funding 
and the domains of incomplete outcome data (Chi – 
square p = 0.023, Fisher exact p = 0.005) and free of 
other bias (Chi – square p = 0.033, Fisher exact p = 
0.038) (Table 6). The association between source of 
funding and incomplete outcome data was such that 
industry-funded trials had significantly less missing data 
than non-industry funded trials. The association between 
source of funding and free of other bias (such as out- 
comes bias) was such that a significantly higher percent- 
age of industry-funded trials were free of other bias 
compared to non-industry-funded trials. 
 
Association between source of funding (sponsor) 
and clinical outcomes 
There was no significant association between source of 
funding and reporting of clinical outcomes: Growth pa- 
rameters, stool characteristics, microflora, infections 
(Tables 7, 8, 9, 10 and 11), immune parameters, adverse 
events and mortality (data not shown). There was a 
significant association between the source of  funding 
and reporting of antibiotic use in formula fed infants 
(Chi-square p = 0.031, Fisher exact p = 0.039) such that 
industry funded trials were more likely to decrease the 
use of antibiotics than  non-industry  funded  trials 
(Table 11). 
 
Association between source of funding (sponsor) and 
overall study conclusion 
There was no significant association between sources of 
funding and overall study conclusion (Chi-square p = 
0.505, Fisher exact p = 0.373). Majority of RCTs, 49 
(73.1%), had a positive study conclusion; 32 (47.8%) of 
these RCTs, were industry sponsored, 7 (10.4%) non- in- 
dustry and 10 (14.9%) which did not declare their source 
of funding (Table 12). A sensitivity analysis was con- 
ducted with respect to combining industry sponsored 
studies with those that had not declared their source of 
funding. There was no change in the results. There was 
no significant association between source of funding and 
overall study conclusion (Chi-square p = 0.483, Fisher 
exact p = 0.425). 
 
Association between source of funding (sponsor) and 
conclusion on reported clinical outcomes 
There was  a significant association  between source of 
funding and conclusion on weight gain (Chi-square p = 
0.037, Fisher exact p = 0.024) such that industry-funded 
 
Table 12 Association between sponsor and OVERALL study conclusion 
Source of funding Positive Negative    Neutral    No clear conclusion Total Chi-square 
 
 
Fisher’s exact 
 
 
Overall conclusion N = 67 Industry 
None/Not clear 
Non industry     
Total 
n (%)$$ n (%)$$ n (%)$$ n (%)$$ n (%)$$ p value p value 
$$ Overall percentage. 
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Table 13 Association between sponsor and conclusion on reported outcome: Growth parameters 
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Authors conclusion on: Source of funding No conclusion on reported outcome 
n (%)$$ 
Positive n 
(%)$$ 
Negative 
n (%)$$ 
Chi-square 
p value 
Fisher’s exact p 
value 
Weight gain N = 56 Industry 23 (41.1%) 14 (25.0%)  0.037# 0.024# 
 None/Not clear 10 (17.9%) 1 (1.8%) 1 (1.8%)   
 Non industry 7 (12.5%)     
Length gain N = 40 Industry 18 (45%) 14 (35%)  0.068 0.051 
 None/Not clear 6 (15%)     
 Non industry 2 (5)     
Head circumference N = 31 Industry 13 (41.9) 14 (45.2)  0.151 0.232 
 None/Not clear 3 (9.7)     
 Non industry 1 (3.2)     
#Significant p < 0.05, $$ Overall percentage. 
 
 
trials were more likely to report positive conclusions on weight 
gain than non-industry-funded trials (Table 13). There was no 
significant association between source of funding and 
conclusion on other reported clinical out- comes (Tables 
14, 15, 16 and 17). 
Discussion 
This review revealed that majority of RCTs (from 1980 
to 2012) on infants fed formula supplemented with pro- 
biotics, prebiotics or synbiotics are funded by the food 
industry.   This   is   consistent   with   the   trend   that 
 
Table 14 Association between Sponsor and conclusion on reported outcome: Tolerance symptoms 
Tolerance Source of Funding No conclusion on reported outcome Positive 
n (%)$$ 
Negative 
n (%)$$ 
Chi-Square p 
value 
Fisher’s 
Exact p 
value 
n (%)$$ 
Colic N = 13 Industry 10 (76.9) 2 (15.4)  0.657 1.00 
 None / Not Clear      
 Non Industry 1 (7.7)     
Spitting up / Regurgitation N = 26 Industry 19 (73.1) 1 (3.8)  0.032 0.062 
 None / Not Clear 2 (7.7) 2 (7.7)    
 Non Industry 2 (7.7)     
Vomiting N = 32 Industry 19 (59.4) 5 (15.6)    
 None / Not Clear 3 (9.4) 3 (9.4)    
 Non Industry 2 (6.3)     
Crying Fussiness N =20 Industry 10 (50) 6 (30)  0.648 1.00 
 None / Not Clear 2 (10) 2 (10)    
 Non Industry 0     
Gastric Residuals, Abdominal 
distension N = 6 
Industry  1 (16.7)  0.513 1.00 
 None / Not Clear 1 (16.7) 1 (16.7)    
 Non Industry 2 (33.3) 1 (16.7)    
Volume of formula consumed / 
daily intake N = 30 
Industry 19 (63.3) 2 (6.7) 1 (3.3) 0.867 0.733 
 None / Not Clear 3 (10.0)     
 Non Industry 4 (13.3) 1 (3.3)    
Days to full enteral feeding N = 8 Industry 2 (25)  1 (12.5) 0.547 1.00 
 None / Not Clear 1 (12.5) 1 (12.5)    
 Non Industry 2 ()25 1 (12.5)    
$$Overall percentage 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
Mugambi et al. BMC Medical Research Methodology 2013, 13:137 
http://www.biomedcentral.com/1471-2288/13/137 
Table 15 Association between sponsor and conclusion on reported outcome: Stool characteristics 
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Stool characteristics Source of funding No conclusion on reported outcome Positive Negative Pearson’s Fisher’s exact 
n (%)$$ n (%)$$ n (%)$$ 
   chi Square  p value 
Stool frequency N = 38 Industry 21 (55.3) 9 (23.7)  0.809 1.00 
 None / Not clear 5 (13.2) 2 (5.3)    
 Non industry 1 (2.6)     
 Total 27 (71.1) 11 (28.9)    
Stool consistency n =39 Industry 18 (46.2) 13 (33.3)  0.699 1.00 
 None / Not clear 4 (10.3) 3 (7.7)    
 Non industry 1 (2.6)     
 Total 23 (59) 16 (41)    
Stool pH N =12 Industry 5 (41.7) 3 (25)  0.679 1.00 
 None / Not clear 2 (16.7) 2 (16.7)    
 Non industry      
 Total 7 (58.3) 5 (41.7)    
Stool short chain fatty acids N = 9 Industry 3 (33.3) 3 (33.3)  0.638 1.00 
 None / Not clear 1 (11.1) 1 (11.1)    
 Non industry 1 (11.1)     
 Total 5 (55.6) 4 (44.4)    
Flatulence/Gas N = 15 Industry 10 (66.7) 4 (26.7)  0.533 1.00 
 None / Not clear      
 Non industry 1 (6.7)     
 Total 11 (73.3) 4 (26.7)    
Diarrhoea, Diarrhoea episodes N = 18 Industry 7 (38.9) 5 (27.8) 1 (5.6) 0.484 0.557 
 None / Not clear 2 (11.1)     
 Non industry 3 (16.7)     
 Total 12 (66.7) 5 (27.8) 1 (5.6)   
Constipation N = 4 Industry 2 (50) 1 (25)  0.505 1.00 
 None / Not clear      
 Non industry 1(25)     
 Total 3 (75) 1 (25) 1 (25)   
$$ Overall percentage.       
 
biomedical research is increasingly being funded by in- dustry 
[1,2] There was a trend that more RCTs on pre- term infants 
failed to report their source of funding. The reason(s) for this 
trend needs to be explored further. 
Cochrane guidelines were used to assess the risk of bias of 
included RCTs. The reporting of several domains was 
however suboptimal particularly sequence generation, 
allocation concealment and blinding domains. Considering 
completed data, there was no significant association be- 
tween funding source and methodological quality of RCTs in 
the domains of sequence generation, allocation conceal- 
ment, blinding and selective reporting. There was a signifi- 
cant association between funding and methodological 
quality of RCTs in the domains of incomplete outcome 
data and free of other bias. Industry funded trials had sig- 
nificantly less missing data than non-industry funded trials. A 
higher percentage of industry funded trials were free 
of other bias compared to non-industry funded trials. More 
industry sponsored trials had low risk of bias in 5 out of 6 
domains, even though our results did not show a statistical 
significant association between funding and methodo- 
logical quality in most domains. Our results confirm find- 
ings from previous reviews on infants given enteral feeds 
with probiotics, prebiotics and synbiotics [157-159]. 
There was no significant association between funding 
source and clinical outcomes or majority of authors’ 
conclusions. There was a significant association between 
funding and conclusion on weight  gain. Regardless of 
the reported clinical outcomes, nearly all RCTs in this 
review reported neutral results. That is supplementation 
with probiotics, prebiotics or synbiotics did not have a 
significant effect or there were no significant differences 
between study groups of infants given supplemented for- 
mula or placebo. Our findings confirm the results of two 
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 n (%)
$$
  n (%)
$$
  n (%)
$$
 
NEC N = 12 Industry 3 (25)    1 (8.3) 
 None/Not clear 2 (16.7)  1 (8.3)  1 (8.3) 
 Non industry 2 (16.7)  2 (16.7)  0 
  7 (58.3)  3 (25)  2 (16.7) 
Sepsis N = 10 Industry 2 (20)     
 None/Not clear 2 (20)    1 (10) 
 Non industry 5 (50)     
Antibiotic use N = 16 Industry 4 (25)  3 (18.8)   
 None/Not clear 4 (25)     
 Non industry 5 (31.3)     
$$ Overall percentage.       
 
 
 
 
Table 16 Association between sponsor and conclusion on reported outcome: Microflora 
Microflora Source of funding No conclusion on reported outcome 
n (%)$$ 
Positive n 
(%)$$ 
Negative 
n (%)$$ 
Neutral 
n (%)$$ 
Chi-square 
p value 
Fisher’s exact 
p value 
Bifidobacteria N = 30 Industry 7 (23.3) 11 (36.7)   0.249 0.195 
 None/Not clear 2 (6.7) 5 (16.7) 1 (3.3) 1 (3.3)   
 Non industry 1 (3.3) 1 (3.3)  1 (3.3)   
Lactobacillus N = 19 Industry 5 (26.3) 4 (21.1)   0.084 0.294 
 None/Not clear 3 (15.8) 4 (21.1)  1 (5.3)   
 Non industry 1 (5.3)  1 (5.3)    
Pathogens N = 25 Industry 7 (28) 6 (24)   0.152 0.269 
 None/Not clear 4 (16) 5 (20) 1 (4)    
 Non industry 1 (4)  1 (4)    
$$Overall  percentage.        
 
systematic reviews which found that supplementation with 
probiotics, prebiotics or synbiotics did not offer any 
distinct advantage over placebo [158,159]. However, re- 
sults of this review did not agree with two nutrition re- 
lated reviews or reviews on pharmaceutical industry 
supported RCTs, which reported that industry sponsored 
RCTs had results and conclusions in favour of the spon- 
sor [2-4,6,8,160-162]. Despite reporting neutral out- 
comes, authors from industry sponsored RCTs had a 
tendency to advocate for the consumption of the sponsors’ 
products. Similar findings were reported by Nestle, who re- 
ported that research investigators “who received company 
grants tended to publish results, give advice and prescribe in 
favour of the sponsor.” This applied to research that was 
supported by pharmaceutical and food industries [163]. 
Effects of sponsorship on overall study conclusion have 
been equally documented in biomedical literature. 
Reviews by Lessor and Nkansah reported positive con- 
clusions in favour of the sponsor [6,8]. Although no sta- 
tistically  significant  association  between  funding  and 
authors conclusion was found in this review, more than 
70% of RCTs reported positive  conclusions, 47.8% of 
these were industry sponsored. Often, these positive 
conclusions in the RCTs were not supported by the re- 
ported data as demonstrated by the neutral clinical out- 
comes. Our findings are consistent with those of previous 
reviews, which found that, results from RCTs may be ac- 
curate, but authors may distort the meaning of the results, 
present conclusions that are more favourable, and  that 
were not supported by the data presented [2,5,163]. Even 
meta – analyses were not spared from this trend [2,5,163]. 
Despite overwhelming positive overall study conclusions, 
majority of RCTs did not have any conclusion on their re- 
ported clinical outcomes. The RCTs that reported any 
conclusion on their clinical outcomes, majority were posi- 
tive in favour of the sponsors’ products. 
 
Limitations 
This review did not document the role of the sponsor in 
study  design,  data  collection,  and  analysis.  Few  RCTs 
 
 
Table 17 Association between sponsor and conclusion on reported outcome: Necrotising Enterocolitis Sepsis and 
antibiotic use 
Source of funding No conclusion on reported outcome Positive Negative Pearson’s 
chi Square 
Fisher’s exact 
p value 
 
0.511 0.782 
 
 
 
 
0.274 0.500 
 
 
 
0.093 0.141 
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reported this. More detailed documentation and disclos- 
ure in RCT reports would help evaluate if there was an 
association between funding and reported outcomes or 
conclusions. Many RCTs had missing data especially on 
the domains of sequence generation, allocation conceal- 
ment and blinding. Attempts were made to contact 
authors for missing information but none  responded. The 
sample size (number of RCTs) was small and skewed 
towards industry. 
 
Conclusion 
This study assessed the impact of funding by the food 
industry on trial  outcomes  and  methodological  quality of 
synbiotics, probiotics and prebiotics research in in- fants. 
There was no significant association between source of 
funding and methodological quality of study in the 
domains of sequence generation, allocation conceal- 
ment and blinding. Industry funded trials had less miss- 
ing data and were free of other bias than non-industry 
funded trials. 
There was no significant association between funding 
and majority of reported clinical outcomes or authors’ 
conclusions. However, there was a significant association 
between funding source and reported antibiotic use and 
conclusion on weight gain. Majority of RCTs were in- 
dustry funded, more non-industry funded research is 
needed to further assess the impact of funding on meth- 
odological quality, reported clinical outcomes and au- 
thors’ conclusions. 
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Abstract 
Background: This study assessed how the food industry applies the knowledge and evidence gained from 
synbiotics, probiotics or prebiotics research in infants, on the general paediatric population. This study also 
explored: what happens after the clinical trials using infant formula are completed, data is published or 
remains unpublished; the effectiveness and type of medium the formula manufacturers use to educate 
consumers on probiotic, prebiotic or synbiotic infant formula. 
 
Methods: This was a descriptive study (a survey) that used a structured questionnaire. All listed companies 
that manufacture and / or market food products with added probiotics, prebiotics or synbiotics for infants 
were identified and invited to participate. People responsible for research and development were invited to 
participate in the survey. A letter of invitation was sent to selected participants and if they expressed 
willingness to take part in the study, a questionnaire with a written consent form was sent. Descriptive 
statistics and associations between categorical variables were to be tested using a Chi-square test, a p<0.05 
was statistically significant. 
 
Results: A total of 25 major infant formulas, baby food manufacturers were identified, invited to participate 
in the survey. No company was willing to participate in the survey for different reasons: failure to take any 
action 5 (20%), decision to participate indefinitely delayed 2 (8%), sensitivity of requested information 3 
(12%), company does not conduct clinical trials 1 (4%), company declined without further information 4 
(16%), erroneous contact information 6 (24%), refusal by receptionists to forward telephone calls to 
appropriate staff 3 (12%), language barrier 3 (12%), company no longer agrees to market research 1(4%). 
 
Conclusion: Due to a poor response rate in this study, no conclusion could be drawn on how the food 
industry applies evidence gained through probiotics, prebiotics or synbiotics research on infants for the 
benefit of the general paediatric population. More information and greater transparency is needed from the 
infant formula manufacturers on how they apply the evidence gained from the research on probiotics, 
prebiotics and synbiotics on infants. 
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Background 
 
Scientific evidence from numerous studies in the last 25 years confirms that breastfeeding is the optimal way 
to feed infants, since breast milk contains all the essential nutrients to meet babies’ needs, as well as 
antibodies that fight off infection. [1, 2, 3, 4] 
 
The World Health Organisation (WHO) estimates, that if 
women breastfed their infants, up to 1.5 million infant deaths or 13% of deaths in children under 5 years old 
could be prevented annually. [5] Despite the well documented benefits of breastfeeding, more women are 
choosing formula feeding, either exclusively or giving mixed feeds (both formula and partial breastfeeding). 
Globally, this has resulted in sales of infant formula skyrocketing creating stiff competition among infant 
formula companies to manufacture new and innovative products. [5]
 
 
One objective of the infant food industry is to provide infants with nutrition support,  that accommodates the 
development and function of rapidly developing organ systems. [6]
 
A factor driving research and innovation 
in the infant food industry is the need to understand the composition and functional characteristics of breast 
milk. Therefore, scientists continuously conduct research to identify how infant formula can be adapted to 
more closely resemble the composition and function of human milk. This has resulted in different 
components being added to infant formula such as docosahexaenoic acid (DHA), arachidonic acid, 
synbiotics, probiotics or prebiotics. [6 - 9] 
 
Probiotics, prebiotics and synbiotics 
Probiotics are defined as “live microorganisms” which when administered in adequate amounts may confer a 
health benefit to the host. [9, 10, 11] The main probiotics that are used worldwide are Lactobacillus and 
Bifidobacteria which are found in the gastrointestinal (GI) microflora. [11, 12] Formula companies have 
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been adding probiotics to infant formula. Probiotics are also consumed in the form of fermented foods, dairy 
products such as yogurt and cheese and can be added to other foods such as cereals, biscuits, soy milk, 
sausages and numerous other foods. [11 - 16] 
 
Prebiotics are non- digestible food ingredients that may benefit the host by selectively stimulating the growth 
and/or activity of one or a limited number of bacteria in the colon and improving the host’s health. [9, 10, 17] 
A prebiotic is also an ingredient that is selectively fermented by indigenous bacteria (especially lactobacilli, 
bifidobacteria) resulting in changes in the composition and / or activity of the GI microbiota resulting in 
optimum colon function which improves the host’s health. [18] The most widely studied prebiotics are inulin 
and fructooligosaccharide (FOS). FOS and inulin are added to different foods as fat and sugar replacements 
to improve texture or for their functional benefits. [9, 10]
 
The latter is why formula companies now add 
prebiotics to infant formula. Adding prebiotics to formula stimulates the growth of only beneficial bacteria in 
the gastrointestinal tract to levels found in breastfed infants. [17, 18, 19]  
 
When probiotics and prebiotics are administered simultaneously, the combination is termed Synbiotics. [9, 
10, 19]
 
A new trend in the infant food industry is the addition of synbiotics to infant formula. 
 
How strong is the evidence for adding probiotics, prebiotics and synbiotics to infant formula?  
 
There is evidence that a healthy GI microflora in infants is necessary to achieve optimal health and growth. 
[20] For infants who are not breastfed, there is a rational to adapt infant formulas to promote an intestinal 
microbiota resembling that of breastfed infants, which has a greater concentration of bifidobacteria, fewer 
potentially pathogenic bacteria than formula fed infants. Strategies to achieve this goal include the addition 
of probiotics, prebiotics or synbiotics to infant formula for full term and preterm infants to improve growth, 
development and decrease infections. [11] Adding these ingredients to infant formula changes the intestinal 
microbiota of infants. [19, 21, 22] 
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Guidelines from the Oxford Centre for Evidence- based Medicine state that a systematic review of 
randomized clinical trials offers the highest level of evidence for information on the effectiveness of an 
intervention. This is followed by RCT(s). [23, 24, 25] Health benefits conferred by probiotic bacteria are 
strain specific. [12, 20] Systematic reviews on full term infants given probiotics show certain strains of 
probiotics improve stool consistency and frequency (Lactobacillus GG) [26], other strains increase average 
formula intake (L. reuteri, .B. lactis) [22], and support normal growth (B. lactis, B. longum BL999, L. 
rhamnosus LPR, Lactobacillus GG, L. reuteri ATCC 55730). [26] For preterm infants, administration of 
probiotics results in reduced risk of Necrotising Enterocolitis (from combinations of Lactobacillus bifidus, 
streptococcus thermophillus, and bifidobactrium infantis) and mortality (L acidophilus and B infantis). [27] 
 
Two systematic reviews on formula fed infants show that addition of synbiotics, probiotics or prebiotics to 
infant formula does not always have a significant effect on clinical outcomes in infants. [22, 28] In full term 
infants, addition of synbiotics to infant formula did not have any significant effect on growth, frequency of 
colic, regurgitation or vomiting. Addition of probiotics to infant formula did not have any significant effect 
on growth, episodes of diarrhoea, stool frequency or consistency. Addition of prebiotics to infant formula 
had no significant effect on length gain, head circumference, stool consistency or incidence of diarrhoea, 
regurgitation, counts of bifidobacteria or lactobacillus. [22] For preterm infants, probiotics did not have any 
significant effect on growth, risk reduction of NEC, sepsis and death. [28] 
 
Probiotics have been granted GRAS (generally regarded as safe) status by the Food and Drug Administration 
(FDA) due to the long history of safe use, and the bacteria used in the probiotic preparations are identical to 
those found in the GI tract. [29] In healthy people, probiotics rarely cause disease. The risk of developing 
bacteraemia from ingested lactobacilli is less than 1 per 1 million users; risk of developing fungaemia (from 
Saccharomyces Boulardii) is less than 1 per 5.6 million users. [30, 31, 32] Systemic infections such as 
endocarditis, fungaemia are extremely rare. Predisposing factors include immunosuppression, prior 
hospitalization, severe underlying co-morbidities, previous antibiotic therapy, invasive procedures that 
involve the gastrointestinal tract and other organs. [33, 34, 35] Risk factors for probiotic associated sepsis are 
prematurity in infants, presences of a central venous catheter, impairment of the intestinal epithelial barrier 
and concurrent administration of broad spectrum antibiotics to which the probiotic is resistant. [36]  
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Prebiotics have a good safety record at levels found in existing food components. Flatulence or abdominal 
bloating are reported at doses greater than 20g / day. Abdominal cramps or diarrhoea are reported at doses 
greater than 50 g / day. [19, 29] Adding prebiotics to formula stimulates the growth of only beneficial 
bacteria in the gastrointestinal tract to levels found in breastfed infants. [12, 37, 38] As these beneficial 
bacteria increase, they exclude pathogens; the gut mucosal barrier improves preventing infections with 
enteric pathogens or trans-located gut bacteria. [10, 18, 39] Other benefits reported from consuming 
prebiotics are improved intestinal architecture from increased villi height, thicker mucus layer, deeper crypts 
and increased globlet cells which improves intestinal permeability [19, 29, 40]  
 
Communication of best evidence to the consumer 
 
Communicating effectively with the consumer is challenging. Communication of health and nutrition 
messages comes from many sources. The consumer is inundated with information from the media, 
government, non-profit groups, advocacy organizations, food and beverage industry. [41] Furthermore, the 
environment for communicating health and nutrition information has changed in recent years due to an 
increase of television channels, internet usage and new media such as social networking sites, podcasts and 
webinars. [42]  
 
Health information is not always disseminated by experts. Fewer media outlets have medical and health 
reporters in their staff to cover complex topics. As a result, new scientific information maybe reported by 
people who do not have the necessary background to understand the content of complex journal articles or 
presentations. Often due to time pressure, these people depend on single sources of information such as press 
releases or wire services. This increases the chances of inaccurate information being disseminated to the 
consumers. Ultimately, the consumers are overwhelmed and confused. [41] In addition, more than 50 percent 
of literate adults are actually NOT health literate. They are unable to obtain, interpret or understand basic 
health information and make sound decisions. [43] The health information messages have to be tailored to 
the target audience, using appropriate communication channels and techniques. [44] 
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To communicate with the consumers, the food industry uses multiple channels to promote and sell their 
products with a goal of achieving profitable growth. The food industry uses subtle messages of better 
nutrition as part of their promotional activities. [41] In the context of probiotics, prebiotics containing food 
products, the consumer may not understand the meaning or importance of scientific terms such as probiotics, 
Lactobacillus, fructooligosaccharide or inulin. Thus, there is a great need for clear information in a language 
that the consumer can understand. 
 
Rationale for research 
To our knowledge, there are no studies that have assessed how the food industry applies the knowledge and 
evidence gained from research on probiotics, prebiotics or synbiotics on the general paediatric population. 
This study attempted to explore what happens after research trials using infant formula have been conducted 
and the data is published or remains unpublished. Based on the new scientific evidence, do the companies 
routinely develop and market a new probiotic, prebiotic or synbiotic containing infant formula, or improve 
on one that is already sold on the market?  
 
Probiotic infant formulas have been sold in Europe and Asia in the last 15 years but are not used widely in 
North America. [45] A physical check of several retail outlets in the Western Cape, South Africa, yielded 
few brands (sometimes only two) of probiotic containing infant formula. Yet several companies (in 
collaboration with academic institutions) have conducted research projects using probiotics and prebiotics on 
infants in Southern Africa. [46, 47] There is little or no information on the differences between the study 
formula and the retailed product. It is not clear how the manufacturers of probiotic, prebiotic or synbiotic 
containing infant formula educate the consumers on their products. This study set out to answer product 
specific questions on genera of probiotics used, product viability at end of shelf life, differences between 
study and retailed product. As well as, explore the effectiveness and type of medium the infant formula 
manufacturers use to educate the consumers on probiotic, prebiotic or synbiotic infant formula. 
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Safety issues are also an area of concern. The two probiotic infant formula brands available in the Western 
Cape, South Africa retail outlets state that using water with temperatures above 40 
0
C (degrees centigrade) 
will compromise the natural cultures. This contradicts the WHO “Guidelines for safe preparation, storage 
and handling of powdered infant formula” which recommends that water with a minimum temperature of 70 
0
C should be used to minimize the risk of potentially deadly infections caused by Enterobacter Sakazakii, 
bacteria that has been found in infant formula. [48] In addition there is a lack of published evidence on 
clinical benefits from long term use of probiotic containing infant formula. [26, 49] This study tried to 
explore how the infant formula companies address the contradiction to WHO guidelines on formula 
preparation and safety issues of long term usage of probiotic infant formula. 
 
Research question 
How does the food industry apply the evidence gained through probiotics, prebiotics and synbiotics research 
on infants for the benefit of the general paediatric population? 
 
Research Aim 
To investigate how the infant food industry applies evidence gained through probiotics, prebiotics and 
synbiotics research on infants. 
 
Objectives: 
The objectives of this study were to determine the following: 
Application of evidence: 
1. If new research evidence resulted in new infant formula products been developed, 
2. If there were any differences in study and retailed infant formula, 
3. The frequency of conducting research using probiotics, prebiotics or synbiotics containing infant 
formula 
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Publication of results: 
4. If the infant formula companies had intentionally NOT published study results that were viewed as 
negative or having no clinical benefit to infants? 
5. If study results perceived to be negative, were these withheld and was new research conducted to 
confirm the results? 
Medium for consumer education: 
6. The type and effectiveness of medium used to educate the consumer, 
7. The presence of bias in promoting formula feeding more than breastfeeding. 
Compliance to WHO guidelines: 
8. How formula companies complied with WHO guidelines on formula preparation with a focus on 
high water temperature and its effects on probiotics, synbiotics containing infant formula? 
Safety of long term use of probiotic or synbiotic containing infant formula, 
9. How companies addressed safety, since there is a lack of published evidence on the clinical benefits 
of long term consumption of probiotic containing formula (longer than 1 year). 
Product viability, 
10. If the probiotic, synbiotic containing infant formula remain viable throughout storage or were there 
substantial changes in the number of colony forming units at the end of shelf life? 
How companies keep abreast of the latest research on probiotics, prebiotics and synbiotics in infant formula 
and weaning foods? 
11. If the formula companies had staff designated to keep track of research or was it on “ ad hoc” basis? 
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Methodology  
Study design  
This was a descriptive study (a survey) employing the use of a structured questionnaire developed by the 
researcher. 
 
Company selection 
Companies that manufacture and / or market food products with added probiotics, prebiotics or both 
(synbiotics) for infants and children were identified through several databases such as EBSCOhost, Business 
Source Premier and DATAMONITOR
360
. In addition, company websites were visited to acquire the contact 
information of individual companies. The person / people responsible for research and development were 
invited to participate in the survey. Study participants included clinical research managers and individual 
researchers in the infant food companies. Worldwide, the numbers of infant food companies (especially 
infant formula manufactures) are few. Therefore all listed companies were invited to participate in the study. 
The number of study participants per company was one or two.  
 
Data collection and processing 
A letter of invitation was sent to selected participants, inviting them to take part in the study. The letter of 
invitation explained all aspects of the study, and if they expressed willingness to take part in the study, a 
questionnaire with a written consent form was sent via post, email or fax. If the questionnaire was posted, a 
stamped envelope was included for returning the completed questionnaire to the researcher. A maximum of 
four reminders were given to the participants to complete the questionnaire. The participants were free to 
withdraw from the study at any time without any consequence. 
 
Due to the expected small sample size, maintaining anonymity of study participants with the corresponding 
company name was difficult. Therefore, data processing was done according to product and company name. 
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However, during report writing, all identifying details (name of study participant, product and company 
name) were excluded. Only the researcher and statistician had access to the data. 
 
Questionnaire description 
A questionnaire was designed for this study based on relevant published information. The questionnaire 
focused on product specific questions, research based questions, education of consumers and safety issues. It 
was validated for content by sending it to experts in the field of probiotics, prebiotics and infant nutrition, 
who were able to judge if the questionnaire met the objectives of the study. These experts did not partake in 
the study nor were they associated with the infant food industry. 
 
Data analysis 
Researchers planned to enter the collected data into SPSS (Statistical Program for Social Sciences) for 
analysis. The data was to be analysed using descriptive statistics and associations between categorical 
variables, be tested using a Chi-square test. A p<0.05 was considered statistically significant. A statistician 
was consulted at every step of the study process. 
 
Ethics approval 
Ethics approval to conduct this study was given by the Human Research Ethics Committee at the University 
of Stellenbosch, Faculty of Medicine and Health Sciences, reference number N11/07/203.  
 
Results 
A total of 25 major infant formula and baby food manufacturers were identified from around the world and 
invited to participate in the survey. (Table 1) A total of 5 (20%) companies initially agreed to participate but 
took no action by not signing the informed consent form and completing the questionnaire. The decision to 
participate in the study was delayed indefinitely for 2 (8%) companies since their head of department was too 
busy to make a final decision. Sensitivity that the requested information would give the competition an 
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advantage was cited by 3 (12%) companies for not participating in the study, while 1 (4%) company stated 
they manufacture baby food and distribute it for retail without conducting any clinical trials. A total of 4 
(16%) companies declined to participate without giving any further information. Erroneous contact 
information given on company websites hindered any contacted being made with 6 (24%) companies. 
Company representatives from 3 (12%) companies refused to forward telephone calls from the researchers to 
the appropriate department and staff. Three (12%) companies cited language barrier (Mandarin, German, 
Dutch) as a reason for not participating in the study, despite offers to professionally translate the study 
documents into a language of their choice. One (4%) company stated that it was overwhelmed with people 
making requests for market research, as a result it had restructured and “market research was no-longer a 
priority.” (Table 2) In the end no company was willing to participate in the survey. 
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Table 1. List of 25 baby food companies and infant formula manufacturers invited to participate in survey. 
 
Company Name Company Name 
Abbott Laboratories / Abbot Nutrition Milupa 
Aspen Phamarcare Morinaga Milk industry Co. Ltd 
Beech-nut nutrition corporation Nestle (South Africa and Switzerland) 
Danone baby and medical nutrition BV Organix brands 
Earth's Best (Hain Celestian Group) Pfizer Inc  (SA) and Pfizer Head office 
FrieslandCampina (Netherlands) Raptakos Brett & Co. Ltd. 
Gerber products company SMA Nutrition (Ireland and UK) 
Hangzhou Beingmate Group Co Ltd. Synutra International 
HiPP GmbH & Co Vertrieb KG Tiger brands  
JH J Heinz Wakodo Co. Ltd 
Kewpie Wockhardt Limited 
Mead Johnson  Hero AG 
Meiji Dairies   
 
 
Table 2. Reasons for not participating in survey. 
Reason(s) for not participating in survey 
N = 25 
Number of companies 
n (%) 
No Action taken by company after agreeing to participate in survey 5 (20%) 
Head of department too busy to make decision 2 (8%) 
Requested information too sensitive - may give competition an advantage 3 (12%) 
Company does not conduct clinical trials, just manufacture infant food, distribute it for retail 1 (4%) 
No reason given for declining to participate in survey 4 (16%) 
Researchers unable to make contact with company through use of internet (emails, “contact 
us” features in company websites), telephone, fax or post office. 
6 (24%) 
Company receptionist / contact person refuses to forward call / put researchers in touch with 
appropriate person to answer questions 
3 (12%) 
Quote: “Too many people conducting market research on company, company has other 
priorities than answering market research questions.” 
1 (4%) 
Language barrier  – “prefer questionnaire in local dialect” such as Mandarin, Dutch, German. 3 (12%) 
Note: Several companies gave more than one reason for not participating in survey 
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Discussion 
To our knowledge, this was the first study to explore how the food industry applies evidence gained through 
research on probiotics, prebiotics and synbiotics on infants for the benefit of the general population. As a 
direct result of the poor response rate in this survey, several key questions remain unanswered. These are 
discussed below. 
 
Application of evidence 
Despite more than 30 years of research on probiotics, prebiotics or synbiotics on infants and children, any 
differences between studied and retailed infant formula such as the strains of probiotic bacteria used could 
not be established. It remains unknown if new evidence from clinical trials led to the improvement of 
existing formula, development of new infant formula or weaning foods containing probiotics or synbiotics. 
 
Publication of results (Publication bias) 
Publication bias is defined as “the tendency for investigators, journal editors and reviewers to submit or 
accept a manuscript for publication based on the directions or strength of the study findings. [50] Publication 
bias can have far reaching consequences on the public. For example, if an intervention that is not effective is 
falsely considered effective and administered to patients, an effective treatment that is available is withheld. 
Not publishing results from research where the intervention is discovered to be harmful; may indirectly harm 
study participants taking part in future research. This is because other investigators will (unknowingly) 
repeat the same research, testing the harmful intervention, causing suffering on a different group of people. 
[50] This study was not able to establish if companies engaged in research had intentionally NOT published 
study results that were viewed as negative or not having any clinical benefits to infants and children. 
Whether companies conducted new research to confirm results that may have been perceived as negative 
could not be established. 
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Medium for consumer education 
The type and effectiveness of medium used to educate the consumer on probiotics, prebiotics or synbiotics 
containing formula or baby foods could not be established. The numerous techniques used by the formula 
and baby food industry to increase awareness of their products are beyond the scope of this study and are 
described elsewhere. Only one education and promotion technique is illustrated below. 
 
Internet 
The internet is an important source of health information for parents. [51, 52, 53] Company websites offer 
advice on infant feeding, child rearing and health care issues. Some websites have useful product 
information, most websites use information on breastfeeding to jump to the second best option; formula 
feeding. [3]  
 
Most websites of formula manufacturers have product specific content concerning infant formula brands. 
Websites present images of branded packs linked with information about specific infant formula. These 
website links are accessible to the public, health and medical professionals. Research has shown consumers 
(mothers) get confused with formula advertising. [51] In situations where infant formula and follow-on 
formula share brand identities, consumers recall advertising and messages for follow-on formula and think it 
also applies to infant formula. As a result, information and promotional messages designed around follow-on 
formula are transferred to infant formula products. This type of confusion has far reaching implications. [51] 
 
Navigating the websites of the 25 companies invited to participate in this study, in addition to the product 
specific content in the websites, only eight companies had brief descriptions of probiotics or prebiotics, five 
companies had health claims on probiotics and one company had a health claim on prebiotics. There was no 
mention of the strains of probiotics or type of prebiotics in their products. In addition, the information on 
probiotics and prebiotics was difficult to obtain from the websites and could be inaccessible to consumers 
without advanced computer skills, tertiary education or sufficient knowledge on what to look for. 
 
In South Africa (SA), formula companies are able to market probiotics, prebiotics or synbiotics 
supplemented formula without providing evidence for health claims. Furthermore, South Africa’s 
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“Regulations Relating to Foodstuffs for Infants and Young Children, Government Gazette number 
35941”prohibit health or nutritional claims on the formula labels. The government gazette strictly prohibits 
the distribution of any information or education material on nutrition or feeding of infants and young 
children that promotes produsts such as infant formula or follow-on formula. However, for formula for 
infants with specific medical conditions, the government gazette does make provision for information leaflets 
(in 5 official languages) to be inserted inside the label. (54)  
 
The SA government gazette could be amended to allow for distribution of educational material on feeding of 
infants and young children. For example, the SA Government gazette would be changed to allow the formula 
companies to provide information leaflets inside the labels of all formula types including probiotics, 
prebiotics or synbiotics supplemented formula. For all health claims, supporting evidence would be included 
in the information leaflets (in 5 or more official languages). These information leaflets would be strictly 
regulated to offer only relevant information and not promote any products, brands or formula feeding. 
Compliance to WHO guidelines 
The position of formula companies on how they comply with WHO guidelines on water temperature during 
formula preparation could not be established. WHO recommends diluting the powdered formula in water at a 
temperature of at least 70
0
 C to inactivate cronobacter spp (Enterobacter sakazakii). [48] South Africa’s 
“Regulations Relating to Foodstuffs for Infants and Young Children, Government Gazette number 35941” 
state that labels for any infant formula, follow-up formula must “provide instructions for appropriate use 
according to the latest FAO / WHO guidelines.” The gazette requires the labels to state that infant formula is 
not always sterile and may contain harmful microorganisms, emphasizing appropriate preparation. [54] Yet 
the labels of infant formula found in retail stores of Western Cape, South Africa do not recommend to use 
water above 40
0
C.  
 
The European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) committee on 
nutrition and French Food Safety Agency (AFSSA) disagree with WHO guidelines and state that heating 
water to temperatures greater than 70
0
C is not necessary and maybe harmful to the nutritional quality of 
formula. Using hot water (greater than 70
0
C) may lead to formation of curds, risk of severe burns and the 
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loss of 10 to 25% of some nutrients: Thiamine, Vitamins B1, B6, B12, Folic acid, and Vitamin C. [55, 56] 
The effect of water temperature on Cronobacter spp (Enterobacter sakazakii) is striking. At 37 to 39
0
C, there 
is optimal growth, at 5.5 to 8
0
C there is minimal growth. At room temperature, Cronobacter spp has the 
potential for rapid growth. [55, 56] It is worth noting the rate of contamination with Cronobacter spp has 
decreased over the years from 14% in 1980s to 2.4% in mid 2000s. [55, 56, 57] 
 
A study by Sani et al found preparation instructions on formula labels were “insufficient, ambiguous or 
difficult to follow.” The study concluded that formula labels could be improved to cater for special consumer 
groups such as the less educated and the preparation instructions must be consistent with WHO guidelines. 
[58] 
 
Safety of long term use of probiotics or synbiotics containing formula 
The way companies address the question on safety of long term consumption of probiotics, synbiotics of 
infant formula could not be established. Safety of long term use is an important issue since majority of 
consumers of probiotics, synbiotics containing formula and baby foods use these products for more than a 
year. According to ESPGHAN committee on nutrition, there is a lack of published evidence on the clinical 
benefits and safety from long term consumption of probiotic containing formula. [26, 49] How the formula 
and baby food companies educate the consumer on this issue is yet to be determined or observed. 
 
Product viability 
Whether bacteria in retailed probiotics or synbiotics containing infant formula remain viable throughout shelf 
life was not established in this study. There are few reports on the stability of probiotics in powdered formula 
for infants and toddlers. [59] Several studies have conducted long term stability tests on bifidobacteria in 
powdered formula and results show the viability of live bacteria (such as bifidobacteria) decreased with 
length of time in storage and with increase in temperature. [59, 60] Consumers usually store powdered 
formula at room temperature. However, the formula may be exposed to high temperatures during 
transportation, during hot seasons or, in countries with hot weather conditions. If there is a large reduction in 
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viable cell counts of probiotic bacteria, the consumer does not benefit from the expected probiotic effects due 
to the insufficient number of viable cells in the infant formula. [59] The change in stability at various storage 
temperatures should be made clear by formula manufacturers. 
 
How companies keep abreast of the latest research on probiotics, prebiotics and synbiotics in 
infant formula and weaning foods. 
How companies keep abreast of the latest research on probiotics, prebiotics and synbiotics in infants could 
not be established. This study tried to find out if there are any formal mechanisms in place to ensure that 
employees or researchers keep abreast of the latest research. That is, are the employees or researchers offered 
regular training programs, workshops, symposiums, refresher courses, lectures, conferences or other methods 
for them to stay abreast of the latest research on probiotics, prebiotics and synbiotics in infant formula? The 
formula and baby food industry needs to be more open on this issue. 
 
Limitations 
 
Sampling frame 
Only online electronic databases were used to identify the companies around the world that manufacture 
infant food products with probiotics, prebiotics or synbiotics. Small regional companies that were not listed 
in the electronic databases were missed and subsequently not invited to participate in the study. Different 
methods could have been used to identify small regional companies. For example: contacting regional 
chambers of commerce (such as European Union Chamber of Commerce, American Chamber of Commerce, 
All-China Federation of Industry and Commerce or International Chamber of Commerce Netherlands) would 
provide the contact details of small companies that manufacture infant formula. Another method would to 
browse unknown small business databases such as Business Monitor international. Use of business listings 
such as local directories (example white or yellow pages, phone books) would have been unfeasible. 
 
Selection bias (under-coverage bias) 
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Efforts were concentrated on inviting people responsible for research and development such as clinical 
research managers and individual researchers. Other staff such as product managers could have been invited 
to participate in the study. 
 
Survey participation rates,  
Survey participation rates were nil. Many company staffs were cautious after the initial contact and invitation 
to participate in the study. After continued dialogue, they were unwilling to participate in the survey. During 
telephone conversations with the some company employees, the researchers were perceived to be in 
collaboration with the competition. 
 
Conclusion 
Due to a total lack of response from the formula companies, no conclusion could be drawn on how the food 
industry applies evidence gained through probiotics, prebiotics or synbiotics research on infants and children 
for the benefit of the general paediatric population. More information with greater transparency is needed 
from the infant formula and baby food companies on how they apply the evidence gained from the extensive 
research conducted using probiotics, prebiotics and synbiotics on infants and children. Legislation (in each 
country that the formula companies operate in) and recommendations from international bodies such as 
WHO, ESPGHAN, must be introduced to compel the industry to be transparent on how they apply the 
evidence gained from research.  
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6.0 Conclusion and recommendations 
 
6.1 Summary of findings 
 
6.1.1 Probiotics, prebiotics infant formula use in preterm or low birth weight infants: a systematic review 
 
Objective of review was: To assess if addition of probiotics or prebiotics to preterm infant formula led to 
improved growth and clinical outcomes in preterm or low birth weight infants. 
 
Hypothesis for this review was: Consumption of probiotics, prebiotics by preterm infants leads to improved 
clinical outcomes. 
 
Probiotics:  
The four included probiotic studies had short treatment duration of 30 days, with small sample sizes ranging 
from 20 to 87 study participants, a total of 212 participants. All studies used different live probiotics at 
various doses. There was information missing on the methodological quality (risk of bias) domains including 
sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting and 
other biases. For preterm infants, addition of probiotics to formula had no significant effect on weight, linear 
and head growth, amount of feed volume (ml/day) and frequency of vomiting. Probiotic supplementation 
failed to significantly reduce the risk of complications, such as NEC, sepsis and death. Preterm infant 
formula with probiotics was well tolerated as no gastric aspirates, abdominal distension or diarrhoea were 
reported. Probiotic effects on stool characteristics were under-reported. Outcomes, such as number of days 
on parenteral nutrition and other infections were not reported. Effects on intestinal permeability could not be 
evaluated because two different laboratory tests were reported and their results could not be pooled. 
Outcomes, such as age at full enteral feeds and intestinal micro flora (pathogens) could not be evaluated as 
medians (inter quartile ranges) were reported. There was no data on low birth weight infants, therefore no 
conclusions could be made on this population. 
 
Prebiotics: 
The four included prebiotic studies also had short treatment duration, ranging from 15 to 28 days, with small 
sample sizes ranging from 20 to 56, a total of 126 study participants only. The doses of the prebiotics used 
(GOS, FOS) varied from 0.4 g/dl to 1g/dl. Addition of GOS /FOS or FOS alone to preterm infant formula 
did not have any significant effect on weight gain or head growth. Addition of GOS / FOS to preterm infant 
formula did not have any effect on linear growth but addition of FOS alone did have a significant effect on 
linear growth. There was no significant effect on the age at which infants reached full enteral feeds, or 
volume of feed tolerated. There were no reports of vomiting, gastric aspirates, abdominal distension or 
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diarrhoea reported, showing that prebiotic preterm formula was well tolerated. Prebiotic supplementation did 
result in a higher stooling frequency; effects on stool consistency were inconclusive. There was an effect on 
intestinal micro flora as evidenced by significant increases of bifidobacteria counts, however effects on 
lactobacillus levels were not clear as actual figures were unavailable. The sum of studied pathogens and 
some selected pathogens (E- coli, enterococci) were significantly fewer in the prebiotic group. No prebiotic 
study reported any data on low birth weight infants, therefore no evaluations could be made on this group. 
Prebiotic effects on NEC, sepsis, other infections, mortality (death), parenteral nutrition, or changes in 
intestinal permeability were not reported; therefore these outcomes could not be evaluated. 
 
6.1.2 Synbiotics, probiotics or prebiotics in infant formula for full term infants: a systematic review 
 
Objectives of the review were: 
1. To determine the effects of infant formula containing synbiotics, probiotics, or prebiotics on clinical 
outcomes in full term infants 
 
2. To explore if synbiotics are superior over probiotics or prebiotics. 
 
Hypothesis for this review was: Consumption of probiotics, prebiotics or both (synbiotics) by full term 
infants leads to improved clinical outcomes 
 
Synbiotics: 
The three synbiotic studies had: a short treatment duration, ranging from 4 to 6 months; a small sample size, 
ranging from 122 to 227 study participants; a total of 475; and treatment (combinations of probiotics and 
prebiotics) also varied among the studies. Synbiotic addition to infant formula did not have any significant 
effect on growth (weight gain, length and head circumference), or on the incidence and frequency of colic, 
spitting up / regurgitation, crying, restlessness, or vomiting. There was increased stool frequency but effects 
on stool consistency were inconclusive. Synbiotic effects on frequency of infections and antibiotic intake 
were also inconclusive. Several outcomes were not reported, including volume of formula tolerated, 
hospitalization, GI microflora and immune response.  
 
Probiotics: 
The 10 included probiotic studies had: a short treatment duration, ranging from 14 days to 7 months; small 
sample sizes, ranging from 54 to 142 study participants; and a total of 933 participants. All 10 probiotic 
studies used various strains with different doses of bifidobacteria and lactobacillus. A limited number of 
studies analysed the effects of probiotic supplementation on growth by gender. Probiotics did not have any 
significant effect on growth (weight gain, length gain or head circumference) in boys or girls. No study 
reported any weight loss. Probiotics did not have any significant effect on stool frequency or consistency, 
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episodes of diarrhoea, incidence of colic, spitting up / regurgitation, restlessness, or vomiting. Effects on 
infections, antibiotic use and length of hospitalization were inconclusive. There was a significant effect on 
volume of formula intake, in the probiotic group. Effects on intestinal microflora were conflicting as there 
was no increase either in bifidobacteria or lactobacillus counts.. Probiotics significantly reduced 
enterobacteria counts but failed to reduce bacteriode counts. Probiotic effects on immune response (CRP, IL-
6) were not reported.  
 
Prebiotics: 
The 12 included prebiotic studies had a short treatment duration, ranging from 28 days to 12 months; small 
sample sizes, ranging from 32 to 206 study participants, with a total of 1563 participants. The prebiotic doses 
ranged from 0.15 g to 0.8 g/100 ml. Addition of prebiotics to infant formula did have a significant effect on 
weight gain but had no effect on length gain, or head circumference. None of the studies reported any weight 
loss. There was an increase in stool frequency but no improvement in stool consistency. Prebiotic 
supplementation did not reduce incidences of diarrhoea, spitting up / regurgitation, vomiting / crying, or 
increasing volume of formula tolerated. There was no significant reduction in upper respiratory infections, 
however there was a significant reduction in overall infections and antibiotic intake. Prebiotics 
supplementation did not increase counts of bifidobacteria, lactobacillus, or decrease pathogen levels  
(enterobacteria, bacteriodes, E – coli). Outcomes not reported in any study included colic, hospitalization 
(days in hospital) and immune response (CRP, IL-6). 
 
6.1.3 Associations among funding source, methodological quality and research outcomes in randomized 
controlled trials of synbiotics, probiotics and prebiotics added to infant formula: A Systematic Review  
 
Objective of review was: To compare the methodological quality and outcomes of industry sponsored trials 
versus non- industry sponsored trials, with regard to synbiotics, probiotics and prebiotics supplementation in 
infant formula. 
 
Hypotheses for this review were: The source of funding in research trials using probiotics, prebiotics or 
synbiotics supplemented formula in infants is associated with outcomes in favour of the sponsor’s products 
and authors’ conclusions. Methodological qualities of non-industry sponsored trials are equivalen to industry 
sponsored trials. 
 
Sixty seven published RCTs were included: 45 (67.2 %) on full term infants; 22 (32.8%) on preterm infants. 
Of these, 40 (59.7%) were funded by food industry; 11 (16.4%) were funded by non-industry; and 16 
(23.9%) did not specify funding source.  
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Methodological quality: For risk of bias several domains were inadequately reported; particularly, the 
domains of sequence generation (37.3%), allocation concealment (52.2%) and blinding (53.7%). Most RCTs 
had a low risk of bias in the domains of incomplete outcome data, selective reporting and other biases. There 
was no significant association among funding source and the domains of sequence generation, allocation 
concealment, blinding and selective reporting. There was a significant association among funding and the 
domains of incomplete outcome data and there were no other sources of bias such as RCT being stopped 
early, baseline imbalances of characteristics of study participants or inappropriate administration of 
intervention (that is deviating from the pre-specified methods).  
 
Outcomes: In most RCTs, outcomes were assessed as neutral, that is, supplementation with synbiotics, 
probiotics or prebiotics did not have a significant effect. There was no significant association between source 
of funding and reporting of clinical outcomes, except antibiotic use in infants.  
 
RCT conclusions: A total of 73.1% of RCTs had a positive overall study conclusion in favour of sponsor 
products. There was no significant association between sources of funding and overall study conclusion; and 
conclusions on reported clinical outcomes, except for weight gain. 
 
6.1.4 Application of evidence on probiotics, prebiotics and synbiotics by food industry: A descriptive study 
 
The research aim was to investigate how the infant food industry applies the evidence gained through 
synbiotics, probiotics and prebiotics research on infants. 
 
The objectives were to determine the following: application of evidence on probiotics, prebiotics on infants 
by the food industry; publication of results; type and effectiveness of medium used for consumer education; 
compliance to WHO guidelines, regarding water temperature for formula preparation; safety issues, 
regarding long term use of probiotic or synbiotic infant formula; product viability following long term 
storage; and how companies keep abreast of the latest research. 
 
Hypothesis for this study was: Evidence gathered through research trials that use probiotics, prebiotics and 
synbiotics in infants is implemented by the food industry for the benefit of the general paediatric population. 
 
A total of 25 major infant formula and baby food manufacturers were identified and invited to participate in 
the survey. No company was willing to participate in the survey. As a result, none of the study objectives 
could be met. The hypothesis could not be tested.  
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The reasons for companies declining to participate in the survey were: No action by company (refusal to sign 
informed consent form or complete questionnaire); indecision by department heads, sensitivity of requested 
information; company does not conduct clinical trials; company declined with no further information; 
erroneous contact information on company websites; telephone calls not forwarded to key staff; language 
barriers; and market research no longer a company priority. 
 
6.2 Limitations 
 
Phase 1: Systematic reviews on preterm and full term infants; Phase 2: Systematic review on source of 
funding, methodological quality and research outcomes 
 
6.2.1 Language bias 
Accessing non - English language RCTs indexed in foreign language databases (such as Chinese Biomedical 
database, Chinese Medical Current Content database) was difficult, as the researcher is primarily English 
speaking. Similarly, accessing foreign language RCTs (such as RCTs in Spanish, Chinese, Dutch languages) 
not indexed in English language databases, such as PubMed and LILACS was also difficult. A number of 
RCTs, thus may have been unintentionally missed and not included in the systematic reviews. For the 
identified foreign language RCTs, (especially Japanese language RCTs), the lack of a knowledgeable 
translator further resulted in some RCTs being excluded, or poorly translated, using computer software; this 
may have compromised the study report content. 
 
6.2.2 Selection bias 
All efforts were made to locate unpublished RCTs from experts in the field, researchers, research institutions 
and companies conducting research using synbiotics, probiotics and prebiotics on infants and children. Only 
one company agreed to avail three unpublished RCTs. There were as a result, few unpublished RCTs in the 
systematic reviews. The meta analyses were based mainly on published RCTs. As a result, the effectiveness 
of an intervention may have been over estimated. Accessing more unpublished RCTs, may change the results 
and conclusions of the systematic reviews. 
 
6.2.3 Inconclusive findings and failure to establish an association 
In the RCTs included in the systematic reviews, many outcomes were not reported or data presentation was 
inappropriate for a meta-analysis. As a result, there were many inconclusive findings and the systematic 
reviews could not establish an association or effect of the intervention (probiotics, prebiotics or synbiotics). 
Examples include (in the review on preterm infants) no reporting on lactobacillus counts, stool consistency 
or intestinal permeability. In the review on full term infants, there was no reporting on effects on immune 
response or GI microflora. 
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6.2.4 Loss of power 
In the phase 2 systematic review (on source of funding, methodological quality and research outcomes), 
majority of clinical outcomes were categorized as neutral; majority of the conclusions categorized as “no 
clear conclusion.” This resulted in loss of information and the review losing power to detect significant 
associations between source of funding and clinical outcomes or study conclusions. 
 
6.2.5 Type 1 and type 2 errors 
Type 1 error occurs if a difference is concluded when no difference actually exists. There is a possibility that 
a type 1 error could have occurred in the preterm and full term systematic reviews. When multiple tests are 
done (as in our systematic reviews), the probability of type 1 errors (significance level) increases. One way 
of compensating for multiple tests is to divide the significance level by the number of tests. However, no 
adjustments for multiple tests were done in all our reviews.  
Type 2 error occurs if a difference is not detected when a difference actually exists. In the systematic 
reviews, a type 2 error could not be avoided due to the following reasons. In the reviews on preterm and full 
term infants, for majority of outcomes analysed, the number and sample sizes of RCTs were too low to 
provide sufficient power to detect a difference even when the difference could actually have existed. In 
chapter 2, there is a distinct possibility that a true effect of probiotics on preventing NEC was missed. There 
were few RCTs reporting NEC and each had low power. The risk ratio was 0.42 (p=0.09) and if there were 
more RCTs, there could have been a significant effect   
 
In the phase 2 review (on source of funding, methodological quality and research outcomes) a type 2 error 
could not be avoided as many outcomes and study conclusions were inconclusive. That is, they were 
categorized as “neutral outcome and no clear conclusion.” 
 
 
Phase 2: Descriptive study 
 
6.2.6 Sampling Frame 
Identification of manufacturers of infant food products with probiotics, prebiotics or synbiotics was done 
using online electronic databases only. Regional companies not listed in the electronic databases were missed 
and as a result, not invited to participate in the study. Different methods could have been used to identify 
small regional companies to participate in the survey. 
 
6.2.7 Selection bias (under-coverage bias) 
Efforts were concentrated on inviting people responsible for research and development, such as clinical 
research managers and individual researchers to participate in the survey. Other staff, such as product 
managers could have been invited to participate in the study. 
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6.3 Study conclusions 
 
Phase 1 
 
6.3.1 Probiotics, prebiotics in infant formula use in preterm or low birth weight infants: A  
systematic review 
 
The evidence on the effects of probiotics or prebiotics on formula-fed, preterm infants was based on RCTs: 
of short duration, few in number,  having small sample sizes; using different strains and doses of probiotics; 
or using similar prebiotics with different doses. For most clinical outcomes (except weight gain), only 2 to 3 
RCTs reported or assessed any given outcome. The null hypothesis is accepted for majority of clinical 
outcomes. Therefore in formula fed preterm infants, there is not enough evidence at this time to state that 
supplementation of preterm infant formula with probiotics or prebiotics does result in improved growth and 
majority of clinical outcomes.  
 
The null hypothesis is rejected for the outcomes of linear growth, bifidobacteria counts and stool frequency. 
There was enough evidence to support that supplementation of preterm infant formula with prebiotics FOS 
alone significantly increased linear growth and bifidobacteria counts. There was also enough evidence 
indicating that supplementation with a combination of GOS/ FOS or FOS alone significantly increased stool 
frequency.  
 
6.3.2 Synbiotics, probiotics or prebiotics in infant formula for full term infants: A systematic  
review 
 
The evidence on the effects of infant formula containing synbiotics on full term infants was based on only 
three studies, using different probiotic strains and doses; similar prebiotics with different doses; and different 
treatment duration. Similarly, the effects of probiotics or prebiotics on full term infants was based on RCTs 
with different probiotic strains, doses and duration; similar prebiotics with different doses; and different 
duration. Therefore in formula fed full term infants, there is not enough evidence at this time to state that 
supplementation of term infant formula with synbiotics, probiotics or prebiotics does result in improved 
growth and majority of clinical outcomes in full term infants. There was no data available to establish if 
synbiotics are superior to probiotics or prebiotics.For this study, the null hypothesis is accepted for majority 
of clinical outcomes except weight gain. Supplementation of term infant formula prebiotics significantly 
increased weight gain. 
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Phase 2 
 
6.3.3 Association between source of funding, methodological quality and research outcomes: 
 
The null hypothesis is accepted for methodological quality (in the domains of sequence generation, 
allocation concealment and blinding), majority of study outcomes and authors’ conclusions (except for the 
outcome of antibiotic use and conclusion on weight gain). Therefore in RCTs on infants fed infant formula 
supplemented with synbiotics, probiotics or prebiotics, there was no significant association between source 
of funding and methodological quality of study in certain domains (sequence generation, allocation 
concealment and blinding).  There was no significant association among funding source and most reported 
clinical outcomes and conclusions (overall study conclusion, conclusions on reported outcomes). Source of 
funding is not associated with methodological quality (in the domains of sequence generation, allocation 
concealment and blinding), majority of outcomes and authors’ conclusions in favour of sponsor products. 
 
The null hypothesis is rejected for methodological quality (in the domains of incomplete outcome data, and 
free of other bias), antibiotic use and conclusion on weight gain. 
Therefore there was a significant association between source of funding and methodological quality (in the 
domains of incomplete outcome data, and free of other bias), outcome of antibiotic use, and conclusions on 
weight gain 
 
 
6.3.4 Application of evidence on probiotics, prebiotics and synbiotics by food industry: A  
Descriptive study 
 
The food industry was unwilling to participate in the descriptive study.The hypothesis, as a result was not 
tested; and the study objectives were not met. Therefore no conclusion could be drawn on how the food 
industry applies evidence gained through synbiotics, probiotics or prebiotics research on infants for the 
benefit of the general paediatric population. It is necessary for the food industry to be transparent on how it 
implements the evidence gained from probiotic, prebiotic or synbiotic research on infants for the benefit of 
the general paediatric population. Legislation (in each country that the formula companies operate in) and 
recommendations from international bodies such as WHO, ESPGHAN, must be introduced to compel the 
industry to be transparent with how they apply the evidence gained from research.  
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6.4 Overall thesis conclusion 
 
The included studies had several limitations (small sample size, use of different strains of probiotics, 
different prebiotics and short-duration); a few studies could be combined in a meta-analysis or even in meta-
analysis, there was not enough power to demonstrate an effect. Therefore at this time, there is not enough 
evidence to: state that consumption of probiotics, prebiotics or synbiotics leads to improved growth, or 
clinical outcomes in formula fed infants; or support the routine supplementation of infant formula with 
probiotics, prebiotics or synbiotics. 
 
In RCTs using infant formula with probiotic, prebiotics or synbiotics in preterm, low birth weight and full 
term infants, the source of funding is not associated with outcomes and authors’ conclusions in favour of 
sponsor products. It is necessary for the food industry to be transparent on how it applies the evidence gained 
from probiotic, prebiotic or synbiotic research on infants for the benefit of the general paediatric population. 
 
6.5 Summary of contributions 
 
New knowledge generated by this research project includes the following: 
 
Phase 1 
 
At this time, there is not enough evidence to state that: 
1. Probiotics or prebiotics supplemented infant formula has a distinct advantage, or adverse effects compared 
to conventional infant formula, in strictly formula fed preterm infants. 
2. Synbiotics, probiotics or prebiotics supplemented infant formula has a distinct advantage, or adverse 
effects compared to conventional infant formula, in strictly formula fed full term infants. 
3. Synbiotics supplemented infant formula is superior to either probiotics or prebiotics containing infant 
formula. 
 
 
Phase 2 
 
1. In RCTs using synbiotics, probiotics or prebiotics supplemented infant formulas, the funding source has 
no impact over methodological RCT quality, study outcomes, or conclusions. 
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2. The food industry is unwilling to reveal how they implement the evidence gained from synbiotics, 
probiotics or prebiotics research in infants, for the benefit of the general paediatric population. 
 
6.6 Implications for practice using synbiotics, probiotics or prebiotics supplemented infant 
formula 
 
The limited evidence shows that synbiotics or probiotics supplemented infant formula did not have any 
adverse effects; significant impact on growth; or clinical outcomes in infants. All studies used different 
probiotic strains, the effects of one type of probiotic cannot be extrapolated to other types of probiotic 
bacteria. In addition, the limited evidence shows prebiotic supplemented infant formula did not result in any 
adverse effects on infants. There are some clinical benefits, such as improved weight gain and stool 
frequency. The limited evidence does not support the routine supplementation of infant formula with 
synbiotics, probiotics or prebiotics. However, the researcher acknowledges that in South Africa and many 
parts of the world, synbiotics, probiotics and prebiotics supplemented infant formulas are sold directly to the 
public in retail outlets. 
 
6.7 Recommendations for further research  
 
6.7.1 Research on preterm and low birth weight infants: 
 
The evidence on probiotics and prebiotics use in preterm and low birth weight infants is based on RCTs 
having short treatment duration, small sample sizes and different interventions. Therefore, well designed, 
long term, large RCTs on exclusively formula fed preterm and low birth weight infants are required to: 
1. investigate the effects of probiotics and prebiotics supplementation in preventing NEC, sepsis, death / 
mortality; changes in intestinal micro flora; and intestinal permeability 
2. explore the effectiveness of different doses of the same probiotic on clinical outcomes, because available 
studies used different probiotic doses 
3. explore the effectiveness of different doses of the same prebiotic on clinical outcomes, because available 
studies used similar prebiotics with different doses and treatment duration. 
 
6.7.2 Research on full term infants 
 
The evidence on synbiotics, probiotics and prebiotics use in full term infants is based on RCTs also having 
short treatment duration, small sample sizes and different interventions. Therefore, well designed, large 
RCTs with long term follow-up are required on exclusively formula fed term infants to investigate the 
following:  
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1. effects of the same synbiotic combinations on clinical outcomes 
2. effects of the same probiotics (with similar doses and treatment duration) on clinical outcomes, because 
available studies used different probiotic doses and treatment durations  
3. effects of the same prebiotics (with similar doses and treatment duration) on clinical outcomes, because 
available studies used similar prebiotics with different doses and treatment duration  
4. effects of synbiotics, probiotics or prebiotics on clinical outcomes  not  adequately addressed in previous 
studies  
5. synbiotics superiority to probiotics or prebiotics: RCTs should have treatment arms to include both 
synbiotics, probiotic and prebiotics. 
 
6.7.3 Research exploring the associations among funding sources, methodological quality and research 
outcomes in RCTs, using synbiotics, probiotics or prebiotics supplemented formula in infants . 
 
 Most RCTs using supplemented formula in infants were industry funded. More non-industry funded 
research is needed to further assess funding impact on methodological quality (risk of bias); reported clinical 
outcomes; and conclusions (overall study conclusion, conclusions on reported outcomes) in RCTs, using 
synbiotics, probiotics or prebiotics supplemented formula in infants. 
 
6.7.4 Research on the implementation of evidence on synbiotics, probiotics and prebiotics by food industry: 
 
Greater transparency is needed from the infant formula and baby food companies on how they apply the 
evidence gained from the extensive research they have conducted (from 1980 to 2012), using probiotics, 
prebiotics and synbiotics in infants. 
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Appendix 2: Study eligibility form (Preterm infants) 
 
Probiotics, prebiotics infant formula use in preterm or low birth weight infants: 
A systematic review 
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Review title:
Study ID (Author last name, initials)
Refworks ID number
Date of review for eligibility (DD-MM-YYYY)
Journal title
Title of study/article
Year/volume/issue/page
Extractor (Last name, initials)
Type of study
Is this study a Randomized controlled study? YES UNCLEAR NO
Exclude
Trial intervention
Preterm infant formula containing probiotic(s) YES UNCLEAR NO
Preterm infant formula containing prebiotic(s) YES UNCLEAR NO
Conventional preterm formula / placebo
Exclude
Study Participants
Premature infants <37 weeks gestation YES UNCLEAR NO
Low birth weight infants < 2.5 kg at birth YES UNCLEAR NO
Exclude
Study Outcomes ( >1 outcomes below)
Short term growth parameters (Wt, Ht, Hd Circum) YES UNCLEAR NO
Adverse events (# days on parenteral, full enteral 
nutrition, maximal enteral feed, vomiting, GI aspirates, 
abdomen distension, stool characteristics- consistency, 
frequency) YES UNCLEAR NO
Complications (NEC, Sepsis, other infection, death) YES UNCLEAR NO
Intestinal permeability YES UNCLEAR NO
YES UNCLEAR NO
Other reasons for excluding study NO Yes
Final decision Include Unclear Exclude
For 
discussion
Comments
STUDY ELIGIBILITY FORM
Probiotic, prebiotics infant formula use in preterm or low birth 
weight infants: A systematic review
Clarify missing information
Go to next question
Go to next question
GI Microflora (Bifidobacteria, Lactobacillus, pathogen cfu)
Go to next question
Put a check (√ ) mark in appropriate box.
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Appendix 3: Data extraction form (Preterm infants) 
 
Probiotics, prebiotics infant formula use in preterm or low birth weight infants: 
A systematic review 
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Data Extraction Form 
Review Ttitle: Probiotic, prebiotic formula versus conventional preterm formula for feeding  
preterm or low birth weight infants. 
Section 1 
Study ID (Author last name, initials)  ________________  Extractor ID (Last name, Initials) _____________________ 
Refworks ID __________________ Date of reviewing eligibility (dd/mm/yyyy) __________________ 
Source ID (e.g PMID: 19707025 or database name) __________________________________________________ 
Author(s) [Last name, initials]_____________________________________________________________ 
Title of study: ___________________________________________________________________________ 
______________________________________________________________________________________ 
Journal name, yyyy/vol/iss/page: ______________________________________________________________ 
_______________________________________________________________________________________ 
Language of publication ________________ Translation Needed? YES____ NO_____ 
Date of trial (dd/mm/yyyy) ____________________ Duration of trial  _________________________________ 
Ethics approval: NO___ Unclear____YES ____  If yes Who granted ethics approval____________________ 
Informed consent: NO____ YES ______if yes, consent was: Oral  ____ Written _______ Not clear _______ 
Location of study (country) __________________________ Sponsor _______________________________ 
 
Section 2 
Eligibility Criteria 
 
Does this study meet the following eligibility criteria? 
Type of study: Randomized Controlled trial YES NO Not Clear 
Study participants: 
Preterm infants < 37 weeks gestation 
Low Birth weight infants < 2.5 kg at birth 
YES NO Not Clear 
Intervention: 
Preterm infant formula containing probiotic(s) 
Preterm infant formula containing probiotic(s) 
Conventional preterm formula or placebo 
YES NO Not Clear 
Outcomes: 
Does this study have any of these outcomes? 
Growth parameters, adverse events, complications (NEC,infections),  
Changes in GI permeability, GI microflora 
 
YES NO Not Clear 
 
Include or exclude this study? 
 
Include this study?      
 
Yes NO 
Exclude this study ?   
 
Yes NO 
Reasons fro excluding 
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Methodological design 
Sequence generation / Randomization method 
 YES NO Unclear 
Allocation concealment 
Adequate: 
 Central allocation (including telephone, web based, pharmacy randomization) 
 Onsite computer systems which can be assessed after entering the characteristics of an 
enrolled participant. 
 Precoded or sequentially numbered containers identical in appearnce. 
 Sequentially numbered, opaque, sealed envelopes. 
YES NO 
Inadequate: 
 Date of birth, case record number 
 Open random allocation schedule (list of random numbers) 
 Unsealed, non opaque envelopes 
 Alternation or rotation 
YES NO 
Unclear 
 Sealed envelopes but not sequentially numbered, opaque 
 Randomization stated but no details given 
 Insufficient informationto permit judgement of YES or NO 
YES NO 
Not reported YES NO 
Blinding YES NO Unclear 
Who was blinded? (Participant, care giver, asssessors) 
 
Loss to Follow –up 
(attrition Bias)  
Adequate Unclear Inadequate Not used 
 
Intervention  
N= _______ Arm 1 
______________ 
n= ___ 
Arm 2 
______________ 
n=____ 
Arm 3 
______________ 
n=____ 
Comments 
Name / Strain of 
probiotic(s) 
    
DOSE: Probiotics only 
Number of Viable cells 
(cfu) / ______. 
    
Name of prebiotic(s)     
DOSE: Prebiotics only 
g/__ml 
    
Name of Placebo     
Intervention continued 
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N= 
Arm 1   n= ____ 
______________ 
Arm 2   n=_____ 
______________ 
Arm 3   n=_____ 
______________ 
Comments 
Volume of feed given 
(mls/24 hours) 
    
     
Frequency of 
administration per 24 
hours 
    
Treatment Duration      
Time points     
Specify time points used 
for measurements. (e.g 
Day 1,2,3 or week 1,2,3 
or Month 1,2,3. 
    
Withdrawl / losses     
Reasons for withdraw/ 
losses 
    
1     
2     
3     
4     
6     
5     
6     
7     
 
Outcomes 
Description of Outcomes 
Primary Outcomes 
 
Secondary Outcomes 
 
Description of Outcomes continued 
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Adverse events due to treatment. Definition of Adverse event. 
 
 
Section 3 
Results  
 N % Unclear  
Number recruited Number randomized  
 Arm 1   n= ____ 
______________ 
Arm 2   n=_____ 
______________ 
Arm 3  n=_____ 
______________ 
Comments 
Total Number     
Male     
Female     
Gestation Age 
Unit of measurement: 
 
 
    
 
1. Primary Results 
N= 
Growth Parameters Arm 1   n= ____ 
______________ 
Arm 2  n=_____ 
______________ 
Arm 3  n=_____ 
______________ 
P value Statistical test 
used / 
Comments 
Weight gain 
Unit of measurment ___ 
     
Linear growth 
Unit of measurment ___ 
     
Head growth 
Unit of measurment ___ 
     
 
Secondary Results 
2. Adverse events 
Feed intolerance Arm 1 
n=___ 
_______ 
Arm 2  
n=___ 
________ 
Arm 3 
n=____ 
________ 
P value 95% CI Statistical test 
used/ 
Comments 
Gastric aspirate 
(mls/day) 
      
Stellenbosch University  http://scholar.sun.ac.za
 pg. 174 
Adverse events continued 
 
 
N= 
Arm 1 
n= ___ 
______ 
Arm 2 
n=____ 
______ 
Arm 3 
n=____ 
______ 
P value 95% CI Statistical test used / 
Comments 
Colour of aspirate 
(Green, milky, clear) 
      
Abdominal distention       
Number of days on 
Parenteral nutrition 
      
Number of days to 
full enteral nutrition 
      
Stool characteristics 
(Hard, firm, loose, 
watery) 
      
Code for Hard, 
firm,lose, watery 
stool 
      
Stooling Frequency / 
evacuations 
      
Other adverse events       
       
       
       
3. Complications 
 
N= 
Arm 1 
n= ___ 
______ 
Arm 2 
n=____ 
______ 
Arm 3 
n=____ 
______ 
P value 95% CI Statistical test used / 
Comments 
Necrotizing 
Enterocolitis (NEC) 
      
Sepsis       
Mortality / Death       
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Complications continued. 
 
Other complications 
continued 
Arm 1 
n= ___ 
______ 
Arm 2 
n=____ 
______ 
Arm 3 
n=____ 
______ 
P value 95% CI Statistical test used / 
Comments 
       
       
       
       
       
       
       
 
4. Changes in intestinal permiability 
N= 
 
L/M ratio 
Arm 1 
n= ___ 
______ 
Arm 2 
n=____ 
______ 
Arm 3 
n=____ 
______ 
P value Statistical test used / 
Comments 
      
      
 
5. Changes in Gastrointestinal Microflora 
N= Day/Week 1 Day / Week 2   
List of bacteria Arm 1 
n= ___ 
_____ 
Arm 2 
n=___ 
_____ 
Arm 3 
n=___ 
_____ 
Arm 1 
n= ___ 
_____ 
Arm 2 
n=___ 
_____ 
Arm 3 
n=___ 
_____ 
P 
Value 
Statistical 
test used / 
Comments 
 cfu/g of feces cfu/g of feces   
1         
2         
3         
4         
Statistical test used 
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Changes in Gastrointestinal Microflora continued. 
N= Day/Week 3 Day / Week 4   
List of bacteria Arm 1 
n= ___ 
_____ 
Arm 2 
n=___ 
_____ 
Arm 3 
n=___ 
_____ 
Arm 1 
n= ___ 
_____ 
Arm 2 
n=___ 
_____ 
Arm 3 
n=___ 
_____ 
P 
Value 
Statistical test 
used / 
Comments 
 cfu/g of feces cfu/g of feces   
1         
2         
3         
4         
5         
6         
7         
8         
Statistical test used 
 
Section 4 
Author’s contact: Telephone___________________  Cell Phone _______________ Fax ______________ 
Email ________________________________________________________________________________ 
Address:_______________________________________________________________________________ 
______________________________________________________________________________________ 
 
Correspondence with Author 
Additional information needed from Author 
_______________________________________________________________________________________ 
 
_______________________________________________________________________________________ 
 
_______________________________________________________________________________________ 
 
Information received from Author: __________________________________________________________ 
_______________________________________________________________________________________ 
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Section 5 
Information from Reference list. 
Reference scaned  Yes ________ NO __________ 
 
Additional studies identified from reference list. 
 
1.______________________________________________________________________________________ 
_______________________________________________________________________________________ 
____________________________________________________ Sent to Refworks Yes______NO________ 
2.______________________________________________________________________________________ 
_______________________________________________________________________________________ 
____________________________________________________ Sent to Refworks Yes______NO________ 
3.______________________________________________________________________________________ 
_______________________________________________________________________________________ 
____________________________________________________ Sent to Refworks Yes______NO________ 
4.______________________________________________________________________________________ 
_______________________________________________________________________________________ 
___________________________________________________ Sent to Refworks Yes______NO________ 
5.______________________________________________________________________________________ 
_______________________________________________________________________________________ 
___________________________________________________ Sent to Refworks Yes______NO________ 
6.______________________________________________________________________________________ 
_______________________________________________________________________________________ 
___________________________________________________ Sent to Refworks Yes______NO________ 
7.______________________________________________________________________________________ 
_______________________________________________________________________________________ 
___________________________________________________ Sent to Refworks Yes______NO________ 
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Appendix 4: Study eligibility form (Full term infants) 
 
Synbiotics, probiotics or prebiotics in infant formula for full term infants: A 
systematic review 
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Review title:
Study ID (Author last name, initials)
Refworks ID number
Date of review for eligibility (DDMMYYYY):
Title of study/article
Journal title
Year/volume/issue/page
Extractor (Last name, initials)
Type of study
Is this study a Randomized controlled study? YES UNCLEAR NO
Exclude
Intervention used 
in study:
Trial intervention Circle below
Experimental group: Term infant formula containing either probiotic(s) 
or prebiotic(s) or synbiotic(s) YES UNCLEAR NO Probiotic
Control group: Conventional term formula with or without placebo YES UNCLEAR NO Prebiotic
Note: All formulas are Cow based milk formula, no soy based formula. 
Breastmilk when used as reference only YES UNCLEAR NO Synbiotic
Study Participants Exclude
Healthy Full term infants (>37 weeks gestation or > 2.5 kg birth weight), 
Age: 0-12 months. Strictly formula fed infants only. YES UNCLEAR NO
Exclude: If infants have Congenital malformations, chromosomal 
abnormalities. Breastfed infants (unless they are used as a reference 
group) NO UNCLEAR YES
Study Outcomes. Does the study have one or more of the 
following outcomes: Exclude
Growth parameters: (weight, Height/length, Head Circum) YES UNCLEAR NO
Tolerance to feed: stool pattern (frequency, consistency), vomiting, 
diarrhoea, volume of feed tolerated YES UNCLEAR NO
Infections: frequency, type, use of meds YES UNCLEAR NO
Immune respone: CRP, IL-6, other immune system parameters YES UNCLEAR NO
Stool Microbiology: levels of bifidobacteria, lactobacilli, pathogens YES UNCLEAR NO
Hospitalization: # days in hospital, ICU (if any) YES UNCLEAR NO
Other reasons for excluding study NO Yes
Final decision Include Unclear Exclude
For 
discussion
Comments
Clarify missing 
information
Go to next question
Go to next question
Go to next question
Put a check (√ ) mark in 
appropriate box.
STUDY ELIGIBILITY FORM
Effects of probiotic, prebiotic and, synbiotic 
containing infant formula on clinical outcomes in 
term infants
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Appendix 5: Data extraction form (Full term infants) 
 
Synbiotics, probiotics or prebiotics in infant formula for full term infants: A 
systematic review 
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Data Extraction Form 
Review Ttitle: Protective effects and tolerance of Synbiotic containing infant formula 
compared to probiotic, prebiotic infant formula. 
 
Section 1 
Study ID (1stAuthor last name, initials)________________  Extractor ID (Last name, Initials) ___________________ 
Refworks ID __________________ Date of reviewing eligibility (dd/mm/yyyy) __________________ 
Author(s) [Last name, initials]_____________________________________________________________ 
Title of study: ___________________________________________________________________________ 
______________________________________________________________________________________ 
_______________________________________________________________________________________ 
Journal name, yyyy/vol/iss/page: ______________________________________________________________ 
Language of publication ________________ Translation Needed? YES____ NO_____ 
Date of trial (dd/mm/yyyy) ____________________ Duration of trial  _________________________________ 
Ethics approval: NO___ Unclear____YES ____  If yes Who granted ethics approval____________________ 
Informed consent: NO____ YES ______if yes, consent was: Oral  ____ Written _______ Not clear _______ 
Location of study (country) __________________________ Sponsor _______________________________ 
 
Section 2 
 
Eligibility Criteria 
 
Does this study meet the following eligibility criteria? 
Type of study: Randomized Controlled trial YES NO Not Clear 
Study participants: 
Full term infants, non hospitalized, strictly formula feed only 
YES NO Not Clear 
Intervention: 
Experimental group: Infant formula containing synbiotics, probiotic(s), or prebiotic(s) 
Control group: conventional infant formula with placebo or without placebo.All 
formulas will be cow based milk formula (soy based formulas will be excluded 
YES NO Not Clear 
Outcomes: 
Does this study have any of these outcomes: Growth parameters: (weight, Height/length, Head  
circum, Tolerance to feed: stool pattern, vomiting, colic 
Infections: frequency type, use of meds, Immune respone: CRP, IL-6, Stool Microbiology: 
levels of Bifidobacteria, lactobacilli, pathogens, Hospitalization: # days in hospital, ICU (if any) 
YES NO Not Clear 
 
Include or exclude this study? 
 
Include this study?      
 
Yes NO 
Exclude this study ?   
 
Yes NO 
Reasons fro excluding 
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Methodological design 
Item  Judgment Description 
Adequate Sequence 
generation?  
YES NO UNCLEAR  
Allocation concealment? YES NO UNCLEAR  
Blinding of study participants, 
study personnel, assessors? 
YES NO UNCLEAR  
Incomplete outcome data 
addressed? 
YES NO UNCLEAR  
Free of selective reporting? YES NO UNCLEAR  
Free of othe bias? YES NO UNCLEAR  
 
Intervention  
N= _______ Arm 1 
______________ 
n= ___ 
Arm 2 
______________ 
n=____ 
Arm 3 
______________ 
n=____ 
Comments 
Name / Strain of 
probiotic(s), Synbiotic(s) 
    
DOSE: Probiotics only 
Number of Viable cells 
(cfu) / ______. 
    
Name of prebiotic(s)     
DOSE: Prebiotics only 
g/__ml 
    
Name of Placebo     
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Intervention continued 
 
 
N= 
Arm 1   n= ____ 
______________ 
Arm 2   n=_____ 
______________ 
Arm 3   n=_____ 
______________ 
Comments 
Volume of feed given 
(mls/24 hours) 
    
     
Frequency of 
administration per 24 
hours 
    
Duration of study/ 
treatment 
    
Time points     
Specify time points used 
for measurements. (e.g 
Day 1,2,3 or week 1,2,3 
or Month 1,2,3. 
    
Withdrawl / losses     
Reasons for withdraw/ 
losses 
    
1     
2     
3     
4     
5     
Outcomes 
Description of Outcomes 
Primary Outcomes 
 
Secondary Outcomes 
 
Adverse events due to treatment. Definition of Adverse event. 
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Section 3 
Characteristics of study participants 
 N % Unclear  
Number recruited Number randomized  
 Arm 1   n= ____ 
______________ 
Arm 2   n=_____ 
______________ 
Arm 3  n=_____ 
______________ 
Comments 
Total Number     
Male     
Female     
Gestation Age 
Unit of measurement: 
    
Birth weight 
Unit of measurement 
    
 
1. Results: Growth 
N= 
Growth Parameters Arm 1   n= ____ 
______________ 
Arm 2  n=_____ 
______________ 
Arm 3  n=_____ 
______________ 
P value Statistical test 
used / 
Comments 
Weight gain 
Unit of measurment ___ 
     
Linear growth 
Unit of measurment ___ 
     
Head growth 
Unit of measurment ___ 
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2. Tolerance to formula 
 
N= 
Arm 1 
n= ___ 
______ 
Arm 2 
n=____ 
______ 
Arm 3 
n=____ 
______ 
P value 95% CI Statistical test used / 
Comments 
Stool characteristics 
(Hard, firm, loose, 
watery) 
      
Code for Hard, 
firm,lose, watery 
stool 
      
Stooling Frequency / 
evacuations 
      
Vomiting       
Spitting up       
Colic       
Crying episodes       
Other forms of feed 
intolerance 
      
       
       
 
3. Infections 
 
N= 
Arm 1 
n= ___ 
______ 
Arm 2 
n=____ 
______ 
Arm 3 
n=____ 
______ 
P value 95% CI Statistical test used / 
Comments 
Type of infection       
1       
2       
3       
4       
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3. Infections continued 
 
N= Arm 1 
n= ___ 
______ 
Arm 2 
n=____ 
______ 
Arm 3 
n=____ 
______ 
P value 95% CI Statistical test used / 
Comments 
Use of Medication 
(antibiotic) 
      
Number of days on 
antibiotic 
      
       
       
 
4. Immune Response 
 
N= 
 
 
Arm 1 
n= ___ 
______ 
Arm 2 
n=____ 
______ 
Arm 3 
n=____ 
______ 
P value Statistical test used / 
Comments 
C- reactive  protein 
(CRP) 
     
IL-6      
Other       
1      
2       
 
5. Hospitalization, Adverse events 
N= 
 
Arm 1 
n= ___ 
______ 
Arm 2 
n=____ 
______ 
Arm 3 
n=____ 
______ 
P value Statistical test used / 
Comments 
Number of days in 
hospital 
     
General ward      
ICU      
Other adverse events      
1 Mortality / Death      
2      
3      
4      
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6. Stool Microbiology: Changes in Gastrointestinal Microflora 
N= Day/Week 1 Day / Week 2   
List of bacteria Arm 1 
n= ___ 
_____ 
Arm 2 
n=___ 
_____ 
Arm 3 
n=___ 
_____ 
Arm 1 
n= ___ 
_____ 
Arm 2 
n=___ 
_____ 
Arm 3 
n=___ 
_____ 
P 
Value 
Statistical test 
used / 
Comments 
 cfu/g of feces cfu/g of feces   
1         
2         
3         
4         
Statistical test used 
 
Changes in Gastrointestinal Microflora continued. 
N= Day/Week 3 Day / Week 4   
List of bacteria Arm 1 
n= ___ 
_____ 
Arm 2 
n=___ 
_____ 
Arm 3 
n=___ 
_____ 
Arm 1 
n= ___ 
_____ 
Arm 2 
n=___ 
_____ 
Arm 3 
n=___ 
_____ 
P 
Value 
Statistical test 
used / 
Comments 
 cfu/g of feces cfu/g of feces   
1         
2         
3         
4         
Statistical test used 
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Section 7 
Author’s contact: Telephone___________________  Cell Phone _______________ Fax ______________ 
Email ________________________________________________________________________________ 
Address:_______________________________________________________________________________ 
______________________________________________________________________________________ 
 
Correspondence with Author 
Additional information needed from Author 
_______________________________________________________________________________________ 
 
_______________________________________________________________________________________ 
 
_______________________________________________________________________________________ 
 
Information received from Author: __________________________________________________________ 
_______________________________________________________________________________________ 
 
_______________________________________________________________________________________ 
Section 5 
Information from Reference list. 
Reference scaned  Yes ________ NO __________ 
 
Additional studies identified from referencen list. 
 
1.______________________________________________________________________________________ 
_______________________________________________________________________________________ 
____________________________________________________ Sent to Refworks Yes______NO________ 
2.______________________________________________________________________________________ 
_______________________________________________________________________________________ 
____________________________________________________ Sent to Refworks Yes______NO________ 
3.______________________________________________________________________________________ 
_______________________________________________________________________________________ 
____________________________________________________ Sent to Refworks Yes______NO________ 
4.______________________________________________________________________________________ 
___________________________________________________ Sent to Refworks Yes______NO________ 
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Appendix 6: Study eligibility forms (Systematic review on food industry) 
 
Association among funding source, methodological quality and research 
outcomes in randomized controlled trials of synbiotics, probiotics and prebiotics 
added to infant formula: A Systematic Review 
 
 
  
Stellenbosch University  http://scholar.sun.ac.za
 pg. 190 
 
Review title:
Study ID (Author last name, initials)
Date of review for eligibility (DD-MM-YYYY)
Journal title
Year/volume/issue/page
Extractor (Last name, initials)
Type of study
Is this study a Randomized controlled study? YES UNCLEAR NO
Intervention 
used in study:
Exclude Circle below
Trial intervention Probiotic
Preterm infant formula containing probiotic(s) YES UNCLEAR NO Prebiotic
Preterm infant formula containing prebiotic(s) OR 
Synbiotics YES UNCLEAR NO Synbiotic
Conventional preterm formula / placebo
Exclude
Study Participants
Premature infants <37 weeks gestation YES UNCLEAR NO
Low birth weight infants < 2.5 kg at birth YES UNCLEAR NO
Exclude
Study Outcomes ( >1 outcomes below)
Short term growth parameters (Wt, Ht, Hd Circum) YES UNCLEAR NO
Adverse events (# days on parenteral, full enteral 
nutrition, maximal enteral feed, vomiting, GI aspirates, 
abdomen distension, stool characteristics- consistency, 
frequency) YES UNCLEAR NO
Complications (NEC, Sepsis, other infection, death) YES UNCLEAR NO
Intestinal permeability YES UNCLEAR NO
YES UNCLEAR NO
Other reasons for excluding study NO Yes
Final decision Include Unclear Exclude
For 
discussion
Title of study/article
Go to next question
Put a check (√ ) mark in appropriate box.
Comments
STUDY ELIGIBILITY FORM - (PRETERM INFANTS )
Association between funding source, methodological quality and 
research outcomes in RCTs of synbiotics, probiotics and prebiotics in 
infant formulas: A systematic review
Clarify missing information
Go to next question
Go to next question
GI Microflora (Bifidobacteria, Lactobacillus, pathogen cfu)
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Review title:
Study ID (Author last name, initials)
Date of review for eligibility (DDMMYYYY):
Title of study/article
Year/volume/issue/page
Extractor (Last name, initials)
Type of study
Is this study a Randomized controlled study? YES UNCLEAR NO
Exclude
Intervention used 
in study:
Trial intervention Circle below
Experimental group: Term infant formula containing either probiotic(s) 
or prebiotic(s) or synbiotic(s) YES UNCLEAR NO Probiotic
Control group: Conventional term formula with or without placebo YES UNCLEAR NO Prebiotic
Note: All formulas are Cow based milk formula, no soy based formula. 
Breastmilk when used as reference only YES UNCLEAR NO Synbiotic
Study Participants Exclude
Healthy Full term infants (>37 weeks gestation or > 2.5 kg birth weight), 
Age: 0-12 months. Strictly formula fed infants only. YES UNCLEAR NO
Exclude: If infants have Congenital malformations, chromosomal 
abnormalities. Breastfed infants (unless they are used as a reference 
group) NO UNCLEAR YES
Study Outcomes. Does the study have one or more of the 
following outcomes: Exclude
Growth parameters: (weight, Height/length, Head Circum) YES UNCLEAR NO
Tolerance to feed: stool pattern (frequency, consistency), vomiting, 
diarrhoea, volume of feed tolerated YES UNCLEAR NO
Infections: frequency, type, use of meds YES UNCLEAR NO
Immune respone: CRP, IL-6, other immune system parameters YES UNCLEAR NO
Stool Microbiology: levels of bifidobacteria, lactobacilli, pathogens YES UNCLEAR NO
Hospitalization: # days in hospital, ICU (if any) YES UNCLEAR NO
Other reasons for excluding study NO Yes
Final decision Include Unclear Exclude
For 
discussion
Association between funding source, methodological quality and 
research outcomes in RCTs of synbiotics, probiotics and prebiotics in 
infant formula: A systematic Review
STUDY ELIGIBILITY FORM- (FULL TERM INFANTS)
Clarify missing 
information
Go to next question
Go to next question
Go to next question
Put a check (√ ) mark in 
appropriate box.
Comments
Journal title
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Appendix 7: Data extraction form (Systematic review on food industry) 
 
Association among funding source, methodological quality and research 
outcomes in randomized controlled trials of synbiotics, probiotics and prebiotics 
added to infant formula: A Systematic Review 
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Data Extraction Form 
Review Ttitle: Association between funding source, methodological quality and research outcomes in 
randomized control studies of Synbiotics, probiotics and prebiotics infant formula: A Systematic 
Review.  
A) Study ID (1stAuthor last name,)_____________________ Publication date __________________________ 
Extractor Last name, Initials _______________________________________________________________ 
Journal name, yyyy/vol/iss/page: ___________________________________________________________ 
______________________________________________________________________________________ 
Title of study: __________________________________________________________________________ 
______________________________________________________________________________________ 
B) Location of study:1) Country _____________________2) City ________________________________ 
3) Hospital(s) _________________________________________________________ 
C) Source of funding or support 
1 
 
Name of Sponsor(s):   
F
o
r 
o
ff
ic
ia
l 
u
se
 
 Category of sponsor (Tick only one)   
2 
 
Industry: 
 For – profit company,  
 Donation of study product by a for – profit company which manufactures 
the study product, 
 Not - for – profit company that promotes the consumption of synbiotics, 
probiotics or prebiotics. 
 Mixed funding (For profit company and other source ) 
Specify sources of 
funding:__________________________________________________________________________________ 
(Note: No assumptions are to be made: the study report must state who the sponsor is. If study report lists the name of a formula and puts a 
company name next to it, there should be no assumption that the company is sponsoring the study) 
 2 
 
3 Non-Industry: 
Government: National government,  
Regional (provincial, county) government body with NO industry association. 
 3 
 Foundation / Philanthropies: examples include Rockefeller foundation, Bill 
and Melinda Gates foundation. 
 
Institution: University, Research centres, hospitals, teaching and academic hospitals.  
Other:(Specify the source of 
funding)__________________________________________________ 
 
4 None / Not Clear. No source of support is disclosed in study report.  4 
Source of funding for this study was: (CHECK 
ONE) 
Industry Non- Industry 
None / Not 
clear 
General comments: 
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D) Methodological quality of RCTs 
 Item 
Judgment 
(circle one) 
F
o
r 
o
ff
ic
ia
l 
u
se
 
1 Adequate Sequence generation?  
For low risk: there is description of a random component in the 
sequence generation process such as:  
 Referring to a random number table;  
 Using a computer random number generator;  
 Coin tossing;  
 Shuffling cards or envelopes;  
 Throwing dice;  
 Drawing of lots 
 Minimization 
 
YES / (Low risk) 
 
NO / (High risk) 
 
Unclear 
1 
2 Allocation concealment? 
For low risk: Investigators enrolling participants could not foresee 
assignment because one of the following, or an equivalent method, was 
used to conceal allocation:  
 Central allocation (including telephone, web-based and pharmacy-
controlled randomization);  
 Sequentially numbered drug containers of identical appearance;  
 Sequentially numbered, opaque, sealed envelopes.  
 
YES / (Low risk) 
 
NO / (High risk) 
 
Unclear 
2 
3 Blinding of study participants, study personnel, 
assessors? 
Low risk: Any one of the following:  
 No blinding or incomplete blinding, but the review authors judge 
that the outcome is not likely to be influenced by lack of blinding;  
 Blinding of participants and key study personnel ensured, and 
unlikely that the blinding could have been broken.  
 
YES / (Low risk) 
 
NO / (High risk) 
 
Unclear 
3 
4 Incomplete outcome data addressed? 
For low risk: Any one of the following:  
 No missing outcome data;  
 Reasons for missing outcome data unlikely to be related to true 
outcome (for survival data, censoring unlikely to be introducing 
bias);  
 Missing outcome data balanced in numbers across intervention 
groups, with similar reasons for missing data across groups;  
 For dichotomous outcome data, the proportion of missing outcomes 
compared with observed event risk not enough to have a clinically 
relevant impact on the intervention effect estimate;  
 For continuous outcome data, plausible effect size (difference in 
means or standardized difference in means) among missing 
outcomes not enough to have a clinically relevant impact on 
observed effect size;  
 Missing data have been imputed using appropriate methods.  
 
YES / (Low risk) 
 
NO / (High risk) 
 
Unclear 
4 
5 Free of selective reporting? 
For low risk: Any of the following:  
 The study protocol is available and all of the study’s pre-specified 
(primary and secondary) outcomes that are of interest in the review 
have been reported in the pre-specified way;  
 
YES / (Low risk) 
 
NO / (High risk) 
 
Unclear 
5 
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 The study protocol is not available but it is clear that the published 
reports include all expected outcomes, including those that were 
pre-specified  
6 Free of other bias? 
For Low risk: The study appears to be free of other sources of bias.  
 
For High risk: Had a potential source of bias related to the specific  
 Study design used;  
 Has been claimed to have been fraudulent; 
 Had some other problem. 
 
YES / (Low risk) 
 
NO / (High risk) 
 
Unclear 
6 
Please refer to Cochrane guidelines for further description on each item 
 
E) Intervention.  
  
N= _______ 
Arm    n= ___ 
 
Arm 2    n= ___ 
 
Arm 3 n= ___ 
 
Arm 4 n= ___ 
  
1 Name(s) intervention 
(probiotics, prebiotic, 
synbiotic) 
    1 
2 DOSE: (cfu) / ____.     2 
3 Treatment duration  3 
 
F) Study outcomes (At END of study / intervention) 
 
In General Outcomes were:   (Circle either YES or NO for the answer that applies) 
  For 
official 
use 
1 Positive: synbiotic, probiotic or prebiotic supplementation had a statistically significant effect, 
p<0.05. There were significant differences between study groups (in favour of experimental 
group). 
  1 
1a Growth Parameters: Weight gain, Length gain, Head circumference YES NO 1a 
1b Tolerance: Significant differences in frequency / incidence of:        Colic YES NO 1b1 
 Spitting up / 
regurgitation 
YES NO 1B2 
 Vomiting YES NO 1B3 
 Crying YES NO 1B4 
 Volume of infant formula consumed / daily intake 
of formula 
YES NO 1B5 
1c Stool characteristics: Frequency,  YES NO 1c 
1d Consistency YES NO 1d 
1e Microflora: Significant difference in colony forming units of Bifidobacteria, 
lactobacillus 
YES NO 1e 
1f Significant difference in colony forming units of pathogens YES NO 1f 
1g Immune response: CRP, Interleukin 6, other cytokines, Other immunity parameters YES NO 1g 
1i Infections: Frequency, incidence of different type of infections  
Specify type of infection(s)___________________________________ 
____________________________________ 
YES NO 1i 
1f Other parameters. Specify: 
1) __________________________________________________________ 
2) ___________________________________________________________ 
YES NO 1f 
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3) ___________________________________________________________ 
     
2 Negative: synbiotic, probiotic or prebiotic supplementation had a statistically significant 
increase in an adverse event / negative outcome such as weight loss, diarrhoea, vomiting,  
p<0.05.  
   
2a Specify: 
1) __________________________________________________________ 
2) ___________________________________________________________ 
3) ___________________________________________________________ 
YES NO 2a 
     
3 Neutral: synbiotic, probiotic or prebiotic supplementation did not have a statistically significant 
effect, p>0.05, No significant differences between study groups. 
  3 
3a Growth Parameters: Weight gain, Length gain, Head circumference YES NO 3a 
3b Tolerance: No significant difference in frequency / incidence of:             Colic YES NO 3b1 
 Spitting up / 
regurgitation 
YES NO 3B2 
 Vomiting YES NO 3B3 
 Crying YES NO 3B4 
 Volume of infant formula consumed / daily intake 
of formula 
YES NO 3B5 
3c Stool characteristics: Frequency,  YES NO 3c 
3d Consistency YES NO 3d 
3e Microflora: No significant difference between study groups in colony forming  
units of bifidobacteria, lactobacillus 
YES NO 3e 
3f No significant difference in colony forming units of pathogens YES NO 3f 
3g Immune response: CRP, Interleukin 6, other cytokines, Other immunity parameters YES NO 3g 
3i Infections: Frequency, incidence of different type of infections 
Specify type of infection(s)___________________________________ 
____________________________________ 
YES NO 3i 
3f Other parameters. Specify:  
1) __________________________________________________________ 
2) ___________________________________________________________ 
3) ___________________________________________________________ 
YES NO 3f 
 
G) Authors’ conclusions 
 
Auhors conclusions were:                           (Tick only one) 
 For 
official 
use 
1 Positive: Interpretation of data supports the sponsor’s products over control. The 
sponsor’s products were preferred over control / placebo. 
 1 
2 Negative: Interpretation of data does NOT support the sponsors’ products. The sponsor’s 
products were NOT preferred over control / placebo. 
 2 
3 Neutral: The authors’ conclusion was neutral to the sponsor’s product  3 
4 No clear conclusion offered by author  4 
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H) Authors’ conclusions on outcomes 
 
Primary Outcome(s) 
Author’s conclusion  
(Positive, negative, neutral, not clear/not mentioned) 
1 1 
2 2 
3 3 
4 4 
5 5 
6 6 
7 7 
8 8 
9 9 
Secondary Outcome(s) 
Author’s conclusion  
(Positive, negative, neutral, not clear/not mentioned) 
1 1 
2 2 
3 3 
4 4 
5 5 
6 6 
7 7 
8 8 
9 9 
10 10 
11 11 
Comments 
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Appendix 8: Sample invitation letter to participate in descriptive study 
 
Application of evidence on probiotics, prebiotics and synbiotics by food 
industry: A descriptive study 
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Mr. John Doe 
Clinical Project Manager 
(Insert company name) 
Tel: +01 21 123. 456 789 
Fax: +01 21 123 456 789 
E-mail: John.doe@gmail.com 
 
Mrs. Mary Mugambi 
Researcher & PhD student 
Division of Human Nutrition 
Faculty of Health Sciences 
University of Stellenbosch 
P.O box 19063, Tygerberg, 7505. South 
Africa 
Fax +27 21933 2991 
Cell Phone: +27 73 992 4774 
Email: nkmugambi@hotmail.com 
 
October 17th 2011 
 
Dear Mr. John Doe 
Re: Invitation to participate in a research study 
You are being invited to take part in a unique research study being conducted at the Division of 
Human Nutrition at the University of Stellenbosch in Cape Town, South Africa. The aim of the 
study is to investigate how the infant food industry applies evidence gained through probiotic, 
prebiotic and synbiotic related research on infants. The study is being conducted since there is little 
or no information on how the food industry applies the knowledge and evidence gained in 
research on probiotics, prebiotics or synbiotics on the general paediatric population. The study will 
explore what happens after the research trials using infant formula have been conducted and the 
data is published or remains unpublished. 
 
This study is unique and the first of its kind since it seeks information directly from people within 
the infant food industry. The study is targeting companies that market and /or retail food products 
with added probiotics, prebiotics or both (synbiotics) for infants and children. The person / people 
responsible for research and development will be invited to participate in the study. Study 
participants will include clinical research managers and individual researchers in the infant food 
companies. The study is a descriptive study (a survey) employing the use of a structured 
questionnaire developed by the researcher. 
 
If you agree to participate in the study the following will be sent directly to you: 
1) Informed consent form, 
2) Structured questionnaire. 
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As a study participant, you will be required to do the following: 
1) Read, sign the informed consent form, 
2) Complete the questionnaire which will take 20 to 25 minutes to fill out, 
3) Send back (by fax, email, post) the signed informed consent form and completed questionnaire 
to the researcher. (contact details are provided above) 
Please note: The researcher will sign your signed informed consent form and send it to you, to 
keep for your own records. 
 
The questionnaire will have 5 sections. Information from the following sections includes: 
1. Contact details: Company name, position in company, fax number, email address, mailing 
address.  
2. Product specific questions: Company brands of infant food containing or not containing 
probiotics, prebiotics, synbiotics and reasons for exclusion. Types of infant food: formula, weaning 
products. Type and dose of probiotic, prebiotic and synbiotic. Product viability issues. 
3. Research based questions: frequency of research, application of evidence from research, 
scientific proof for claims on labels, differences between study formula and retail formula 
4. Education of consumers: Medium used, perceived efficacy of specified medium, translation to 
sales, 
5. Safety issues: complying with WHO guidelines for formula preparation instructions, safety of 
long term consumption of products. 
 
As a study participant, you will be free to withdraw from the study at any time. The information you 
provide will be extremely valuable; will be used for publication in a scientific peer reviewed journal 
and university thesis as part of my PhD studies. All the information you provide will be kept 
confidential and protected.  
 
To ensure confidentiality of data and anonymity of study participants in relation to the information 
given, the following will take place: 
1) Data processing will be done according to product and company name, 
2) Only the researcher and statistician will have access to the data, 
3) In the final report: 
 All identifying details (product and company name) will be excluded, 
 Only a list of participating companies will be included, 
 The formula brands will be given generic names such as “brand X, brand Y or brand Z,”  
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 Study participants will be anonymously acknowledged for contributing to the success of 
the study. The following clause will be inserted to thank the participants: “We wish to 
thank all the people who participated in the study. Your insights contributed to the 
successful completion of this study.” 
 
This study has been approved by the Committee for Human Research at Stellenbosch University 
and will be conducted according to the ethical guidelines and principles of the international 
Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the Medical 
Research Council (MRC) Ethical Guidelines for Research. If you have questions about this study, 
first discuss them with the researcher (contact details are provided above).  You can also get more 
information from the Committee for Human Research by contacting Dr Lyn Horn (contact details 
are provided below). After you have consulted the researcher or the Committee for Human 
Research and if they have not provided you with answers to your satisfaction, you should write to 
Professor Renee Blaauw of the Division of Human Nutrition at: 
 
Prof Renee Blaauw.  
Division of Human Nutrition,  
University of Stellenbosch 
Faculty of Health Sciences 
P.O Box 19063, Tygerberg,  
7505 South Africa 
Telephone: +27 21 938 9135 
Fax: +27 21 933 2991;  
E-mail rb@sun.ac.za 
 
 
 
Dr Lyn Horn:  
Committee for Human Research 
University of Stellenbosch 
PO Box 19063, Tygerberg, 7505 
Cape Town, South Africa 
Tel: +27 21 938 9677 or +27 21 938 9207 
Fax: +27 21 931 3352 
Email: lhorn@sun.ac.za 
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It is my sincere hope that you agree to participate in this unique study. If you agree to participate in the 
study, please contact me using either fax, email or postal address as listed above. I will then send you 
the informed consent form and questionnaire. 
 
Thank you 
 
Sincerely 
 
Mrs. Mary Mugambi 
Researcher, PhD student 
Division of Human Nutrition 
University of Stellenbosch, 
Cape town, South Africa 
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Appendix 9: Informed consent form for descriptive study 
 
Application of evidence on probiotics, prebiotics and synbiotics by food industry: A 
descriptive study 
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PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT: 
 
An evaluation of the application of evidence on probiotics, prebiotics and synbiotics by 
the food industry. 
 
REFERENCE NUMBER:  N11/07/203 
 
PRINCIPAL INVESTIGATOR:     Mary Mugambi 
 
ADDRESS:     University of Stellenbosch, Tygerberg campus 
Division of Human Nutrition 
P.O Box 19063 
Tygerberg, 7505 
 
Contact Number (cell phone):   +27 73 992 4774 
E-mail:      nkmugambi@hotmail.com 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the principle 
investigator any questions about any part of this project that you do not fully understand.  It is very 
important that you are fully satisfied and clearly understand what this research entails and how you 
will be involved.  Also, your participation is entirely voluntary and you are free to decline to 
participate.  If you say no, this will not affect you negatively in any way whatsoever.   
 
This study has been approved by the Committee for Human Research at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the 
Medical Research Council (MRC) Ethical Guidelines for Research. This  
 
What is this research study all about? 
 
Venue: This study is being conducted at the Division of Human Nutrition, Faculty of Health  
Sciences, University of Stellenbosch. 
 
Objectives of study: 
 To evaluate the application of evidence on probiotics, prebiotics and synbiotics by the food 
industry for the benefit of the general paediatric population. 
 
Methodology: 
 A structured questionnaire will be sent to the companies that manufacture and / or retail 
infant formula (for premature or full term infants) containing probiotic(s), prebiotic(s) or 
synbiotic(s). 
 People responsible for research and development in these companies will be asked to 
participate in the survey. 
 
Your responsibilities will be: 
 Reading and signing this consent form, 
 Completing the provided questionnaire on probiotics, prebiotic and synbiotics. The 
questionnaire is divided into  sections which are: general questions, product specific 
questions, education of consumers and safety issues, 
 The questionnaire will take 15 to 20 minutes to complete, 
 Email, fax or mail the completed questionnaire to the address above. 
 
Why have you been invited to participate? 
Stellenbosch University  http://scholar.sun.ac.za
 pg. 205 
 You have been invited to participate in this study because as clinical research manager / 
researcher you have one or more unique roles such as: 
 
 Keeping track of: 
o All research trials being conducted or sponsored by your company 
o Individual trial results 
o Published and unpublished trials conducted by your company 
 Dissemination of information to interested parties 
 Liaise with manufacturing sector on how to use new evidence gained from research 
on probiotic, prebiotic or synbiotic 
 
Benefit of taking part in this research? 
There is little or no information on how the food industry uses evidence gathered from research on 
probiotics, prebiotics and / or synbiotics for the benefit of the general paediatric population. By 
participating in this study, the information you provide will help answer the question of “what 
happens after research trials have been concluded, the results published / unpublished?” The 
information you provide will also help answer the question of “how does the general paediatric 
population benefit from probiotic, prebiotic research outside of the clinical setting?” That is, does 
your company come up with new commercial infant formula, or products containing probiotics, 
prebiotics or synbiotics for use by the general paediatric population? Or does your company 
improve on already existing infant formula or products sold on the market? 
 
Are there any risks involved in taking part in this research? 
 There are no risks involved.  
 All identifying information will be kept confidential and protected. There will be no mention of 
any names or any information that may identify you. Only company names will be used.  
 Preliminary study results will be sent to you for further comment. 
 The information collected will be published in a scientific paper and University Thesis.  
 You will be anonymously acknowledged for your contribution to the success of this study 
during publication of the scientific paper and university thesis. 
 
What If you do not agree to take part in the study? 
 This study is purely on a voluntary basis.  Refusal to participate in the study will not affect 
you in any way. 
 
Who will have access to the information you provide? 
The following people will have access to the information you provide: 
 Principle investigator (researcher). 
 Biostatistician. 
 
Will you be paid to take part in this study and are there any costs involved? 
No, you will not be paid to take part in this study. Your participation is purely on a voluntary basis. 
There are little or no costs involved. There will be the cost of sending (by email, fax or post) the 
completed questionnaire to the researcher. 
 
Is there anything else that you should know or do? 
 You can contact the Committee for Human Research at:  
Tel: +27 21 938 9677 or +27 21 938 9207 
Fax: +27 21 931 3352 
Postal address: 
 
Attention: Dr Lyn Horn:  
Committee for Human Research 
University of Stellenbosch 
PO Box 19063, Tygerberg, 7505 
Cape Town, South Africa 
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Email: lhorn@sun.ac.za 
 
 If you have questions about this trial you should first discuss them with the researcher or the 
Committee for Human Research (contact details as provided above). After you have 
consulted the researcher or the Committee for Human Research and if they have not 
provided you with answers to your satisfaction, you should write to Professor Renee Blaauw 
of the Division of Human Nutrition at: 
 
Prof Renee Blaauw.  
Division of Human Nutrition, University of Stellenbosch 
Faculty of Health Sciences 
P.O Box 19063, Tygerberg, 7505 South Africa 
Telephone: +27 21 938 9135 
Fax: +27 21 933 2991;  
E-mail rb@sun.ac.za 
 
 You will receive a copy of this signed consent form for your own records. 
 
A.  Declaration by study participant: 
 
By signing below, I (name) …………………………………...……. agree to take part in a research 
study entitled: An evaluation of the application of evidence on probiotics, prebiotics and synbiotics 
by the food industry. 
  
I declare that: 
 
 I have read and understood this consent form and that it is written in a language with 
which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately 
answered. 
 I understand that taking part in this study is voluntary and I have not been pressurised 
to take part. 
 I may choose to withdraw and will not be penalised or prejudiced in any way. 
 
Declaration to participate in the study: 
 
Signed at (place) ......................…........…………….. On (date) …………....……….. 20__ . 
DD/MM/YYYY 
 
___________________________ 
Name of study particpant (Print letters) 
 
 .................................................................  ..............................................................  
Signature of study participant Signature of witness 
 
Declaration by the investigator: 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to the study participant 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understand all aspects of the research, as 
discussed above 
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 I did/did not use a translator (if a translator is used, then the translator must sign the 
declaration below). 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 20__ . 
DD/MM/YYYY 
 
 
___________________________ 
Name of investigator (print letters) 
 
 
 
 
 
 ...............................................................  ............................................................. 
Signature of investigator Signature of witness 
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Appendix 10: Questionaire for descriptive study 
 
Application of evidence on probiotics, prebiotics and synbiotics by food industry: A 
descriptive study 
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An evaluation of the application of evidence on probiotics, prebiotics and synbiotics by the infant 
food industry  
 
Questionnaire for Study Participants in Infant Food Industry 
This questionnaire has been sent to companies that manufacture and / or retail infant foods 
containing probiotic(s) or prebiotic(s) or synbiotic(s) such as infant formula (for premature or full 
term infants), weaning foods and beverages. 
 
This study seeks the view point of the infant food industry, making it unique and the first of its kind. 
The information you provide is extremely valuable, will be kept confidential and protected. Only the 
Principle investigator (researcher) and statistician will have access to the information you provide. 
During data processing only initials, pseudonyms and Product names will be used. In the final 
published report of this study all identifying details will be omitted. You may consult the appropriate 
professional in your company to obtain the required technical information. 
 
Please complete and send this form to the researcher:  
Mary Mugambi,  
Division of Human Nutrition, University of Stellenbosch, Tygerberg.  
P.O Box 19063 Tygerberg 7505 South Africa 
Email: nkmugambi@hotmail.com, Fax: +27 21 933 2991  
 
Participant Contact details 
Company Name 
Address 
Email address Telephone Fax 
Your position in the company 
 
Product questions 
Put an “X” next to the answer(s) that apply to your company 
1 My company routinely manufactures infant formula containing: 
a. 
Probiotics 
Yes  If yes, what is the target age group(s): 
 Preterm ___, 0 – 5 months____, 6 – 11 months____, >12 months ___  
No  If no, give reason not having any probiotic in your company formula  
Uncertain   
b. 
Prebiotics 
Yes  If yes, what is the target age group(s): 
 Preterm ___, 0 – 5 months____, 6 – 11 months____, >12 months ____ 
No  If no, give reason not having any prebiotic in your company formula  
Uncertain   
c. 
Synbiotics 
Yes  If yes, what is the target age group(s): 
 Preterm ___, 0 – 5 months____, 6 – 11 months____, >12 months ___ 
No  If no, give the reason(s) for not having any synbiotic in your company’s formula  
Uncertain   
Definitions: Synbiotics are combinations of probiotics and prebiotics in same food product. Probiotics are “live microorganisms” which when 
administered in adequate amounts may confer a health benefit to the host. Prebiotics are non- digestible food ingredients that benefit the 
host by selectively stimulating the growth and/or activity of a limited number of bacteria in the colon, improving the host’s health. 
Put an “X” next to the answer(s) that apply to your company 
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2 My company routinely manufactures other infant foods (such as cereals, porridges, other beverages) 
containing: 
a. Probiotics 
Yes  If yes, specify type of infant food / beverage: 
No  If no, give reason for omitting probiotics in infant food – if any 
Uncertain   
b. Prebiotics 
Yes  If yes, specify type of infant food / beverage 
No  If no, give reason for omitting prebiotics in infant food – if any 
Uncertain   
c. Synbiotics 
Yes  If yes, Specify type of infant food / beverage: 
No  If no, give reason for omitting synbiotics in infant food – in any 
Uncertain   
 
3. Please provide the following information on your company’s Probiotic infant formula or follow-on 
formula 
 Formula 
1 
Formula 
2 
Formula 
3 
Formula 
4 
Formula 
5 
Formula 
6 
a. Formula name       
b. Target age group 
(preterm, full term, > 1 year) 
      
c. Type of probiotic used 
(Genus, species) 
      
d. Shelf life period (months)       
e. Dose of probiotic on label: 
Colony forming units/__ 
      
f. Dose at manufacture:  
Colony forming units/ __ 
      
g. Dose of probiotic at mid 
shelf life. Colony forming units/ 
__ 
      
h. Dose of probiotic at 
expiration date, Colony 
forming units/ __ 
      
i. Type of bioavailability tests 
conducted 
      
j. Specify the time intervals 
when bioavailability tests are 
conducted 
      
k. Not applicable (company does not manufacture infant formula)   (Place an X here)  
For additional products, use / add a separate page 
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4. Please provide the following information on your company’s Prebiotic infant formula or follow-on 
formula. 
 Formula 1 Formula 2 Formula 3 Formula 4 Formula 5 Formula 6 
       
a. Formula name       
b. Target age group 
(preterm, full term, > 1 
year) 
      
c. Type of prebiotic used       
d. Shelf life period 
(months) 
      
e. Dose of prebiotic on 
label: __ g / __ 
      
f. Dose of prebiotic at 
manufacture: __ g / __ 
      
g. Dose of prebiotic at mid 
shelf life. __ g / __ 
      
h. Dose of prebiotic at 
expiration date __ g / __ 
      
i. Type of stability tests 
conducted 
      
j. Specify the time 
intervals when stability 
tests are conducted 
      
k. Not applicable (company does not manufacture infant formula)  (Place an X here)  
For additional products, use / add a separate page 
 
5. Please provide the following information on your company’s Synbiotic infant formula or follow-on 
formula. 
 Formula 1 Formula 2 Formula 3 Formula 4 Formula 5 Formula 6 
a. Formula name       
b. Target age group 
(preterm, full term, > 1 year) 
      
c. Type of probiotic 
(Genera, strain) 
      
Shelf life period (months)       
d. Dose of probiotic on 
label: Colony forming units/ ____ 
      
e. Dose of probiotic at  
manufacture: Colony forming 
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units/ ____ 
f. Dose of probiotic at mid 
shelf life Colony forming units/ _ 
      
g. Dose of probiotic at 
expiration date: Colony forming 
units / __ 
      
h. Type of prebiotic       
i. Dose of prebiotic on label:  
Grams / ____ 
      
j. Dose of prebiotic at 
manufacture:  
Grams / ____ prebiotic 
  
 
    
k. Dose of prebiotic at 
expiration date: Grams / __  
      
l. Type of bioavailability tests 
conducted 
      
m. Specify the time intervals 
when bioavailability tests are 
conducted 
      
o. Not applicable (company does not manufacture infant formula) (Place an X here)  
For additional products, use / add a separate page 
 
6. Please provide the following information on your company’s Probiotic weaning foods such as 
cereals, porridges, other beverages. 
 Product 1 Product 2 Product 3 Product 4 Product 5 Product 
6 
a. Product name       
b. Target age group       
c. Type of probiotic used 
(Genus, species) 
      
d. Shelf life period (months)       
e. Dose of probiotic on label: 
Colony forming units/ __ 
      
f. Dose of probiotic at 
manufacture: Colony 
forming units/ __ 
      
g. Dose of probiotic at mid 
shelf life. Colony forming 
units/ __ 
      
h. Dose of probiotic at 
expiration date. Colony 
forming units/ __ 
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i. Type of bioavailability tests 
conducted 
      
j. Specify the time intervals 
when bioavailability tests are 
conducted 
      
k. Not applicable (company does not manufacture weaning foods)                (Place an X here)  
For additional products, use / add a separate page 
 
7. Please provide the following information on your company’s Prebiotic weaning foods such as 
cereals, porridges, other beverages. 
 Product 1 Product 2 Product 3 Product 4 Product 5 Product 6 
a. Product name       
b. Target age group       
c. Type of probiotic used 
(Genus, species) 
      
d. Shelf life period (months)       
e. Dose of prebiotic on 
label: __ g / __ 
      
f. Dose of prebiotic at 
manufacture: __ g / __ 
      
g. Dose of prebiotic at mid 
shelf life. __ g / __ 
      
h. Dose of prebiotic at 
expiration date. __ g / __ 
      
i. Type of stability tests 
conducted 
      
j. Specify the time intervals 
when stability tests are 
conducted 
      
k. Not applicable (company does not manufacture weaning foods)                        (Place an X here)  
For additional products, use / add a separate page 
 
8. Please provide the following information on your company’s Synbiotic weaning foods such as 
cereals, porridges, other beverages 
 Product 1 Product 2 Product 3 Product 4 Product 5 Product 6 
a. Product name       
b. Target age group       
c. Type of probiotic 
(Genera, strain) 
      
d. Shelf life period (months)       
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e. Dose of probiotic on 
label:Colony forming units/ _ 
      
f. Dose of probiotic at  
manufacture: Colony forming 
units/ ____ 
      
g. Dose of probiotic at mid 
shelf life Colony forming 
units/ ____ 
      
h. Dose of probiotic at 
expiration date: Colony 
forming units / __ 
      
i. Type of prebiotic       
j. Dose of prebiotic on label:  
__ g / __ 
      
k. Dose of prebiotic at 
manufacture: __ g / __ 
  
 
    
l. Dose of prebiotic at 
expiration date: __ g / __  
      
m. Type of bioavailability 
tests conducted 
      
n. Specify the time intervals 
when bioavailability tests are 
conducted 
      
o. Not applicable (company does not manufacture weaning foods)                     (Place an X here)  
For additional products, use / add a separate page 
 
Put an “X” next to the answer(s) that apply to your company 
9. In which parts of the world are your company’s probiotics(s) / prebiotic(s) / synbiotic(s) infant formula or 
follow-on formula sold? 
America: North ___, Central ___,  South ___ 
Europe: East ___, Central ___, West ___,  
Africa: North ___, East ___, Central ___, West ___, South ___ 
Australia: North ___, West___, South ___, Queensland ___, New South Wales ___, Victoria ___, Tasmania 
___,  
New Zealand ___,  
Asia: North___, Central ___, South ___, East ___, South East Asia ___, West ___,  
Oceania: Melanesia___, Micronesia ___, Polynesia ___,  
Other: Please specify _____________________________________________________  
______________________________________________________________________ 
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Research questions 
Put an “X” next to the answer that apply to your company. 
10 How does your company officially keep abreast of latest research on the type of probiotic(s) / prebiotic(s) / synbiotic(s) used in your 
company’s infant formula, follow – on formula, weaning foods or beverages? 
Designated person with a specific job description. Specify job title of this designated person.  
Each researcher / technician is responsible for keeping up to date  
Focus group discussions. Specify with whom.  
Workshops: invited researchers presenting their work  
Other, please specify  
Uncertain  
Not applicable  
 
Put an “X” next to the answer that applies to your company while providing the following information 
11. In the last 10 years, what proportion of research in your company was conducted in collaboration with independent / external entities such as universities 
or research institutions? 
 a. For Probiotics in infant 
formula, follow – on formula 
b. For Prebiotics in infant 
formula, follow – on formula 
c. For Synbiotics in infant 
formula, follow – on formula 
Uncertain     
0% – all research is conducted inside our company     
__ % of research conducted in collaboration with other institutions 
(specify)    
All company research is done independently by external 
institutions without any collaboration with our company.  
   
Not applicable    
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Put an “X” next to the answer that apply to your company while providing the following information 
12. In the last 10 years, what proportion of research in your company was conducted in collaboration with independent / external entities such as universities 
or research institutions? 
 a. For Probiotics in 
weaning foods 
b. For Prebiotics in 
weaning foods 
c. For Synbiotics in 
weaning foods 
Uncertain     
0% – all research is conducted inside our company     
__ % of research conducted in collaboration with other institutions 
(specify) 
   
All company research is done independently by external 
institutions without any collaboration with our company.  
   
Not applicable    
 
 
 
Questionnaire continued below. 
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Put an “X” next to the answer(s) that apply to your company while providing the following information. 
13. Has your company’s infant formula(s) been studied using one or more randomized controlled clinical trials 
(RCTs)? 
a. Probiotic 
formula 
Yes  If yes, specify: Formula 1 Formula 2 Formula 3 Formula 4 Formula 5 Formula 6 
Formula Name       
Target group       
Estimated 
Number of RCTs 
      
Month/Year RCTs 
conducted 
      
Were the RCTs 
published? Y/N 
      
No Why not? Please give reason 
Uncertain  
 Not 
applicable 
 
b. Prebiotic 
formula 
Yes  If yes, specify: Formula 1 Formula 2 Formula 3 Formula 4 Formula 5 Formula 6 
Formula Name       
Target group       
Estimated 
Number of RCTS 
      
Month/Year RCTs 
conducted 
      
Were the RCTs 
published? Y/N 
      
No Why not? Please give reason 
Uncertain  
Not 
applicable 
 
c. 
Synbiotic 
formula 
Yes  If yes, specify: Formula 1 Formula 2 Formula 3 Formula 4 Formula 5 Formula 6 
Formula Name       
Target group       
Estimated 
Number of RCTS 
      
Month/Year RCTs 
conducted 
      
Were the RCTs 
published? Y/N 
      
No Why not? Please give reason 
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Uncertain  
Not 
applicable 
 
For additional products, use / add a separate page 
 
Put an “X” next to the answer(s) that apply to your company while providing the following information. 
14. Does your company sell infant formula or follow – on formula that is identical to its study formula after RCTs 
produced positive results? 
a. Probiotic 
formula 
Yes  If yes, specify: Formula 
1 
Formula 
2 
Formula 
3 
Formula 
4 
Formula 
5 
Formula 
6 
Formula Name       
Target group       
Estimated 
Number of RCTS 
      
Month/Year RCTs 
conducted 
      
Were the RCTs 
published? Y/N 
      
No Why not? Please give reason 
Uncertain  
Not 
applicable 
 
b. Prebiotic 
formula 
Yes  If yes, specify: Formula 
1 
Formula 
2 
Formula 
3 
Formula 
4 
Formula 
5 
Formula 
6 
Formula Name       
Target group       
Estimated 
number of RCTS 
      
Month/Year RCTs 
conducted 
      
Were the RCTs 
published? Y/N 
      
No Why not? Please give reason 
Uncertain  
Not 
applicable 
 
c. 
Synbiotic 
Yes  If yes, specify: Formula 
1 
Formula 
2 
Formula 
3 
Formula 
4 
Formula 
5 
Formula 6 
Formula Name       
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formula Target group       
Estimated 
number of RCTS 
      
Month/Year RCTs 
conducted 
      
 Were the RCTs 
published? Y/N 
      
No Why not? Please give reason 
Uncertain  
Not 
applicable 
 
For additional products, use / add a separate page 
 
 
 
 
Questionnaire continued below. 
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Put an “X” next to ALL the answers that apply to your company while providing the following information 
15. How often does your company conduct research trials to re-evaluate infant formula or follow on formula that is already in the market? 
 a. For Probiotic infant formula or 
follow – on formula, every:  
b. For Prebiotic infant formula or 
follow – on formula, every: 
c. For Synbiotic infant formula 
or follow – on formula, every: 
Never    
Every ____ Months (Specify)    
Every ____ Years (Specify)    
Other specify     
Only when a new formulation / 
ingredient is added / changed ___ 
   
Uncertain    
Not Applicable    
 
 
16. How often does your company conduct research trials to re-evaluate weaning foods (such as infant cereals / porridges) already in the market 
 a. For other Probiotic infant 
foods / beverages  
b. For other Prebiotic infant foods 
/ beverages: 
c. For other Synbiotic infant 
foods/ beverages 
Never    
Every ____ Months (Specify)    
Every ____ Years (Specify)    
Other specify     
Only when a new formulation / 
ingredient is added / changed ___ 
   
Uncertain    
Not applicable    
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17. How often does your company conduct research trials to re-evaluate infant beverages already in the market 
 
a. For Probiotic infant beverages b. For Prebiotic infant beverages 
c. For Synbiotic infant 
beverages 
Never    
Every ____ Months (Specify)    
Every ____ Years (Specify)    
Other specify     
Only when a new formulation / 
ingredient is added / changed ___ 
   
Uncertain    
Not applicable    
 
 
 
Questionnaire continued below. 
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Put an “X” next to the answer(s) that apply to your company while providing the following 
information. 
18. Based on scientific evidence that has emerged since the year 2000, has your company developed and 
marketed a new infant formula or follow – on formula containing probiotics(s) / prebiotic(s) / synbiotic(s): 
a. 
Probiotic 
formula 
Yes  
If yes, specify: Formula 
1 
Formula 
2 
Formula 
3 
Formula 
4 
Formula 
5 
Formula 
6 
Formula 
Name 
      
Target group       
Month/Year of 
introduction 
      
No   
Uncertain  
Not 
applicable 
 
b. 
Prebiotic 
formula 
Yes  
If yes, specify: Formula 
1 
Formula 
2 
Formula 
3 
Formula 
4 
Formula 
5 
Formula 
6 
Formula 
Name 
      
Target group       
Month/Year of 
introduction 
      
No   
Uncertain  
Not 
applicable 
 
c. 
Synbiotic 
formula 
Yes  
If yes, specify: Formula 
1 
Formula 
2 
Formula 
3 
Formula 
4 
Formula 
5 
Formula 
6 
Formula 
Name 
      
Target group       
Month/Year of 
introduction 
      
No   
Uncertain  
Not 
applicable 
 
For additional products, use / add a separate page 
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Put an “X” next to the answer(s) that apply to your company while providing the following 
information. 
19. Based on scientific evidence that has emerged since the year 2000, did your company improve on infant 
formula or follow – on formula containing probiotics(s) / prebiotic(s) / synbiotic(s) that was already sold in the 
market? 
a. 
Probiotic 
formula 
Yes  
If yes, specify: Formula 
1 
Formula 
2 
Formula 
3 
Formula 
4 
Formula 
5 
Formula 
6 
Formula Name       
Target group       
Month/Year of 
improvement 
      
Specify type of 
improvement 
      
No   
Uncertain   
Not 
applicable 
 
b. 
Prebiotic 
formula 
Yes  
If yes, specify: Formula 
1 
Formula 
2 
Formula 
3 
Formula 
4 
Formula 
5 
Formula 
6 
Formula Name       
Target group       
Month/Year of 
improvement 
      
Specify type of 
improvement 
      
No   
Uncertain  
Not 
applicable 
 
c. 
Synbiotic 
formula 
Yes  
If yes, specify: Formula 
1 
Formula 
2 
Formula 
3 
Formula 
4 
Formula 
5 
Formula 
6 
Formula Name       
Target group       
Month/Year of 
improvement 
      
Specify type of 
improvement 
      
No   
Uncertain  
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Not 
applicable 
 
For additional products, use / add a separate page 
 
Put an “X” next to ALL the answers that apply to your company while providing the following 
information 
20. Based on scientific evidence that has emerged since the year 2000, has your company developed and 
marketed a new weaning food or beverage containing probiotics(s) / prebiotic(s) / synbiotic(s): 
a. 
Probiotic 
weaning 
food or 
beverage 
Yes  
 Product 
1 
 Product 
2 
Product 
3 
Product 
4 
Product 
5 
Product 
6 
Product Name       
Target group       
Month/Year of 
introduction 
      
No   
Uncertain  
Not 
applicable 
 
b. 
Prebiotic 
weaning 
food or 
beverage 
Yes  
 Product 
1 
 Product 
2 
Product 
3 
Product 
4 
Product 
5 
Product 
6 
Product Name       
Target group       
Month/Year of 
introduction 
      
No   
Uncertain  
Not 
applicable 
 
c. 
Synbiotic 
weaning 
food or 
beverage 
Yes  
 Product 
1 
 Product 
2 
Product 
3 
Product 
4 
Product 
5 
Product 
6 
Product Name       
Target group       
Month/Year of 
introduction 
      
No   
Uncertain  
Not 
applicable 
 
For additional products, use / add a separate page 
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Put an “X” next to the answer(s) that apply to your company while providing the following 
information. 
21. Based on scientific evidence that has emerged since the year 2000, did your company improve on 
weaning food or beverage that was already sold in the market? 
a. 
Probiotic 
weaning 
food or 
beverage 
Yes  
 Product 1  Product 2 Product 3 Product 4 Product 5 Product 6 
Product Name       
Target group       
Month/Year of 
improvement 
      
Specify type 
of 
improvement 
      
No   
Uncertain  
Not 
applicable 
 
b. 
Prebiotic 
weaning 
food or 
beverage 
Yes  
 Product 1  Product 2 Product 3 Product 4 Product 5 Product 6 
Product Name       
Target group       
Month/Year of 
improvement 
      
Specify type 
of 
improvement 
      
No   
Uncertain  
Not 
applicable 
 
c. 
Synbiotic 
weaning 
food or 
beverage 
Yes  
 Product 1  Product 2 Product 3 Product 4 Product 5 Product 6 
Product Name       
Target group       
Month/Year of 
improvement 
      
Specify type 
of 
improvement 
      
No   
Uncertain  
Not  
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applicable 
For additional products, use / add a separate page 
 
Put an “X” next to the answer(s) that apply to your company while providing the following 
information. 
22. Have the health claims on the infant formula labels been substantiated through randomized controlled 
clinical trials for each infant formula that your company markets / sells. 
a. 
Probiotic 
formula 
 Formula 1 Formula 2 Formula 3 Formula 4 Formula 5 Formula 6 
Formula 
name 
      
Yes        
No        
Uncertain        
Not 
applicable 
      
b. 
Prebiotic 
formula 
 Formula 1 Formula 2 Formula 3 Formula 4 Formula 5 Formula 6 
Formula 
name 
      
Yes        
No        
Uncertain        
Not 
applicable 
      
c. 
Synbiotic 
formula 
 Formula 1 Formula 2 Formula 3 Formula 4 Formula 5 Formula 6 
Formula 
name 
      
Yes        
No        
Uncertain        
Not 
applicable 
      
For additional products, use / add a separate page 
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Put an “X” next to the answer(s) that apply to your company while providing the following 
information. 
23. Have the health claims on the weaning food labels been substantiated through randomized controlled 
clinical trials for each weaning food product that your company markets / sells. 
a. 
Probiotic 
weaning 
food 
 Product 1 Product 2 Product 3 Product 4 Product 5 Product 6 
Product 
name 
      
Yes        
No        
Uncertain        
Not 
applicable 
      
b. 
Prebiotic 
weaning 
food 
 Product 1 Product 2 Product 3 Product 4 Product 5 Product 6 
Product 
name 
      
Yes        
No        
Uncertain        
Not 
applicable 
      
c. 
Synbiotic 
weaning 
food 
 Product 1 Product 2 Product 3 Product 4 Product 5 Product 6 
Product 
name 
      
Yes        
No        
Uncertain        
Not 
applicable 
      
For additional products, use / add a separate page 
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Put an “X” next to the answer(s) that apply to your company while providing the following 
information. 
24. Are there any differences between your company’s study probiotic formula (used in RCTs) and 
retailed infant formula or follow-on formula? 
 Study 
formula 
Formula 1 Formula 2 Formula 3 Formula 4 Formula 5 Formula 6 
a. No (study 
and retailed 
formula are 
identical) 
       
b Uncertain        
c. Not 
applicable  
       
d. Yes 
(specify 
difference 
below) 
       
i. Formula 
name 
       
ii. Type of 
probiotic(s) 
       
iii. Dose cfu / g        
iv. Target 
group 
       
v. Other  
ingredient 
       
vi. Other 
difference 
(liquid / powder 
formulation) 
       
Reason(s) for the change (Please specify) 
For additional products, use / add a separate page 
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25. Are there any differences between your company’s study prebiotic formula (used in RCTs) and 
retailed infant formula or follow-on formula? 
 Study 
formula 
Formula 1 Formula 2 Formula 3 Formula 4 Formula 5 Formula 6 
a. No (study 
and retailed 
formula are 
identical) 
       
b Uncertain        
c. Not 
applicable  
       
d. Yes 
(specify 
difference 
below) 
       
i. Formula 
name 
       
ii. Type of 
prebiotic(s) 
       
iii. Dose  __ 
g/__ 
       
iv. Target 
group 
       
v. Other  
ingredient 
       
vi. Other 
difference 
(liquid / powder 
formulation) 
       
Reason(s) for the change (Please specify) 
 
For additional products, use / add a separate page 
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26. Are there any differences between your company’s study synbiotic formula (used in RCTs) and 
retailed infant formula or follow-on formula? 
 Study 
formula 
Formula 
1 
Formula 
2 
Formula 
3 
Formula 
4 
Formula 
5 
Formula 
6 
a. No (study and 
retailed formula 
are identical) 
       
b Uncertain        
c. Not applicable         
d. Yes (specify 
difference below) 
       
i. Formula name        
ii. Type of 
probiotic(s) 
       
iii. Probiotic dose  
__ cfu / g 
       
iv. Type of 
prebiotic(s) 
       
v. Prebiotic dose  
__ g/ __  
       
vi. Target group        
vii. Other 
ingredient 
       
viii. Other 
difference (liquid / 
powder 
formulation) 
       
Reason(s) for the change (Please specify) 
 
For additional products, use / add a separate page 
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Put an “X” next to the answer that applies to your company while providing the following 
information. 
27. Has your company used scientific evidence gained through research on company infant formula to 
manufacture other products (containing probiotics, prebiotics or synbiotics) for infants and children? 
       
No (no new product 
developed) 
      
b Uncertain       
c. Not applicable        
d. Yes (Give details 
below) 
Product 1 Product 2 Product 3 Product 4 Product 5 Product 6 
i. Type of product (milk 
drink, fruit drink, chewable 
tablets) 
      
ii. Type of probiotic(s)       
iii. Probiotic dose __  cfu / g       
iv.Type of prebiotic(s)       
v. Prebiotic dose  __ g/ __       
vi. Target group       
For additional products, use / add a separate page 
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Put an “X” next to the answer(s) that apply to your company while providing the following 
information. 
28. Has your company intentionally not published any RCT results on probiotics / prebiotics / 
synbiotics use in infants that were viewed as being negative or having no clinical benefit(s) to infants or 
children? 
Uncertain        
No       
Not applicable       
b. Yes (Please 
answer questions 
below) 
RCT 1 RCT 2 RCT 3  RCT 4 RCT 5 RCT 6  
i. Type of product 
being tested / 
studied 
      
ii. Probiotic / 
prebiotic name 
      
iii. Study population       
iv. Reason(s) for 
not publishing 
study results 
      
c. Was new research 
was conducted to 
confirm negative 
results?  
YES / NO / Uncertain 
      
d. Were the new 
study results 
published in peer 
review journals   
YES / NO / Uncertain 
      
i. If Yes, specify: 
author, journal name, 
title of article, year, 
volume and page 
      
ii. If no, specify the 
reason(s) for not 
publishing the new 
study results 
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Education of consumers 
Put an “X” next to all the option(s) that apply to your company 
29. What type(s) of method does your company use to educate the consumer on your probiotic(s) / 
prebiotic(s) / synbiotic(s) infant formula or follow – on formula? 
Company websites (Provide website 
address) 
 Formal workshops  
Brochures / leaflets  Home visits by staff  
Press releases  Mass media (Television, radio, 
newspaper) 
 
Focus group discussions  Information booklets in health care 
facilities 
 
Free Telephone hotlines for consumers  Uncertain  
Educate health care workers who then 
educate the consumers 
 None: our company does not educate 
consumers on this topic. 
 
Not applicable (company does not manufacture infant formula)  
Other, Please specify  
 
30. What type(s) of method does your company use to educate the consumer on your probiotic(s) / 
prebiotic(s) / synbiotic(s) weaning foods such as cereals, porridges, other beverages? 
Company websites (Provide website 
address) 
 Logos, slogans on posters  
Brochures/leaflets  Mass media advertising (Television, radio, 
newspaper) 
 
Formal workshops of parents and potential 
consumers 
 In-store promotion: tasting  
Free samples distributed by medical 
professionals 
 Distribution of trial size samples by 
company 
 
Information booklets  Product education to health workers   
Home visits  None  
Discount coupons  Uncertain  
Gift items with logos and slogans   Not applicable (company does not 
manufacture weaning foods) 
 
Other please specify 
 
 
 
Questionnaire continued next page  
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31. Which education method is the most effective based on consumer usage. That is which method 
of education resulted in increased use of company infant formula, follow-on formula or weaning 
foods? 
 Rank your answer from very effective (5) to not effective (1). 
 
Not effective  Neutral  
Very 
effective 
 1 2 3 4 5 
Focus group discussions      
Brochures / leaflets      
Press releases      
Home visits by staff      
Free Telephone hotlines for consumers      
Educate health care workers who then 
educate the consumers 
     
Formal workshops      
Company website      
Mass media (Television, radio, newspaper)      
Information booklets in health care facilities      
Other, Please specify  
Uncertain  
Not applicable  
None  
(our company does not educate consumers 
on infant formula, follow- on formula or 
weaning foods) 
 
 
Please provide the following information. 
32. How does your company test the effectiveness of the method(s) used to educate consumers? 
 
 
Uncertain 
Not applicable 
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Put an “X” next to the answer that applies to your company 
Since 2005 has your company given:      
33. Any type of literature (such as brochures, leaflets) to 
potential consumers of infant formula or follow – on 
formula in health care institutions such as in hospital 
maternity or pediatric wards, clinics, doctor’s offices? 
Uncertain 
 
No  
 
Not 
applicable 
 
Yes 
 
Please 
specify 
 
34. Any type of literature (such as brochures, leaflets) to 
distributors or retailers of infant formula or follow – on 
formula to give to potential consumers? 
Uncertain 
 
No  
 
Not 
applicable 
 
Yes 
 
Please 
specify 
 
35. Formula samples to potential consumers in health 
care institutions such as in hospital maternity or pediatric 
wards, clinics, doctor’s offices to promote this type of 
formula? 
Uncertain 
 
No  
 
Not 
applicable 
 
Yes 
 
Please 
specify 
 
 
Safety issues 
World Health Organization’s (WHO) “Guidelines for safe preparation, storage and handling of powdered 
infant formula” recommends that water with a minimum temperature of 700 C should be used to 
minimize the risk of potentially deadly infections caused by Enterobacter sakazakii, a bacteria that has 
been found in infant formula. (WHO 2007) Preparation instructions on majority of probiotic or synbiotic 
containing formula tin labels state to boil water for 5 minutes, allow to cool down to 370 C or to 
lukewarm temperature (similar to body temperature). Then add powder according to the provided 
feeding table. 
36. How does your company address the above contradiction to WHO guidelines on formula 
preparation? 
 
 
Put an “X” next to the answer that applies to your company 
37 Has your company routinely tested for pathogens in formula prepared as per the instructions on the 
label? 
Uncertain  No  Not applicable Yes 
If Yes, the main pathogens routinely tested for are: 
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Put an “X” next to the answer that applies to your company while providing the following 
information. 
A commentary by the ESPGHAN committee on nutrition states that “There is a lack of published 
evidence on clinical benefits from long term use of probiotic containing infant formula.” (ESPGHAN 
2004) 
38. In the last 10 years has your company conducted 
randomized controlled trials using probiotic(s) or synbiotic(s) 
infant formula in which the supplementation and test 
period was greater than 12 months?  
Yes 
 
No 
 
Not 
applicable 
 
Uncertain 
 
39. Have these results been published in a peer reviewed 
journal? 
 
Yes 
 
No 
 
Not 
applicable 
 
Uncertain 
 
If yes, please specify: Author, Journal, Title of article, Year, volume and page 
40. How does your company address concerns on safety of long term use (longer than 12 months) of 
probiotic or synbiotic containing infant formula or follow-on formula? 
 
Uncertain Not applicable 
 
References: 
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